{
  "OPTISAGE": {
    "TITLE": "full title  phase iii study comparing gvhd prophylaxis with atg\nthymoglobulin to atlggrafalon in elderly patients with\nacute myeloid leukemia or myelodysplatic syndrome and\nreceiving an allogeneic hematopoietic stem cell\ntransplantation with a 10 10 hla matched unrelated\ndonor following a reduced intensity conditioning regimen\nby fludarabinetreosulfan",
    "JUSTIFICATION": "scientific justification  allogeneic hematopoietic stem cell transplantation  allo\nhsct  remains the only curative therapy in acute myeloid\nleukemia  aml  and myelodysplastic syndrome  mds  \nmost of the patients requiring an allohsct are above 50\nyears of age and are transplanted with a reduced intensity\nconditioning  ric  regimen  the optimal ric and gvhd\nprophylaxis regimen allowing a good control of the\ndisease while preventing gvhd remains to be\ndetermined for elderly patients  a phase iii trial comparing\nthe conventional ric fludarabinebusulfan 2 days to\nfludarabinetreosulfan demonstrated an advantage for\nthe flutreosulfan arm in terms of event free survival\n efs   that should therefore be considered as the new\nstandard of ric regimen for aml and mds  gvhd\nprevention has a crucial role in posttransplant outcomes\nby potentially interfering with the graftversusleukemia\n gvl  effect and immune reconstitution  antithymocyte\nglobulins  atg  are recommended to reduce the risk of\nacute and chronic gvhd in transplants performed with\nmatched unrelated donors  however  the optimal type of\natg between the 2 approved brands  atg\nthymoglobulin and atlggrafalon  displaying distinct\ncharacteristics and the optimal dose of atg are still\nunknown  in a retrospective study of patients\ntransplanted mainly with ric with matched related and\nunrelated donors for haematological malignancies  we\nobserved that atlg was associated with a reduction of\ngrade iiiv acute gvhd in comparison to atg without\nincreasing the incidence of relapse  in this phase iii randomized study  we propose to\ncompare gvhd prevention with atg versus atlg in\naml and mds patients above 50 years of age\ntransplanted with a matched unrelated donor following a\nfludarabinetreosulfan ric  with the hypothesis that\natlg would better control gvhd in this population of\npatients thus limiting the risk of morbidity and mortality\nof the procedure ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to compare the incidence of grade iiiv\nacute gvhd at day 100 posttransplantation in mds or\naml patients transplanted with a 10 10 matched\nunrelated donor  mud  following a reduced intensity\nconditioning with fludarabinetreosulfan between patients\nreceiving a gvhd prophylaxis with atgthymoglobulin\nversus atlggrafalon \nprimary endpoint\nincidence of grade iiiv acute gvhd according to the\nmagic classification  appendix 19 9 section 1  at day\n100 posttransplantation  secondary objectives and\nendpoints  secondary objectives \n1  to evaluate the effect of the 2 gvhd prophylaxis\non the engraftment and graft failure \n2  to evaluate the effect of the 2 gvhd prophylaxis\non the incidence of grade i acute gvhd and of\nchronic gvhd \n3  to evaluate the effect of the 2 gvhd prophylaxis\non incidence of infections\n4  to evaluate the effect of the 2 gvhd prophylaxis\non progression free survival\n5  to evaluate the effect of the 2 gvhd prophylaxis\non relapse incidence\n6  to evaluate the effect of the 2 gvhd prophylaxis\non nonrelapse mortality\n7  to evaluate the effect of the 2 gvhd prophylaxis\non overall survival\n8  to evaluate the effect of the 2 gvhd prophylaxis\non gvhd and relapse free survival  grfs \n9  to evaluate the effect of the 2 gvhd prophylaxis\non healthrelated quality of life  fact bmt \n10  to evaluate the effect of the 2 gvhd prophylaxis\non chimerism\n11  to evaluate the effect of the 2 gvhd prophylaxis\non immune reconstitution  t  b  nk  regulatory t\ncell levels in the peripheral blood \n12  to evaluate the effect of the 2 gvhd prophylaxis\non days of hospitalisation during the first 12\nmonths posttransplantation 13  to evaluate the effect of the 2 gvhd prophylaxis\non incidence and severity of vod\n14  to identify prognostic factors associated with the\nprimary endpoint for each prophylaxis arm \nsearch for treatmentbycovariate interactions on\nthe primary endpoint\n15  to evaluate the effect of the 2 gvhd prophylaxis\non the incidence of late acute gvhd  after day\n100   overlap syndromes and chronic gvhd \nsecondary endpoints \n1  hematopoietic recoveries  at least 7consecutive\ndays with neutrophils   0 5 g l  with platelets  \n20 g l\n2  immune reconstitution by analyzing t  b  nk \nregulatory t cell and gammaglobulin levels in the\nperipheral blood at m1  d 100  m6  m12 and m24\nposttransplantation\n3  chimerism at m1  d 100  m6  m12\n4  grade i acute gvhd incidence  appendix 19 9 \nsection 1  and acute gvhd treatments  first line\ntreatment  response to steroids  treatment\ncourses for refractory acute gvhd\n5  chronic gvhd incidence  date and grading  at\nm12 and m24  nih classification  48   appendix\n19 9 section 4 \n6  relapse incidence at m12 and m24  relapse will\nbe defined by the reappearance of leukemic cells\nor mds features after allohsct in the bonne\nmarrow  cytology    cytogenetic analysis from\nbone marrow aspiration  or extramedullary sites\n proven by a biopsy  \n7  progression free survival at m12 and m24\n8  severe infections  ctae grade 34  at d 100 and\nm12 will be fully described\n9  incidences of cmv and ebv reactivations at\nd 100  m6 and m12\n10  nonrelapse mortality at m6  m12 and m24\n11  overall survival at m12 and m24\n12  gvhd and relapse free survival  grfs  defined\nby being alive without disease relapse and without\nhaving developed acute grade iiiiv or severe\nchronic gvhd\n13  healthrelated quality of life  assessed by using\nthe factbmtv4 questionnaire at inclusion and\nat d 100  m6  m12 posttransplantation 14  number of days of hospitalization for the\ntransplant and after the hospitalization for\ntransplantation related complications until m12\n15  incidence and severity of vod at d 100\n16  lymphocyte counts on standard blood counts\nbefore conditioning  d7 \n17  late acute gvhd  overlap syndromes and chronic\ngvhd from d 100 to d 120 ",
    "DESIGN": "design of the study  phase iii multicenter randomized  controlled openlabel\ntrial  comparing gvdh prophylaxis with atg versus\natlg in patients with aml or mds transplanted with a\nmud following fludarabinetreosulfan ric  ancillary study    bio collection of pbmc  plasma and dry pellets from\ntotal blood cells will be performed on d9  base line  \nd14  21  28  56  100  m6 and m12 in 60 patients per\narm for future biological studies that would be\nperformed after finding complementary funding  the\ncollections will be organized via cryostem  in order\nto better understand the modulation of the immune\nresponse between the two atg brands \n  plasma collection for atg pk analysis in the atlg\narm  samples collected before and after each\nadministration of atlg on days3 to 1 and at day\n0  14  m1  m2 and d 100  frozen in each center  \ndata will be analyzed according to preconditioning\nlymphocyte counts and correlated to posttransplant\noutcomes  gvhd  relapse  nrm  to be able to\ndetermine of a formula to optimize atlg dose to\nlymphocyte counts for future studies  this plasma\ncollection will start including patients after finding\ncomplementary funding ",
    "INCLUSION CRITERIA": "population of study participants  patients above 50 years of age presenting aml or mds\nwith an indication for allogeneic stem cell transplantation inclusion criteria  1  age   50 and   70 years\n2  patient between 50 and 55 years should be unfit\nfor a myeloblative conditioning \n3  aml requiring allogeneic stem cell\ntransplantation  intermediate or highrisk aml  in\ncomplete cytologic response  cr1 or above \nor mds requiring allogeneic stem cell\ntransplantation  ipss  1 5 or ipssr   4 5 or\nipssr   34 5 with risk features  rapide blast\nincrease  lifethreatening neutropenia   0 3 g l \nor thrombopenia   30g l  or high transfusion\nneeds   2 month for 6 months  \n4  without an hla matched related donor\n5  having an identified matched hla 10 10\nunrelated donor\n6  with usual criteria for hsct \na  ecog performans status   2\nb  no severe and uncontrolled infection\nc  cardiac left ventricular ejection fraction\n 50 \nd  lung dlco   40 \ne  adequate organ function  asat and\nalat   3n  total bilirubin   2n  creatinine\nclearance   50 ml min  except if those\nabnormalities are linked to the\nhematological disease \n7  with health insurance coverage\n8  having signed a written informed consent\n9  contraception methods must be prescribed\nduring all the duration of the research\nnb  the authorized contraceptive methods are   for women of childbearing age and in absence\nof permanent sterilization  oral  intravaginal or\ntransdermal combined hormonal contraception\n oral  injectable or implantable progestogenonly\nhormonal contraception\n intrauterine device  iud \n intrauterine hormonal releasing system  ius \n bilateral tubal occlusion\n vasectomised partner\n sexual abstinence  only if this the preferred and\nusual lifestyle of the participants \n for man in absence of permanent sterilization \nsexual abstinence  condoms",
    "EXCLUSION CRITERIA": "exclusion criteria  1  carcinomas in the last 5 years  except basal cell\ncarcinoma of the skin or  in situ  carcinoma of\nthe cervix \n2  uncontrolled infection\n3  seropositivity for hiv or htlv1 or active\nhepatitis b or c\n4  yellow fever vaccine and all others live virus\nvaccines within 2 months before transplantation\n5  heart failure according to nyha  ii or more  or\nleft ventricular ejection fraction   50  \n6  lung dlco   40 \n7  preexisting acute hemorrhagic cystitis\n8  renal failure with creatinine clearance   50ml  \nmin\n9  pregnancy  βhcg positive  or breastfeeding\n10  patients with any debilitating medical or\npsychiatric illness  which would preclude the\nrealization of the sct or the understanding of\nthe protocol\n11  patient under state medical aid\n12  patient under legal protection  protection of the\ncourt  or in curatorship or guardianship  \n13  for grafalon  any contraindication mentioned in\nthe smpc of grafalon\n14  for thymoglobulin  hypersensitivity to rabbit\nproteins or to any of the excipients\n15  participation in other clinical trials on medicinal\nproducts for human use or being in the exclusion\nperiod at the end of a previous study\n16  any contraindication mentioned in the smpc of\nall auxiliary medicinal products planned to be\nused in the trial  cyclosporine  mycophenolate\nmofetil  fludarabine  treosulfan",
    "INTERVENTION": "investigational medicinal\nproduct s   phase iii\n  grafalon  10 mg kg day iv for 3 consecutive days\n day 3 to 1 before transplantation    thymoglobuline  5 mg kg iv over 2 to 3 days\nbefore transplantation transplantation modalities  1  conditionning regimen \nall patients will receive the same conditioning regimen \n fludarabine 30 mg m2 day iv for 5 days  day6 to day\n2 \n treosulfan 10 g m2 day iv for 3 days  day 4 to day 2 \n2  donor and stem cell source \nhla 10 10 matched unrelated donor\nonly gcsfmobilized peripheral blood stem cells will be\naccepted  cd34 target dose  4   10 6 kg of body weight\n3  gvhd prophylaxis \nprophylaxis of gvhd will depend on the randomization\narm \natlggrafalon 10 mg kg day iv for 3 consecutive days\n day 3 to 1   atlggrafalon \nor\natgthymoglobuline  atgthymo  \ntwo schedules of administration of antithymocyte\nglobulin  atg  are accepted \n2 5 mg kg day iv for 2 consecutive days  day3 and 2  \nor\n0 5 mg kg iv on day 4  followed by 2 mg kg iv on day 3\nand 2 5 mg kg on day 2 \nin addition  patients will receive cyclosporine  csa   3\nmg kg day  and mycophenolate mofetil  mmf   30\nmg kg day  as follows  csa from day1 to month 4 or 6\nafter a progressive withdrawal starting by 3 months post\nsct if no agvhd and according to the practice of the\ncenter and mmf from day   1 to day  45 in both arms",
    "STATISTICS": "statistical analysis  our hypotheses are based on a reduction on the\nincidence on day 100 posthsct of grade iiiv acute\ngvhd from 40   atg arm  to 23   atlg arm   and\nassuming a 10  risk of randomised patients who would\nnot reach transplant and an incidence of 5  for the\ncompeting risk  death without gvhd  in each arm \nwhen accounting for competing risks  a twosided\nlogrank test with an overall sample size of 324 subjects\n 162 in the control group and 162 in the treatment group \nachieves 91  power at a 0 05 significance level to detect\na hazard ratio of 0 50 with a followup time of 100 days \nin total  162 162 324 patients will be included \nno interim analysis is scheduled to be performed  ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  optisage   aphp230276   eu ct n 202350455527\n00",
    "INVESTIGATOR": "coordinating investigator  pr régis peffault de latour\nbmt department\nhôpital saint louis  avenue vellefaux  75010 paris\nemail   regis peffaultdelatour aphp fr scientific director  pr marie thérèse rubio\nhematology department\nchru nancy  hôpital brabois  allée du morvan\n54500 vandoeuvre les nancy  france\nemail   m rubio chrunancy fr",
    "NUMBER OF INCLUSIONS": "number of participants included  324",
    "SITES": "number of centres  26 in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  the study is funded by industrial support from neovii\nand medac"
  },
  "CAALLF01": {
    "TITLE": "name of the study  caallf01  a french protocol for the treatment of acute lymphoblastic leukemia\n all  in children and adolescents",
    "JUSTIFICATION": "main backgrounds  1  all is now a curable disease in 8090  of children and 7080  of the adolescents \nnevertheless numerous problems remain\nthese good results are obtained with intensive and prolonged treatments which\ninclude risk of toxic death  sequelae  and secondary malignancies \nresults are still insufficient for highrisk forms  particularly those exhibiting an early\nresistance to chemotherapy\nearly bone marrow relapses  less than 30 months after diagnosis  still have a dismal\nprognosis which renders their prevention mandatory\nall is an extremely heterogeneous disease in terms of biology and response to\ntreatment  to envisage targeted treatments in the future renders key to decipher this\nheterogeneity \nthe two cooperative groups fralle and the french centers of the eortcclcg have\ndecided to elaborate a common protocol for the treatment of childhood and\nadolescent all  childhood and adolescent allfrance 01 caallf01  \nthe two previous studies from these groups have comparable results \neventfree survival overall survival\n5 years 8 years 5 years 8 years\nfralle 2000\n 2146 pts  84 0  82  91  89 \neortc 58951\n 1947pts  82 6   81 3  89 7  88 1 \n2  a still major question in the field of all is the optimal use of lasparaginase\n asnase \nit is known that administering asnase results in the depletion of asparagine\ncirculating in the blood  which starves the leukemic cells and results in their death \nbut indeed the use of asnase varies between protocols considering the different\nbrands  the dose and the administration modalities  rythm  routeim or iv  \nthree major forms of asnase are currently available  e  coli asparaginase  kidrolase \nin france   erwinia asparaginase  erwinase   for patients with allergy  and a pegylated\nform of e coli asparaginase  oncaspar  in usa and in europe  \n2 1 oncaspar in the usa\noncaspar   pegylated e  coli asparaginase or pegaspargase manufactured initially by\nenzon and now shire servier  was developed with the goal of reducing the\nimmunogenicity of the native asnase  in addition  oncaspar   because of its\nprolonged serum terminal halflife  t1 2   can be dosed less frequently than native\nasnase with achievement of similar pd \nin the usa  ccg1962 was the pivotal clinical trial supporting firstline use of\noncaspar   children with standard risk all  n 118  were randomized to receive\nnative or pegylated e  coli asparaginase  api from merck  as part of induction and 2\ndelayed intensifications  di  phases  oncaspar  was administered intramuscularly  im  at a dose of 2 500 iu m2 once during the 4week induction phase and once\nduring each of two 8week di phases  native e  coli asparaginase from merck  elspar  \nwas administered im at a dose of 6 000 iu m2 three times weekly for 9 doses during\ninduction and for 6 doses during each di phase  children treated with oncaspar  had\na more rapid clearance of lymphoblasts from day 7 and day 14 bone marrow\naspirates and a more prolonged asparaginase activity than those treated with the\nnative form  in the first di phase  26  of native asparaginase patients had hightiter\nantibodies compared to 2  of those patients receiving oncaspar   high titer\nantibodies were associated with low asparaginase activity in the native arm  but not\nthe oncaspar  arm  the rate of infections  hospitalizations and the safety profile were\nsimilar between the arms  avramis et al   2002   oncaspar  is approved for the\ntreatment of all as a component of multiagent chemotherapy in the usa since 1994 \nincluding for firstline use since 2006  this first line use has been transferred to a\n new  oncaspar  manufactured by sigmatau  pegaspargase  asparaginase from\nlonza  in 2011  and now by shire \n2 2  oncaspar in europe\nuntil now  oncaspar   currently available in europe differed from the oncaspar \nmarketed in the usa in terms of the asparaginase origin  kyowahakko v  lonza  \nalthough both products are pegylated by sigmatau in the usa \nin germany and poland  oncaspar kh  kyowahakko  is registered as a component of\nantineoplastic combination therapy for reinduction in patients with a known\nhypersensitivity to native lasparaginase  secondline  \noncaspar kh has been used as the first line asparaginase preparation in at least three\neuropean all protocols  uk mrc protocols for all since 2003  uk   bfmaieop\nprotocol for all since 2010  germany  italy  austria  switzerland  czech republic \nisrael   interfant  a protocol dedicated to infants with all  since 2006  many\ncountries  \nsince january 2016  the european commission has granted marketing authorization\nfor use of oncaspar as a combination therapy in acute lymphoblastic leukaemia\n all  in paediatric patients from birth to 18 years  and adult patients  with this\napproval  baxalta is authorized to market oncaspar in the 28 member countries of\nthe european union  eu   as well as iceland  liechtenstein and norway  this\nauthorization is related to the onacaspar incorporating the api manufactured by\nlonza\n2 3 current status of asparaginase preparations in france\nuntil january 2016  only kidrolase  was registered for first line use \nerwinase  is available for patients that are allergic to native or pegylated asparaginase\n maa in france  30 03 2015  \noncaspar    oncaspar kh  was available under a named patient program  atuon 19\nnovember 2015    until oncaspar   received a marketing authorization on january\n2016  3  different dosing and schedules using oncaspar  during induction therapy\nare currently proposed according to firstline all protocols\n 2500 iu m2 one infusion  cog and dfci protocols us   using oncaspar lonza \n 3500 iu m2 one infusion  st jude protocol us   oncaspar lonza \n 2500 iu m2 two infusions  aieopbfm protocol  europe  oncaspar kh \n 2500 iu  m2 two infusions  eortc protocol belgium   oncaspar kh \n 2500 iu  m2 one infusion  interfant 06 protocol  mainly europe  oncaspar kh \n 1000 iu m2 two infusions  ukall protocol  uk  oncaspar kh \n 1500 iu m2 two infusions  dcog protocol  nl  oncaspar kh \n4  the results of the 2003 protocol ukall are interesting  efs 86  at 5 years  overall\nsurvival at 5 years 92   vora a et al  lancet oncol 2013 and 2014   they have been\nobtained by using a low dosage per infusion of oncaspar kh  1000 iu m2 im  but\nrepeated at 15 day intervals for induction  in a subgroup of 482 patients treated in ukall 2003  cyk fong et al  ash 2011  show\nthat the dose that provides adequate asparaginase activity    100 iu l  in 86  of\nsamples studied after the 1st and second injection ",
    "OBJECTIVE": "questions asked in\nthe caallf01\nprotocol  this french protocol will be the first in europe to use the oncaspar  lonza used in\nthe usa since 2012  first approval in 1994 was for another  oncaspar \nmanufactured with a merck api  \nrandomized question  what is the best way to administer pegaspargase  a cohort of\nchildren and adolescents with standard or medium risk all will be randomized to\nreceive during induction either one infusion of oncaspar   lonza  2500 iu m2 at\nd12 or two infusions of oncaspar   lonza  at 1250 iu m2 each at d12 and d26 \npatients will then receive 2500 iu m2 or 1250 iu m2 per dose during consolidation\nand delayed intensification according to the initial arm of randomization \nnon randomized question  in the high very high risk groups  a non randomized\nintensification of the scheme of asparaginase administration is proposed during\ninduction therapy  2 infusions of 2500 iu m2 day  d12 and d26  will be administered \nall patients will receive 2500 iu m2 per dose during consolidation and delayed\nintensifications  primary objectives  1  for children and adolescents with standard or medium risk all  the study has\ntwo primary objectives  1  to assess the superiority in terms of pk at d33 of\nthe fractionated scheme  2  to assess the equivalence in the tolerance of the\n2 schemes  from d12 of induction to d49 \n2  in the high very high risk group two primary objectives have been defined \n1  to assess the pk at d33  2  to assess the toxicity of the intensified scheme\nfrom d12 of induction to d49 main endpoints  o adequate asparaginase activity   100 iu l  at d33 of induction\no toxicity  incidence of severe toxicities  grade   3  directly asparaginase\nrelated  cns thrombosis  pancreatitis  anaphylaxia  and hyperbilirubinemia \nbetween d12 and d49 of treatment and anyway before d8 of consolidation secondary endpoints  1  linked to the study drug\npharmacokinetics  pharmacodynamics  immunogenicity \na comparison of the 2 arms will be made for the patients with standardrisk or\nmediumrisk all  a non comparative assessment will be made for patients belonging\nto the highrisk very high riskgroups \nthe criteria will include \n cid 16  asparaginase activity and asparagine levels at defined timepoints\n cid 16  incidence of asparaginase antibodies\n cid 16  incidence of silent inactivation in both arms during induction  consolidation\nand intensification phase s \n cid 16  allergic reaction rate in both arms during induction  consolidation and\nintensification phase s \n cid 16  percentage of patients without switch to erwinia asparaginase\n cid 16  percentage of patients receiving more than 95  of the intended dose of\nasparaginase\nefficacy\na comparison of the 2 arms will be made for the patients with standardrisk or\nmediumrisk all  a non comparative assessment will be made for patients belonging\nto the highrisk very high riskgroups \nthe criteria for efficacy will include \n cid 16  morphological cr rates assessed on the whole population or on subgroups\n blineage all  tcell all  \n cid 16  minimal residual disease  mrd  at the end of induction  tp1  and at the later\ntimepoint  tp2  tp3 for a subgroup of patients  assessed by ig tcrbased\nrqpcr  this evaluation will be made in the whole population and within\nsubgroups\n cid 16  cumulative incidence of relapses overall   cid 16  cumulative incidence of bm relapses  cns relapses  gonadal relapses \ncombined relapses\ntoxicity\na comparison of the 2 arms will be undertaken for the patients with standardrisk or\nmediumrisk all  a non comparative assessment will be made for patients belonging\nto the highrisk very high riskgroups \n cid 16  all other adverse events  ae  related to asparaginase occurring within the\nfirst 7 weeks  d49  of treatment and anyway before d8 of consolidation \no hyperglycemia   induced diabetes  coagulopathy  allergy \nhyperlipidemia  hypertriglyceridemia and or\nhypercholesterolemia \no non cns thrombosis\no grade 12 ae  pancreatitis  hyperbilirubinemia \n cid 16  adverse events related to asparaginase but occurring after d49 of induction\nor anyway at d8 of consolidation or after\n cid 16  incidence of all grade 34 adverse events  whatever their imputability \nsurvival timepoints\n5year eventfree survival  diseasefree survival and overall survival are classical outcome\nmeasures for the evaluation of survival in children with all \neventfree survival is the survival time free of treatment failure  relapse or secondary\nmalignancy from day 1 of treatment or after randomization  in randomized arms   disease\nfree survival is the eventfree survival in responders measured from the time of complete\nremission following induction  treatment failure is defined after induction at day 35day 42 \nby at least 5  blasts and mrd    5x102  in case of no available mrd  only the   5  blasts\ncriterion will be required \n2other secondary objectives\n cid 16  to evaluate the incidence of rare subgroups of all and their prognostic value\ne g  socalled  bother  subgroup  bcrabl like  including ebf1pdgfrb  \nmef2dx  znf384x  tcf3hlf \n cid 16  5 year efs  dfs and os of the rare patients with suboptimal reponse to\ntherapy  induction failure or mrdtp1   103  and ablclass fusions alls\ntreated with imatinib\n cid 16  imatinib related adverse events  immediate and long term  cf appendix 9  in\nthe rare patients with suboptimal reponse to therapy  induction failure or\nmrdtp1   103  and ablclass fusions alls treated with imatinib",
    "DESIGN": "study design  this is a french prospective multicentric cohort study of children and adolescents\nwith all  stratified on  i  the type of all  b vs t  and  ii  the anticipated risk  stratified\nin 3 groups for bcpall and 2 groups for tcell all \na randomized clinical trial will be performed in the population of patients\ncomposed of the bsr bmr tsr  after checking the eligibility criteria  using a two\nparalell arm randomization design  patients will be allocated either to receive one\ninfusion of oncaspar  2500 iu m2 vs  or 2 infusions of 1250 iu m2 during induction\ntherapy  the dose per infusion after induction therapy is the dose per infusion\nattributed by the initial randomization\nno randomized question will be asked in the high very high risk groups of the b and\nt lineage  these patients receiving 2 infusions of oncaspar  2500 iu m2 during\ninduction and 2500 iu m2 infusion afterwards  nevertheless  these patients will be\nsubmitted to the same evalauation in terms of pk pd  toxicity and efficacy \nall patients will be included in the caallf01 study before day 8 of induction\ntreatment \nrandomization will take place between d8 and d11  i e  14 days before the first\ninfusion of pegaspargase  d12   for patients belonging to the bsr bmr tsr\ngroups ",
    "INCLUSION CRITERIA": "inclusion criteria   cid 120  children and adolescents\nage   12 months but   18 yearsblineage or t lineage all\n cid 120  written informed consent obtained before day 8 of treatment\nnb  patients with down syndrome can be included but not randomized  see details in\nthe protocol section 532 ",
    "EXCLUSION CRITERIA": "non inclusion criteria   cid 120  l3  burkitt s leukemia   lmb type protocols \n cid 120  mixed phenotype acute leukemia  who criteria  \n cid 120  infant all  age   365 days  interfant 06 protocol \n cid 120  secondary leukemia  cid 120  patients previously treated with chemotherapy  steroid exposed pts can be\nincluded and stratified according to section 3 5  known allergy to pegylated\nproducts\n cid 120  pregnancy  women of childbearing potential  defined as all women\nphysiologically capable of becoming pregnant must have a negative serum\npregnancy before inclusion and a reliable contraception exceptoral\ncontraceptives  the contraception should be maintained throughout the\nstudy and for 3 months after treatment discontinuation \n cid 120  known hiv positivity\n cid 120  cns thrombosis during prophase exclusion criterion   cid 120  ph  bcrabl all  esphall protocol \n cid 120  cns thrombosis before d12",
    "INTERVENTION": "investigational drug  oncaspar   pegaspargase   is supplied as a sterile solution at the beginning of the trial\nand replaced by a powder for solution for injection  both are packaged in type i\nsingleuse vials containing 3 750 international units of native asparaginase per 5 ml\nsolution  oncaspar  is to be stored under refrigeration at 2 c to 8 c  product must not\nbe shaken or frozen and must be protected from light ",
    "STATISTICS": "first interim analysis  will be performed based on all patients randomized before january  1  2018  as\nrequested by the dsmb of the study on november 2017",
    "DSMB": "",
    "ACRONYM": "",
    "INVESTIGATOR": "",
    "NUMBER OF INCLUSIONS": "number of subjects\nchosen  2000 patients could be enrolled to obtain \nbsr  bmr  tsr  1578 evaluable patients\nbhr  thr  250300 evaluable patients",
    "SITES": "centres  28  amiens nantes\nangers nice\nbesançon paris  \nbordeaux armand trousseau \nbrest robert debré\ncaen saintlouis\nclermontferrand poitiers\ndijon reims\ngrenoble rennes\nlille rouen\nlimoges saintetienne\nlyon strasbourg\nmarseille toulouse\nmontpellier tours\nnancy",
    "FUNDING": "study sponsor  assistance publiquehôpitaux de paris"
  },
  "HAPLO-EMPTY": {
    "TITLE": "full title  haploidentical allogeneic hematopoietic stem cell transplantation\nwith posttransplant cyclophosphamide in patients with acquired\nrefractory aplastic anemia  a nationwide phase ii study",
    "JUSTIFICATION": "scientific justification  outcomes for patients with severe aplastic anemia  saa  who are\nrefractory to firstline immunosuppressive therapy  ist  and who\nlack a matched unrelated donor  mud  remain poor  recently  the\nuse of eltrombopag  elt  has shown blood count improvements in\n40  of these patients  1   however  most refractory patients do not\nrespond to elt or other secondline treatment and are therefore\nexposed to lifethreatening infections  and bleeding  during the\npast 2 decades  there has been a significant decrease in infection\nrelated mortality in patients with saa unresponsive to initial ist but\nclonal evolution including paroxysmal nocturnal hemoglobinuria\n pnh   myelodysplastic syndrome  mds   and acute myeloid\nleukemia  aml  still occur in the longterm with a grim prognosis \noverall  the overall survival of such patients with acquired\nrefractory saa to elt is about 6070  at 2 years  2  \nhematopoietic stem cell transplantation  hsct  using alternative\ndonor sources  i e   mismatched unrelated donors  cord blood\n cbt   and haploidentical family donors  may be curative in\npatients with refractory saa  despite carrying much higher rates of\ncomplications than in transplantations from matched related or\nunrelated donors  recently  our group showed that cbt is a\nvaluable curative option for young adults with refractory saa  3  \nhowever  not all patients have available cb and cbt treatment\nrelated mortality is high in adult patients  haploidentical  haplo \nrelated donor stem cell transplantation  haplosct  have\nimproved dramatically outcomes using tcell replete grafts with\nadministration of posttransplantation cyclophosphamide  ptcy  \npreliminary results in a little number of patients with refractory saa\nat kings college  london  uk  and john hopkins  baltimore  usa \nseem promising  4  5   we retrospectively analyzed data from 36\npatients  median age 42 years  transplanted between 2010 and\n2017 in europe on behalf of the saa working party of the european\nblood and marrow transplantation group  the 1year overall\nsurvival was about 80  suggesting that this approach might be a\nvalid option in this particular poor clinical situation  6  ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to demonstrate a benefit in term of the 2year\noverall survival rate from 60   historical rates in patients with\nacquired refractory idiopathic aplastic anemia  up to 80  using\nhaplosct with ptcy \nprimary endpoint  2year overall survival rate of 80  secondary objectives and\nendpoints  secondary objectives\nclinical and biological outcomes \n graft failure  graft versus host disease  gvhd   progression free\nsurvival  relapse  nonrelapse mortality  overall survival\n quality of life  chimerism\n immune reconstitution\nsecondary endpoints \n graft failure incidence\n neutrophils and platelets engraftment at day 100  3\nconsecutive days with neutrophiles  0 5 g l and 7\nconsecutive days with platelets  20 g l \n absolute numbers of neutrophils and platelets at m1  m2 \nm3  m6 and m12  day of last platelet and red blood cell\ntransfusions\n incidence of use of growth factors for poor hematopoietic\nreconstitution\n acute gvhd incidence at month 3  m3   date and\nmaximum grading  first line treatment  response to\nsteroids  treatment courses in case of steroid refractory\ngvhd  \n chronic gvhd incidence  date and grading  at m24 \n relapse incidence at m12 and m24\n progression free survival at m12 and m24\n incidence of cmv and ebv infection at m12\n severe infections  ctae grade 34  à m3  m6  m12 and\nm24\n nonrelapse mortality m24\n incidence of cardiac toxicities at m12\n overall survival at m12\n quality of life questionnaire at inclusion  post\ntransplantation  m3  m6  m12  m24\n chimerism at m1  m3  m6  m12 m24\n immune reconstitution by analyzing t  b  nk  regulatory t\ncell levels in the peripheral blood at m3  m6  m12 and m24\nposttransplantation\n ferritin levels at m3  m6  m12  m24",
    "DESIGN": "design of the study  a phase ii multicenter  national  prospective cohort study ",
    "INCLUSION CRITERIA": "population of study participants  patients aged from 3 to 35 years with acquired refractory idiopathic\naplastic anemia and with an indication of an haploidentical\nallogeneic hematopoietic stem cell transplantation  inclusion criteria  patients \n aged from 3 to 35 years old\n suffering from refractory acquired idiopathic aplastic anemia  at\nleast one course of immunosuppression with antithymocyte\nglobulin\n absence of genoidentical donor or 10 10 matched donor\n with identification of a haploidentical donor  brother  sister \nparents  adult children or cousin \n absence of donor specific antibody detected in the patient with a\nmfi   1500  antibodies directed towards the distinct haplotype\nbetween donor and recipient \n with usual criteria for hsct \n  ecog   2\n  no severe and uncontrolled infection\n  cardiac function compatible with high dose of\ncyclophosphamide\n adequate organ function  asat and alat   2 5n  total bilirubin\n  2n  creatinine   150 µmol l  with health insurance coverage\n contraception methods must be prescribed during all the\nduration of the research  women and men of childbearing age\nmust use contraceptive methods within 12 months and 6\nmonths after the last dose of cyclophosphamide  respectively \n having signed a written informed consent  2 parents for\npatients aged less than 18 \nnb   the authorized contraceptive methods are \n for women of childbearing age and in absence of\npermanent sterilization  oral  intravaginal or transdermal\ncombined hormonal contraception  oral  injectable or\ntransdermal progestogenonly hormonal contraception \nintrauterine hormonalreleasing system  ius   sexual\nabstinence  need to be evaluated in relation to the duration of\nclinical trial and the preferred and usual lifestyle of the\nparticipants  \n for man in absence of permanent sterilization  sexual\nabstinence  condoms ",
    "EXCLUSION CRITERIA": "exclusion criteria  patients \n with no morphologic evidence of clonal evolution  patients\nwith isolated bone marrow cytogenetic abnormalities are also\neligible  \n with uncontrolled infection\n with seropositivity for hiv or htlv1 or active hepatitis b or c\ndefined by a positive pcr hbv or hcv and associated\nhepatic cytolysis\n cancer in the last 5 years  except basal cell carcinoma of the\nskin or  in situ  carcinoma of the cervix \n pregnant  βhcg positive  or breastfeeding \n who received attenuated vaccine within 2 months before\ntransplantation\n uncontrolled coronary insufficiency  recent myocardial infarction\n 6 month  current manifestations of heart failure  uncontrolled\ncardiac rhythm disorders  ventricular ejection fraction  50 \n with heart failure according to nyha  ii or more \n preexisting acute hemorrhagic cystitis\n renal failure with creatinine clearance  30ml   min\n with urinary tract obstruction\n with contraindications to treatments used during the research\n who have any debilitating medical or psychiatric illness  which\npreclude understanding the inform consent as well as optimal\ntreatment and followup\n under tutorship or curatorship",
    "INTERVENTION": "transplant modalities  1 conditioning regimen\nfludarabine  30mg m2 day i v  day 6 to day 2   pretransplant\ncyclophosphamide  14 5 mg kg day i v  day 6 and day 5   and\ntotal body irradiation  2 gray on day1 \n2 stem cell source\nbone marrow\n3  gvhd prophylaxis\nrabbit atg dosed at 0 5 mg kg on day  9 and 2 mg kg on days  8\nand  7  cyclophosphamide 50 mg kg day at d 3 and d 4 \ntacrolimus  residual 812 microg l  and mycophenolate  mmf  from d 5  in absence of gvhd  mmf will be stopped at d35 and\ntacrolimus at day 365 \n4  prevention of ebv reactivation\nrituximab 150mg m2 intravenously at day 5 post hsct \neach infusion of rituximab will be preceded by administration of\nantipyretic and an antihistaminic  e g  paracetamol and\ndiphenhydramine ",
    "STATISTICS": "statistical analysis  justification of sample size\nwe hypothesize the 2year overall survival  os  will be of 80 \n versus 60  in historical controls   a twosided  onesample\nlogrank test calculated from a sample of 31 subjects achieves\n80 7  power at a 0 050 significance level to detect a proportion\nos of 80  in the new group when the proportion os in the\nhistoric control group is 60  at 2 years \nterminal analysis\nwill be realized after the observation of the required number of\nevents",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  haploempty",
    "INVESTIGATOR": "coordinating investigator  pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included  for an objective of 31 patients to be allografted  we anticipate 35\npatients to include ",
    "SITES": "number of centres  36 centres in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  ministry of health  phrcn 2019"
  },
  "KAPVEC": {
    "TITLE": "full title  phase ii multicenter study of talimogene laherparepvec in\nclassic or endemic kaposi sarcoma",
    "JUSTIFICATION": "scientific justification  kaposi sarcoma  ks  is a lymphangioproliferation\nassociated with human herpes virus 8  hhv8  promoted\nby immunosuppression  hivrelated ks and iatrogenic\nposttransplantation ks are treated by immune restoration \nin association with local or systemic therapies as\nchemotherapies if required  conversely in classic and\nendemic ks  the underlying relative immunosuppression\ncannot be directly targeted  treatment is poorly codified \nmostly based on surgery or radiotherapy for localized ks \nmost aggressive forms with visceral involvement are\ntreated with chemotherapies or interferon  which give at\nbest 3060  of transient responses and may not be well\ntolerated in elderly patients \ntalimogene laherparepvec is the first oncolytic\nimmunotherapy approved by the fda  in metastatic or\nunresectable melanoma with injectable nodal or\ncutaneous lesions  it is designed to induce tumor\nregression of injected lesions through direct lytic effects \nand of uninjected lesions through induction of systemic\nantitumor immunity \nin merkel cell carcinoma  mcc   another virusinduced\ntumor  treatment with pd1 pdl1 axis inhibitors have\nproven efficacy  thus providing a proof of principle that\nimmunotherapy could be effective in virusinduced tumors \ntwo cases of metastatic mcc succesfully treated with\ntalimogene laherparepvec were recently reported \nsuggesting that talimogene laherparepvec may also be an\neffective therapeutic option  considering the high\nimmunogenicity of viral epitopes in ks tumors  the role of\nthe immune evasion in the development of ks  and the\ncutaneous manifestations   90  of patients  that can be\neasily injected  classic and endemic ks is a good tumor\nmodel to be targeted with talimogene laherparepvec ",
    "OBJECTIVE": "main objective and primary\nendpoint  the main objective is to assess whether talimogene\nlaherparepvec is clinically inactive  partial complete\nresponse probability π0 10   or truly active\n partial complete response probability π1 40   in classic\nand endemic kaposi sarcoma \nthe primary endpoint is the best overall response rate\n borr  defined by the occurrence of complete response\nor partial response of the injected lesions following pga\ncriteria  pga 0 to 4  recorded from the start of treatment until 6 months or the beginning of any other specific\ntherapy for kaposi sarcoma if it occurs before 6 months  secondary objectives and\nendpoints  secondary objectives \n safety profile of talimogene laherparepvec in classic and\nendemic kaposi sarcoma\n other parameters of efficacy  best response  response\nrate  duration of response \n efficacy on injected and uninjected lesions\n quality of life\nexploratory objectives\n to characterize the efficacy of talimogene laherparepvec\nrelated to immunologic and viral assessment on tumor\nbiopsies and blood samples\nsecondary endpoints \n adverse events  following the ctcae v5 0 \n borr according to the actg criteria  response rate at\nmonth 3 and 6  response rate on lymphedema  time to\nresponse  duration of response\n response on injected and uninjected target lesions\n deaths from any cause\n ksadapted dlqi score\nexploratory endpoints \n characterize the immune tumor infiltrate  immune cells\nquantification   viral infiltrate and tumor necrosis before\nand after treatment\n hhv8 viral load in blood and tumor cells  hhv8\nsequencing",
    "DESIGN": "design of the trial  phase ii multicentre single arm open label trial scope of the trial  kaposi sarcoma",
    "INCLUSION CRITERIA": "population of trial subjects  adult patients inclusion criteria   classic or endemic histologically confirmed kaposi\nsarcoma  ks  that is progressive  but does not require a\nsystemic therapy  \n injectable and measurable disease  defined as \n  at least 2 cutaneous lesion  10mm in its largest\ndiameter  in a not previously irradiated field \n  at least 2 other cutaneous lesion  10mm in their\nlargest diameter available for repeated cutaneous\nbiopsies  in a not previously irradiated field \nnb  each cutaneous lesion can be replaced by a cluster of\nsmall lesions with edge to edge distance  2 mm  if the\nbiggest diameter of each cluster meet the previous criteria \n be willing to provide tissue from cutaneous biopsy \n at least 4 weeks washout for all ks specific therapies\nincluding topical treatment  chemotherapy  radiotherapy\nand immunotherapy including interferon \n provide written  informed consent prior to the\nperformance of any study specific procedures   be more than 18 years of age on day of signing informed\nconsent \n have a performance status of 0 or 1 on the ecog\nperformance scale \n demonstrate adequate organ function \nhaematological   absolute neutrophil count  anc \n 1500 mm3  platelets  100 000 mm3  haemoglobin  8\ng dl \nrenal  serum creatinine   1 5 x upper limit of normal\n uln   or calculated creatinine clearance   40ml min\n using mdrd formula  for subject with creatinine levels  \n1 5 x uln \nhepatic  ast  sgot  and alt  sgpt    2 5xuln  serum\ntotal bilirubin   1 5xuln or direct bilirubin   uln for\nsubjects with total bilirubin levels  1 5xuln \npt 1 5  ptt  tca   1 5\n female subject of childbearing potential should have a\nnegative serum pregnancy within 72 hours prior to\nreceiving the first dose of study medication\n have a health insurance ",
    "EXCLUSION CRITERIA": "exclusion criteria   known history of organ transplantation  including\nallogeneic stemcell transplantation  or hiv  hiv 1 2\nantibodies detected at selection  \n symptomatic visceral involvement of ks including brain\nmetastases \n active autoimmune disease that requires systemic\ntreatment or has required systemic treatment in the past 2\nyears  i e  with use of disease modifying agents \ncorticosteroids or immunosuppressive drugs  \nreplacement therapy  eg   thyroxine  insulin  or\nphysiologic corticosteroid replacement therapy for adrenal\nor pituitary insufficiency  etc   is not considered a form of\nsystemic treatment  patients with vitiligo  type i diabetes\nmellitus  hypothyroidism  psoriasis non requiring systemic\ntreatment are permitted to enrol \n evidence of clinically significant immunosuppression\nsuch as the following  primary immunodeficiency state\nsuch as severe combined immunodeficiency disease \nconcurrent opportunistic infection \n receiving systemic immunosuppressive therapy\nincluding oral steroid doses   10 mg day of prednisone or\nequivalent within 7 days prior to enrolment \n clinically significant cardiac dysfunction  symptomatic\nheart failure  clinically significant arrhythmia or conduction\ndisorders  \n active herpetic skin lesions or prior complications of hsv\n1 infection  eg  herpetic keratitis or encephalitis    intermittent or chronic systemic  intravenous or oral \ntreatment with an antiherpetic drug  eg  acyclovir   other\nthan intermittent topical use \n previous treatment with talimogene laherparepvec or any\nother oncolytic virus \n prior radiotherapy in which the fields overlap the injection\nsites \n prior immunosuppressive  chemotherapy  radiotherapy \nbiological cancer therapy  or major surgery within 28 days\nprior to enrollment or has not recovered to ctcae grade\n1 or better from adverse event due to ks therapy\nadministered more than 28 days prior to enrollment \n prior therapy with tumor vaccine \n received live vaccine within 28 days prior to enrolment \n currently treatment with another investigational device or\ndrug study  or less than 28 days since ending treatment\nwith another investigational device or drug study s  \n acute or chronic active hepatitis b  hbs ag detected  or\nc infection  hcv rna detected  at inclusion  or active tb\n bacillus tuberculosis  \n known additional malignancy that is currently\nprogressing or requires active treatment within the last 3\nyears  exceptions include basal cell carcinoma of the skin\nor squamous cell carcinoma of the skin that has undergone\npotentially curative therapy or in situ cervical cancer \n sensitivity to any of the products or components to be\nadministered  \n psychiatric or substance abuse disorders that would\ninterfere with cooperation with the requirements of the trial \n pregnant or breastfeeding  or expecting to conceive or\nfather children within the projected duration of the trial and\n3 months after the last dose of talimogene laherparepvec \n subjects who are unwilling to minimize exposure with\nhis her blood or other body fluids to individuals who are at\nhigher risks for hsv1 induced complications such as\nimmunosuppressed individuals  individuals known to have\nhiv infection  pregnant women  or infants under the age of\n3 months  during talimogene laherparepvec treatment and\nthrough 30 days after the last dose of talimogene\nlaherparepvec \n pregnant or breastfeeding  or expecting to conceive or\nfather children within the projected duration of the trial \n female subject of childbearing potential who are\nunwilling to use acceptable method s  of effective\ncontraception during study treatment and through 3\nmonths after the last dose of talimogene laherparepvec   sexually active subjects and their partners unwilling to\nuse male or female latex condom to avoid potential viral\ntransmission during sexual contact while on treatment and\nwithin 30 days after treatment with talimogene\nlaherparepvec  in addition  male participants should not\ndonate sperm from 3 months after last dose \n vulnerable subjects  prisoners incarcerated following\nadministrative or court decision  subjects with psychiatric\ndisorders who are involuntary hospitalized  subjects under\nlegal protection measure  subjects who cannot express\ntheir consent ",
    "INTERVENTION": "investigational medicinal\nproduct s   talimogene laherparepvec\ndose  10 6 pfu ml at week 1 then 10 8 ml at week 4 and\nevery 2 weeks  up to 4ml for each injection \nroute  intralesional injection\nduration of treatment  6 months  12 cycles  comparator treatment  ",
    "STATISTICS": "statistical analysis  simon s 2 stage optimal design\ninterim analysis planned after 9 patients",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  kapvec",
    "INVESTIGATOR": "coordinating investigator  pr céleste lebbe\noncodermatologie  hopital saint louis",
    "NUMBER OF INCLUSIONS": "number of subjects included  9 patients will be enrolled in the first part of the study with\nanother 11 patients in the second part  total 20 patients  \nit implies to screen a maximum of 40 patients ",
    "SITES": "number of sites  national multicenter study  2 sites",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  amgen"
  },
  "FIBRAPLO": {
    "TITLE": "full title  haploidentical transplantation in patients with\nmyelofibrosis a phase 2 prospective multicentric study",
    "JUSTIFICATION": "scientific justification  the only curative treatment in patients with primary or\nsecondary myelofibrosis is allogeneic hematopoietic stem\ncells  hsct   it has been reported that intermediate and\nhigher risk patients according to international prognostic\nscores benefit from hsct in terms of survival  kröger et\nal  2015   in 2013  we conducted in france a prospective\ntrial testing the use of ruxolitinib before transplantation\n  jakallo study  nct01795677   outcome of patients\nwas better in patients transplanted with a matched sibling\ndonor than an unrelated donor confirming other studies\n kröger et al  2009  rondelli et al  2014   in the jakallo\ntrial  acute gvhd incidence was high  often hyperacute\nand severe  recently  the ebmt group has reported a\nregistry study on familial haploidentical transplantation\n haplo  in patients with myelofibrosis  raj et al  2018  \nposttransplant cyclophosphamide was used in 59  of\ncases  oneyear overall survival  os  and diseasefree\nsurvival  dfs  were 61 and 58  which favorably\ncompared to outcome after unrelated transplantation \ngenova team has also reported impressive results after\nhaploidentical transplantation in their center  bregante et\nal  2015   bregante et al have reported outcome of 2\ncohorts transplanted from 2000 to 2010 and from 2011 to\n2014  the main difference between the 2 periods is the\nmore frequent use of haplo in the second period  54 \nversus 5    outcome was much better in the second\nperiod with os at 70  versus 49  and authors suggest\nthat this improvement is related to the best outcome\namong haplo transplantation  the improvement of\noutcome after haplo has been attributed to a better gvhd\nprophylaxis  especially with the use of posttransplant\ncyclophosphamide  given the poor outcome after\nunrelated transplantation and especially in hla\nmismatched unrelated setting and encouraging results in\nfamily haplo identical transplantation  this current study\nproposes to test haploidentical transplantation in\nmyelofibrosis patients without a matched related donor ",
    "OBJECTIVE": "main objective and primary\nendpoint  the main objective is diseasefree survival and without\nrejection one year after haploidentical transplantation in\npatients with primary or secondary myelofibrosis \nthe main criteria of judgement is disease and rejection\nfree survival 12 months after hsct  secondary objectives and\nendpoints  to assess\nincidence of acute gvhd grade 2 4 at 100 days\nincidence of acute gvhd grade 3 or 4 at 100 days\nengraftment at 100 days\nincidence of chronic gvhd at 12 months\nnonrelapse mortality at 12 months\noverall survival at 12 months\nrelapse progression incidence at 12 months\nrejection incidence at 12 months\ntime to neutrophil engraftment at 100 days\ntime to platelet engraftment at 100 days\ninfection incidence at 100 days and at 12 months\ncytokine profile during transplantation  day7   1 day  \nday 0 and day 7   1 day  \nimpact of genetic alterations on overall survival at 12\nmonths and nonrelapse morality at 12 months",
    "DESIGN": "design of the trial  this a phase 2 multicentric study scope of the trial  our goal is to show that haploidentical hsct using\nthiotepa  fludarabine in combination with treosulfan\ngives acceptable results which can even be better than a\ntransplantation from an hla mismatched 9 10 donor  and\nclose to a matched unrelated donor in patients with\nmyelofibrosis",
    "INCLUSION CRITERIA": "population of trial subjects  patients with a myelofibrosis who have no\ncontraindication to transplant and who have an advanced\ndisease by international scores could be proposed to the\ntrial if they do not have an hlamatched donor  inclusion criteria\n \n \n     patients aged between 18 and 70 years\n  primary myelofibrosis or myelofibrosis secondary to\nessential thrombocythemia or polycythemia vera\nproven by marrow biopsy\nthe myelofibrosis should combine at least 2 of the\nfollowing criteria \no constitutional symptoms  weight loss   10 \nin one year  fever  without infection  \nrecurrent muscle  bone or join pains  extreme\nfatigue\no anemia with hemoglobin   10 gr dl or red\nblood cell transfusion requirement\no thrombocytopenia   100 g l\no peripheral blast count   1  at least found 2\ntimes\no white blood cell count   25 g l  before a\ncytoreductive treatment \no karyotype   8  7 7q  i 17q   5  5q  12p \ninv 3   11q23\nperformance status according to ecog at 0  1 or 2\nwith health insurance coverage\nhaving signed a written informed consent   women agreed to take nomegestrol acetate as\ncontraception during and up to 6 months after\ntreatment by treosulfan\n  men agreed not to conceive child during and up to 6\nmonths after treatment by treosulfan",
    "EXCLUSION CRITERIA": "exclusion criteria    myelofibrosis transformed into acute leukemia\n  poor performance status with ecog 3 or more\n  cardiac failure with ef   or   50  currently or in\nthe past  even if corrected after treatment \n  renal failure with creatininemia   130 µmol l or\nclearance   50ml min\n  respiratory function altered with vital capacity  \n70  or forced expired volume   70 \n  biological significant liver abnormalities  asat or\nalat  2 x normal range  bilirubin   1 5 x normal\nrange\n  hla matched donor available\n  tutorship or curatorship\n  unwilling or unable to comply with the protocol\n  pregnant woman or breastfeeding\n  contraindications to treosulfan\no hypersensitivity to the active substance\no active noncontrolled infectious disease\no fanconi anaemia and other dna\nbreakage repair disorders\no administration of live vaccine\n  contraindications or any circumstance that\nprecludes the use of the drugs involved in the\nprotocol  especially thiotepa and fludarabine ",
    "INTERVENTION": "investigational medicinal\nproduct  treosulfan  the investigational medicinal product  will be\nused in conditioning regimen for haploidentical\ntransplantation \ntreosulfan  which received euwide approval for toxicity\nreduced conditioning therapy prior to allogeneic\nhaematopoietic stem cell transplantation on june 25\n2019  will be provided by medac \ntreosuflan  in the conditioning regimen will be\nadministered as followed  \n10 gr m2 per day at 4  3 and 2  iv route \nit will be used in combination with the standard\nassociation \nthiotepa 5 mg kg on day 6\nfludarabine 30 mg m2 per day from day 5 to day 1\ntherefore thiotepa and fludarabine  indissociable of\ntreosulfan will be also considered as medicinal product comparator treatment  na",
    "STATISTICS": "statistical analysis  the analysis will be based on the intenttotreat basis  that\nis  including all patients whatever they were administered\nthe treatment under study or not  a sensitivity analysis will\nbe performed in patients who will actually receive the\ngraft  only patient consent withdrawals with positive\nreport of not using their data  if any  will be excluded \nbaseline summary statistics  namely percentages or\nmedian  interquartile range  iqr   will be performed \nthe right censored endpoint will be estimated using\nnonparametric methods  kaplan meier curves and\ncumulative incidence curves will be considered in case of\nnoninformative or informative censoring based on the\nlogrank test or the gray test  respectively  adjustment on\npotential confounders will used the cox proportional\nhazards models  model assumptions will be checked\nusing a test for proportional hazards and spline smoothing\nof residuals for the loglinearity assumption \nstatistical analyses will be performed on sas  sas inc \ncary  nc  and r  https   www rproject org   software\npackages ",
    "DSMB": "trial will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym  fibraplo",
    "INVESTIGATOR": "coordinating investigator  dr marie robin\nhôpital saintlouis  aphp  paris",
    "NUMBER OF INCLUSIONS": "number of subjects included  28",
    "SITES": "number of sites  22",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  industrial grant"
  },
  "SONIMEL": {
    "TITLE": "full title  safety and efficacy of blood brain barrier  bbb  opening with\nimplantable device sonocloud  combined with nivolumab\nused alone or an association with ipilimumab in brain\nmetastases from patients with malignant melanoma",
    "JUSTIFICATION": "scientific justification  anti pd1 monoclonal antibodies  nivolumab and\npembrolizumab  alone or in association with antictla4\n ipilimumab  are established as indisputable treatment of\nmetastatic melanoma  with unprecedented overall survival \nand are indicated for firstline treatment including patients with\nbraf mutation  given their high molecular weight  their\npenetration in the brain sanctuary is uncertain and relies on\ndisruption of the bbb which occurs occasionally \nsonocloud  is an implantable device delivering low intensity\npulsed ultrasound  us   along with systemic injection of an us\nresonator  sonocloud  demonstrated safe and efficient at\nrepetitively opening the bbb \nwe anticipate that bbb opening could help at increasing brain\npenetration of monoclonal antibodies and potentially boosting\nimmunity in the brain  this could translate in controlling brain\ndisease with the same magnitude as for extracranial disease \nthis would also open avenues for optimizing the treatment of\nbrain metastases in combination with checkpoint inhibitors in\nmany other cancers ",
    "OBJECTIVE": "main objective and\nprimary endpoint  one single objective  one single endpoint\nthe main objective will be the determination of the most\nsuccessful dose  msd   defined as the dose with the highest\nprobability of bbb opening efficacy without toxicity directly\nrelated to the ultrasound emission \nprimary endpoint \nsuccess defined as grade 2 or 3 bbb opening disruption with\npulsed us using the sonocloud  system without toxicity\nrelated to the device assessed clinically and using brain mri\n dlt evaluated during the first 4 weeks of treatment for\nnivolumab alone and 6 week of treatment for nivolumab  \nipilimumab \nthus  the primary endpoint will be the success defined as\nefficacy without toxicity during the first 4 weeks of treatment for\nnivolumab alone and 6 week of treatment for nivolumab  \nipilimumab  secondary objectives and\nendpoints  secondary objectives \n clinical efficacy of nivolumab    ipilimumab in the context of\nbbb opening in the study population\nsafety of nivolumab alone or combined to ipilimumab in the\ncontext of bbb opening secondary endpoints \n best overall response rate and orr at 3 months\n best intracranial overall response rate  bicorr  and icorr\nat 3 months\n best extracranial overall response rate  becorr  and\necorr at 3 months\n progression free survival  pfs  at 3 months 6 months  12  \n18 and 24 months\n intracranial progression free survival  intracranial ipfs  at 3\nmonths 6 months  12   18 and 24 months\n extracranial progression free survival  extracranial epfs  at\n3 months 6 months  12   18 and 24 months\n overall survival  os  at 4 months 6 months  12   18 and 24\nmonths\n safety using ctcae version 5 0\nclinical activity will be assessed using tep tdm scans\n extracranial lesions  and mri  intracranial metastases  \nclinical objective response rate  orr   defined with the rano\nand immunotherapy rano and recist version 1 1 and the\nimmunerelated response criteria  and pfs defined as time\nfrom day 1 of immunotherapy perfusion and sonication to\ndisease progression  according to the recist version 1 1and\nrano  and the immune related response criteria or death \nwhichever is first ",
    "DESIGN": "design of the study  21 patients treated at maximum\nconsidering that a maximum of 10  would withdraw from\nparticipating in the research a budget for 21 2   23 patients\nwill be considered",
    "INCLUSION CRITERIA": "population of study\nparticipants  advanced brain metastases melanoma patients \nage   18 years inclusion criteria   patients with histologically confirmed metastatic\nmelanoma\n patients must have recovered from all side effects\nof their most recent systemic or local treatment for\nmetastatic melanoma  grade   1  \n at least one measurable brain metastasis between\n5mm and 35mm in diameter  not previously treated\nwith surgery and or radiosurgery and located less\nthan 5 cm from the skull\n patients may have received or not prior\nradiosurgery and or surgery for brain metastases  if\nthey have received prior local treatment  they must\nhave at least 1new rano and recist assessable\nbrain metastases \n braf status wild type or mutated  and in that case\nprevious treatment with braf inhibitor and mek\ninhibitor allowed \n eastern cooperative oncology group  ecog \nperformance status  ps    1 \n age   18 years\n hemoglobin  10g dl\n platelets   100000mm3  neutrophils   1500 mm3\n creatinine clearance   50ml mn\n ast   3n\n alt   3n\n total bilirubin   1 5n\n alkaline phosphatase   3n\n inr   1 5\n prothrombin   70 \n tca   1 2\n no hepatocellular insufficiency\n no unhealed wound on the head\n no allergy to poly isoprene\n signed informed consent\n patient with health insurance coverage\n life expectancy   3 months",
    "EXCLUSION CRITERIA": "noninclusion criteria   ocular melanoma\n symptomatic leptomeningeal involvement \n symptomatic hemorrhagic brain metastases \n symptoms of incoercible intracranial pressure \npatients receiving corticosteroids and patients\npresenting intermittent seizures can be enrolled if\nthey have a stable dose of corticosteroids   \n30mg day corticotherapy  and antiepileptic\ntreatment since at least 2 weeks before enrolment \n indication for urgent neurosurgery or radiotherapy\n prior malignancy active within the previous 2 years\nexcept for locally curable cancers that have been\napparently cured or stage i untreated chronic\nlymphoid leukemia \n known hiv infection and any ongoing infectious\ndisease or significant background \n concurrent administration of any anticancer\ntherapies other than those administered in this\nstudy \n treatment with any cytotoxic and or investigational\ndrug  antictla4 or targeted therapy   4 weeks or  \n5 halflives for targeted therapies or chemotherapy \nprior to day 1 of study \n prior whole brain radiotherapy\n pregnant or lactating women\n patient with auto immune disease\n contraindications to nivolumab alone or an\nassociation with ipilimumab as defined in spc\n https   www vidal fr substances 24410 nivolumab  \n serious or uncontrolled medical disorders that  in\nthe opinion of the investigator  may increase the risk\nassociated with study participation or study drug\nadministration impair the ability of the patient to\nreceive protocol therapy  or interfere with the\ninterpretation of study results \n allergy to iodine  gadolinium  lidocaine\n contraindications to sonovue   \nhypersensibility to sulfur hexafluoride \nrecent acute coronary syndrome or unstable\nischemic heart disease congestive heart failure   class iii or iv as defined\nby new york heart association\nconcurrent treatment with dobutamine\nsevere pulmonary arterial hypertension\nuncontrolled systemic hypertension\nrespiratory distress syndrome\n concurrent treatment for the cns   such as\n benzodiazepin  or any other sedative hypnotic \n antihistaminic\n pro convulsing drug\n butyrophenons  phenothiazin or any other\n conventional  antipsychotic\n barbituric\n mao inhibitor\n anticholinergic\n any other drug according investigator to cause\ncerebral toxicity due to bbb opening\n concurrent anticoagulant or antiplatelet therapy\n uncontrolled epilepsy\n mri contra indication  claustrophobia  intracorporal\nmetallic material  \n phlebitis  active pulmonary embolism\n prisoners or subjects who are involuntarily\nincarcerated\n psychological  familial  sociological  or\ngeographical conditions that potentially hamper\ncompliance with the study protocol and followup\nschedule  those conditions should be discussed\nwith the subject before registration in the trial\n treatment with any drugs authorized under special\nconditions of stable dosage   1 month prior inclusion \n  inhibitors of acetylcholine esterase  i e   donepezil aricept \ngalantamine  rivastigmine  memantine\n  atypical antipsychotics  eg quetiapine \n  antidepressants  other than mao inhibitors and\nanticholinergics  dose  20 mg   kg\n  thyroid hormones exclusion criteria     implantation of the sonocloud  not possible according\nto neurosurgeon  any patient morphological\ncharacteristics  e g  skin characteristics  bone thickness \nother   which  from neurosurgeons  opinion  prevent\nimplantation of the device or may impair the ability of the\npatient to receive treatment with sonocloud   would be\nexcluded ",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis  an adaptive bayesian doseescalation model  continual\nreassessment method  crm  will be used  the selected\nversion of the crm is a modelbased design  where the dose \ndlt relationship is modelled through a cumulative function\ncorresponding to a oneparameter power model  the parameter\nof which is sequentially estimated from the data via a bayesian\nestimation  in this setting  the mtd is a populationparameter \nand refers to the π 10th percentile of the dosetoxicity\nrelationship \na total of 3 us dose levels will be evaluated  0 78  0 9 and 1 03\nmpa   a minimum of three patients will be included at each\ndose level \nas of october 3  2022  3 patients were treated at level 1\n 0 78mpa  and 1 patient was at level 2  0 9mpa   no side\neffects or toxicity were observed  very good tolerance  \nsince the crm design recommends that a new patient could\nbe treated at the higher level  1 03mpa   the patient n 5 will\nreceive the 1 03mpa dose ",
    "DSMB": "trial will have a data\nsafety monitoring board  yes",
    "ACRONYM": "acronym  sonimel 01",
    "INVESTIGATOR": "coordinating investigator  pr céleste lebbe\nservice de dermatologie 2\nhôpital saint louis\n1  avenue claude vellefaux  75 010 paris\ntel   0142499590   fax  0142499078\nemail   celeste lebbe aphp fr",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of monetary\nsupport  phrc 2016"
  },
  "DREPA-RIC": {
    "TITLE": "full title  a prospective multicenter trial comparing allogeneic matched\nrelated haematopoietic stem cell transplantation after a reduced\nintensity conditioning regimen  with standard of care in\nadolescents and adults with severe sickle cell disease",
    "JUSTIFICATION": "scientific justification  although the survival of children with sickle cell disease  scd \nhas dramatically improved over the last decades in the us and\neurope  mortality remains high in adults  moreover  many\nchildren and most adults develop a chronic debilitating\ncondition due to organ damage  allogeneic hematopoietic stem\ncell transplantation  hsct  is currently the unique curative\napproach  it allows the cure of more than 95  of children\ntransplanted from a matched related donor  mrd  after a\nmyeloablative conditioning regimen 1   2   to date  few studies\nhave addressed the role of hsct in scd adults  due to the risk\nof graft versus host disease  gvhd  and to the toxicity\nexpected in older patients with a higher risk of organ damage \nthe development of safe  nonmyeloablative conditioning\nregimens that allow stable mixed chimerism and avoid gvhd\nappears as an attractive option for hsct to cure adults with\nsevere scd  four groups have previously reported encouraging\nresults in a total of 81 patients transplanted from matched\nrelated mobilized peripheral blood cells after a non\nmyeloablative conditioning regimen  alemtuzumab and low\ndose of total body irradiation  tbi   followed by posttransplant\nsirolimus  these studies demonstrate a high scd free survival\nrate  no death related to transplant  6 graft failures  and no\ngvhd  ninety two percent of these patients were cured with\nnormalized hemoglobin levels  resolution of hemolysis and\nstable hemoglobin a levels identical to the proportion observed\nin the donor 3 6   however  outcome comparison of patients\ntransplanted with patients not transplanted are lacking  we\ndesign a prospective multicenter trial targeting patients over 15\nyears with severe scd  and compare nonmyeloablative\ntransplant  when a matched related donor  mrd  is identified \nversus no hsct  for patients lacking mrd  ",
    "OBJECTIVE": "main objective and primary\nendpoint  the main objective is to assess the benefit of hsct on the 2\nyear event free survival calculated from inclusion  compared to\nstandard care  the primary endpoint is the 2year event free\nsurvival  an event is defined as \na  death from any cause\nb  or an acute grade iiiv gvhd according to the magic\nconsortium 2016  appendix 20 3  or a moderate or severe\nchronic gvhd according to the nih classification \nc  or 3 hospitalizations for voc defined according to usual\ncriteria\nd  or one acs defined by usual clinical criteria and a\npulmonary infiltrate on chest film and or thoracic\ncomputedtomography  ct  scan\ne  or a stroke defined as a clinical event confirmed by an mri\nor a cerebral or cervical stenosis   25  in a new territory \nevaluated by mri and mra or apparition of a silent\ninfarct\nf  or increased of at least  10  of tricuspid regurgitation\nvelocity   confirmed by 2 echocardiographies performed\nwith a delay of at least 3 months  compared with pre\ninclusion value for patients with trv   2 7 at inclusion\nwe hypothesize that the 2year event free survival will be of\n80  after hsct versus 40  in the notransplant group  secondary objectives and\nendpoints  the secondary objectives \ncompare in the both groups at 2 years \n  overall survival\n  total days requiring hospitalization after the first 5\nmonths postinclusion \n  acute complications of scd  voc  acs  priapism\n  stroke  silent infarct  cerebral or cervical stenosis on\nmra mri\n  hemolytic index  hematologic and biochemical\nparameters\n  organ function  kidney  eyes  heart  lung  liver  bone \n  grade iiiiv infectious complications\n  need for transfusion from 6 months postinclusion\n  alloimmunization rate\n  iron overload\n  chronic used of oral opioids\n  nutritional involvement\n  gonadic function and fertility\n  quality of life  anxiety and depression\n  cost\nto evaluate in the transplant group  chimerism  engraftment \ngvhd  patients free of sirolimus at 1 and 2 year posttransplant\nthe secondary end points \n  death\n  number of days requiring hospitalization with\nexclusion of the 5 first months postinclusion\n  clinical adverse events  number of voc and acs\nrequiring hospitalization  number of hospitalization in\nintensive care unit\n  number of priapism\n  number of stroke   changes in biological parameters  ldh \naminotransferase  gammagt  alkaline phosphatase \nbilirubin  pr  aptt  hemoglobin level  hematocrit \nmean corpuscular volume  percentage of hemoglobin\nvariants  reticulocyte  white blood cells and platelets\ncounts  estimated glomerular function rate\n  microalbuminuria creatininuria ratio\n  ferritin and transferrin saturation level\n  gonadic function  spermogram in men  lh  fsh \noestrogen in women  testosterone in men at m24 \nnumber of amenorrhea in women  number of parity\n  eye function\n  heart  pulmonary hypertension  auricular or\nventricular dilatation  left ventricular mass and\nfunction  by a transthoracic echocardiography \n  lung function  pulmonary function tests  6 min walk\ntest \n  bone function  new episode of avascular osteonecrosis\nand of fracture\n  central nervous system function   with mra mri \n  liver and heart magnetic resonance imaging for iron\noverload evaluation in patients with ferritin  1000\nmicrog l at the inclusion  m12 and m24\n  number of red blood cell packed transfused from 6\nmonths postinclusion\n  number of delayed hemolytic transfusion reaction\n dhtr \n  oral opioid consumption\n  quality of life questionnaire  mos sf36 \n  hospital anxiety and depression scale  hads \nquestionnaire\n  change in weight\n  severe infections  ctae score  grade 34 \n  gvhd incidence and grading in hsct patients\n  chimerism in hsct assessed on total blood population\nand t lymphocyte subset\n  cost  evaluated by the days of hospitalization from the\ninclusion",
    "DESIGN": "design of the study  quasi experimental design  phase 3  prospective controlled\nmulticenter  cohort study with 2 groups of patients defined by\ngenetic randomization \nonce the eligibility criteria and the informed consent have been\nobtained  hla typing will be performed to identify potential\nhla mrd and define 2 groups \n  group 1  exposed  patients  if an hla identical sibling is\nidentified  patients will receive hsct\n  group 2  unexposed patients   patients lacking an\nhla identical sibling will received the best standard\ncare\ntransplant arm \n redcell exchange will be performed to reduce hemoglobin s\nlevels to 30  or less during the 3 months preceding transplant  the conditioning regimen will consist in 300cgy tbi at d2\nand alemtuzumab iv  total dose  1mg kg  for 5 days  d7 to\nd3 \n the stem cell source will be gcsf mobilized peripheral\nblood stem cells  cd34 target dose is 10 x 106 or more per kg\nbody weight \n gvhd prophylaxis will consist in sirolimus for during 1 year \nthen sirolimus will be tapered and stopped at 15 months post\ntransplant \nno transplant arm  patients will receive the best standard care\naccording to their situation and their previous treatment \ninitiation of hydroxyurea  continuation or optimization of the\ndose of hydroxyurea  initiation or continuation of transfusion\nprogram  tp   initiation of a new drug proved to improve scd\nand having authorization to use in france ",
    "INCLUSION CRITERIA": "population of study participants  adolescents and young adults  1545 years  inclusion criteria of patients    scd patients  ss sβ0 \n  aged 15 to 45 years\n  with at least one nonscd sibling   16 years from the\nsame parental couple\n  who presented at least one of the following criteria \n 2 voc requiring hospitalization over the last 2 years\n at least 1 severe acs within the past 2 years defined\nas followed  acs requiring red cell transfusion  or\nhospitalization in intensive care unit  or acs with pao2\n  60mmhg or arterial blood ph   7 35 or pac02  \n50mmhg or need more than 4 liters of 02  mn for\nreaching sat02   98 \n 1 voc requiring hospitalization over the last 2 years\nand history of recurrent acs  three or more \n history of ischemic stroke or cerebral cervical arterial\nstenosis   25  or apparition of silent infarct in the last 2\nyears\n pulmonary hypertension defined by mean pulmonary\nartery pressure   25 mmhg at rest  determined by right\nheart catherization\n osteonecrosis of at least 2 joints including one\ndiagnosed in the past 2 years \n sickle nephropathy  estimated glomerular filtration\nrate  by ckd epi formula   100 ml min 1 73m2 and\npersistant microalbuminuria\n microalbuminuria creatininuria ratio  10 mg mmol \nwithout other cause of nephropathy \n  requiring treatment with hydroxyurea or chronic\ntransfusion  or already treated by hydroxyurea or\ntransfusion program  tp  at inclusion \n  for   patients already receiving chronic transfusions for\nvoc or acs not responding to hydroxyurea   they will\nbe eligible  if they provided before the beginning of\nchronic transfusions at least  \n 2 voc requiring hospitalization over the last 2 years\n at least 1 severe acs within the past 2 years defined\nas followed  acs requiring red cell transfusion  or\nhospitalization in intensive care unit  or acs with\npac02   60mmhg or arterial blood ph   7 35 or pac02   50mmhg or need more than 4 liters of o2 mn for\nreaching sat02   98 \n 1 voc requiring hospitalization over the last 2 years\nand history of recurrent acs  three or more \n  contraception during all the study period by sirolimus\nfor women of child bearing potential\n  signed informed consent\n  amenable to hla typing  hsct if an hlaidentical\nsibling is available \n  patients affiliated to the french health care insurance inclusion criteria of donors    age  16 to 60 years\n  hb electrophoresis  aa  as or ac\n  donor with usual clinical and biological eligibility\ncriteria for gcsf mobilization and peripheral blood\nstem cell bone collection including legal viral\nserologies assessment authorizing the transplant\n  being hla identical with the patient\n  negative covid19 test at time of hsct mobilization\nin patient with several potential donors  several matched sibling\ndonor   abo matched donor will be chosen in priority ",
    "EXCLUSION CRITERIA": "exclusion criteria of patients    performance status  ecog scale 1\n  pulmonary function  fev1 et fvc   50  of the theorical\nvalue\n  post capillary and severe precapillary pulmonary\nhypertension with measured mean pulmonary artery\npressure at rest  35 mmhg\n  cardiac ejection fraction   45 \n  estimated glomerular fraction rate  gfr   50ml mn\n 1 73m2\n  conjugate bilirubin  50 µmole l  cirrhosis  alat 4n\n  severe uncontrolled infection\n  known hypersensitivity of alemtuzumab\n  known hypersensitivity to murin proteins and to the\nfollowing excipients  disodium edetate  polysorbate 80 \npotassium chloride  potassium phosphate monobasic \nsodium chloride  dibasic sodium phosphate  water for\ninjections\n  positivity for hiv\n  pregnancy or breastfeeding women\n  alloimmunization or delayed hemolytic transfusion\nreaction precluding red cell transfusions\n  previous solid organ transplant or hematopoietic stem cell\ntransplant \n  uncontrolled hypertension\n  history of arterial dissection of the cervicocephalic arteries\n  history of angina pectoris or myocardial infarction",
    "INTERVENTION": "comparator arm  patients will receive the best standard care according to their\nsituation and their previous treatment  initiation of\nhydroxyurea  continuation or optimization of the dose of\nhydroxyurea  initiation or continuation of tp  initiation of a\nnew drug proved to improve scd and having authorization to\nuse in france ",
    "STATISTICS": "statistical analysis  a single efficacy analysis is planned  efs will be compared\nbetween two groups using logrank test  and the effect of hsct\nassessed by hazard ratio using a cox model  the primary\nendpoint is event free survival at 2 years calculated from\ninclusion  event will be defined as followed \na  death from any cause\nb  or an acute grade iiiv gvhd according to the magic\nconsortium 2016  appendix 20 3  or a moderate or severe\nchronic gvhd according to the nih classification \nc  or 3 hospitalizations for voc defined according to usual\ncriteria\nd  or one acs defined by usual clinical criteria and a\npulmonary infiltrate on chest film and or thoracic\ncomputedtomography  ct  scan\ne  or a stroke defined as a clinical event confirmed by an mri\nf  or a cerebral or cervical stenosis   25  in a new territory \nevaluated by mri and mra\ng  or increased of at least  10  of tricuspid regurgitation\nvelocity   confirmed by 2 echocardiographies performed\nwith a delay of at least 3 months  compared with pre\ninclusion value for patients with trv   2 7 at inclusion\nh  or apparition of a silent infarct or a cerebral cervical\nstenosis  25  in a new territory  or increase  25  of\nprevious stenosis evaluated mri and mra\nevent free survival at 2 years calculated from inclusion will\nalso be described in the hsct group  overall survival will be\ndefined as the time between date of inclusion and death due to\nany cause or to date of last followup  a propensity score\nmatching analysis will be also performed as a sensitivity\nanalysis to handle potential residual imbalances between arms\nin confounders \na sequential analysis of tolerance data will be performed  using\nbayesian methods \nwe hypothesize that the 2year event free survival will be of\n80  after hsct versus 40  in the notransplant group ",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  dreparic",
    "INVESTIGATOR": "coordinating investigator  dr nathalie dhedin\nhematology  saint louis hospital  aphp  paris  scientific director  adult scientific director \ndr jean benoit arlet\ninternal medicine\ngeorges pompidou hospital  aphp  paris\npediatric scientific director \ndr corinne pondarre\npediatric hematology\nchi créteil",
    "NUMBER OF INCLUSIONS": "number of participants included  78 patients",
    "SITES": "number of valued sites  37 centres  22 recruiting centres and 15 transplant centres\n some recruiting site  also transplant patients ",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of monetary support  french ministry of health  phrc n2017"
  },
  "PARADISE": {
    "TITLE": "full title  prospective randomized controlled trial of crohn s disease exclusion diet vs\ncorticosteroids in adults and pediatric patients with active crohn s disease",
    "JUSTIFICATION": "",
    "OBJECTIVE": "main objective and\nprimary endpoint  main objective  to assess whether cded is superior to corticosteroids  in terms of\nendoscopic response  in patients with mildly to moderately active  luminal \ninflammatory cd \nprimary endpoint  endoscopic response at week 16  without corticosteroids or\nfurther therapeutic intervention  assessed by a centralized  pseudonymized and\nblinded  double lecture panel of panenteric pillcam crohn s capsule  pcc  \nendoscopic response is defined by a decrease of at least 50  in the lewis score for\npatients with small bowel cd  decrease of sescd of at least 50  in patients with\ncolonic cd and both of these in patients with small bowel and colonic cd \ncompared to baseline values  secondary\nobjectives and\nendpoints  compare between the 2 arms of the trial \n  steroidfree  clinical remission  hbi  5  and response  a decrease of at least 3\npoints in hbi \n  steroidfree  clinical remission  cdai  150  and response  a decrease of at\nleast 70 points in cdai \n need for further therapeutic intervention  i e   steroids  immunosuppressants \nnew biologic or surgery \n decrease of fecal calprotectin of at least 50  off steroids \n fecal calprotectin of less than 250 µg g  less than 100 µg g and less than 50\nµg g\n crp serum level\n median hbi  cdai  calprotectin and crp\n endoscopic remission as defined as lewis score  135 in the small bowel and or\nsescd 02 in the colon  without further therapeutic intervention  surgery \nbiologics or dietary intervention \n endoscopic response and remission graded by eliakim scores\n segmental endoscopic response and remission\n gut microbiota composition  pcr 16s  pcr 18s for fungi and protists \nmetabolomics and shotgun metagenomics \n compliance to corticosteroid treatment  medication adherence report scale\n compliance to cded \no dietary habits questionnaires\no 72h food diaries\n body weight  arterial pressure and fasting serum glucose\n safety will be assessed by the adverse events  either severe or not  and the\nsusar  quality of life will be assessed by short ibdq\n work productivity and activity will be assessed by the wpai questionnaire",
    "DESIGN": "design of the study  this is a multicentre  openlabel  comparative  randomized  2 1  controlled  single\nblind  superiority",
    "INCLUSION CRITERIA": "population of study\nparticipants  patients with active crohn disease inclusion criteria   patients aged 16 to 70 years \n with mild to moderate  luminal  active cd  defined by a hbi of 5 to 16 \ninvolving the small bowel  and or the colon\n not treated with corticosteroids at baseline\n patients either naïve or previously exposed to a maximum of two classes of\nbiologics or currently receiving a biologic therapy  and exposed to a\nmaximum of two classes of biologic therapy  including the current one\n patent small bowel as assessed by the patency capsule\n active endoscopic lesions  as defined by lewis score   225 in the small bowel\nand or sescd  4 in the colon  the eligibility of the patient will be determined\nby at least one central reader \n informed consent to participate in this study \n in patients from france and israel who are aged less than 18  parents \ninformed consent to participate in this study  parents  agreement is not\nrequired in patients aged 16 to 18 in the netherlands \n affiliation to social security or any health insurance",
    "EXCLUSION CRITERIA": "exclusion criteria   inability to follow the cded during 16 weeks \n prior intolerance to corticosteroids \n ongoing infections  evolving virus diseases \n live vaccines \n psychotic state not controlled by treatment \n arthritis or uveitis as main presenting symptoms \n patients with severe and or predominant rectal or perianal disease \n heavy smokers  more than 10 cigarettes per day  \n infliximab  adalimumab  vedolizumab  ustekinumab  rizankizumab \nupadacitinib  methotrexate or azathioprine initiated less than 3 months before\ninclusion in this trial \n change in methotrexate  azathioprine  infliximab  adalimumab  vedolizumab \nupadactinib  risankizumab or ustekinumab dosage less than 2 months before\ninclusion \n severe pubertal delay  tanner 1 or tanner 2  and or height velocity zscore  \n2 5 and or bone mineral density zscore  hip or lumbar spine   2 5  if known  \n pregnant or lactating women \n patients already included in a biomedical research other than an observational\nstudy  e g  registry  cohort  biobank   persons deprived of their liberty by a\njudicial or administrative decision  persons subject to psychiatric care under\nsections l 32121 and l 32131 and persons admitted to a health or social\ninstitution for purposes other than research  l 11216  in france\n present or past history of eating disorder including anorexia nervosa",
    "INTERVENTION": "comparator arm  oral corticosteroids  prednisolone or budesonide ",
    "STATISTICS": "statistical analysis  it will be based on the intenttotreat principle  itt  \nbased on the available literature  we hypothesize that 50   of patients will reach\nthe primary endpoint in the cded arm versus 20  in the corticosteroid arm  we\nplan to screen 140 patients to include 80 patients  54 will be randomized to cded\nand 26 to corticosteroids ",
    "DSMB": "data safety\nmonitoring board  no  because there is no expected safety issue raised by cded  however  longterm compliance of een is poor    it is aimed to restore intestinal barrier and improve microbiota composition   it is aimed to restore intestinal barrier and improve microbiota composition",
    "ACRONYM": "acronym reference  paradise",
    "INVESTIGATOR": "coordinating\ninvestigator  prof franck carbonnel\naphp  chu kremlinbicêtre\nservice de gastroentérologie\nuniversité paris saclay\n78  rue du général leclerc  94275  le kremlinbicêtre cedex france\nfranck carbonnel aphp fr",
    "NUMBER OF INCLUSIONS": "number of\nparticipants\nincluded  80 randomized\nabout 140 screened",
    "SITES": "number of centres  17 in france  israel and the netherlands",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  phrc  nestlé  gift of a patient"
  },
  "MARVEL": {
    "TITLE": "full title   exploring venlafaxine pharmacokinetic variability by a phenotyping\napproach  ",
    "JUSTIFICATION": "scientific justification  regarding the direct costs and the social value of depression  the\ndecision of an antidepressant treatment prescription must be\noptimized as much as possible  the development of a personalized\nmedicine in psychiatry may reduce treatment failure  intolerance or\nresistance  and hence burden and costs of affective disorders \nthere is hope that biomarkers will be found to guide treatment\nselection  it might be of decisive interest to be able to assess an\nindividual s metabolism activity  we propose here to explore the\nrelationship between the activity of drugmetabolizing enzymes  dme \nand transporters assessed by a phenotypic approach and the\nefficacy of antidepressants  we will focus on venlafaxine  v  that\nprovides a reasonable secondstep choice for patients with\ndepression and is used extensively in psychiatric practice  and the\nmetabolism of which involves several cytochromes  cyp  p450\nenzymes and the transporter pgp ",
    "OBJECTIVE": "primary objective  to study the correlation between the concentration of v and its\nmetabolite odesmethylv  v odv  and drug metabolism variability\nassessed by a phenotypic approach  secondary\nobjectives  to compare between responders and non responders  as well as\nbetween patients with or without side effects \n the cyp2c19 activity and the prevalence of each profile of\nmetabolism\n the cyp2d6 activity and the prevalence of each profile of\nmetabolism\n the cyp3a4 activity and the prevalence of of each profile of\nmetabolism\n the pgp activity and the prevalance of each profile of\ntransport\nto study the correlation between v odv concentration dose and\nv odv concentration and antidepressant efficacy and tolerance to study the correlation between the ratio odv v and cyp2d6\nactivity\nto study the correlation between the concentration at 2 hours and the\nauc  2 3 6 hours  of the metabolic ratio\nhydroxyomeprazole omeprazole\nto conduct exploratory association analyses between blood\nbiomarkers  candidate mrna and mirna  and the tolerance and\nefficacy of v\nto analyse the role of genetic variations of dna in the determination\nof cyp2c19 and 2d6 phenotypes  in patients with pm profile  criteria of\nassessment     v odv  concentration\n  the cyp2c19 activity  5hydroxyomeprazole omeprazole at 2\nhours and auc of the metabolic ratio 2  3 and 6 hours after\n2 3 6\nomeprazole oral administration\n  the cyp2d6 activity  dextrorphan dextromethorphan ratio two\nhours after dextromethorphan oral administration\n  the cyp3a4 activity  1hydroxymidazolam  midazolam ratio two\nhours after midazolam oral administration\n  the pgp activity  fexofenadine auc based on fexofenadine\n2 3 6\nconcentrations at 2  3 and 6 hours after fexofenadine oral\nadministration\n  antidepressant efficacy  madrs  hamd  qids\n  antidepressant tolerance  prisem  fisber\n  antidepressant observance  mars\n  circulating mrna and mirna transcripts\n  allelic variations  cyp2c19 2* and cyp2d6 4* and 5*",
    "DESIGN": "experimental design  interventional study  recherche biomédicale ",
    "INCLUSION CRITERIA": "population involved  patient with major depressive disorder and madrs   20\ndespite 4 weeks of v regardless of the dose inclusion criteria  patient  hospitalized or outpatient  with major depressive disorder\nand madrs   20 at visit of selection\npatients non responders to v after 4 weeks of v regardless of the\ndose\ndecision of the psychiatrist to increase the dose of v at visit of\nselection\nmale and female age   18 years understanding of french language\nand able to give a written inform consent \ninformed consent signed to participate to the study\nindividuals covered by social security regimen",
    "EXCLUSION CRITERIA": "noninclusion\ncriteria  patients treated by more than one antidepressant other than\nmirtazapine or mianserine\npatients currently treated with one of the drug substrate of the cocktail\nand or by esomeprazole\nsensitivity or contraindication to any of the substrate drugs used\ncurrent pregnancy  desire to get pregnant  or breastfeeding\nbipolar disorder and schizophrenia",
    "INTERVENTION": "challenge agents  for the assessment of drugmetabolizing enzyme activity  the patients\nwill be given the cocktail probe drugs  by oral route  one time\nduring the study \n  a capsule of omeprazole 10mg\n  6 8 ml of an oral liquid formulation of dextrométhorphane\nbromhydrate  tussidane 1 5mg ml   syrup \n  1 mg of an injectable solution of midazolam for oral\nadministration  midazolam 1mg ml  injectable solution \n  a tablet of fexofenadine 120mg",
    "STATISTICS": "statistical analysis  the statistical analysis will be performed once the sample size has\nbeen reached  and all the end point measures available \nour hypothesis is that the prevalence of patients with a cyp2c19 um\nprofile is twice as high in nonresponders in comparison with\nresponders  who have a cyp2c19 metabolic profile comparable to\nthat of caucasians  20    to demonstrate that the prevalence is two\nfold that observed in nonresponders  with a type i error at 0 05 and a\nstatistical power of 80   the sample size is tabulated below according to the prevalence of response \nthus  to anticipate for potential large disproportion in responders non\nresponders  that will be only defined after study inclusion  we decided\nto include 205 patients  this will allow to control for type i and type ii\nerror rates in the comparison of the prevalence of cyp2c19 um\nprofile among these groups  in addition the sample size will allow to\nstudy sufficient numbers of cyp2d6 pm  im  and um to determine\nthe effects of cyp2d6 variations on v and odv plasma levels and\ntheir efficacy or risk of adverse events \nthe type i error rate will be fixed at 0 05  all tests will be twosided\nand compared thus to 0 05 \nmultiple imputations  which are a popular approach for handling the\npervasive problem of missing data in biostatistics  will be used  it is\nusually performed under a missing at random  mar  assumption \nmultiple imputations by chained equation are to our knowledge the\nmost flexible approach to handle complex patterns of missing data\n including categorical data  quantitative data  and survival data  \nprimary analyses will be performed on an intenttotreat basis \nsecondary exploratory analyses will consider the population of\ncompliers  that is  those who completed the treatment according to\nthe scheduled protocol ",
    "DSMB": "data safety\nmonitoring board\nanticipated  non",
    "ACRONYM": "acronym  marvel",
    "INVESTIGATOR": "coordinating\ninvestigator  frank bellivier\ndepartment of psychiatry\nfernand widal hospital\n200 rue du faubourg saint denis\n75475 paris cedex 10\ninserm umrs 1144 variabilité de réponse aux psychotropes\nuniversités paris descartes   paris diderot\ntel  01 40 05 42 01",
    "NUMBER OF INCLUSIONS": "number of subjects\nchosen  205",
    "SITES": "number of centers  12 clinical centers in france\n7 centers of clinical investigations in france\n4 centers involved in biological analysis  3 in france and 1 in\nswitzerland ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding source  phrc aom 14562\nand for dosages for the determination of phenotypes  department of\npharmacologytoxicology  geneva"
  },
  "PIPAC": {
    "TITLE": "full title  pressurized intraperitoneal aerosol chemotherapy\n pipac  in gastric carcinomatosis \nphase ii randomized study ",
    "JUSTIFICATION": "scientific justification  peritoneal metastasis is a common pattern in advanced\ngastric cancer leading to a terminal condition in a very\nshort time  whatever recent progress regarding systemic\nchemotherapy using multi drugs association median\nsurvival is limited to 6 months with altered quality of life\n qol  after 4 months for all patients  we postulated that a\nnew innovative health technology for delivering\nintraperitoneal pressurized aerosol of chemotherapy\n doxorubicin and cisplatin  during laparoscopy can\ntransform that situation offering to double the survival\nwith qol preservation  interestingly  pipac procedure is\nmade to be applied repeatedly  every 6 weeks     2\nweeks   this therapeutic strategy allows to improved ip\ndrugs impregnation and maintained iv chemotherapy\nmeanwhile \nour pipac estok 01 project is supported by the six main\ncarcinomatosis national centers and should gather\nmedical and surgical teams that daily support peritoneal\ncarcinomatosis  to demonstrate the efficacy of pipac\nprocedure in gastric carcinomatosis and make a radical\nshift in management of these patients that will break with\npast strategies ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective of the clinical study\nthe primary objective is to evaluate and compare 24\nmonth progression freesurvival in patients with\nperitoneal carcinomatosis of gastric cancer treated either\nwith iv chemotherapy and pressurized intraperitoneal\naerosol chemotherapy  pipac  or with iv chemotherapy\nalone  with preservation of quality of life \nprimary endpoint\nthe primary endpoint corresponds to the 24month\nprogression freesurvival  defined as the number of\npatients with no clinical or morphological sign of\nprogression or death 24 months after the treatment  secondary objectives and\nendpoints  secondary objectives and assessment criteria\n  patients related \n the morbidity will be evaluated on postoperative\nday 30 by the clavien dindo classification  i to v \n 17  and the comprehensive complication index \nranging from 0 to 100 and calculated on a website\n https   www assessurgery com about cci\ncalculator   19 \n evaluation of treatmentrelated toxicity based on\nct cae classification  v5 0 \n postoperative pain measured using a numeric rating scale from 0 to 10 from postoperative day\n0 to day 2  every 6 hours  not obligatory during\nsleeping and night break  \n quality of life evaluated at each visit by the patient\nwith the eortc qlqsto22 questionnaire \nspecific to gastric cancer  annexe 19 8  and with\neortc qlqc30 questionnaire  annexe 19 7  \n quality of health status evaluated at each visit by\nthe patient with the eq5d5l questionnaire\n annexe 19 6 \n  treatment related \n feasibility of 3 successive pipac procedures\ndefined as the possibility to perform 3 pipac with\nno problem of access to the peritoneal cavity\n  disease related \n overall survival at 24 months defined as the time\nfrom randomization to death\n secondary resecability rate defined as an ipc   8\nat laparoscopy after the treatment",
    "DESIGN": "design of the trial  prospective  multicenter  randomized  openlabel \ncontrolled  parallelgroup  phase ii clinical trial designed\nto evaluate the effects of pipac with doxorubicin and\ncisplatin on patients with gastric peritoneal metastasis\nand pci 8  scope of the trial  peritoneal carcinomatosis of gastric cancer",
    "INCLUSION CRITERIA": "population of trial subjects  major subjects with peritoneal carcinomatosis of gastric\ncancer inclusion criteria  patients related \n1  age   18 years\n2  performance status  who    2\n3  white blood cells   3 500  mm3  neutrophils  \n1 500  mm3  platelets   100 000  mm3\n4  creatinemia   1 5 mg dl and creatinine\nclearance  60 ml min  and serum total bilirubin \n2 mg dl  \n5  an acceptable nutritional condition with bmi  \n18 5 kg m2 and or albumin   30 g l and or pre\nalbumin   110 mg l\n6  effective contraception for patients of childbearing\nage\n7  written consent obtained prior any act of the\nresearch\n8  patient with social insurance\ndisease related \n9  patient having synchronous or metachronous\nperitoneal  or ovarian  metastasis  pathologically\nproven   of a gastric and or siewert iii\nadenocarcinoma cancer including adci\n adenocarcinoma with independent cells  and or\nlinitis\n10  patients with or without primary gastric tumor can\nbe included\n11  pci  peritoneal cancer index    8",
    "EXCLUSION CRITERIA": "exclusion criteria  patients related \n1  weight loss   20  of total body weight in the last three months\n2  presence of uncontrolled comorbidities including\nsevere chronic disease or organ insufficiency\n3  contraindication to any drug contained in the\nchemotherapy regimen  according to summary of\nproduct characteristic s  rcp \n4  contraindication to cisplatin iv and\ndoxorubicin iv according the summary of\nproduct characteristics in force  allergies  severe\ntoxicity to cisplatin  renal function impairment \ncontraindicated if the calculated  cockcroft\nformula  or measured creatinine clearance is less\nthan 60 ml min  the only measure of creatinine\ndoes not adequately reflect renal function \ncisplatin has cumulative nephrological toxicity  or\ndoxorubicin  risk of cardiotoxicity that can occur\nimmediately or delayed with sinus tachycardia\nand or electrocardiogram abnormalities     cf\nrcp on the following website   http   agence\nprd ansm sante fr php ecodex rcp r0289737 htm \n5  complete deficiency of the enzyme\ndihydropyrimidine dehydrogenase \n6  for patients in arm a  pipac   the debulking\nsurgery  out of ovariectomy or omentectomy  is\nnot permitted during pipac surgical procedure\nscheduled in accordance with the protocol  3\nsuccessive pipac   the debulking surgery after\nthese 3 pipac procedures is authorized \n7  pregnancy or breastfeeding\n8  patient under guardianship\ndisease related \n9  any other malignancies within the last 5 years\n other than curatively treated basal cell carcinoma\nof the skin and or in situ carcinoma of the cervix \nor other systemic metastases  liver  lung  bone \nbrain or lomboaortic lymph node involvement \n10  pleural effusion requiring evacuation for\nrespiratory failure\n11  small bowel occlusion with no possible food\nintake\n12  ascites   3 liters\n13  participation in other clinical trials for the\ntreatment of gastric peritoneal metastasis in the\nyear preceding inclusion",
    "INTERVENTION": "investigational medicinal\nproduct s   intraperitoneal pressurized aerosol of chemotherapy of\ncisplatin 10 5 mg m2 and doxorubicin 2 1 mg m2 during\nlaparoscopy were given for 30 min at 37 c and 12 mmhg\nat 6weeks     2 weeks  intervals  at least 3 successive\npipac are scheduled by the protocol  the patient will\nreceive pipac procedure until progression  toxicity or\nnonfeasibility of the procedure \nthe research is opened by the sponsor only in centers\nthat already practice the pipac procedure as part of the\ntreatment \nthe investigators who will be declared as part of this\nresearch will have to undergo training in the use of this\nnew pipac procedure comparator treatment  patient will receive standard poly chemotherapy\nproposed by the oncologist as eox  epirubicin \noxaliplatin  and capecitabine   ecx  epirubicin  cisplatin \nand capecitabine   folfox  folfiri  ecf  epirubicin \ncisplatin  and fluorouracil  or flot  or any new standard\nvalidated during the study  until progression or toxicity ",
    "STATISTICS": "statistical analysis  the 24month progression freesurvival will be estimated\nusing kaplan meier estimator on the total sample and per\narm  estimation with 95  confidence intervals  ci  will\nbe given  test between survival curves will be performed\nusing logrank test  hazard ratio will be estimated using\ncox model \nsensitivity analyses will be performed considering per\nprotocol population ",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  pipac estok 01",
    "INVESTIGATOR": "coordinating investigator  clarisse eveno  puph  digestive surgery department \nclaude huriez hospital  chu of lille",
    "NUMBER OF INCLUSIONS": "number of subjects included  94 patients  47 in each arm ",
    "SITES": "number of sites  20 participating national centres",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  inca phrc k 2016"
  },
  "JAKAHDI": {
    "TITLE": "full title  jak inhibitor in acquired hemophagocytic syndrome in\nthe intensive care unit",
    "JUSTIFICATION": "scientific justification  hemophagocytic syndrome  hs  is a rare condition that can be\nresponsible for severe organ failure  therapeutic guidelines are\nmainly based on observational studies and expert opinions  no\ntherapeutic advance has been developed for years  explaining\nwhy mortality in hs remains high  icu mortality ranging from\n40 to 70    if etoposide remains the gold standard in critically\nill hs patients  nearly 20  of patients are refractory to this\ntherapy  treatment escalation is common  most often requiring\nthe administration of intensive treatments generating high\ntoxicity \nruxolitinib is the first approved jak inhibitor  it has been\nassociated with improvement of hs manifestations and survival\nin a preclinical murine model  data in humans are scarce but\npromising ",
    "OBJECTIVE": "main objective and primary\nendpoint  we aim to demonstrate that ruxolitinib  in association with\nstandard of care  may reverse organ failure  as represented by\nsofa score  better than standard of care alone in critically ill\npatients with acquired hs\nthe primary end point will be survival with a decrease in sofa\nscore   3 points at day 7  secondary objectives and\nendpoints   to demonstrate that ruxolitinib may improve overall survival\nin hs critically ill patients\n to demonstrate that ruxolitinib may reverse clinical\n temperature  sofa score  and biological  ferritin level  cd25\nsoluble receptor dosage  fibrinogen level  triglycerides level \nhemoglobin level  white blood cells count  platelets count \nmanifestations related to hs\n to analyse the impact of ruxolitinib on biological inflammatory\nmarkers  il2  il6  il10  il12  gmcsf  ifn gamma  tnf\nalpha \n to demonstrate the safety of ruxolitinib in critically ill hs\npatients",
    "DESIGN": "design of the study  this will be a multicenter  national  uncontrolled  phase ii trial \nbased on a fleming 2stage design",
    "INCLUSION CRITERIA": "population of study participants  adult patients older than 18 years inclusion criteria   adult patients older than 18 years\n acquired hemophagocytic syndrome  regardless of etiology \ndefined by the presence of 5 or 6 hlh2004 criteria or hscore\n  200\n admission in the icu\n need for symptomatic treatment of hs in relation with organ\nfailure  as defined by sofa score   4\n informed consent signed \n  by the patient \n  or informed consent signed by a family\nmembers trustworthy person if his condition does not allow\nhim to express his consent in written as per l11116   or in an emergency situation and in the absence of family\nmembers trustworthy person  the patient can be enrolled  the\nconsent to participate to the research will be requested as soon\nas the condition of the patient will allow  \n the inclusion of women of childbearing potential requires the\nuse of a highly effective contraceptive measure  contraception\nshould be maintained during treatment and one day after ",
    "EXCLUSION CRITERIA": "exclusion criteria   moribund  defined by a life expectancy   48 hours \n pregnant or lactating patients  women of childbearing\npotential must have a negative urine or blood human\nchorionic gonadotropin pregnancy test prior to trial entry  \n no affiliation to health insurance \n known hypersensitivity to ruxolitinib \n lactose intolerance \n hypersensitivity to cellulose  microcrystalline  magnesium\nstearate  silica  colloidal anhydrous  sodium starch\nglycolate  type a   povidone k30  hydroxypropylcellulose\n300 to 600 cps \n preexisting decisions of withholding withdrawing care \n history of progressive multifocal leukoencephalopathy\n uncontrolled cutaneous cancer\n persons under psychiatric care that would impede\nunderstanding of informed consent and optimal treatment\nand followup\n adults subject to a legal protection measure  guardianship \ncuratorship and safeguard of justice \n patients deprived of their liberty by a judicial or\nadministrative decision\n participation in another interventional research",
    "INTERVENTION": "investigational medicinal\nproduct s   patients will receive oral ruxolitinib twice a day  10 mg x 2\nduring 28 days  in association with standard of care in hs  comparator treatment  none",
    "STATISTICS": "statistical analysis  based on the 2stage fleming design  an interim analysis will\nbe performed once day 7 status of the 21th consecutively\nenrolled patient has been observed \nterminal analysis  based on the intentiontotreat population \nwill be performed once all patients have been recruited unless\nearly stopping ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  jakahdi",
    "INVESTIGATOR": "coordinating investigator  dr sandrine valade scientific director  dr eric mariotte",
    "NUMBER OF INCLUSIONS": "number of participants included  42  maximal sample size ",
    "SITES": "number of centres  9",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  ministry of health"
  },
  "GRAALL-2014": {
    "TITLE": "",
    "JUSTIFICATION": "",
    "OBJECTIVE": "objectives  primary objective \n  to prospectively validate the new risk model  based on mrd1 response level and\nkmt2a   mll  and ikzf1 gene status by comparing historical results of graall\n2005 with those of graall2014 in an identical population of patients  ph b\nlineage all  aged 18 to 59 years old  \n  to evaluate the efficacy of blinatumomabbased consolidation and maintenance\ntherapy in term of dfs in hr patients  graallquest substudy  by comparing to\nhistorical results of graall2005 in an identical population of patients with hr\nfeatures  graallquest study  \nsecondary objectives \n  to appreciate the tolerance of blinatumomabbased consolidation cycles  in bridge\nto allosct or within further consolidation and maintenance therapy \n  to evaluate mrd level  monitored by igtcr \nto evaluate cumulative incidence of relapse  cir  and nonrelapse mortality\n nrm   diseasefree survival  dfs   and overall survival  os  \n  to evaluate rfs  cir  nrm  and os after censoring at sct in first cr  evaluation criteria  primary evaluation criterion\n  disease free survival  dfs  at 4 years  depending on the status of kmt2a   mll \nand ikzf1 genes and on mrd1 assessed after the induction cure or on d1 of\nconsolidation 1 \n  dfs at 3 years in the graallquest study \nsecondary evaluation criteria\n  cir  nrm  and os \n  dfs  cir  nrm and os after censoring at allosct in first cr \n  mrd followup at different treatment times  cf infra   mrd monitoring  \n  adverse events after blinatumomab  graallquest  ",
    "DESIGN": "type of study  multicenter  open  not controlled study  sr patients \nphase ii  multicenter  open non controlled  graallquest  hr patients ",
    "INCLUSION CRITERIA": "indication  patients aged 1859 years old with de novo phnegative blineageall  graall2014 b\ninclusion criteria  patient \n1  whose blood and bone marrow explorations have been completed before the\nsteroids prephase\n2  aged 18 to 59 years old with not previously treated  including intrathecal\ninjection  blineageall newly diagnosed according to the who 2008 definition\nwith   20  bone marrow blasts\n3  whose karyotype shows no t 9 22  and or the absence in molecular biology of\nbcrabl\n4  with ecog  3\n5  with or without central nervous system  cns  or testis involvement\n6  without other evolving cancer  except basal cell carcinoma of the skin or  in\nsitu  carcinoma of the cervix  or its radiotherapy or chemotherapy treatment\nshould be finished at least since 6 months\n7  having signed a written informed consent\n8  with efficient contraception for women of childbearing age  excluding\nestrogens and iud \n9  with health insurance coverage\n10  who have received or being receiving the steroid prephase\nsecondary all  antecedent of chemo or radiotherapy  can be included  graallquest\ninclusion criteria  patient \n1  included in graall2014 b\n2  with hr ball\n3  ecog   3\n4  in cr after one or two induction cures and having received the three blocks of\nconsolidation n 1\n5  with or without allogeneic donor",
    "EXCLUSION CRITERIA": "graall2014 b\nnon inclusion\ncriteria  patient \n1  with lymphoblastic lymphoma and bone marrow blasts   20   burkitttype\nall  or with antecedents of cml or other myeloproliferative neoplasm\n2  with contraindication to anthracyclines or any other general or visceral\ncontraindication to intensive therapy except if considered related to the all \na  asat  sgot  and or alat  sgpt    5 x uln\nb  total bilirubin   2 5 x uln\nc  creatinine  1 5x uln or creatinine clearance  50 ml mn\n3  myocardial infarction within 6 months prior to inclusion in the trial \ncardiomyopathy  nyha grade iii or iv   lvef   50  and or rf   30  \n4  hiv  htlvi or hcv seropositivity or chronic hbv hepatitis  hbsagpositive  \n5  pregnant  βhcg positive  or nursing woman\n6  not able to bear with the procedures or the frequency of visits planned in the\ntrial\n7  unable to consent  under tutelage or curatorship  or judiciary safeguard \n8  women of childbearing potential not willing to use an effective form of\ncontraception during participation in the study and at least three months\nthereafter  patients not willing to ensure not to beget a child during participation\nin the study and at least three months thereafter\n9  treated with any other investigational agent or participation in another trial\nwithin 30 days prior to entering this study graallquest\nnon inclusion\ncriteria  patient \n1  with ecog status   3 after consolidation 1\n2  with abnormal laboratory values as defined below after consolidation 1 a  ast  sgot  and or alt  sgpt    5 x uln\nb  total bilirubin   1 5 x uln\nc  creatinine   1 5 x uln or creatinine clearance   50 ml min\nd  serum amylase and lipase   1 5 x uln\n3  with active uncontrolled infection  any other concurrent disease or medical\ncondition that is deemed to interfere with the conduct of the study as judged\nby the investigator\n4  nyha grade 34 cardiac disease\n5  infection with human immunodeficiency virus  hiv  or chronic infection with\nhepatitis b virus  hbsag positive  or hepatitis c virus  antihcv positive \nprimary monitoring of asparaginase activity and of ammoniemia  annex 5  has to be done\n48h after the 3rd injection  theoretically d14  and  secondary monitoring has to be done\n48 h after the 6th injection  theoretically d26   for all patients  45 years old  sample\ncollection must be performed immediately before the 7th injection not able to bear with\nthe procedures or the frequency of visits planned in the trial",
    "INTERVENTION": "experimental drug\nprescription\noutside ma  blinatumomab  blincyto     hr patients enrolled in the graallquest study experimental drugs\nprescription\naccording to ma  cyclophosphamide  methotrexate  vincristine  cytarabine  vp16  dexamethasone  6\nmercaptopurin  daunorubicin  idarubicin  prednisone  lasparaginase  granulocyte colony\nstimulating factor  gcsf   reference\ntreatment  induction\nall patients will receive an induction course  patients without hcr at the end of induction\nwill receive salvage therapy \nthe differential diagnosis of ph  blineageall should be done during the prephase  so that\nthese patients receive graaph2014\nigtcr mrd1 level will be evaluated at the end of the induction cycle orat day 1 of the first\nconsolidation phase \nconsolidation 1\nall patients in hcr  after induction eventually followed by salvage  will receive 0  1 or 2\ninterim  standby  blocks before the first consolidation comprising 3 blocks of\nchemotherapy  blocks s1  s2  s3  \nthese standby blocks will allow to recover from potential toxicities of the induction \nnotably hepatic  to avoid modifying the order of the following consolidation blocks and to\nrespect the dosage intensity \nhr versus sr\npatients will be attributed to a risk group during the first consolidation according to mrd1\nlevel  need for salvage to obtain chr  presence of ikzf1 gene deletion and kmt2a   mll \ngene rearrangements \nall hr patients will be proposed the phase ii graallquest study  up to 95 inclusions \nafter this number has been reached  hr patients who would have been eligible for graall\nquest will continue to participate to the study and its followup planned in graall\n2014 b \nigtcr mrd2 level will be evaluated at the end of the consolidation 1 or on day one of\nconsolidation 2 \nconsolidation 2\nafter first consolidation  sr patients will continue the standard protocol and receive the\nconsolidation 2  blocks s4  s5  s6  \n95 hr patients will be traited in phase ii graallquest study and will receive\nblinotumomab  consolidation 2 is composed of 3 blocks  b4  blina   b5  hdarac   b6  hd\nmtx  \nhr versus vhrmrd\nvhrmrd is defined by mrd1  103 or the need of a salvage cure to reach hcr or mrd2  104\npatients eligible for allosct with a suitable donor will receive blinatumomab continuous\ninfusion until conditioning regimen  \nigtcr mrd3 level will be evaluated at day 1 of late intensification  or prior to sct in\nallografted patients   late intensification will be administered to all nonallografted patients  whatever their risk\ngroup \nconsolidation 3\nafter late intensification  patients sr will receive a third consolidation  blocks s7  s8  s9  \nhr patients will receive a second investigational blinatumomabbased consolidation\ncomposed of 3 blocks  b7  blina   b8  hdarac   b9  hdmtx  \nigtcr mrd4 level will be evaluated at day 1 of maintenance therapy  or day 100 after\nsct  \nmaintenance therapy\nthe whole duration will be two years\nit is a classical maintenance therapy for all patients  based on the association of 6\nmercaptopurin   methotrexate  with monthly reinductions associating vincristine and\nprednisone during the first year  \npatients hr  patients will receive 3 blinatumomab courses instead of vincristine pulses at\nmonth 1  3  and 5\nallogeneic stem cell transplantation  sct \nallogeneic sct in first cr will be offered to all vhrmrd patients with a genoidentical\nfamilial or unrelated donor  10 10 or 9 10   allosct has to be done as early as possible\nafter the second consolidation phase  in patients   45 years old  conditioning will be\nmyeloablative  tbi 12 gy fractionated  and cyclophophamide  120 mg kg    atg in case of\nunrelated allosct  \npatients aged  45 years old or with comorbidity criteria will benefit from a reduced\nintensity conditioning with tbi  fractionated 8 gy dose and fludarabine  120 mg m2    atg\nin case of unrelated allosct  \npatients hr  becarfull  sct has to be done not earlier than end of the first blinatumomab\ncycle \ncentral nervous system involvement\npatients with cns  disease at diagnosis will receive intensified it therapy by lumbar\npuncture during induction and cns irradiation will be performed after consolidation 3  no it\nafter cns irradiation during maintenance  chemotherapy  induction  graall2014 b \nprednisone 60 mg m2 d  po    d114 *\nvincristine 2 mg d  ivd    d1  d8  d15  d22\ndaunorubicin 50 mg m2 d  iv 30 min  **   d1 d2 d3\n30 mg m2 d  iv 30 min    d15  d16\ncyclophosphamide 750mg m2 d  iv 3h    d1  d15\nlasparaginase  6000 ui m2 d  siv 1h    d8  d10  d12  d20  d22 \nd24  d26  d28 ***\ngcsf 5 µg kg d  sc or iv    d18 until neutrophil  1g l\nit mtx   arac   depomedrol   d1  d8\n*  only from d1 to d7 if age  45y\n**  reduced to 30 mg m2 d if age  45y\n***  at d8  d10  d12  d20  d22  d24 if age  45y  \n   substituted by erwinase  if immunization to e coli lasparaginase \nsalvage\nidarubicin 12 mg m2 d  iv 1h    d1  d2  d3 aracytine 2000 mg m2 12h  iv 3h    d1  d2  d3  d4\ngcsf 5 µg kg d  sc or iv    d8 until neutrophil  1g l\nstandard consolidation  sr patients \nweekly standby block  0  1 or 2 if needed \nvp16 150 mg m2 d  iv 1h    d1\naracytine 30 mg m2 12h  sc    d1 d2\nblocks s1 s4 s7  d1d14 \naracytine 2000 mg m2 12h  iv 2h    d1  d2\ndexamethasone 10 mg 12h  iv    d1  d2\ngcsf 5 µg kg d  sc or iv    d8 tod12\nblocks s2 s5 s8  d15d28 \nmethotrexate 5000 mg m2 d  civ 24h  *   d15\nvincristine 2 mg d  ivd    d15\n6mercaptopurin 60 mg m2 d  po    d15 to 21\ngcsf 5 µg kg d  sc or iv    d22 to 26\nit mtx   arac   depomedrol   d16  h24 after start mtx \n*  500 mg m2 over 30 minutes  then over 23 hours and 30 minutes\nfollowed by folinic acid rescue  reduced to 3000 mg m2 d if age  45y\nblock s3 s6 s9  d29d35 \ncyclophosphamide 500 mg m2 d  iv 3h    d29  d30\nvp16 75 mg m2 d  iv 1h    d29  d30\nmethotrexate 25 mg m2 d  iv    d29\ngcsf 5 µg kg d  sc or iv    d31 until neutrophil  1g l\nit mtx   arac   depomedrol   d29\nlate intensification  for patients who did not receive salvage after induction \nprednisone 60 mg m2 d  po    d1 to d 14 *\nvincristine 2 mg d  ivd    d1  d8  d15  d22\ndaunorubicin 30 mg m2 d  iv 30 min    d1  d2  d3  d15**  d16 **\ncyclophosphamide 750mg m2 d  iv 3h    d1  d15\nlasparaginase   6000 ui m2 d  siv 1h    d8  d10  d12  d20  d22 \nd24  d26  d28 ***\ngcsf 5 µg kg d  sc or iv    d18 until neutrophil  1g l\nit mtx   arac   depomedrol   d1  d8\n*  only d1 to d7 if age  45y\n**  d1516 only if age  45y\n***  at d8  d10  d12  d20  d22  d24 if age  45y\n   substitution by erwinase if immunization to e coli lasparaginase\nlate intensification  for patients who received salvage after induction \nidarubicin 9 mg m2 d  iv 1h    d1  d2  d3\naracytine 2000 mg m2 12h  iv 3h    d1  d2  d3  d4\ngcsf 5 µg kg d  sc or iv    d8 until neutrophil  1g l\nit mtx   arac   depomedrol   d8  d15 maintenance therapy  2 years \nvincristine 2 mg  ivd    d1  month 1 to 12\nprednisone 40 mg m2 d  po    d1 to d7 month1 to 12\nmtx 25 mg m2 wk  po    24 months\n6mercaptopurin 60 mg m2 d  po    24 months\nit mtx   arac   depomedrol   d1 month 1 3 5\nblinatumomab   consolidation  hr   patients not proceeding to asct\nbegins after block s3\nblocks b4 b7  d1d34 \ndexamethasone 40 mg   d1  1 h before blina\nblinatumomab 28 µg d  ivc    d1 to d28\nit mtx   arac   depomedrol   d1\nblocks b5 b8  d35d49 \naracytine 2000 mg m2 12h  iv 2h    d1  d2\ndexamethasone 10 mg 12h  iv    d1  d2\ngcsf 5 µg kg d  sc or iv    d8 tod12\nblocks b6 b9  d50d65 max \nmethotrexate 5000 mg m2 d  civ 24h  *   d1\nvincristine 2 mg d  ivd    d15\n6mercaptopurin 60 mg m2 d  po    d1 to d7\ngcsf 5 µg kg d  sc or iv    d8 to 12\nit mtx   arac   depomedrol   d2  h24 after start mtx \n*  500 mg m2 over 30 minutes  then over 23 hours and 30 minutes\nfollowed by folinic acid rescue  reduced to 3000 mg m2 d if age  45y\nlate intensification  for patients who did not receive salvage after induction \nprednisone 60 mg m2 d  po    d1 to d 14 *\nvincristine 2 mg d  ivd    d1  d8  d15  d22\ndaunorubicin 30 mg m2 d  iv 30 min    d1  d2  d3  d15**  d16 **\ncyclophosphamide 750mg m2 d  iv 3h    d1  d15\nlasparaginase   6000 ui m2 d  siv 1h    d8  d10  d12  d20  d22 \nd24  d26  d28 ***\ngcsf 5 µg kg d  sc or iv    d18 until neutrophil  1g l\nit mtx   arac   depomedrol   d1  d8\n*  only d1 to d7 if age  45y\n**  d1516 only if age  45y\n***  at d8  d10  d12  d20  d22  d24 if age  45y\n   substitution by erwinase if immunization to e coli lasparaginase\nlate intensification  for patients who received salvage after induction \nidarubicin 9 mg m2 d  iv 1h    d1  d2  d3\naracytine 2000 mg m2 12h  iv 3h    d1  d2  d3  d4\ngcsf 5 µg kg d  sc or iv    d8 until neutrophil  1g l\nit mtx   arac   depomedrol   d8  d15\nblinatumomabbased maintenance therapy  2 years  n 24  dexamethasone 40 mg   d1  1h before blinatumomab\nblinatumomab 28 µg d  ivc    d1 to d28  month 1  3 and 5\nvincristine 2 mg  ivd    d1  month 2  4  6 to 12\nprednisone 40 mg m2 d  po    d1 to d7 month 2  4  6 to 12\nmtx 25 mg m2 wk  po    24 months*\n6mercaptopurin 60 mg m2 d  po    24 months*\nit mtx   arac   depomedrol   d1 month 1 3  5\n* except during the 4week blinatumomab  month 1 3 and 5 \nblinatumomab   consolidation  hr   patients proceeding to asct\nbegins after block s3\ndexamethasone 40 mg   d1  1 h before blina\nblinatumomab 28 µg d  ivc    d1 to d28\nit mtx   arac   depomedrol   d1\nvhr patients with a suitable donor will receive blinatumomab continuously until allosct\nconditioning regimen  stop 7 days before  ",
    "STATISTICS": "statistical\njustification of\nsample size  each year  approximately 100 patients with phnegative bcpall may be recruited\nfrontline in the graall2014 b trial  after hcr achievement  one may anticipate\napproximately 40 sr patients year and 50 hr patients year  including 3035 vhrmrd\npatients  \nafter consolidation 1  \n  all sr patients will be treated by the standard graall protocol  without new\nagent nor hsct in first chr  the objective is here to demonstrate in an\nuncontrolled study  the noninferiority in terms of 4year dfs which must be at\nleast of 60  in the control group  historical reference   with a margin of inferiority\nof 15   justifying the absence of allosct in first cr  with a 0 05 unilateral alpha\nrisk and a 0 90 power the calculated sample size is 110 patients \n  about 50 hr patients year will be eligible for graallquest study  with dfs as\nprimary endpoint  dfs will be compared to historical graall2005 results  50  at\n3 years   the objective is here to demonstrate a 50  to 65  dfs improvement \nwith a 0 05 alpha risk and a 0 90 power in the twosided setting  the calculated\nsample size is 91 patients  considering a dropout rate of about 5   95 patients\nshould be included in the present study  ref  sample size tables for clinical\nstudies  machin d  campbell m et al  wiley  2009  ",
    "DSMB": "independent\nsurveillance\ncommittee planned  yes",
    "ACRONYM": "acronym  graall2014 b and graallquest",
    "INVESTIGATOR": "coordinator  pr  hervé dombret\nhématologie  hôpital saint louis  paris\ntél   33  0 1 57 27 68 47   0 1 42 49 96 48\nemail  herve dombret aphp fr",
    "NUMBER OF INCLUSIONS": "number of selected\nsubjects  500 patients frontline\n95 patients for the graallquest study",
    "SITES": "number of centers  about 80 centers expected  belgium  france  switzerland ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris financing  phrc"
  },
  "METIMGAST": {
    "TITLE": "full title  phase ii trial to evaluate the combination of capmatinib  \nspartalizumab in advanced oesogastric adenocarcinoma",
    "JUSTIFICATION": "scientific justification  oesoastric advanced adenocarcinoma have a poor\nprognosis without improvement in the last decades \nrecently immunotherapy with antipd1 antibodies\nprovides encouraging results on a subset of patients \ncapmatinib  a met inhibitor shown imunomodulatory\neffect and a synergy with spartalizumab a pd1 inhibitor \nthis combination is currently evaluated in the treatment\nof hepatocellular carcinoma whatever met expression ",
    "OBJECTIVE": "main objective and primary\nendpoint  to evaluate the tumor response to the regimen at 6\nmonths after inclusion \nthe overall response rate  orr  will be assessed by\nimaging every 9 weeks and will be defined as the\nproportion of patients with at least one objective tumour\nresponse  complete or partial  according to recist v1 1\ncriteria within 6 months  secondary objectives and\nendpoints   to evaluate the safety of the regimen during the first and\nsecond cycles of administration  up to day 42  d42    cf\nchap 4 1 2  \n to evaluate the safety and tolerability of the regimen\nduring the whole course of treatment for all kind of\ntoxicities and up to 2 years for immunotherapyrelated\ntoxicity  cf chap 10 3 2  \n to characterize the tumor response to the regimen\n duration  time to response \n to estimate the progression free survival  up to 2 years\nafter inclusion\n to estimate the overall survival  up to 2 years after\ninclusion\n according to the results of interim analysis  to evaluate\ntolerance and efficacy of spartalizumab monotherapy in\npatient with nonamplified met tumor\nancillary studies  to evaluate pharmacokinetics of capmatinib according\nto the presence of a gastrectomy and of a concurrent\ntreatment with a proton pump inhibitor\n to evaluate the tumor response in specific subgroups \na  according to the residual level of capmatinib at cycle\n2 day1  c2d1 \nb  according to met amplification level in fish on the\narchival tumor sample\nc  according to the baseline and c2d1 neutrophil count\nand circulating hgf level",
    "DESIGN": "design of the study  multicenter singlearm phase ii trial with 2 cohorts\naccording met amplification level  cohort 1  tumor\nwithout met amplification    6 copies   cohort 2  tumor\nwith met amplification   6 copies  \ntreatment  \ncapmatinib 400 mg mgbid   spartalizumab300 mg\nq3w for a maximum of 12 months or until progression \npatient s refusal or unacceptable toxicity \nfor the cohort 1 interim analysis for the primary endpoint\non the first 30 evaluable enrolled patients  the rules for\nstopping or continuing the trial are specified in table 1 of\nparagraph 12 1 ",
    "INCLUSION CRITERIA": "population of study participants  patients with advanced oesogastric adenocarcinoma that\nhave received at least one previous chemotherapy line\nwith platinium salt and fluoropyrimidin and with a\ndocumented progression during or after chemotherapy   inclusion criteria   histologically or cytologically documented locally\nadvanced or metastatic oesogastric adenocarcinoma \n unresectable tumor \n patients must have received at least one prior systemic\nchemotherapy based on platinium salt and\nfluoropyrimidine with documented progression during or\nafter chemotherapy \n patients must have received trastuzumab in case of\nher2 positive tumor  her2     or her2   and fish or\nsish  \n determination of tumor met amplification by fish\navailable\n ecog performance status   1 \n measurable tumoral disease according to recist 1 1\ncriteria \n patients must be willing and able to swallow and retain\noral medication \n age  18 years \n women of childbearing potential and males who are\nsexually active must agree to follow instructions for\nmethod s  of contraception for the duration of study\ntreatments with capmatinib and spartalizumab until 7\ndays after the last dose of capmatinib and 150 days after\nthe last dose of spartalizumab\n consent to participate in the trial after information\n affiliated to a social security system",
    "EXCLUSION CRITERIA": "exclusion criteria   previous treatment with immunotherapy or met inhibitor\n impossibility to take oral medication\n persistent toxicities related to prior treatment of grade\ngreater than 1  except for alopecia any grade and grade\n2 neuropathy related to previous treatment with platinium\nsalt \n presence or history of another malignant disease that\nhas been diagnosed and or required therapy within the\npast 3 years  exceptions to this exclusion include \ncompletely resected basal cell and squamous cell skin\ncancers  and completely resected carcinoma in situ of\nany type \n use of any live vaccines within 4 weeks of initiation of\nstudy treatment \n history of severe hypersensitivity reactions to other\nmonoclonal antibodies  mabs  \n history or current interstitial lung disease or non\ninfectious pneumonitis\n active autoimmune disease or a documented history of\nautoimmune disease  patients with vitiligo  controlled\ntype i diabetes mellitus on stable insulin dose  residual\nautoimmunerelated hypothyroidism only requiring\nhormone replacement or psoriasis not requiring systemic\ntreatment are permitted  \n allogenic bone marrow or solid organ transplant\n uncontrolled active infection\n human immunodeficiency virus  hiv  infection\n untreated active hepatitis b infection  hbsag positive \n patients with active hepatitis b  hbsag positive  may be\nenrolled provided viral load  hbv dna  at screening is\n 100 ui ml  patients may receive antiviral treatment with\nlamivudine  tenofovir  entecavir  or other antiviral agents\nbefore the initiation of study treatment to suppress viral\nreplication  \n untreated active hepatitis c  hcv rna positive \n patients that achieved a sustained virological response\nafter antiviral treatment and show absence of detectable\nhcv rna  6 months after cessation of antiviral treatment\nare eligible \n untreated or symptomatic central nervous system\n cns  lesion  however  patients are eligible if  a  all\nknown cns lesions have been treated with radiotherapy\nor surgery and b  patient remained without evidence of\ncns disease progression  4 weeks after treatment and\nc  patients must be off corticosteroid therapy for  2 weeks\n clinically significant  uncontrolled heart diseases \n recent acute coronary syndrome or unstable ischemic\nheart disease\n congestive heart failure   class iii or iv as defined by\nnew york heart association\n long qt syndrome    480 ms in women and 470 ms in\nmen   family history of idiopathic sudden death or\ncongenital long qt syndrome   uncontrolled hypertension defined by a systolic blood\npressure  sbp   150 mm hg and or diastolic blood\npressure  dbp    100 mm hg  with or without\nantihypertensive medication  initiation or adjustment of\nantihypertensive medication s  is allowed prior to\nscreening \n surgery less than 4 weeks\n radiotherapy less than 2 weeks\n pregnancy or breastfeeding or women of childbearing\npotential  unless they are using highly effective methods\nof contraception \n sexually active males unless they use a condom during\nintercourse while taking capmatinib and for 7 days after\nstopping treatment and should not father a child in this\nperiod \n participants receiving treatment with strong inducers of\ncyp3a and could not be discontinued   1 week prior to\nthe start of treatment \n systemic chronic steroid therapy   10 mg day\nprednisone or equivalent  or any immunosuppressive\ntherapy 7 days prior to planned date of first dose of study\ntreatment \n patient having out of range laboratory values defined as \n total bilirubin   1 5 x upper limit of normal  uln \n alkaline phosphatase  alp    5 x uln\n alanine aminotransferase  alt    3 x uln\n aspartate aminotransferase  ast    3 x uln\n coagulation  prothrombin time  pt   4 seconds\nmore than the uln or international normalized ratio\n inr   1 7\n absolute neutrophil count  anc   1 5 x 109 l\n platelet count  75 x 109 l\n hemoglobin  9 g dl\n creatinine clearance  calculated using cockcroft\ngault formula  or measured   45 ml min\n serum lipase  2 uln\n cardiac troponin i  ctni  elevation  2 x uln\n potassium  magnesium  phosphorus  total calcium\n corrected for serum albumin  outside of normal limits\n patients may be enrolled if corrected to within normal\nlimits with supplements during screening \n patients under legal protection\nparticipation to another interventional study whith\ntreatment",
    "INTERVENTION": "investigational medicinal\nproduct s   capmatinib 400 mg bid   spartalizumab 300 mg q3w\nfor a maximum of 12 months or until progression \npatient s refusal or unacceptable toxicity  comparator treatment  not applicable",
    "STATISTICS": "statistical analysis  two cohorts will be constituted \n cohort 1 to enrol patients with no met amplification   6\ncopies   specifically  a total of 81 patients will ensure 90 \npower with a 5  type i error rate to detect a 30 \nresponse rate compared to reference 15   including an\ninterim analysis after 30 patients have been included with\na futility stopping rule  using a bayesian optimal timeto\nevent phase ii design  lin r et al  jnci  2020   in case\nthe trial is terminated early for futility  inclusions will\ncontinue but spartalizumab monotherapy  for 51\nadditional patients in cohort 1  total 81   in that case  this\nsample of 50 patients with spartalizumab monotherapy\nwill allow to detect 20  response rate in patients under\nmonotherapy  against 8  as unacceptable  with  80 \npower and a 5  type i error rate  using a binomial exact\ncomparison \n cohort 2 to enrol patient with met amplification   6\ncopie  for exploratory purpose only  the enrolment in\ncohort 2 will be ongoing until cohort 1 is completed and\nfor a maximum of 9 patients \na sequential continuous toxicity montoring will be\nconducted across both cohorts  ivanova et al clin invest\n2015  \nendpoints will be described with count and percentage for\ncategorical endpoints  toxicity  aes   and with mean \nmedian  95  confidence interval  or 95  credibility interval if appropriate   interquartile range for continuous\nendpoints  timeto event endpoints  pfs and os  will be\nestimated using the nonparametric kaplan meier\nestimator  to obtain the survival estimates up to 24\nmonths after inclusion \nanalyses will be performed using r statistical platform \nalong with datamanagement  analyses will be conducted\nin the department of biostatistics and medical information\nof hôpital saint louis  paris  pr sylvie chevret   which is\na labelled centre de traitement des données inca ",
    "DSMB": "study will have a data safety\nmonitoring board  a data safety monitoring board will meet every 6 months\nfor the duration of the study and may be consulted at any\ntime by the vigilance sector or the scientific committee\nthrough drci s promotion sector ",
    "ACRONYM": "acronym reference  metimgast",
    "INVESTIGATOR": "coordinating investigator  pr thomas aparicio  hôpital saint louis  paris scientific director  if applicable   na",
    "NUMBER OF INCLUSIONS": "number of participants included  90",
    "SITES": "number of centres  10 clinical centers of 7 public hospitals or institute located\nin france\n hôpital saint louis  paris   gastroenterology and\ndigestive oncology department  clipp and cic\n centre léon bérard  lyon   medical oncology  clipp\n centre georges françois leclerc  dijon   medical\noncology  clipp and unité de phase précoce\n institut gustave roussy  villejuif   digestive oncology \nclipp\n institut universitaire du cancer  toulouse   medical\noncology  clipp\n hôpital haut levêque   bordeaux   hepato\ngastroenterology and unité de recherche clinique\n centre hospitalier régional universitaire jean minjoz\nde besançon  medical oncology",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  inca and novartis"
  },
  "RUBI": {
    "TITLE": "full title  a multicenter  randomized  multiarm trial comparing the efficacy\nand safety of adalimumab  anakinra and tocilizumab in subjects\nwith noninfectious refractory uveitis",
    "JUSTIFICATION": "scientific\njustification  rubi  is the first prospective randomized  head to head study \ncomparing adalimumab to either anakinra  or tocilizumab in refractory\nniu  there is no firm evidence or randomized controlled trials directly\naddressing the best biologic agent in severe and refractory niu  niu\ncan cause devastating visual loss and up to 20  of legal blindness \ncorticosteroids and immunosuppressants failed to demonstrate\nsustainable remission over 70   of refractory relapsing severe uveitis \nthe incidence of blindness in niu has been dramatically reduced in\nthe recent years with the use of biologics  raising the question of\nwhether these compounds should be used earlier in the treatment of\nsevere non infectious uveitis  contrasting with immunosuppressors \nbiotherapies act rapidly and are highly effective in steroid s sparing\nthus preventing occurrence of cataract and or glaucoma \ndespite a strong rationale  these compounds are not yet approved in\nuveitis  which guarantees the innovative nature of this study that aims\nselecting or dropping any arm when evidence of efficacy already\nexists ",
    "OBJECTIVE": "primary objective\nand assessment\ncriterion  primary objective\n  to evaluate the efficacy of adalimumab  80mg then 40mg 14 days \ncompared to anakinra  100mg day  and tocilizumab  162mg 7 days  in\nsubjects with refractory noninfectious intermediate  posterior  or pan\nuveitis  niu  and with a prednisone dose   0 1 mg kg day of\nprednisone  or equivalent oral corticosteroid  at week 16 \nprimary endpoint\n  efficacy measured by the percentage of patients with at least 2step\nreduction in vitreous haze  according to miami 9step scale  and with\na dose   0 1 mg kg day of prednisone  or equivalent oral\ncorticosteroid  at w16  secondary\nobjectives and\nassessment criteria  secondary objectives\n  to evaluate the change in best corrected visual acuity  bcva  \n  to evaluate the safety of adalimumab  anakinra and tocilizumab in\npatients with niu \n  to evaluate the change in macular edema    to evaluate the change in other signs of ocular inflammation \n  to evaluate the effect on retinal vessel leakage \n  to evaluate the effect of adalimumab  anakinra and tocilizumab on\nsteroid sparing \n  to evaluate the change in ocular inflammation in the anterior\nchamber \n  to evaluate the effect on underlying systemic disease when\nappropriate \n  to evaluate the effect on ocular disease \n  to evaluate the number and time to relapse of uveitis and the\ncharacteristics of uveitis at worsening \n  to evaluate the time to treatment failure\nsecondary endpoints  all measured at 16 weeks\n  best corrected visual acuity  bcva  \n  change in macular edema \n  change in other signs of ocular inflammation \n  retinal vessel leakage \n  steroid sparing \n  ocular inflammation in the anterior chamber \n  underlying systemic disease when appropriate \n  ocular disease \n  number and time to relapse of uveitis and the characteristics of\nuveitis at worsening \n  adverse events\n  time to treatment failure",
    "DESIGN": "experimental\ndesign  this is a prospective phase ii clinical trial  multicenter  multiarm \nrandomized  1 1 1  clinical trial comparing the efficacy and safety of\nadalimumab  anakinra and tocilizumab in subjects with active and\nrefractory noninfectious intermediate  posterior  or panuveitis \noral corticosteroids should be at a stable dose 30 days prior to the first\nstudy drug administration on day 0  all systemic immunosuppressants\nmust have been discontinued 30 days prior to the first study drug\nadministration on day 0  patients will have access to oral\ncorticosteroids if needed before day 0 ",
    "INCLUSION CRITERIA": "population involved  adult patients with active and refractory noninfectious uveitis\n niu \n1  active disease  either the presence of vh  4 on the miami 9step\nscale  and or macular edema  crt  300 microns   and or other signs\nof intraocular inflammation  eg  perivascular sheathing of retinal\nvessels or leakage of retinal vessel on fa  \n2  recently active disease  evidence of activity within the 3 months\nprior to inclusion visit as per vh  4 on the miami 9step scale  or vh\n 1  according to sun classification   and or macular edema  crt\n 300 microns   and or other signs of intraocular inflammation  e g  \nperivascular sheathing of retinal vessels or leakage of retinal vessels\non fa   the activity status  active disease or recently active disease \nhas to be confirmed for all patients before the randomization by the\nreading center evaluation of vh  oct and fa assessments  3  refractory disease  at inclusion  subjects must be receiving oral\ncorticosteroids   10 mg day prednisone equivalent and  80mg day \nand at least one other immunosuppressive  azathioprine \nmethotrexate  mycophenolate mofetyl  cyclosporine  leflunomide \ncyclophosphamide   or interferon  ifn α  or being intolerant to such\nimmunosuppressive therapies  inclusion criteria  the eligibility criteria will be checked at the selection visit  which takes\nplace four weeks maximum prior to inclusion visit  and at the\ninclusion randomization visit  adult patients meeting the following\ncriteria may be included in the study \n1  provide written  informed consent prior to the performance of any\nstudyspecific procedures\n2  diagnosis of noninfectious intermediate  posterior  or panuveitis in\nat least one eye fulfilling the international study group classification\ncriteria  standardization of uveitis nomenclature  sun  criteria  of\nposterior  or pan uveitis confirmed by documented medical history\n3  currently uncontrolled uveitic disease  uncontrolled uveitic disease\nis defined as fulfilling 1 of the two following criteria within 4 weeks prior\nto inclusion \na  active inflammatory chorioretinal and or inflammatory retinal\nvascular lesions and or macular edema  crt  300 microns   or\nb  vitreous haze grade  4 on the miami 9step scale  or vh  1 \naccording to sun nei classification \n4 a  patient who are receiving prednisone  10 mg day and  80mg day\n or equivalent dose of another corticosteroid  at stable dose 30 days\nprior to the first study drug administration on day 0 and who received\nat least 1 other systemic immunosuppressant  all systemic\nimmunosuppressants must have been discontinued 30 days prior to\nthe first study drug administration on day 0   or \nb  patient who received ifn   all systemic immunosuppressants must\nhave been discontinued 30 days prior to the first study drug\nadministration on day 0   or \nc  to be intolerant to immunosuppressant\n5  best corrected visual acuity  bcva  by etdrs   to 20 400 in either\neye\n6  stable dose for two weeks prior to inclusion of topical corticosteroids\nand or nsaids\n7  male or female  age   18 years at inclusion\n8  weight 40   120 kg  88 2   264 lbs  at inclusion\n9  chest xray or thoracic ct scan results  posteroanterior and\nlateral  within 12 weeks prior to inclusion with no evidence of active\ntuberculosis  active infection  or malignancy\n10  for female subjects of childbearing age  a negative serum or urine\npregnancy test\n11  for subjects with reproductive potential  a willingness to use\ncontraceptive measures adequate to prevent the subject or the\nsubject s partner from becoming pregnant during the study and 3 and 5\nmonths after stopping therapy for roactemra and adalimumab  respectively  birth control methods which may be considered as highly\neffective methods that can achieve a failure rate of less than 1  per\nyear when used consistently and correctly are considered as highly\neffective birth control methods  according to ctfg recommendations  \nsuch methods include \n combined  estrogen and progestogen containing  hormonal\ncontraception\nassociated with inhibition of ovulation 1 \no oral\no intravaginal\no transdermal\n progestogenonly hormonal contraception associated with\ninhibition of ovulation 1 \no oral\no injectable\no implantable\n intrauterine device  iud \n intrauterine hormonereleasing system   ius \n bilateral tubal occlusion\n vasectomised partner\n sexual abstinence  in the context of this guidance sexual\nabstinence is considered a highly effective method only if\ndefined as refraining from heterosexual intercourse during the\nentire period of risk associated with the study treatments  the\nreliability of sexual abstinence needs to be evaluated in relation\nto the duration of the clinical trial and the preferred and usual\nlifestyle of the subject  \n12  a quantiferon tuberculosis  tb  test within 6 months prior to\nscreening",
    "EXCLUSION CRITERIA": "noninclusion\ncriteria  subjects will not be included in the study if they meet any of the\nfollowing criteria \n1 infectious uveitis  masquerade syndromes  idiopathic uveitis is\npermitted \n2  isolated anterior uveitis\n3  presence of cataract or posterior capsular opacification so severe\nthat an assessment of the posterior segment of either eye is\ninadequate or impossible\n4  contraindication to mydriasis in either eye or presence of posterior\nsynechiae in the study eye such that mydriasis is inadequate for\nposterior segment examination\n5  intraocular pressure   25mmhg by goldmann tonometry or\nadvanced glaucoma in either eye\n6  monocular patient\n7 active tuberculosis\n8  known positive syphilis serology  hiv antibody  hepatitis b surface\nantigen and or antinucleocapsid antibody of hepatitis b virus and or\nhepatitis c virus  within 1 month prior to inclusion \n9  history of malignancy within 5 years prior to inclusion other than carcinoma in situ of the cervix  nonmetastatic squamous or basal cell\ncarcinoma of the skin \n10  history of severe allergic or anaphylactic reactions to monoclonal\nantibodies\n11  infectious disease \na  fever or infection requiring treatment with antibiotics within 3\nweeks prior to inclusion\nb  history of recurrent infection or predisposition to infection\n12  known immunodeficiency\n13  history of multiple sclerosis and or demyelinating disorder\n14  laboratory values assessed during inclusion \na  hemoglobin   8g dl\nb  wbc   2 0   103 mm3\nc  platelet count   80   103 mm3\nd  glomerular filtration rates  gfr   30ml min \ne  transaminases   3 times upper normal value\n15  use of the following systemic treatments during the specified\nperiods \na  any previous systemic biologic therapy\nb  treatment with any systemic alkylating agents within 12 months\nprior to inclusion or between inclusion and day 0  e g  \ncyclophosphamide  chlorambucil \nc  any live  attenuated  vaccine within 3 months prior to inclusion \n16  use of the following ocular treatments during the specified periods \na  previous antivegf intravitreal therapy  applies to both eyes \nwithin 3 months prior to inclusion  or anticipated use during the\nstudy period\nb treatment with dexamethasone intravitreal implant  ozurdex   \nwithin 6 months prior to inclusion\nc  intravitreal corticosteroids within 3 months prior to inclusion \nprevious subtenon s corticosteroid injections are permitted if\nadministered at least 2 months prior to inclusion\n17  stage iii and iv new york heart association  nyha  cardiac\ninsufficiency",
    "INTERVENTION": "treatment being\ntested  eligible patients with active and refractory niu will randomized at 1 1 1\nratio between\n  arm 1  adalimumab  80mg then 40mg 14 days subcutaneously \n n 40  for 16 weeks\n  arm 2  anakinra  100 mg day subcutaneously   n 40  for 16 weeks\n  arm 3  tocilizumab  162 mg 7 days subcutaneously   n 40  for 16\nweeks \nthe three treatment groups will receive the same corticosteroid\nregimen  all patients with niu will receive oral prednisone 0 5\nmg kg day with a maximum of 40 mg day of prednisone or\nequivalence  the following schedule of reduction of prednisone will\napply to both groups as long as the disease is inactive \n 0 5 mg kg day of prednisone until week 4   0 4 mg  kg day of prednisone from week 4 to week 6\n 0 3 mg  kg day of prednisone from week 6 to week 8 \n 0 2 mg  kg day of prednisone from week 8 to week 12\n   0 1 mg  kg day of prednisone from week 12 to week\n16 \ndue to the csi recommendation of the 18 06 2019  inclusion in the\nanakinra arm has been stopped and the investigational medicinal\nproduct anakinra has been discontinued in patients undergoing follow\nup  thus we modified the planned analyses and the randomisation\naccordingly  after the inclusion and randomisation of 54 patients  the\nnext patients will be randomized 1 1 either in the 2 remaining arms \n  arm 1  adalimumab  80mg then 40mg 14 days subcutaneously \n n 40  for 16 weeks\n  arm 3  tocilizumab  162 mg 7 days subcutaneously   n 40  for 16\nweeks \nin practice  it means that the remaining 66 planned patients will be\nrandomized  33 in arm 1 and 33 in arm 3  ",
    "STATISTICS": "statistical analysis  we will use a bayesian multiarm multistage  mams  design that aim\nat comparing several new treatments  multiarm   in order to select or\ndrop any treatment arm to move forward when such evidence already\nexists based on interim analyses\nthe randomization will be stratified by retinal vasculitis  macular\noedema and underlying disease  at randomization  the patient will be\nunder treatment with prednisone as single therapy ",
    "DSMB": "data safety\nmonitoring board\nanticipated  yes",
    "ACRONYM": "acronym  rubi   refractory uveitis biotherapies",
    "INVESTIGATOR": "coordinating\ninvestigator  pr david saadoun\ncentre national de référence des maladies autoimmunes et\nsystémiques rares\ndepartment of internal medicine and clinical immunology  hospital\npitie salpetriere\ntel 0142178088   email david saadoun psl aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects\nchosen  120",
    "SITES": "number of centres  37 departments of 17 french public hospitals",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding source  phrc 2015"
  },
  "MSC-AT-SSC": {
    "TITLE": "full title  phase i ii randomized clinical trial of allogeneic adipose\ntissuederived mesenchymal stromal cells systemic\ninfusion in severe systemic sclerosis",
    "JUSTIFICATION": "scientific justification  systemic sclerosis  ssc  is a rare  severe and chronic\nsystemic autoimmune disease  ad  characterized by\nvasculopathy  immune dysregulation and fibrosis leading\nto multiorgan dysfunction  primarily skin  lungs  heart\ngastrointestinal tract and kidneys   with high morbidity\nand mortality  altered healthrelated quality of life  all at\nhigh cost for patients and society \ntreatment are mostly symptomatic and only autologous\nhematopoietic stem cell transplantation  ahsct  has\nshown long term improvement in overall and eventfree\nsurvival with diseasemodifying properties  however \nahsct is contraindicated in case of advanced visceral\ninvolvement and in eligible patients  it is still associated\nwith risk of toxicity  there is an urgent need to identify\nsafe and effective treatments for severe ssc \nmesenchymal stromal cells  msc  are multipotent cells\nwhich carry immunomodulatory  proangiogenic and anti\nfibrotic properties  that can target ssc pathogenesis and\nits clinical manifestations  the increasing use of msc \nharvested from bone marrow  msc m    adipose tissue\n msc at    or umbilical cord  msc uc   in a variety of\nindications  provides consistent evidence supporting their\nsafety in humans  the efficacy of msc m  intravenous\n iv  injection for treating acute graft versus host disease\nled to their marketing approval in 2012 and msc at \n alofisel  were approved for severe crohn s fistula in\n2018 \nmsc represent a promising therapeutic approach for\nssc  we have previously a  shown diseasespecific\nabnormalities in msc m  from ssc patients  providing\nstrong rationale to use allogeneic msc to treat ssc\npatients  b  published the first phase i ii dose escalation\ntrial using allogenic msc m  infusion in 20 severe ssc\npatients  clinicaltrials gov  nct02213705  phrc aom\n11250  with no safety issues  significant improvement in\nskin fibrosis at 3 to 6 months after infusion which\nappeared lower thereafter  thereby supporting the need\nfor repeated infusions  in vitro  experimental and clinical studies suggest that\nmsc properties vary according to their tissue of\norigin source  we demonstrated that compared to\nmsc m   msc at  are easier to harvest and display\nhigher proliferative capability before entering\nsenescence  higher genetic stability  and superior\nimmunosuppressive properties \nconsidering the above rationale  we hypothesize that use\nof healthy donors allogeneic msc at  produced by\netablissement français du sang  efs  will demonstrate\na  no safety issues  b  an efficacy profile that will increase\nwith repeated infusion of allogeneic msc at  to treat ssc",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to evaluate the safety one month after\nallogeneic 2x106 msc at  kg intravenous administration\nonce or twice at 3 months interval  m0  m3  in severe ssc\npatients\nprimary endpoint  the rate of treatmentrelated severe\nadverse events  sae  defined as adverse events  ae  of\ngrade equal or above 3 using the nci common\nterminology criteria for adverse events  ctcae  v5 0\nclassification  at one month after each infusion  m1  m4  \nall adverse events will be adjudicated by a data and\nsafety monitoring committee  secondary objectives and\nendpoints  secondary objectives \n safety during the infusion  within the first 24\nhours of infusion and during all study followup \n efficacy signals to inform future studies  using\noutcome measures on skin sclerosis  lung\nfunction and quality of life  previously validated in\nssc or used in other cell therapy trials \n analysis of the response to treatment \nprogressionfree survival  pfs   global rank\ncomposite score  grcs  at m3  m6and m12\nand acr provisional composite response index\nfor clinical trials in early diffuse cutaneous\nsystemic sclerosis  criss  for early ssc\npatients at m3  m6 and m12 \n analysis of the overall survival and assess\ncauses of death \n impact of allogeneic msc at  iv once or twice at\n3 months interval on the immune response \nincluding immunophenotyping and\nalloimmunization up to m6 after starting therapy \n cost effectiveness of the allogeneic msc at \ninfusion once or twice versus no treatment in\nsevere ssc patients \nsecondary endpoints \n rate of treatmentrelated sae defined as ae of\ngrade equal or above 3 ctcae v5 0 at time and within the first 24 hours of infusion and during all\nfollowup at  m0  m3  m6  m9 and m12 \n main efficacy endpoint  modified rodnan skin\nscore  mrss  difference between m0 and m12 \n other efficacy disease related endpoints  \no mrss at m3  m6 and m9\no who performance status  ps  and\nhealthrelated quality of life  hrqol \nquestionnaires   sclerodermahealth\nassessment questionnaire  shaq   the\nshort form  36  health survey  sf36v2 \nand eq5d5l at m0  m3  m6  and m12 \no forced vital capacity  fvc  and diffusing\ncapacity of lung for carbon monoxide\n dlco  at m0  m6 and m12 \n response to treatment  defined as any of the\nfollowing  decreased mrss   25   increased\nfvc   10  and or increased dlco 10   without\nneed for further immunosuppression except low\ndose steroids  below 10mg daily  at m3  m6 and\nm12 \n pfs at m12  with progression defined as any of\nthe following  decreased in fvc   10  or in\ndlco   15   decrease in lvef    15  \ndecrease in weight   15   decrease in creatinine\nclearance   30   increased mrss   25    and or\nincrease in shaq  0 5 \n grcs values at m3  m6 and m12 \n criss values for early ssc patients at m3  m6\nand m12 \n overall survival at m12\n myeloid and lymphocyte subpopulations in all\nincluded patients at m0  m1  m3  m4  m6 \n alloimmunization in all included patients through\nthe detection and identification of donorspecific\nantihla antibodies at m0  m3 and m6 \n extracost per qaly  qualityadjusted life year \ngained by unique and repeated iv infusion of\nallogeneic msc at  in severe ssc after 12\nmonths \n extracost per sae of grade above or equal to 3\nctcae avoided by unique and repeated iv\ninfusion of allogeneic msc at  in severe ssc\nafter 12 months ",
    "DESIGN": "design of the study  multicentre  threearm  randomized  placebocontrolled \ndoubleblind phase iii trial",
    "INCLUSION CRITERIA": "population of study participants  adult patients with refractory severe systemic\nscleroderma inclusion criteria  1  provide signed and dated informed consent \n2  willing to comply with all study procedures and be\navailable for the duration of the study \n3  male or female  aged   18 and   70 years of age 4  ssc patients according to american college of\nrheumatology european league against\nrheumatism  acr eular  2013 classification\ncriteria for ssc \n5  severe disease with either \na  disease duration of 2 years or less with a modified\nrodnan skin score  mrss    20 and  abnormal\ncrp   5 mg l and or hemoglobin   11 g dl   or\nb  mrss   15 without any restriction as to disease\nduration plus at least one major organ\ninvolvement as defined by \n 1  respiratory involvement consisting of lung\ndiffusion capacity for carbon monoxide\n dlco  and or forced vital capacity  fvc \n  80  predicted and evidence of\ninterstitial lung disease  chest xray and or\nhigh resolution computed tomography\n hrct  scan  and or moderate\npulmonary hypertension with baseline\nresting systolic pulmonary arterial\npressures   35 mmhg and below 50\nmmhg by cardiac echocardiography  or\nmean pulmonary artery pressure   20\nmmhg and   40 mm hg on right heart\ncatheterization \n 2  renal involvement consisting of past renal\ncrisis  microangiopathic hemolytic anemia \nand or renal insufficiency not explained by\nother causes than ssc \n 3  cardiac involvement consisting of\nreversible congestive heart failure  atrial or\nventricular rhythm disturbances such as\nrecurrent episodes of atrial fibrillation or\nflutter  recurrent atrial paroxysmal\ntachycardia  2nd or 3rd degree avblock \nmild to moderate pericardial effusion\nand or presence of mri involvement\n increased t1 or t2 mapping  late\ngadolinium enhancement  septal d sign   \nall causes of organ involvement should be\nattributed to ssc \n6  contraindication  inadequate response or\nunwillingness to undergo ahsct  determined by\npatient and physician judgement \n7  contraindication  inadequate response or\nunwillingness or adverse events necessitating\ndiscontinuation of conventional immunosuppressive\ntherapy  mmf  methotrexate  \n8  women of reproductive potential must use highly\neffective contraception \n9  men of reproductive potential must use condoms\n10  health insurance\nnb the authorized contraceptive methods are  for women of childbearing age and in absence of\npermanent sterilization \n  oral  intravaginal or transdermal combined\nhormonal contraception  \n  oral  injectable or implantable progestogenonly\nhormonal contraception\n  intrauterine device  iud \n  intrauterine hormonal releasing system  ius \n  bilateral tubal occlusion\n  vasectomised partner\n  sexual abstinence  only if this the preferred and\nusual lifestyle of the participants \nfor man in absence of permanent sterilization \nsexual abstinence  condoms",
    "EXCLUSION CRITERIA": "exclusion criteria  1  age   18 years or   70 years\n2  pregnancy or unwillingness to use adequate\ncontraception \n3  lifethreatening endorgan damage defined as \ndlco  corrected for hemoglobin    30  predicted \nleft ventricular ejection fraction   40  by cardiac\nechocardiography  pulmonary hypertension with\nbaseline resting systolic pulmonary arterial\npressures   50 mmhg by cardiac echocardiography \nor mean pulmonary artery pressure   40 mmhg on\nright heart catheterization  glomerular filtration rate  \n30ml min\n4  active or chronic hepatitis  asat  alat   3 upper\nlimit normal \n5  neoplasms of less than 5 years  except for basal cell\nor in situ cervix carcinoma or concurrent\nmyelodysplasia \n6  uncontrolled hypertension\n7  uncontrolled acute or chronic infection\n8  hiv1 or hiv2 infection\n9  bmi   16 5 kg m2\n10  severe psychiatric disorder\n11  bone marrow insufficiency  defined as neutropenia  \n1 x 109 l  thrombopenia   50 x 109 l  anemia   8\ng dl  lymphopenia   0 5 x 109 l\n12  inability to provide informed consent\n13  patient included in another interventional clinical trial\n14  patient under tutelle",
    "INTERVENTION": "investigational medicinal\nproduct s   allogeneic adipose tissue derivedmscs  msc at   or\nplacebo will be injected by slow intravenous infusion\naccording to the recipient body weight and to the study\nexperimental arms \n arm 0   placebo at m0 and m3  arm 1 1 msc at   2x106 cells kg  injection at m0\nand 1 placebo injection at m3\n arm 2  1 msc at   2x106 cells kg  injection at m0\nand 1 msc at   2x106 cells kg  injection at m3\neach allogeneic msc at  is administered intravenously\nover a 45 min to 1h infusion \nsecond infusions of drug product  msc placebo  will be\nperformed only in the absence of treatmentrelated\nsevere adverse events  trsae  \npatients included in arm 1 and in arm 0 will have the\nopportunity according to their willingness  to receive\neither 1  arm 1  or 1 or 2  arm 0  msc at   2x106 cells kg \ninjection s  at the end of the study after unblinding and\nonce evidence of msc at  injection safety is provided  comparator treatment  placebo",
    "STATISTICS": "statistical analysis  we propose to conduct a multicenter  threearm \nrandomized  doubleblind  placebocontrolled trial  we\nwill enroll a total of 18 ssc patients  each patient will be\n1 1 1 randomized to one of two treatment arms  1 infusion\nof msc  m0  or 2 infusions of msc  m0  m3  or a placebo\narm  total of 6 patients per arm  using randomization\nblock of size 6  \ninclusions will be staggered  to allow the detection of sae\nprior to inclusion of subsequent patients  according to the\nfollowing waiting rules \n at least one week between two consecutive\nrandomizations\n interval of at least one month every three\nrandomizations\ncontinuous monitoring of the primary endpoint by the\nsponsor will be implemented to allow continuous\nbayesian toxicity monitoring with a stopping rule\nimplemented on the primary endpoint on cell infusions\n see section 13 for details    first analysis on the first 3 patients with completed m1\nvisits \n then analysis at any trsae at m1 or m4 visits\n final analysis \nthe stopping rule will be defined based on the estimated\nprobability that the risk of treatmentrelated severe\nadverse events  trsae  is  15    criterion 1    the\nprobability that the a posteriori probability of sae is  \n15   the posterior probability of trsae  π   will be\ntrsae\nestimated using a bayesian approach with a beta density \nthe stopping rule will be fulfilled if criterion 1   0 70\n meaning that we have a high probability that there is a\ngreater than 15  risk of trsae   interim analyses results\nwill be presented to the dsmb for their recommendation \nin the case of early stopping  subsequent patients will not\nbe randomized and all patients treated thus far will be\nfollowed up and results analyzed as described below \nthere is no formal statistical test for sample size in a\nbayesian framework  nevertheless  one can invoke the\nfrequentist framework to anticipate the expected\nprecision in terms of safety  indeed  after 18 infusions  6\npatients with 1 infusion  6 patients with 2 infusions   we\nwill be able to estimate a risk of severe adverse events\n sae  of 10  with a width of the exact 95  confidence\ninterval equal to 32  considering independence between\ninfusions ",
    "DSMB": "study will have a data safety\nmonitoring board  yesthe data and safety monitoring board  dsmb  will be\ncomposed of 3 external reviewers with expertise in ssc \nmsc and early phase trials  in case of any safety data\nreported to the safety department  the dsmb will be\ninformed  hold meeting and determine whether the trial\nshould be held or proceed ",
    "ACRONYM": "acronym reference  mscatssc",
    "INVESTIGATOR": "coordinating investigator and\nscientific director  prof  dominique farge\nmathec  centre de référence des maladies auto\nimmunes systémiques rares d iledefrance  filière\nfai2r  irsl  ea3518  université de paris \nhôpital saint louis\n1 avenue claude vellefaux\n75010 paris",
    "NUMBER OF INCLUSIONS": "number of participants included  18 patients",
    "SITES": "number of centres  1 centre for patients treatment  \n unité de médecine interne   uf 04  \nmathec  centre de référence des maladies autoimmunes systémiques rares d ilede\nfrance  filière fai2r  irsl  urp\n3518  université de paris  hôpital stlouis  ap\nhp  1 avenue claude vellefaux  75010\nparis  france  dominique farge  md  phd\n2 centres for patients recruitment and followup  \n unité de médecine interne   uf 04  \nmathec  centre de référence des maladies\nautoimmunes systémiques rares d ilede\nfrance  filière fai2r  irsl  urp\n3518  université de paris  hôpital stlouis  ap\nhp  1 avenue claude vellefaux  75010\nparis  france  dominique farge  md  phd\n service de médecine interne et immunologie\nclinique pôle hospitalouniversitaire des\nmaladies digestives chu rangueil  bât  h2 \n3ème étage 1 avenue du pr jean poulhès tsa\n50032  31059 toulouse cedex 9  grégory\npugnet  md  phd \n",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris"
  },
  "UVB": {
    "TITLE": "full title  multicenter  randomized  prospective trial comparing the efficacy and\nsafety of adalimumab to that of tocilizumab in severe uveitis of behçet s\ndisease",
    "JUSTIFICATION": "scientific justification  uvb  is the first randomized prospective  head to head study  comparing\nadalimumab to tocilizumab in sight threatening uveitis of bd  antitnf \nhas been used for bd uveitis for 15 years  the incidence of blindness in\nbd has been dramatically reduced in the recent years with the use of\nbiologics  there is no firm evidence or randomized controlled trials\ndirectly addressing the best induction therapy in severe bd uveitis  bd\nuveitis is considered as the most devastating inflammatory ocular\ndisease  risk of visual loss reaches 25  at 5 years and 80  of patients\nhave a bilateral involvement  contrasting with immunosuppressors or\ninterferonalpha  biotherapies act rapidly and are highly effective in\nsteroid s sparing thus preventing occurrence of cataract and or\nglaucoma  however  antitnfα failed to demonstrate sustainable\ncomplete remission over 50   of severe sight threatening uveitis  there\nis little published information on use of biologics other than antitnf \nfor severe bd uveitis  tocilizumab has been used with success in severe\nand or resistant cases and is one of the most promising biologics in bd \nil6 expression correlates with bd activity and other immunological data\nprovide a strong rationale for targeting bd with tocilizumab  despite a\nstrong rationale  these compounds are not yet approved in bd  which\nguarantees the innovative nature of this study that aims selecting or\ndropping any arm when evidence of efficacy already exists ",
    "OBJECTIVE": "main objective and\nprimary endpoint    to assess the benefit of tocilizumab comparatively to that of\nadalimumab in sightthreatening behçet s disease uveitis at week 16\n  primary endpoint  efficacy will be defined by a complete remission\nof ocular involvement  complete resolution of retinal vasculitis and or\nmacular edema  with prednisone  or prednisolone  only if prednisone\nis out of stock in the market  lower or equal to 5 mg day at week 16\nafter randomization  secondary objectives and\nendpoints  1  to estimate and compare the change in best corrected visual\nacuity  bcva \n2  time to complete remission at week 4  8  12  24  36 and 48 3  to evaluate and compare the safety of adalimumab and\ntocilizumab\n4  to evaluate and compare the change in macular edema\n5  to evaluate and compare the change in other signs of ocular\ninflammation\n6  to evaluate and compare the effect on retinal vessel leakage\n7  to evaluate and compare the effect of adalimumab and\ntocilizumab on steroid sparing\n8  to evaluate and compare the change in ocular inflammation in\nthe anterior chamber\n9  to evaluate and compare the number and time to relapse of\nuveitis and the characteristics of uveitis at worsening \n10  to evaluate and compare the time to treatment failure  patients\nwill be considered to have treatment failure if any of the following\ncriteria is met in at least 1 eye  new active  inflammatory retinal\nvascular lesions and or macular edema  worsening best\ncorrected visual acuity  bcva  by  3 lines  2step increase in\nanterior chamber  ac  cell grade  2step increase in vitreous\nhaze  vh  grade relative to baseline \n11  to estimate and compare the effect on extra ophthalmologic\nmanifestations of behçet s disease \n12  to estimate and compare the mean change in sf36 quality of\nlife and behçet s disease quality of life measure  bdqol \n13  to estimate and compare the changes in behcet s disease\ncurrent activity form  bdca  and behcet s syndrome activity\nscore  bsas \nsecondary endpoints  \n1  measures of corticosteroid sparing  e g   percent meeting targets\n lower than 0 1 mg day kg of prednisone  or prednisolone  only if\nprednisone is out of stock in the market    mean dose at week 16 \nand cumulative dose  \n2  time to response onset \n3  measures of acutephase reactants  erythrocyte sedimentation rate\n esr   creactive protein  crp   at week 4  8  12  16  24  36 and 48\n4  rate and time to occurrence of relapse or worsening while on\nstudy   relapse will be defined as the reappearance of clinical\nand or paraclinical features of active disease or by the occurrence\nof new lesions or progression of preexisting lesions  \n5  changes in behcet s disease current activity form  bdca  at week\n8  16 and 24\n6  changes in behcet s syndrome activity score  bsas  at week 16\n7  changes in other organs involved by bd at week 4  8  12  16  24 \n36 and 48\n8  changes in quality of life  qol   sf36v2 tm health survey  and\nbehcet s disease quality of life measure  bdqol  at week 16 and\n24\n9  safety and tolerability of treatments in bd patients as assessed by\nfrequency and severity of adverse clinical events at week 4  8  12 \n16  24  36 and 48\n10  time to treatment failure  time to occurence \n11  changes in tyndall  flare and vitreous haze at week 8  16  24  36\nand 48\n12  changes in best corrected visual acuity  snellen score  at week\n8  16  24  36 and 48\n13  changes in central retinal thickness measured with optical\ncoherence tomography  oct  at week 8  16  24  36 and 48 \n14  percentage of patients with central retinal thickness  300 microns\nat week 8  16  24  36 and 48  15  percentage of patients without retinal vessel leakage on retinal\nangiography at week 16  and at week 24  36 and 48  in case of\nretinal vasculitis",
    "DESIGN": "design of the study  bayesian design for phase ii randomized clinical trial that aims at\ncomparing a new treatment to a reference based on a binary end point \nwhich offers greater flexibility and simplicity of inference for the\nmonitoring of patient safety and evidence of efficacy in small randomized\ntrials",
    "INCLUSION CRITERIA": "population of study\nparticipants  adult patients with sightthreatening behçet s disease associated\nuveitis  inclusion criteria  1  age   18 at inclusion\n2  provide written  informed consent prior to the performance of any\nstudyspecific procedures\n3  diagnosis of behçet s disease according to the international\ncriteria for behçet s disease  icbd   see appendix 18 2  or\nhistory of aphtosis \n4  diagnosis of noninfectious intermediate  posterior  or panuveitis\nin at least one eye fulfilling the international study group\nclassification criteria  standardization of uveitis nomenclature\n sun  criteria  of posterior  or pan uveitis\n5  sight threatening uveitis defined according to the validated\ninternational definition as 2 lines of drop in visual acuity on a\n10 10 scale  and or retinal inflammation  macular oedema\nand or retinal vasculitis  \n6  chest xray  posteroanterior and lateral  or ctscanner results\nwithin 12 weeks prior to inclusion with no evidence of active\ntuberculosis  active infection  or malignancy\n7  for female subjects of childbearing potential  premenopausal\nfemale capable of becoming pregnant   a negative serum\npregnancy test  plasmatic or urinary \n8  for subjects with reproductive potential  a willingness to use\ncontraceptive measures adequate to prevent the subject or the\nsubject s partner from becoming pregnant during the study and\n3 and 5 months after stopping therapy for tocilizumab and\nadalimumab  respectively  birth control methods which may be\nconsidered as highly effective methods that can achieve a\nfailure rate of less than 1  per year when used consistently and\ncorrectly are considered as highly effective birth control\nmethods  according to ctfg recommendations   such\nmethods include \nfor female subjects    combined  estrogen and progestogen containing  hormonal\ncontraception associated with inhibition of ovulation \n  oral\n  intravaginal\n  transdermal\n progestogenonly hormonal contraception associated with\ninhibition of ovulation \n  oral\n  injectable\n  implantable\n intrauterine device  iud \n intrauterine hormonereleasing system  ius \n bilateral tubal occlusion\n vasectomised partner\n sexual abstinence  in the context of this guidance sexual\nabstinence is considered a highly effective method only if\ndefined as refraining from heterosexual intercourse during the\nentire period of risk associated with the study treatments  the\nreliability of sexual abstinence needs to be evaluated in\nrelation to the duration of the clinical trial and the preferred\nand usual lifestyle of the subject  \nfor male subjects  \n use of a condom\n vasectomy  with documentation of azoospermia \n sexual abstinence\n9  negative tb test obtained within 12 weeks prior to inclusion  a\npotential subject with a positive interferongamma release\n \nassay  igra   e g   quantiferon tb gold or tspot tb\ntest  is eligible if her his chest xray does not show evidence\nsuggestive of active tb disease and there are no clinical signs\nand symptoms of pulmonary and or extrapulmonary tb\ndisease  these subjects with a latent tb infection who have not\nalready received a prophylactic tb treatment must agree in\nadvance to complete such a treatment course  the treatment\nshould be started at the latest at inclusion \n10  affiliation to a social security system  patients affiliated to\nuniversal medical coverage  cmu  are eligible for the study",
    "EXCLUSION CRITERIA": "non inclusion criteria  1  infectious uveitis  masquerade syndromes  or uveitis due to\ncauses other than bd uveitis\n2  active tuberculosis or history of untreated tuberculosis and or\nsevere infection\n3  positive hiv antibody and or positive hepatitis b surface antigen\nand or positive hepatitis c rna  results obtained within 1 month\nprior to inclusion\n4  history of malignancy within 5 years prior to inclusion other than\ncarcinoma in situ of the cervix  nonmetastatic squamous or basal\ncell carcinoma of the skin \n5  history of severe allergic or anaphylactic reactions to\nmonoclonal antibodies\n6  history of multiple sclerosis and or demyelinating disorder\n7  hypersensitivity to the active substance or an excipient of the imp\nor the auxiliary medicine\n8  active or suspected ocular infection\n9  active or suspected systemic infection\n10  history of intestinal ulceration or diverticulitis\n11  known porphyria 12  laboratory values assessed during inclusion \na  neutrophil   1 0   103 mm3\nb  platelet count   80  103 mm3\nc  asat or alat   5 uln\n13  treatment with antitnf and or tocilizumab therapy within 1\nmonth prior to inclusion\n14  patient on azathioprine  mycophenolate mofetil  or methotrexate\nat the time of inclusion  these drugs must be withdrawn prior to\nreceiving the tocilizumab or adalimumab dose on day 0 \n15  stage iii and iv new york heart association  nyha  cardiac\ninsufficiency\n16  severe renal  glomerular filtration rates  gfr   30ml min  or liver\ninsufficiency  prothrombin  50  without other causes \n17  any live  attenuated  vaccine within 30 days prior to inclusion\n18  breastfeeding or pregnant women",
    "INTERVENTION": "investigational medicinal\nproduct s   after the collection of their free and informed consent  eligible\npatients with sight threatening behçet s disease uveitis will be\nrandomized into one of 2 groups at the randomization visit  d0  \n  arm a adalimumab 80 mg at d0 then 40 mg subcutaneous\nat week 1  3  5  7  9  11  13 and 15\n  arm b tocilizumab 162 mg subcutaneous each week for\n15 weeks comparator treatment  not applicable",
    "STATISTICS": "statistical analysis  the experimental design is an open multicenter randomized clinical trial\nstratified on the characteristics of the initial uveitis in behçet s disease  \nretinal inflammation  retinal vascularitis and or macular edema  and\naccording to the diagnosis  newly diagnosed or relapsing disease   with\nevaluation of the primary assessment criteria at 16 weeks \nthe primary assessment criteria will be reviewed by a scientific\ncommittee blinded of the randomization \nthe rct will use a bayesian design for phase ii randomized national\nmulticenter clinical trial that aims at comparing a new treatment to a\nreference based on a binary endpoint  i e  complete remission at week\n16   which offers greater flexibility and simplicity of inference to the\nmonitoring for patient safety and evidence of efficacy of small\nrandomized trials \nit will use a betabinomial model with a noninformative prior  berry\n2006   the posterior probability that the remission rate is at least 0 65\nwill be estimated in both arms  and the probability that the rate of\nremission in arm b is above that in arm a will be computed  with b\nindicating the tocilizumab group and a the adalimumab group \nwe will use a bayesian inference framework  where 𝜋  𝑃 𝑌  1 𝐴 \n𝐴\ndenotes the probability of remission in the arm a  after inclusion of n\na\npatient in arm a and y complete remission observed  using a beta\na\nbe 𝑎   𝑏   prior for 𝜋   the posterior probability of 𝜋 is still a beta\n𝐴 𝐴 𝐴 𝐴\ndistribution given by be 𝑎  𝑦   𝑏  𝑛  𝑦   due to the natural conjugate\n𝐴 𝐴 𝐴 𝐴 𝐴\nproperty of the beta family for binomial sampling \nin our setting  the efficacy of the drug in arm a will be first assessed by\ncomparison to some historical minimal value of interest  sometimes\ncalled the  minimum required treatment remission rate   it has been set\nat 0 65 in this trial  thus  we will compute\n𝑃 𝜋  0 65 𝑦  𝑛  \n𝐴 𝐴 𝐴\nsimilar analyses will be performed in arm b  however  in randomized phase ii settings  the selection of a new drug\nis mostly based on evaluating the potential benefits of experimental\ntreatments  thus  one may consider dropping a new drug from further\nstudies only if there is a rather low posterior probability that this drug is\nbeneficial over the other by some targeted minimal level  this will be\ndone by computing the posterior probability of the difference in\nremission rates between the two experimental arms  kawasaki in 2012 \nbeing greater than zero  with b being the tocilizumab group and a the\nadalimumab group \n𝑃 𝜋  𝜋  0 𝑦  𝑦  𝑛  𝑛  \n𝐵 𝐴 𝐴 𝐵 𝐴 𝐵\nas we consider a bayesian design an interim analysis will be performed\nwithout any  alpha spending  after inclusion of 30 patients  if\n𝑃 𝜋  0 65 𝑦  𝑛    0 80  𝑃 𝜋  0 65 𝑦  𝑛    0 80 and if\n𝐴 𝐴 𝐴 𝐵 𝐵 𝐵\n𝑃 𝜋  𝜋  0 𝑦  𝑦  𝑛  𝑛    0 80  the trial will be stopped \n𝐵 𝐴 𝐴 𝐵 𝐴 𝐵\nif 𝑃 𝜋  0 65 𝑦  𝑛    0 10 or 𝑃 𝜋  0 65 𝑦  𝑛    0 10 the\n𝐴 𝐴 𝐴 𝐵 𝐵 𝐵\ncorresponding arm will be stopped and the following patients will be\nincluded in the other arm \nif 𝑃 𝜋  0 65 𝑦  𝑛    0 10 and 𝑃 𝜋  0 65 𝑦  𝑛    0 10  the trial will\n𝐴 𝐴 𝐴 𝐵 𝐵 𝐵\nbe stopped ",
    "DSMB": "trial will have a data\nmonitoring committee  yes",
    "ACRONYM": "acronym  uvb  treatment of uveitis in behçet s diseases with biologics",
    "INVESTIGATOR": "coordinating investigator  pr bahram bodaghi\ndepartment of ophthalmology\ncentre national de référence des uvéites\ncentre national de référence des maladies autoinflammatoires et de\nl amylose inflammatoire\nhospital pitie salpetriere\ntel  01 42 16 37 28\nemail bahram bodaghi aphp fr scientific director  pr  david saadoun\ndepartment of internal medicine and clinical immunology\ncentre national de référence des maladies autoimmunes systémiques\nrares\ncentre national de référence des maladies autoinflammatoires et de\nl amylose inflammatoire\npitie salpetrière hospital  43 boulevard de l hôpital  75013 paris\ntel 01 42 17 80 88\nemail david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants\nincluded  60 patients  30 patients in each arm ",
    "SITES": "number of sites  multicenter national study including 26 centers",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the\ntrial  phrc national 2019  ministère des solidarités et de la santé"
  },
  "COMBINATION-LOCK01": {
    "TITLE": "full title  combinationlock01  impact of aminoglycosidesbased\nantibiotics combination and protective isolation on\noutcomes in criticallyill neutropenic patients with sepsis \na randomized 2 by 2 factorial design randomized\npragmatic trial ",
    "JUSTIFICATION": "scientific justification  sepsis remains the leading cause of icu admission in\nneutropenic patients  this condition remains associated\nwith a high morbidity and mortality  with hospital mortality\nof 60  when vasopressors are required \nfull protective isolation  including geographic isolation \ntechnical isolation  highefficiency air filtration  and\ndigestive decontamination  proved to be efficient in\npatients with profound and prolonged neutropenia with\nregard to infection rate  however  these studies are biased\nand were performed up to 40 years ago  more recent\nstudies  performed in patients with less profound\nneutropenia  or performed without digestive\ndecontamination or with partial protective isolation led\nhowever to negative results  more importantly  isolation\nhas been demonstrated to limit access to patients  room\nand to be associated with suboptimal monitoring  with\nincreased rate of severe and avoidable adverse events \nthis may explain the uneven use of protective isolation in\nhematology ward and expert s suggestion to appraise\nprotective isolation benefits using large well conducted\nrct \nin neutropenic patients with suspected sepsis  urgent\nbroad antibiotic therapy is mandatory and failure to initiate\nadequate antibiotic therapy within 1 hour has been\nassociated with a 10 fold increase in adjusted mortality \ncurrent idsa guidelines recommend using preferentially\nlarge antipseudomonas betalactam therapy  routine\nantibiotic combination using aminoglycosides is\ncontroversial and not recommended  on one hand  meta\nanalyses suggested notonly a lack of benefit from this\nassociation but also increased rate of renal failure and a\ntrend towards a higher mortality rate with aminoglycosides\nuse  on the other hand  subgroup analysis and lowlevel\nevidences studies suggest however a benefit from\naminoglycosides in criticallyill patients  patients with\nsevere sepsis  or those with documented gram negative\ninfection  along this line  both the recent cochran\nsystematic review and the recent french guidelines\nfocusing on neutropenia management in criticallyill patients advocated additional trials in this field focusing in\nthe sickest patients \nthe current study aims to assess benefits of protective\nisolation and systematic use of aminoglycosides\ncombination antibiotic therapy in criticallyill patients with\ncancerrelated neutropenia and sepsis or septic shock  to\ndo so  we intend to perform a 2x2 factorial design\nrandomized pragmatic trial comparing on one hand\nbenefits of protective isolation  versus no protective\nisolation  and in the other hand benefits of systematic\naminoglycosides antibiotics combination  versus no\nsystematic combination  ",
    "OBJECTIVE": "main objective and primary\nendpoint  to evaluate the impact on day90 mortality of two\nstrategies  separately  using a 2x2 factorial design rct \n  intervention 1  routine association of aminoglycoside\nto initial antibiotic therapy when compared to standard\nof care\n  intervention 2  lack of routine use of protective\nisolation when compared to standard of care\nprimary endpoint  day90 mortality secondary objectives and\nendpoints  to evaluate the impact of the studied interventions  on\n day28 and hospital outcome\n incidence  severity and duration of aki\n incidence of clinically apparent loss of hearing\n rate of adherence of hand hygiene\n rate of selected adverse events\n rate of nosocomial bacterial  viral and fungal\ninfection episodes\n organ support during icu stay and organ support\nduration\n failure of initial antibiotic therapy\n antibiotic duration\n rate of aminoglycosides overdosage and overuse\nsecondary endpoints\n day28 and hospital mortality\n incidence and severity of aki according to kdigo\ndefinition\n major adverse kidney events at day28 and day 90\n composite of death  new renal replacement therapy  or\npersistent renal dysfunction  \n incidence of clinically apparent loss of hearing at end of\nicu stay and day 90\n rate of adherence to adequate hand hygiene as\nassessed by external observer \n incidence density of selected serious adverse events\nincluding unexpected cardiac arrest \n incidence density of new bacterial  viral or fungal episode \n number of days free from organ support therapy\n mechanical ventilation  vasopressors or rrt  at day 28\n rate of clinical cure\n frequency of initial antibiotic therapy inadequate as\nregard to microbiological documentation   number of day free of antibiotic therapy at day28\n duration of aminoglycoside therapy  rate of\naminoglycoside overdosage according to residual\nconcentration and overuse when compared to experts\nrecommendations",
    "DESIGN": "design of the trial  prospective  randomized  open label  controlled \nmulticenter 2x2 factorial  pragmatic  clinical trial scope of the trial  after checking the eligibility criteria  the patients will be\nrandomized according to a balanced scheme and will be\nallocated in one arm of each intervention   aminoglycoside  either systematic addition of\naminoglycosides to probabilistic antibiotic therapy\nfor a maximum of 3 days  or aminoglycoside only in\nspecific predefined indications\n isolation  either protective isolation  geographical \ntechnical  with air filtration  or universal measures\nexpanded  with mask during viral epidemic\nepisodes ",
    "INCLUSION CRITERIA": "population of trial subjects  adult patients admitted to intensive care inclusion criteria   age   18 years\n admitted in one of the participating icu\n sepsis or septic shock as defined by sepsis3 definition\n underlying tumor  allogeneic stem cell transplantation or\nhematological malignancy\n neutropenia  defined by either absolute neutrophil count\n 500 mm3 or leucocytes  1000 mm3  related to an\nunderlying malignancy or its treatment\n informed or deferred consent",
    "EXCLUSION CRITERIA": "exclusion criteria   pregnancy and breastfeeding\n moribund patients  death expected within 48 hours by\nattending physician \n previous participation to this study\n no affiliation to social security\n patients under legal protection according to french law\n patient having received more than 1 injection of\naminoglycosides in the 3 days preceding icu admission\n contraindication to aminoglycosides as mentioned in\nspc section 4 3 \no hypersensitivity to amikacin  to other antibiotics from\nthe aminoglycoside family  or to any excipient from the\namikacin used \no patients with documented allergy to aminoglycosides\no myasthenia gravis\no concomitant administration of intravenous polymyxin\n delay between onset of sepsis and inclusion 24 hours",
    "INTERVENTION": "investigational strategy and\nmedicinal product s     intervention 1  association of aminoglycoside to initial\nantibiotic therapy\n  intervention 2  lack of routine use of protective\nisolation  weak protective isolation  comparator strategy and\ntreatment    intervention 1  antibiotic therapy without systematic\nadjunction of aminoglycosides\n  intervention 2  standard of care protective isolation",
    "STATISTICS": "statistical analysis  according to previous studies by our study group  day90\nmortality in the studied population is expected to be of 60  \nassuming a 15  target effect for each of the interventions\ncompared with their respective control  a type i error rate\nof 0 05 and a power of 80   each group should include 170\npatients on the basis of a twosided logrank test  no\ncorrelation is expected between interventions  only main\neffects will be estimated  and interaction between\ninterventions tested \naucune analyse intermédiaire n est prévue",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  combinationlock01",
    "INVESTIGATOR": "coordinating investigator  michael darmon\nservice de médecine intensive et réanimation\nchu saintlouis  aphp\ntel   01 42 49 94 22\nmichael darmon aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included  340",
    "SITES": "number of sites  14 icus in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris sources of funding for the trial  phrck18102"
  },
  "INTORETAK": {
    "TITLE": "full title  multicentre  randomized  prospective trial evaluating the efficacy\nand safety of infliximab to tocilizumab in refractory or relapsing\ntakayasu arteritis",
    "JUSTIFICATION": "scientific justification  takayasu arteritis  ta  is a vasculitis of unknown origin  resulting in\nprogressive thickening and stenosis of large and medium arteries\n the aorta and its major branches  and the pulmonary arteries   first\nline therapy of ta consists of high dose corticosteroids  cs \n mukhtyar et al  2009   between 20 and 50  of cases respond to cs\nalone  with subsequent resolution of symptoms and stabilization of\nvascular abnormalities  shelhamer et al  1985  maksimowicz\nmckinnon et al  2007   although secondline agents  methotrexate \nazathioprine  mercaptopurine  mycophenolate mofetil  may result in\ninitial remission  relapses remain common when prednisone is\ntapered  maksimowiczmckinnon et al  2007   thus  50  of cs\nresistant or relapsing ta patients may achieve sustained remission\nwith the addition of methotrexate  hoffman et al  1994   during the\nlast decade  biologics such as antitumor necrosis factor alpha  anti\ntnfα  and antiinterleukin6  antiil6  have been used as thirdline\ntreatment in refractory or relapsing ta  almost 90  of cs \nmethotrexate resistant ta cases responded to infliximab  an anti\ntnfα  and sustained remission was obtained in 37 to 76  of the\ncases  schmidt et al  2012  comarmond et al  2012  mekinian et al \n2012   tocilizumab  an antiil6 has given similar results with 68  of\nsustained remission in refractory ta  abisror et al  2013   irrespective\nof classical cardiovascular risk factors  the systemic inflammation and\ncs use play a pivotal role in the occurrence of cardiovascular\nthrombotic events  cves   roubille et al  2015   as cves overlap with\nta complications it is primordial to drastically taper cs in that\nvasculitis  we therefore hypothesize that infliximab or tocilizumab\ncan achieve a remission in more than 70  of refractory relapsing ta\ncases to cs associated to a secondline agent  intoretak  first\nrandomized prospective study in ta  has an original design testing\ninfliximab and tocilizumab propensity to achieve over 70  of\nsustained remission in refractory relapsing ta and evaluating jointly\nthe 2 arms ",
    "OBJECTIVE": "primary objective and assessment\ncriterion  to obtain  by arm    70  of patients at 6 months posttreatment\nwith prednisone  or the prednisolone *   0 1mg kg per day and\ninactive disease  nih score   1  during the last 3 months \nproportion at 6 months posttreatment of patients with prednisone\n or the prednisolone    0 1mg kg per day and sustained inactive\ndisease  nih score   1  from m3 to m6 and same biological therapy\nfrom since the treatment  among randomized patients in each arm  secondary objectives and assessment\ncriteria  to estimate the incidence of relapse between 3 and 6 months post\ntreatment in each arm \nto estimate the incidence of traitement failure at 3 months post\ntreatment in each arm  to estimate the incidence of revascularization procedures\n endovascular or surgical  required due to the disease at 6   12\nmonths posttreatment in each arm \nto estimate the cumulative dose of prednisone  or the\nprednisolone  at 6   12 months posttreatment in each arm \nto estimate the incidence of adverse events at 6   12 months post\ntreatment in each arm \nto estimate the mean change in sf36 qualityoflife values from d1\nof treatment to 6   12 months posttreatment in each arm \nto estimate the proportion of new vascular lesions at 6   12 months\nposttreatment in each arm measured by angiocomputorized\ntomography or magnetic resonance imaging angiography \nincidence of relapse as defined by the nih criteria between 3 and 6\nmonths after day1 of treatment \nincidence of revascularization procedures  endovascular or surgical \nfrom d1 of treatment to 6 months posttreatment \nincidence of traitement failure at m3 after day1 of treatment i e\ndisease still active according to the nih criteria\nproportion at 6 months after day1 of treatment of patients with\nprednisone  or the prednisolone    0 1mg kg per day and\nsustained inactive disease  modified nih score  without criterion 3 \n  1  from m3 to m6 and same biological therapy from day1 of\ntreatment among the randomized patients in the same arm \nincidence of relapse as defined by the modified nih criteria  without\ncriterion 3   2 between m3 and m6 after day1 of treatment \nincidence of traitement failure at m3 after day1 of treatment i e\ndisease still active according to the modified nih criteria  without\ncriterion 3   2\ncumulative doses of prednisone  or the prednisolone  in each arm\nat 6   12 months after day1 of treatment \nincidence of adverse events of grades iii or iv at 6   12 months after\nday1 of treatment \nmean change in the quality of life questionnaire sf36 from d1 of\ntreatment to 6   12 months after treatment \nproportion of new vascular lesions at 6   12 months after day1 of\ntreatment assessed measured by angioct or mr angiography",
    "DESIGN": "experimental design  this open randomized clinical trial is based on a simon s twostage\ndesign  simon  1989  that will be used separately  in both arms  the\nrandomization and thus allocation concealment between both arms\nwill insure the absence of selection bias in allocating the\nexperimental treatments to the patients  with no betweenarm\ncomparison test  only estimates of difference in the end points\nbetween treatment arms will be provided ",
    "INCLUSION CRITERIA": "population involved  adult patients with refractory or relapsing takayasu arteritis inclusion criteria  diagnosis of takayasu arteritis if at least 3 of the 6\n  criteria of the american college of rheumatology  acr \nare met  appendix 1 \n  age at disease onset or 1st symptoms   40 years old \n  limb claudication \n  anisotension  10mm hg between brachial systolic arterial\npressures \n  decreased brachial artery pulse  one or both arteries  \n  bruit over subclavian arteries or aorta    arteriogram abnormality  arteriographic narrowing or\nocclusion of the entire aorta  its primary branches  or large\narteries in the proximal upper or lower extremities  not due\nto arteriosclerosis  fibromuscular dysplasia  or similar\ncauses  changes usually focal or segmental \n  or otherwise if at least two major or one major and two\nminor criteria or four minor criteria of the ishikawa s\ncriteria modified by sharma are met  appendix 1 \nthree major criteria \n  left mid subclavian artery lesion  the most severe stenosis\nor occlusion present in the mid portion from the point 1 cm\nproximal to the vertebral artery orifice up to that 3 cm distal\nto the orifice determined by angiography\n  right mid subclavian artery lesion  the most severe\nstenosis or occlusion present in the mid portion from the\nright vertebral artery orifice up to that 3 cm distal to the\norifice determined by angiography\n  characteristic signs and symptoms of at least one month\nduration  these include limb claudication  pulselessness or\npulse differences in limbs  an unobtainable or significant\nblood pressure difference    10 mmhg systolic blood\npressure difference in limbs   fever  neck pain  transient\namaurosis  blurred vision  syncope  dyspnea or palpitations\nten minor criteria \n1  high esr  unexplained persistent high esr   20 mm h\n westergren  at diagnosis or presence of the evidence in patient s\nhistory\n2  carotid artery tenderness  unilateral or bilateral tenderness of\ncommon arteries on palpation  neck muscle tenderness is\nunacceptable \n3  hypertension  persistent blood pressure   140 90 mmhg brachial\nor   160 90 mmhg popliteal\n4  aortic regurgitation or annuloaortic ectasia  by auscultation or\nechocardiography or angiography\n5  pulmonary artery lesion  lobar or segmental arterial occlusion or\nequivalent determined by angiography or perfusion scintigraphy  or\npresence of stenosis  aneurysm  luminal irregularity or any\ncombination in pulmonary trunk or in unilateral or bilateral\npulmonary arteries determined by angiography \n6  left mid common carotid lesion  presence of the most severe\nstenosis or occlusion in the mid portion of 5 cm in length from the\npoint 2 cm distal to its orifice determined by angiography \n7  distal brachiocephalic trunk lesion  presence of the most severe\nstenosis or occlusion in the distal third determined by angiography \n8  descending thoracic aorta lesion  narrowing  dilation or\naneurysm  luminal irregularity or any combination determined by\nangiography  tortuosity alone is unacceptable \n9  abdominal aorta lesion  narrowing  dilation or aneurysm  luminal\nirregularity or aneurysm combination \n10 coronary artery lesion  documented on angiography below the\nage of 30 years in the absence of risk factors like hyperlipidemia or\ndiabetes mellitus\n  active disease according to the international criteria of the\nnational institute of health  nih   appendix 2  if at least 2\nof the following criteria are met\ncriterion 1  if at least 1 of the following systemic characteristics \nwithout any other cause identified   erythema nodosum\n  fever   38 c for more than a week\n  polyarthralgia   arthritis\n  episcleritis\ncriterion 2  at least 1 of the following clinical signs have appeared\nsince the previous visit\n  carotidodynia  vascular claudication or pain along an\narterial pathway\n  constituted or transient ischemic stroke  acute coronary\nsyndrome  angina\n  abolition of a pulse\n  vascular bruit\n  anisotension\ncriterion 3  at least 2 of the following biological signs\n  creactive protein  10 mg l\n  fibrinogen  4 g l\n  orosomucoïde   1 2 g l\n  haptoglobine   2 5 g l\ncriterion 4  at least 1 of the following radiological signs\n  arterial wall thickening and wall contrast measurement in\nangiomri or angiotdm\n  appearance of new vascular lesions in angiomri or angio\ntdm\n  refractory relapsing disease or symptomatic severe\narterial involvement\nrefractory relapsing disease is considered if one of\nthe following conditions are met \n1  inability to taper corticosteroids below\n1mg kg day within 1 month because the\ndisease is still active\n2  inability to taper corticosteroids below\n10mg day within 6 months\n3  inability to discontinue corticosteroids after 1\nyear of treatment\n4  relapse of disease after gradual decrease of\ncorticosteroids therapy\nor\nsymptomatic severe arterial involvement defined as\nfollows  stroke  retinopathy  symptomatic coronary\nartery stenosis  symptomatic pulmonary artery\nstenosis  symptomatic mesenteric arteries or celiac\ntrunk stenosis  symptomatic renal artery stenosis \n  patients with one immunosuppressive agent\n methotrexate  azathioprine  mercaptopurine or\nmycophenolate mofetil  leflunomide  ciclosporine \nhydroxychloroquine  with no change in dosage within the\nlast 30 days unless allergy intolerance or\ncontraindication to immunosuppressive agents \n  age of 158 years or older\n  weight 40   120 kg\n  medical followup in a university or general hospital in\nfrance\n  social insurance   willing and able to provide written informed consent\n  willing and able to comply with treatment and followup\nprocedures required by the study protocol\n  for female subjects of childbearing age  a negative serum\npregnancy test and no pregnancy plans within 12 months \n  for subjects with reproductive potential  a willingness to\nuse contraceptive measures adequate to prevent the\nsubject or the subject s partner from becoming pregnant\nduring the study  adequate contraceptive measures include\nhormonal methods used for two or more cycles prior to\nscreening  e g   oral contraceptive pills  contraceptive\npatch  or contraceptive vaginal ring   barrier methods  e g  \ncontraceptive sponge  diaphragm used in conjunction with\ncontraceptive foam or jelly  or condom used in conjunction\nwith contraceptive foam or jelly   intrauterine methods\n iud   sterilization  e g   tubal ligation or a monogamous\nrelationship with a vasectomized partner   and abstinence \n  chest xray results  posteroanterior and lateral  or chest ct\nwithin 12 weeks prior to the inclusion   randomization visit\nwith no evidence of active tuberculosis  active infection  or\nmalignancy\n  tuberculosis assessment meeting one of the following\nconditions \n1  active tuberculosis infection treatment achieved\n2  completion of at least 3 weeks treatment for\nlatent tuberculosis infection\n3  negative tuberculin skin test  tst  or interferon\ngamma release assay  igra   e g   quantiferon \ntb gold or tspot tb  test \n4  a potential subject with a positive tst or igra at\ninclusion is eligible if her his chest xray does not\nshow evidence suggestive of active tuberculosis\ninfection and there are no clinical signs and\nsymptoms of pulmonary and or extrapulmonary\ntuberculosis infection  these subjects with a latent\ntuberculosis infection should have completed the\nfull or currently receive since at least 3 weeks the\ntreatment for latent tuberculosis infection \n  negative human immunodeficiency virus  hiv  serology \nnegative hepatitis c rna  and hepatitis b surface antigen\nwithin 3 months ",
    "EXCLUSION CRITERIA": "noninclusion criteria    active tuberculosis or untreated latent tuberculosis infection\ncurrently treated less than 3 weeks\n  evidence of active infection  includes chronic infection \n  infection requiring treatment with antibiotics within 2 weeks prior\nto the inclusion   randomization visit\n  infection with positive human immunodeficiency virus  hiv \nserology  positive hepatitis c rna   or a positive hepatitis b surface\nantigen \n  pregnancy or lactation\n  inability to comply with study guidelines\n  inability to provide informed consent\n  alcohol or drug abuse  that  in the investigator s opinion  could\nprevent a subject from fulfilling the study requirements or that\nwould increase the risk of study procedures   severe renal insufficiency  creatinine clairance\n 30ml min 1 73m2 \n  hepatic dysfunction as shown by aspartate transaminase  ast  or\nalanine transaminase  alt  levels  5 fold the upper limit of normal\n  heart failure   stage iii   iv nyha \n  history of any malignant neoplasm except adequately treated\nbasal or squamous cell carcinoma of the skin  or solid tumors\ntreated with curative therapy and disease free for at least 5 years \n  history of multiple sclerosis and or demyelinating disorder\n  history of severe allergic or anaphylactic reactions to infliximab \nany chimeric murine monoclonal antibody  tocilizumab  and their\nrespective excipients or prednisone  or the prednisolone \n  history of immediate hypersensitivity reaction to iodinated and\ngadoliniumbased contrast media\n  cytopenia  hemoglobin   8 5 g dl  absolute neutrophil   1 5 g l \nplatelet count   80 g l\n  any live  attenuated  vaccine fewer than 4 weeks before\nenrolment  recombinant or killed virus vaccines fewer than 2\nweeks before the inclusion   ransomization visit \n  use of the following systemic treatments during the specified\nperiods\natreatment with biologic therapy  infliximab  adalimumab \ncertolizumab pegol  golimumab  anakinra  tocilizumab \netanercept  abatacept  ixekizumab  secukinumab \nustekinumab  alemtuzumab  within 3 months prior to the\ninclusion   randomization visit\nbpast treatment with rituximab within the past 12 months  or\npast treatment with rituximab more than 12 months ago\nwhere the b lymphocytes count has not returned to normal at\ntime of the inclusion   randomization visit\nctreatment with any systemic alkylating agents within 3\nmonths prior to the inclusion   randomization visit  e g  \ncyclophosphamide  chlorambucil \n  indication to initiate infliximab or tocilizumab for another active\ndisease than takayasu arteritis\n  lack of affiliation to a social security benefit plan  as a beneficiary\nor assignee \n  presence of any of the following onongoing and ontreatment\ndisease processes \no microscopic polyangiitis\no granulomatosis with polyangiitis\no eosinophilic granulomatosis with polyangiitis\no polyarteritis nodosa\no cogan s syndrome\no behcet s disease\no kawasaki s disease\no atypical mycobacterial infections\no deep fungal infections\no lymphoma  lymphomatoid granulomatosis  or other type of\nmalignancy that mimics vasculitis\no cryoglobulinemic vasculitis\no systemic lupus erythematosus\no rheumatoid arthritis o mixed connective tissue disease or any overlap autoimmune\nsyndrome\no known constitutive immunodeficiency",
    "INTERVENTION": "treatment being tested  arm a   patients will receive infliximab 5mg kg intravenously at week\n0  2  6  14  22  following prescription recommendations  during 6\nmonths \narm b   patients will receive tocilizumab 8mg kg intravenously at\nweek 0  4  8  12  16  20  24  following prescription recommendations \nduring 6 months ",
    "STATISTICS": "statistical analysis  we will randomize 25 patients in each arm \nfor each arm  the null hypothesis  response rate 0 40  will be tested\nagainst a onesided alternative  response rate 0 70  with 0 0248 type\ni error rate and power 0 8061  the first stage includes 10 patients in\neach arm  if 5 or fewer responses are observed in these patients  the\narm is stopped  otherwise  15 additional patients are accrued  the\nnull hypothesis will be rejected if 14 or more responses are observed\nin the 25 patients ",
    "DSMB": "data safety monitoring board\nanticipated  yes",
    "ACRONYM": "acronym  intoretak  infliximab and tocilizumab in refractory relapsing\ntakayasu arteritis ",
    "INVESTIGATOR": "coordinating investigator  dr tristan mirault\nnational reference centre for rare vascular diseases\ngeorgespompidou european hospital\nuniversity hospital paris ouest\nparis descartes university  sorbone paris cite\naphp  paris  france\ntristan mirault aphp fr\n 33 1 56 09 30 51",
    "NUMBER OF INCLUSIONS": "number of subjects chosen  50 patients",
    "SITES": "number of centres  multicentre national study including 18 centres",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding source  phrcn 2016   french ministry of health"
  },
  "TRIBECA": {
    "TITLE": "full title  multicenter randomized doubleblind study comparing\nthe efficacy and safety of belimumab in the treatment of\nnoninfectious active cryoglobulinemia vasculitis\ncompared to placebo",
    "JUSTIFICATION": "scientific justification  cryoglobulinemia vasculitis is associated with significant\nmorbidity and mortality  and requires therapeutic\nintervention  the management of noninfectious mixed\ncryoglobulinemia vasculitis is currently based on\ncorticosteroids  and rituximab  during the last decade \nseveral groups have reported on the efficacy of anti\ncd20 monoclonal antibody  rituximab  in patients with\ncryoglobulinemia vasculitis  rituximab infusions proved\neffective on main vasculitis signs  with a complete\nclinical response in 6570  of patients  however \ncryoglobulinemic vasculitis relapse is noted in up to 40 \npatients within few days to nineteen months after the last\nrituximab infusion  we and other have previously shown\nthat serum blys concentration was correlated with\nserum cryoglobulin level and with cryoglobulinemia\nvasculitis and cryoglobulinemia associated b non\nhodgkin s lymphoma  in agreement with data in systemic\nlupus erythematosus and sjögren s syndrome  we also\nobserved decrease in blys binding and in br3 staining\nwhich was correlated with disease severity  following\nrituximab serum blys concentration significantly\nincreased and may favour the survival of autoreactive b\ncell clones and relapses of cryoglobulinemia vasculitis  a\nrecent study has shown that rituximab does not reset\ndefective early b cell tolerance checkpoints  an obvious\nsolution to prevent the rise in baff levels from\nprecipitating a flare of disease following rituximab\ntherapy  and thus to achieve sustained remission of\ndisease  would be to combine rituximab with baff\nblockade  in mice  a combination of b cell depletion and\nbaff inhibition removes b cells in the marginal zone\nand follicular compartments more effectively than either\ntreatment alone  a combination of b cell depletion and\nbaff blockade was superior to b cell depletion alone\nwith respect to reducing the numbers of plasmablasts\nand plasma cells  as well as reducing disease severity \nin three different mouse models of lupus  in addition \npromising results have been observed in patients with\ncryoglobulinemia vasculitis treated by rituximab plus belimumab and with good safety profile ",
    "OBJECTIVE": "main objective and primary\nendpoint  to evaluate efficacy of belimumab compared to placebo\nin patients with noninfectious active cryoglobulinemia\nvasculitis \ncomplete clinical response rate of vasculitis symptoms\nat week  w  25 with corticosteroid withdrawal\n prednisone at 0 mg day  at week  w  12  secondary objectives and\nendpoints  secondary objectives\n  safety and tolerability of treatments as assessed by\nfrequency and severity of adverse clinical events\n  complete  partial  improvement in some but not all\norgans involved at baseline  and non clinical  no clinical\nimprovement  response rate\n  rate of complete renal response\n  rate of cryoglobulinemia clearance\n  rate of negativation of rheumatoid factor activity\n  rate of normalization of c4 complement level\n  early failure rate at w5  non clinical response at w5 \n  clinical relapse rate and the time to relapse between\nthe two treatments groups \n  cumulative dose of corticosteroids received between\nthe two treatments groups \n  evolution of gammaglobulin and of cd19  b cells\nlevels\n  quality of life scores  sf36   appendix 1  between the\ntwo treatment groups \n  rate of infections  severe or not  and other\ncomplications  lymphoma  \n  bvas activity score  appendix 2 \nsecondary endpoints\n  safety and tolerability of treatments as assessed by\nfrequency and severity of adverse clinical events at\nw25 and at w48\n  complete  partial and non clinical response rate at\nw13  w25 and at w48 \n  complete renal response rate at w13  w25 and w48\n  rate of cryoglobulinemia clearance  of negativation of\nrheumatoid factor activity and of normalization of c4\ncomplement level at w13  w25 and at w48\n  rate of early failures  non clinical response at w5  \n  clinical relapse rate defined by de novo appearance or\nreappearance of a manifestation attributable to\ncryoglobulinemia vasculitis during 48 weeks of follow\nup \n  rate and time to relapse from baseline to w48\n  cumulative dose of prednisone at w25 and at w48 \n  quality of life score sf36 at baseline w25 and w48 \n  rate of infections  severe or not  and other\ncomplications during the 48 weeks of followup\n  evolution of gammaglobulin and of cd19  b levels\nfrom baseline to w48\n  bvas activity score at baseline  w13  w25 and w48 ",
    "DESIGN": "design of the trial  this is a bayesian phase ii randomized clinical trial that\naims at evaluating the best treatment strategy of\ncryoglobulinemia vasculitis  based on difference in the\nresponse rate as measured at week 25 after\nrandomization  scope of the trial  phase ii prospective randomized  multicentre  double\nblind  study \ngroup i  belimumab administered subcutaneously\n200mg weekly from w1 to week 24 \ngroup ii  placebo of belimumab administered\nsubcutaneously weekly from w1 to week 24 \nrandomization will be centralized  stratified on previous\ntreatment history  naive patients versus relapsing\npatients  and the severity of vasculitis  i e  extensive\nskins necrosis  glomerulonephritis  multiple\nmononeuropathy  myocarditis  digestive or central\nnervous system specific involvement  in a 1 1 ratio\nbetween groups \nboth groups will have the same corticosteroid tapering\nscheme  with an initial dose of 30 mg day  the following\nschedule of reduction of prednisone will apply to both\ngroups as long as the disease is inactive \n30 mg day week  w 0w2 \n20 mg day w2w4\n15 mg day w4w6 \n10 mg day w6w8 \n5 mg day w8w10 \nbetween w10w12 the strategy for stopping\nglucocorticoids is left to the investigator s discretion\nstopping glucocorticoid therapy at w12\nat each step  the prednisone dose will be reduced only\nin the absence of signs of vasculitis activity ",
    "INCLUSION CRITERIA": "population of trial subjects  adult patients with noninfectious active\ncryoglobulinemia vasculitis  inclusion criteria  1  age   18 years\n2  written inform consent\n3  active cryoglobulinemia vasculitis  at initiation of\nrituximab  define by a clinically active vasculitis with\nskin  joint  renal  peripheral nerve  central\nneurological  digestive  pulmonary and or cardiac\ninvolvement  and history of positive cryoglobulinemia\n4  affiliated to national french social security system\n5  having received rituximab as induction therapy\nwithin 6 weeks  1 to 4 infusions  dose at the\ndiscretion of the investigator \n6  female subjects of childbearing potential must have\na negative serum or urinary pregnancy test at\ninclusion visit  and confirmed monthly while in study \nout to at least 92 days  5 half lives  post last dose \n7  for subjects with reproductive potential  male or\nfemale   a willingness to use contraceptive measures\nadequate to prevent the subject or the subject s\npartner from becoming pregnant during the study\nfrom 2 weeks prior to administration of the 1st dose\nof study agent until 92 days after the last dose of\nstudy agent  therefore the subjects agree to 1 of the\nfollowing \na  complete abstinence from intercourse from 2\nweeks prior to administration of the 1st dose of\nstudy agent until 92 days after the last dose of\nstudy agent  sexual inactivity by abstinence must\nbe consistent with the preferred and usual\nlifestyle of the subject   periodic abstinence  e g \ncalendar  ovulation  symptothermal  post\novulation methods  and withdrawal are not\nacceptable methods of contraception \nor\nb  consistent and correct use of 1 of the following\nacceptable methods of birth control for 1 month\nprior to the start of the study agent  during the\nstudy  and 92 days after the last dose of study\nagent\no oral contraceptive  either combined or\nprogestogen alone\no injectable progestogen\no implants of levonorgestrel or etonogestrel\no estrogenic vaginal ring o percutaneous contraceptive patches\no intrauterine device  iud  or intrauterine\nsystem  ius  with  1  failure rate as stated\nin the product label\no male partner sterilization  vasectomy with\ndocumentation of azoospermia  prior to the\nfemale subject s entry into the study  and this\nmale is the sole partner for that subject  for\nthis definition   documented  refers to the\noutcome of the investigator s designee s\nmedical examination of the subject or review\nof the subject s medical history for study\neligibility  as obtained via a verbal interview\nwith the subject or from the subject s medical\nrecords\no double barrier method  condom and\nocclusive cap  diaphragm or cervical vault\ncaps  plus spermicidal agent\n foam gel film cream suppository \nthese allowed methods of contraception are only\neffective when used consistently  correctly and in\naccordance with the product label  the investigator is\nresponsible for ensuring subjects understand how to\nproperly use these methods of contraception \n8  hiv negative serology   negative hbs ag test and\nhbc ab test  hcv negative serology or negative\nhcv rna if positive hcv serology within 3 months\nbefore inclusion\n9  neutrophils  anc   1x109 l ",
    "EXCLUSION CRITERIA": "exclusion criteria  1  patient with a vasculitis unrelated to\ncryoglobulinemia\n2  patient with non active cryoglobulinemia vasculitis  at\ninitiation of rituximab  patients with inactive vasculitis\nfollowing rituximab administration may be included \n3  excluded concomitant medications\na  365 days prior to investigational medicinal\nproduct  belimumab or placebo   \no any biologic investigational agent  e g  \nabetimus sodium  anti cd40l antibody \nbg9588  idec 131 \n  investigational agent applies to\nany drug not approved for sale in\nthe country in which it is being\nused\nb  180 days prior to investigational medicinal\nproduct  belimumab or placebo   \nc  intravenous cyclophosphamide 30 days prior to\ninvestigational medicinal product  belimumab or\nplacebo    or 5 half lives  whichever is greater \no any nonbiologic investigational agent\n investigational agent applies to any drug not approved for sale in the country in\nwhich it is being use \nd  live vaccines within 30 days prior to baseline or\nconcurrently with investigational medicinal\nproduct  belimumab or placebo \n4  have a history of malignant neoplasm within the last\n5 years  other than carcinoma in situ of the cervix or\nexcised basal cell  squamous cell carcinoma of the\nskin and lowgrade hemopathy with no indication for\na specific treatment\n5  have a progressive multifocal leukoencephalopathy\n6  have evidence of serious suicide risk including any\nhistory of suicidal behaviour in the last 6 months\nand or any suicidal ideation in the last 2 months or\nwho in the investigator s judgment  pose a significant\nsuicide risk\n7  have a history of a primary immunodeficiency\n8  have a significant igg deficiency  igg level   400\nmg dl  and or significant iga deficiency  iga level  \n10 mg dl  according to results obtained within 1\nmonth prior to inclusion visit\n9  have a history of major organ transplant or\nhematopoietic stem cell marrow transplant or renal\ntransplant \n10  infection history \na  currently on any suppressive therapy for a chronic\ninfection  such as tuberculosis  pneumocystis \ncytomegalovirus  \nb  infection requiring hospitalization and or use of\nparenteral  iv or im  antibiotics  antibacterials \nantivirals  antifungals  or antiparasitic agents \nwithin 60 days of the inclusion visit \n11  have current drug or alcohol abuse or dependence \nor a history of drug or alcohol abuse or dependence\nwithin 365 days prior the inclusion visit\n12  have a historically positive hiv test according to\nresults obtained within 3 months prior to inclusion visit\n13  hepatitis status according to results obtained within 3\nmonths prior to inclusion visit \na  serologic evidence of current or past hepatitis b\n hb  infection based on the results of testing for\nhbsag and hbcab as follows  patients positive\nfor hbsag or hbcab are excluded\nb  positive test for hepatitis c rna\n14  have a history of a hypersensitivity or an anaphylactic\nreaction to parenteral administration of belimumab \ncorticosteroids or any excipients of the treatments\nadministered during the study 15  if women of child bearing potential  wcbp  are\nincluded please see special instructions in inclusion\ncriteria\n16  pregnant or breast feeding women\n17  have any intercurrent significant medical or\npsychiatric illness that the investigator considers\nwould make the candidate unsuitable for the study\n18  patients under legal protection or unable to consent\n19  participation to another interventional study",
    "INTERVENTION": "investigational medicinal\nproduct s   belimumab benlysta  administered subcutaneously 200\nmg weekly from w1 to week 24 comparator treatment  placebo of belimumab administered subcutaneously\nweekly from w1 to week 24",
    "STATISTICS": "statistical analysis  this is a bayesian phase ii randomized clinical trial that\naims at evaluating the treatment strategy of\ncryoglobulinemia vasculitis  based on difference in the\nresponse rate as measured at week 25 after\nrandomization  randomized phase ii trials are still poorly\nused  with still large use of singlearm phase ii trial\nresults that are interpreted relative to historical control\nsubjects  introducing selection bias and confounding that\nmay limit the validity of the conclusions  thus  planning a\nphase ii randomized trial appears a worthy investment\nconsidering finite patient and financial resources  this\ndesign is adapted to binary outcomes observed at the\nend of a fixed followup period and analyzed using an\nabsolute difference in proportions that has been shown\nto greatly reduce sample size requirements  we thus\nused the approach for phase ii randomized trials\nproposed by simon r  wittes re  and ellenberg ss that\naims at controlling the probability of detecting a given\ndifference in response rates  we hypothesize that up to\n70  of the patients receiving placebo of belimumab and\n85  of those treated by belimumab will achieve a\ncomplete remission of cryoglobulinemia vasculitis at\nweek 25  w25  and with steroid therapy stopped  0\nmg day  at w12 ",
    "DSMB": "trial will have a data\nmonitoring committee  yes",
    "ACRONYM": "acronym  tribeca  treatment after rituximab with belimumab in\ncryoglobulinemia associated vasculitis",
    "INVESTIGATOR": "coordinating investigator  pr david saadoun\ndepartment of internal medicine and clinical immunology\ncentre national de référence des maladies autoimmunes\net systémiques rares\nhospital pitié salpétrière\ntel 0142178009\nemail   david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included  48 patients  24 patients in each arm",
    "SITES": "number of sites  multicentre national study including 20 centres",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  gsk who will also provide belimumab benlysta  and\nplacebo of belimumab "
  },
  "MSC-SLE": {
    "TITLE": "full title  treatment of severe refractory systemic lupus erythematosus by\ninjection of allogeneic mesenchymal stem cells derived from the\numbilical cord",
    "JUSTIFICATION": "scientific justification  systemic lupus erythematosus  sle  is a rare  prevalence  40 50 100\n000 persons  heterogeneous autoimmune and autoinflammatory\ndisease  ad   affecting both sexes and all races  with a peak incidence\n  prevalence among black people and a predilection for women in the\n3rd4th decade of life  sle is characterized by successive periods of\nflares and remission  which may all vary in duration and quality \nprognosis of severe forms of sle  which affect lung  heart or brain in\naddition to renal involvement  has improved  but still evolution remains\npejorative in a subset of patients whose 10 years mortality remains 10\n15   even in tertiary referral centers  for 20 years  no new prospective\nclinical trial in the course of sle has demonstrated its effectiveness \nnew biological therapies have not yet made the long awaited\nbreakthrough in the treatment of severe sle and only antiblys\nmonocolonal antibody has gained indication in moderately active sle \nin addition  serious adverse side effects  progressive multifocal\nleukoencephalopathy  observed with several biologics in ad patients\nhas dampened their expected benefits  for sle subjects resistant to 1er\nor 2nd line conventional treatment  there is a need to develop more\neffective therapies with fewer long term side effects  based on new\nimmunomodulatory and immunosuppressive strategies \naccording to their in vitro immunomodulatory properties and ability to\ninduce tissue repair mechanisms  mesenchymal stem cells  msc  have\nbeen proposed as a new therapy for several ad  including sle  the use\nof allogeneic umbilical cordderived msc is based on experimental and\nhuman clinical data  particularly produced by nanjing team  pr sun  in\nchina  it is also logical to select sle patients with the same severity\ncriteria as those used worldwide to validate the efficacy of antiblys\ntherapies  similarly  the analysis of the expected results should take into\naccount criteria similar or comparable to those used for the pivotal\nclinical trials  this trial is a unique opportunity to set up collaboration\nbetween saintlouis aphp  clinical expert center for cell therapy in ad \nand university college london for cell manufacturing ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective \nto assess the tolerance of allogeneic umbilical cord derived msc\nadministration for severe sle refractory to standard therapies\n cyclophosphamide mycophenolate mofetil and corticosteroids with or\nwithout anti cd20 \nprimary endpoint  immediate tolerance as assessed during the first\ninjection and 10 days after the allogeneic msc injection  according to\nstandards ctcae side effects  secondary objectives and\nendpoints  secondary objectives  \n1 feasibility of allogeneic ucmsc administration in the treatment of\nsevere sle subjects refractory to conventional therapies\n2 tolerance three months after injection  considering the observed\nmorbidity and the overall survival in sle treated subjects until 1 year\nafter the procedure \n3 analysis of biological and clinical response on routine clinical and\nbiological examination and criteria for monitoring lupus using\nselena sledai  bilag  sf36  eq5d  sri  sliccsle scores \n4 analysis of the efficacy at 3months after injection of allogeneic uc\nmscs according to the proportion of subjects with major clinical\nresponse  rcm  \n5 percentage of subjects with partial clinical response  cpr  during\nthe 12 months of followup study \n6 evaluation of the immunomodulatory effect of msc by  \na routine laboratory criteria  including immunophenotyping \nevery 3 months during the followup period\nb analysis of specific cytokine production at m0  m1 and m3 \n7 analysis of msc immunogenicity at m0  m1 and m3\nsecondary endpoints  \n1  safety tolerance will be assessed during the injection and within the\nfirst 10 days following the msc injection  at m1  m3  m6 and m12\naccording to side effects defined by ctcae standards  miller\nresults of cancer treatment cancer 1981  47  1   207  214  \ntreatmentrelated toxicity will be analyzed according to the\ninternational world health organization  who   maximum degree of\ntoxic attacks by the body   an injection will be considered as not\ntolerated for any toxicity criteria above grade   3 \n2  proportion of subjects with major clinical response  mcr  and the\nproportion of subjects with partial response clinic  pcr  during the\n12 months of study followup at 3  6  9 and 12 months  m3  m6  m9\nand m12  \n3  disease activity measured by the bilag scores  0 and 72  and\nselenasledai  0 to 105  every 3 months  as compared to\ninclusion  until the end of the followup period  m3  m6  m9 and m12  \n4  sri response rate  measured every three months  m3  m6  m9 and\nm12  during followup  a sri response is defined as a 4 points\nreduction of selena sledaiscore  no new bilag a score for an\norgan and no more than one new bilag b score and no worsening\n increase of 0 3  in the overall evaluation of the physician as\ncompared to inclusion values \n5  presence of comorbidities according scliccsle index at m0 and\nevery three months during study followup  m3  m6  m9 and m12   \nand charlson comorbidity index at eligibility  6  quality of life assessed by the short form 36 version 2  sf36v2 \nand eq5d before injection and every 3 months until the end of the\nmonitoring period  m3  m6  m9 and m12   and at m1 \n7  percentage of subjects with an average dose of prednisone reduced\nby 25  compared to m0 and who will be  7 5 mg   day for weeks 40\nto 52 \nthe average daily corticosteroid dose will be measured every 3 months\nuntil the end of the monitoring period  mo  m3  m6  m9 and m12  \n8  the number of treatment failure defined by one of the following \n end stage renal disease requiring dialysis or transplantation\n sustained doubled creatinine value from the two lowest values\nobserved between screening and baseline and confirmed four weeks\nlater \n active lupus nephritis attributed to active sle as defined by either of\nthe two criteria \ni  a doubling value of proteinuria  proteinuria  1 g   24 hours for the\nsubjects who were  0 5 g   24 hours at baseline or proteinuria  2\ng   24 hours for the subjects who were  1g   24 hours at baseline\nii  nephropathy with a 25  increase in serum creatinine with respect\nto the value at baseline and simultaneously having a value of\nproteinuria doubled up at least 2 g   24 hours  hematuria  two\npositive urine test strips  and the presence cell cylinders \nthese two criteria must be confirmed twice at 2week intervals \n need for steroid therapy intravenously  plasmapheresis \nimmunoglobulin iv or other immunosuppressive therapy to treat\naggravation of sle \n9  standard immunological and biological markers  including\nlymphocytes immunophenotyping  complete blood count  creatinine \nproteinuria 24h  autoantibodies  antidna antibodies and native anas  \ncomplement system c3  c4 and ch50  immunophenotyping  at m0  m1\nand every three months during the followup period of the study  m3 \nm6  m9 and m12  \n10  specific cytokines production at m0  m1  m3 after inclusion \n11  analysis of msc immunogenicity at m0  m1 and m3  according to \n antihla antibodies dosage\n crossmatch analysis",
    "DESIGN": "design of the trial  single center phase iii open study with national recruitment within the\nfai2r network scope of the trial  the immunosuppressive and   or immunomodulatory action of\nallogeneic mscs  from umbilical cords of a healthy donor  will allow\nbeneficial action on patients with severe sle resistant to conventional\ntreatments ",
    "INCLUSION CRITERIA": "population of trial subjects  sle active subjects refractory to prior standard therapies inclusion criteria  patient  \n1 age   18 years and   70 years \n2 diagnosis of systemic lupus erythematosus  sle  according to the\nacr criteria with positive antinuclear antibodies \n3 subjects with sustained disease activity defined by a selena\nsledai sle activity index   6 at baseline \n4 inefficacy or adverse effects necessitating discontinuation of first and\nsecond line therapies of sle including \na  prednisone orally   6 mg   day  or equivalent  for at least 28\ndays \nb  at least one or more of the following immunosuppressive\ntherapies for 3 months in total  i cyclophosphamide  iv bolus  500 mg   month for 3 months\nminimum\nii mycophenolate mofetil  orally or equivalent at a dose  2000 mg\n  day for at least 90 days\niii azathioprine orally at a dose  2 mg   kg   day for at least 90\ndays \niv methotrexate orally or parenterally  at doses   20mg   week\nfor at least 90 days \nv leflunomide orally  at a dose of  10mg   day for at least 90\ndays \nvi rituximab  anticd20  intravenous bolus 375 mg   m2  once a\nweek for four weeks or total dose of 1 g twice a day for two\nweeks\nvii cyclosporine orally  at a dose of 2 55 mg   kg   day  for at\nleast 90 days \nviii belimumab intravenously or subcutaneous at monthly bolus\nof 10 mg   kg infusion   for at least 3 months \n5 patient who received treatment of sle at stable doses for a minimum\nof 30 days prior to eligibility  including one of the following\ntreatments  prednisone  or equivalent  alone or combined with\nantimalarial treatment  an antiinflammatory steroidal and   or an\nimmunosuppressant \n6 negative pregnancy test for women of childbearing age \n7 for men and women   using effective contraceptive methods during\ntreatment and within 3 months after the end of treatment for men with\nher partner of childbearing age\n8 signed informed consent \n9 affiliation to social security ",
    "EXCLUSION CRITERIA": "exclusion criteria  subjects \n1 pregnancy  breastfeeding or lack of appropriate contraception\nduring study duration\n2 presence of \na  renal failure  calculated creatinine clearance of  30 ml   min\nb  cardiac failure  clinical signs of congestive heart failure  left\nventricular ejection fraction  40  on echocardiography \nuncontrolled ventricular arrhythmia \nc  hepatitis defined by abnormal levels of transaminases  ast \nalt  2 x normal  not related to disease activity \nd  respiratory disease  mean pap  50 mmhg  echocardiography  \nrespiratory failure defined by a resting blood pressure of oxygen\nat pao 2   70 mmhg and   or paco2   50 mmhg without\noxygen\n3 severe psychiatric disorders  including severe psychosis related to\nsle  which would prevent to give informed consent or to undergo\nthe procedure \n4 active neoplasia or concomitant myelodysplasia  except for basal\ncell carcinoma or squamous cell carcinoma or in situ cervix\ncarcinoma \n5 bone marrow failure defined by neutropenia  0 5 109 l \nthrombocytopenia  30  109   l  anemia   8 g   dl  lymphopenia cd4\n   200 x 106   l caused by another disease than sle \n6 acute or chronic uncontrolled infection  hiv 1 2  htlv1 2  hepatitis\nb  hbs ag surface antigen   hepatitis c with positive pcr  optional\npcr \n7 patient having received belimumab intravenously or subcutaneous\nwithin 2 months of baseline  or having received rituximab or other b\ncell depleting biologic therapy within 6 months of baseline\n8 current substance abuse or recent  within 60 days  history of\nsubstance abuse\n9 patient in periods of exclusion from the national roster of\nresearchers\n10 patient with linguistic or psychological incapacity to sign informed\nconsent\n11 patient already included in another study at the same time \n12 poor patient compliance \npatient under legal protection ",
    "INTERVENTION": "investigational medicinal\nproduct s   phase iii  allogeneic umbilical cord derivedmscs injected by slow\nintravenous infusion according to the weight of the recipient and patient\ngroups in the study  at doses of \n 1 106 csm   kg\n 2 106 csm   kg\n 4 106 csm   kg\n1 injection during 30min to 1h by intravenous infusion  comparator treatment  na",
    "STATISTICS": "statistical analysis  initially 5 subjects at the initial dose of 2 106 csm kg recipient weight will\nbe included \nthe following 5 subjects will be enrolled in a dose \n 1 106 ms  kg there is a high probability of excessive toxicity* at 2 106\nmsc   kg \n 4 106 csm kg if there is a low probability of excessive toxicity* 2 106\ncsm   kg\n*the toxicity criteria are described in ctcae classification\neach patient cohort will be scanned in a sequential bayesian approach\nto estimate the probability of toxicity to the administered dose allowing\nan adaptation of the function of the toxicity observed in the dose previous\nsubjects ",
    "DSMB": "trial will have a data\nmonitoring committee  yes",
    "ACRONYM": "acronym  mscsle",
    "INVESTIGATOR": "coordinating investigator  professor dominique fargebancel\ninternal medicine   autoimmune diseases and vascular pathology  uf\n04 hôpital stlouis\n1  avenue claude vellefaux  paris 75010 paris",
    "NUMBER OF INCLUSIONS": "number of subjects included  10 patients",
    "SITES": "number of sites  monocentric  st louis hospital ",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial   subvention de recherche thérapie génique et cellulaire en\nnéphrologie  subv thérapie génique fdrafm airg 2014  funding by\n  fondation du rein and l association française contre les myopathies\n afm téléthon     in collaboration with   l airg france  and drci\n sponsor aphp "
  },
  "PCL-2": {
    "TITLE": "full title  primary plasma cell leukemia  a prospective phase ii study\nincorporating daratumumab to chemotherapy and stem cell\ntransplantation",
    "JUSTIFICATION": "scientific justification  primary plasma cell leukemia  ppcl  is a rare form of plasma cell\nmalignancy  24  of multiple myeloma  with poor prognosis\n overall survival  os    12 months with conventional\nchemotherapy   bortezomibbased regimens have shown\npromising results in small retrospective studies  and transplantation\n auto and or allograft  may improve os for selected young patients \nthe ifm group recently published a prospective study in 40 ppcl\npatients  with alternate bortezomibdexamethasone\ndoxorubicin cyclophosphamide  pad vcd  as induction before\nhigh dose melphalan plus autologous stem cell transplantation\n hdm asct   followed by reduced intensity conditioningallograft\n ricallo  or second hdm asct plus consolidation maintenance\nwith bortezomiblenalidomidedexamethasone lenalidomide \noverall  27 patients  69   were responder to induction and 35 \nachieved vgpr or better  one patient underwent a syngeneic\nallograft and 25 hdm asct  16 of them subsequently received a\nricallograft  7 a second transplant followed by\nconsolidation maintenance  the median pfs and os were 15 and\n36 months  respectively  os seems to be superior in the double\ntransplant maintenance group compared to the allotransplant\ngroup on landmark analysis \nthe italian group also recently reported a prospective trial in ppcl\ninvolving 23 patients treated with lenalidomidedexamethasone \noverall the median pfs and os were 14 and 28 months \nrespectively  nine of 15 patients eligible for transplant could receive\nhdm asct after induction and pfs and os were 27 months and\nnot reached  respectively \ndaratumumab  a monoclonal antibody against cd38 that is highly\nexpressed by plasma cells  is highly effective in relapsed refractory\npatients with multiple myeloma  mm   alone and in combination\nwith lenalidomide  the combination daratumumab and\nbortezomiblenalidomidedexamethasone  daravrd  has been\nrecently tested for newly diagnosed multiple myeloma patients with impressive results and acceptable tolerability  the subcutaneous\nformulation of daratumumab have also been tested in this context\nwith no new safety concerns \nwith the aim to improve hematological responses and survival in\nppcl patients  we propose to combine daratumumab sc and\nbortezomiblenalidomidedex  daravrd  as induction  followed\nby double hdm asct and prolonged consolidation of 2 years  with\ndaravrd for 1 year then lenalidomide for 1 year  ",
    "OBJECTIVE": "main objective and\nprimary endpoint  the primary objective is to determine the best overall response\nrate at completion of induction phase  very good partial response\nor better \nthe primary endpoint is the vgpr or better rate at the completion\nof induction phase  according to the imwg response criteria  secondary objectives\nand endpoints  the main secondary objective is to evaluate progressionfree\nsurvival\nthe other secondary objectives are \n to assess overall hematological response rates\n to evaluate overall survival\n to assess safety and toxicity according to nci ctcae\n to assess cytogenetic abnormalities of tumoral plasma cell\n to analyze the prognostic value of minimalresidual disease\n mrd  by sequencing  ngs   after completion of induction \nbefore second consolidation  before len consolidation and\nat the end of treatment \n to evaluate quality of life  eortc qlqc30 domain scores \nthe secondary endpoints are \n progressionfree survival  overall survival  time to\nprogression and duration of response \n overall hematological response rates\n assess safety by type  frequency  severity  relationship of\nadverse events to study treatment and changes in vital\nsigns  physical exams  incidence of treatment emergent\nadverse event  teae   serious adverse event  sae  and\nlaboratory abnormalities using national cancer institute\n nci  common toxicity criteria  cctae v4  \n evaluate response according to chromosomal structural\nabnormalities such as del 17p   t 4 14   t 11 14   t 14 16  \nt 14 20   amp 1q  and del 1p  \n minimal residual disease  mrd  assessed by ngs\n quality of life  eortc qlqc30 domain scores ",
    "DESIGN": "design of the study  induction phase after inclusion in the trial  patients will receive 4 days of\ndexamethasone  according to local practice  one dose of\ndoxorubicine  30 mg m2 iv  or cyclophosphamide  750 mg m2 iv \nmay also be added to reduce the tumoral mass and minimize the\nrisk of tumor lysis syndrome  tls  \ni  induction treatment  4 months   subject will receive 4 x\n28 days cycles of daravrd induction therapy as\ndescribed below \nagent dose day route cycle days\ndaratumumab 1800 mg s c 1 2 3 4 1  8  15  22\n cycle 1 and 2 \n1 15\n cycle 3 and 4 \nbortezomib 1 3 s c 1  2  3  1  4  8  11\nmg m² 4\nlenalidomide* 25 mg  p o 1  2  3  from d1 to d21 of\n4 each cycle\ndexamethasone 20 mg p o  1 2  3  1 2 8 9 15 16 22 \niv 4 23\n*  the start dose of lenalidomide will be reduced depending on\nrenal function  patients with impaired renal function  calculated or\nmeasured creatinine clearance   50 ml minute  will have\nlenalidomide dose reduction otherwise they will receive full dose\nlenalidomide  25mg  \ntumorlysis prophylaxis and monitoring is required during induction\ntreatment  according to local practice  \nii  disease assessment  local assessment  will be performed\nat the end of the induction to determine if patient continue\nwith the study or not\n  responding patients  response   sd and circulating\nplasma cell   1       pursuit of the study\n  nonresponding patient  response   sd or circulating\nplasma cell   1       off study\nmobilization and harvesting stem cells\nstem cell mobilization will be performed using cyclophosphamide\n recommended dose of 3 g m2  after cycle 4 and stem cells will be\nharvested based on response to mobilization  the use of gcsf\nand plerixafor are permitted per institutional practice  sufficient\nstem cells should be harvested to enable two transplants    5 106\ncd34 kg  \nhigh dose melphalan asct n 1 all eligible patients will start intensification with high dose\nmelphalan between 2 and 4 weeks after stem cell collection \n mephalan 200mg m2 as conditioning therapy  for patients\nwith a creatinine clearance   30 ml min  melphalan dose\nshould be reduced to 140 mg m² \n stem cell reinfusion  subjects will have a single reinfusion\nof stem cells\n minimum 2 5 106 cd34 kg  2448 hours after highdose\nmelphalan    permitted tolerance  \n engraftment recovery  day 160 post asct \nsubjects will be monitored for successful engraftment \nsupport therapy will be administered according to\ninstitutional study group standards\nfirst consolidation  60 days \nconsolidation therapy start at time of complete hematological\nrecovery and according to the investigator s opinion  subject fit\nenough to tolerate subsequent systemic therapy  within 2 months\nafter asct  \nsubjects will receive a further 2 x 28day cycles of daravrd \n daratumumab 1800 mg s c d1 d15\n bortezomib 1 3 mg m2 s c d1 d8 d15 d22\n lenalidomide 25 mg p o from d1 to d21\n dexa 20 mg p o iv d1 d8 d15 d22\nhigh dose melphalan asct n 2\n subjects will receive melphalan 200mg m² as conditioning\ntherapy  for patients with a creatinine clearance   30\nml min  melphalan dose should be reduced to 140 mg m² \n stem cell reinfusion  subjects will have a single reinfusion\nof stem cells  minimum 2 5 106 cd34 kg  2448 hours\nafter highdose melphalan    permitted tolerance \n engraftment recovery  day 160 post asct \nsecond consolidation phase  2 years \nconsolidation therapy start at time of complete hematological\nrecovery and according to the investigator s opinion  subject fit\nenough to tolerate subsequent systemic therapy  within 2 months\nafter asct   this phase will be conducted according to two steps \n consolidation 1  1 year   patients will receive daravrd\nevery 2 months for 6 cycles \no daratumumab 1800 mg s c d1\no bortezomib 1 3 mg m2 s c d1 d8 d15 d22\no lenalidomide 25 mg p o from d1 to d21\no dexamethasone 20 mg p o iv d1 d8 d15 d22  consolidation 2  1 year   patient will receive lenalidomide\nevery 28 days\no lenalidomide 25 mg from d1 to d21   28 days\nnote  during all treatment period  lenalidomide dose will be\nreadjusted according to patient s renal function status  the dose\nadaptation will follow usual recommendations ",
    "INCLUSION CRITERIA": "population of study\nparticipants  screening and eligibility\nthe investigator is responsible for keeping a record of all subjects\nwho sign an informed consent form for entry into the study  all\nsubjects will be screened for eligibility that must take place within\n21 days prior to initiation of therapy \nthe patients must meet the eligibility criteria below to enter the\nstudy  inclusion criteria  1  male or female patients 18 to 69 years old \n2  patient with primary plasma cell leukemia disease as defined\nby the recent international myeloma working group  imwg\n2021     5  circulating plasma cells in peripheral blood smears\n3  voluntary written consent must be given before performance of\nany study related procedure not part of standard medical care \nwith the understanding that consent may be withdrawn by the\npatient at any time without prejudice to future medical care\n4  eastern cooperative oncology group  ecog  performance\nstatus and or other performance status 0  1  or 2 \n5  eligible for high dose melphalan therapy with asct\n6  total bilirubin   2   the upper limit of the normal range  uln  \n7  alanine aminotransferase  alt  and aspartate\naminotransferase  ast    3   uln \n8  calculated creatinine clearance   20 ml min  mdrd formula\nshould be used for calculating creatinine clearance values \n9  female patients who \n have been postmenopausal for at least 2 years before the\nscreening visit  or\n are surgically sterile  or if they are of childbearing\npotential  agree to practice 2 effective methods of\ncontraception  at the same time  from the time of signing the\ninformed consent form through 90 days after the last dose\nof study drug  or\n agree to practice true abstinence when this is in line with\nthe preferred and usual lifestyle of the subject   periodic\nabstinence  e g   calendar  ovulation  symptothermal and\npostovulation methods  and withdrawal are not acceptable\nmethods of contraception   10  male patients  even if surgically sterilized  i e   status post\nvasectomy   must agree to one of the following \n agree to practice effective barrier contraception during the\nentire study treatment period and through 90 days after the\nlast dose of study drug  or\n agree to practice true abstinence when this is in line with\nthe preferred and usual lifestyle of the subject   periodic\nabstinence  e g   calendar  ovulation  symptothermal and\npostovulation methods  and withdrawal are not acceptable\nmethods of contraception  \n11  patients agree\n not to share study medication with any other person and to\nreturn all unused study drugs to the investigator \n to abstain from donating blood while taking the study drug\ntherapy and for one week following discontinuation of the\nstudy drug therapy \n12  must be able to adhere to the study visit schedule and other\nprotocol requirements\n13  affiliated with an appropriate social security system ",
    "EXCLUSION CRITERIA": "exclusion criteria  1  male or female patients  18 or  69 years old\n2  history of malignancy within 3 years before the date of inclusion\n exceptions are squamous and basal cell carcinomas of the\nskin  carcinoma of the skin  carcinoma in situ of the cervix or\nbreast  or other noninvasive lesion that in the opinion of the\ninvestigator  with concurrence with the coordinating\ninvestigatior  is considered cured with minimal risk of\nrecurrence within 3 years \n3  prior history of symptomatic myeloma with previous\nchemotherapy for myeloma except corticotherapy\n dexamethasone 40 mg d for 4 days max  \n4  any other uncontrolled medical condition or comorbidity that\nmight interfere with subject s participation \n5  pregnant or breast feeding females\n6  known positive for hiv\n7  known seropositive for hepatitis c  except in the setting of a\nsustained virologic response  svr   defined as a viremia at\nleast 12 weeks after completion of antiviral therapy \n8  seropositive for hepatitis b  defined by a positive test for\nhepatitis b surface antigen  hbsag    subjects with resolved\ninfection  ie  subjects who are hbsag negative but positive for\nantibodies to hepatitis b core antigen  antihbc  and or\nantibodies to hepatitis b surface antigen  antihbs   must be\nscreened using realtime polymerase chain reaction  pcr \nmeasurement of hepatitis b virus  hbv  dna levels  those who\nare pcr positive will be excluded  exception  subjects with\nserologic findings suggestive of hbv vaccination  anti hbs positivity as the only serologic marker  and a known history of\nprior hbv vaccination  do not need to be tested for hbv dna\nby pcr \n9  patient with severe renal failure that require dialysis and\nclairance creatinine   20 ml min\n10  prior local irradiation within two weeks before first dose \nhowever  an exception  that is patients allowed to remain in\nthe treatment phase of the study  is made for radiation therapy\nto a pathological fracture site to enhance bone healing or to\ntreat postfracture pain that is refractory to narcotic analgesics\nbecause pathologic bone fractures do not by themselves fulfil\na criterion for disease progression  \n11  evidence of central nervous system  cns  involvement\n12  unable to take corticotherapy  daratumumab  bortezomib and\nor lenalidomide at study entry \n13  ongoing active infection  especially ongoing pneumonitis\n14  ongoing cardiac dysfunction  specify e g  uncontrolled\nhypertension  mi within 6 months  unstable angina pectoris \ncardiac arrhythmia grade 2 or higher\n15  patients with a left ventricular ejection fraction under to 40  \n lvef  40   \n16  use of any other experimental drug or therapy within 15 days\nof screening \n17  any  grade 2 toxicity unresolved\n18  inability or unwillingness to comply with birth control\nrequirements\n19  unable to take antithrombotic medicines at study entry\n20  major surgery within 14 days before enrolment \n21  any serious medical or psychiatric illness that could  in the\ninvestigator s opinion  potentially interfere with the completion\nof treatment according to this protocol \n22  known allergy to any of the study medications  their analogues \nor excipients in the various formulations of any agent \n23  known gi disease or gi procedure that could interfere with the\noral absorption or tolerance of daratumumab and lenalidomide\nincluding difficulty swallowing\n24  adult under guardianship  curatorship or any legal protection",
    "INTERVENTION": "investigational\nmedicinal product s   bortezomib  daratumumab  lenalidomide and dexamethasone",
    "STATISTICS": "statistical analysis  the primary endpoint of the trial is the vgpr or better rate at\ncompletion of induction phase  according to the imwg response\ncriteria   in our previous published phase ii trial 36  of patients\nachieved vgpr or better after induction  using a phase 2 one\nstage a hern design  with a lowest acceptable response rate of\n35   p0  and an expected response rate of 60   p1   with type 1\nand type 2 error levels of 5  and 20   26 patients are needed  to\naccount for 10  of nonevaluable patients  29 patients will be\nrecruited ",
    "DSMB": "study will have a data\nsafety monitoring\nboard  yes cycle 3",
    "ACRONYM": "acronym reference  pcl2",
    "INVESTIGATOR": "coordinating\ninvestigator  bruno royer\nimmunohematology unit  st louis hospital  paris",
    "NUMBER OF INCLUSIONS": "number of participants\nincluded  29",
    "SITES": "number of centres  16 french sites  ifm sites  are planned",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources   phrck 2018\n pharmaceutical companies will provide the study drugs \nsubcutaneous daratumumab and lenalidomide"
  },
  "ITAC": {
    "TITLE": "full title  multicenter  randomized  prospective trial comparing the\nefficacy and safety of infliximab to that of\ncyclophosphamide in severe behçet s disease",
    "JUSTIFICATION": "scientific justification  itac  is the first randomized prospective  head to head\nstudy  comparing infliximab  to that of cyclophophamide\nin severe manifestations of bd  behçet s disease  bd  is\na systemic vasculitis of arterial and venous vessels of any\nsize  involving young patients  from 12 to 45 years   bd\nsignificantly increases morbidity and mortality  therape\nutic management of bd depends on the clinical\npresentation and organ involved  although colchicine \nnonsteroidal antiinflammatory agents and topical\ntreatments are often sufficient for mucocutaneous and\njoint involvement  more aggressive approach with\nimmunosuppressive agents is warranted for severe\nmanifestations such as retinal vasculitis  cardiovascular \nor neurological involvement  early recognition and\nvigorous use of immunosuppressives with high dose\nsteroids have changed the prognosis of patients with\nsevere bd  bd is a severe systemic vasculitis leading to\na 5year mortality rate of 15  in patients with major vessel\nor neurological involvement  cyclophosphamide has\nbeen used for lifethreatening bd for 40 years  however \nthe outcome of severe complications of bd is still poor \nthe european league against rheumatism  eular \nrecommendation  updated in 2016  for the management\nof bd advocated cyclophosphamide or antitnf  plus\nglucocorticoids for lifethreatening manifestations  i e\nneurological and or major vessel involvement  but\nrecommendations on vascular disease and neurological\ninvolvement are based largely on expert opinion and\nuncontrolled evidence from open trials and observational\nstudies  the need for further properly designed controlled\nclinical trials is apparent   tnfa antagonists have been\nused with success in severe and or resistant cases  in\naddition  the incidence of blindness in bd has been\ndramatically reduced in the recent years with the use of\nantitnf  however  there is no firm evidence or randomized controlled trials directly addressing the best\ninduction immunosuppressive therapy in severe bd\nmanifestations  physicians are still prescribing these\ncompounds offlabel use  we therefore aimed to assess\nthe best induction therapy in severe and difficult to treat\nbd patients ",
    "OBJECTIVE": "main objective and primary\nendpoint  to assess the benefit of infliximab comparatively to that\nof cyclophosphamide in severe lifethreatening behçet s\ndisease \nprimary assessment criterion will be the complete clinical\nresponse at week 22 after randomization secondary objectives and\nendpoints  to estimate and compare the rate and time to occurrence\nof relapses or worsening\nto estimate and compare the cumulative dose of steroids\nto estimate and compare the adverse events\nto estimate and compare the mean change in sf36\nqualityoflife  see appendix 3 \nto estimate and compare the rate of remission according\nto organs involved\nto compare the changes in acutephase reactants \nto estimate and compare the changes in cns\ninvolvement\nto estimate and compare the changes in cardiovascular\ninvolvement\nsurvival and event free survival\nto estimate and compare the changes in other bd\nmanifestations\nto estimate and compare the changes in behcet s\ndisease current activity form  see appendix 2 \nto assess serum concentration measurement of tnfa\ninhibitor\nsecondary endpoints\n complete clinical response at week 12 and 48 \n remission of cns and or cardiovascular involvement\nat week 12  22 and 48 \n measures of corticosteroid sparing  \no percent meeting targets    0 1 mg day kg of\nprednisone  at week 22 and 48 \no mean dose at week 12  22 and 48 \no cumulative dose at week 12  22 and 48 \n time to response onset\n measures of acutephase reactant  \no creactive protein  crp   every 4 weeks\n relapse  \no time to relapse  relapse will be defined as the\nreappearance of clinical and or paraclinical features of\nactive disease or by the occurrence of new lesions at\nweek 48 \no rate of relapse\n worsening o time to occurrence of worsening   worsening will\nbe defined as the progression of preexisting lesions  at\nweek 22 and 48 \no rate of worsening\n gobal survival at week 22 and 48 \n event free survival at week 22 and 48 defined by\nthe occurrence of death  relapse or worsening \n safety and tolerability of treatments in bd patients\nas assessed by frequency and severity of adverse clinical\nevents at week 22 \n change in quality of life  qol   sf36v2tm\nhealth survey  at week 12 and 22   see appendix 3 \n changes in cns involvement on physical exam \nand cerebral and or medullar mri at week 12 and 22 \n changes in vascular involvement on physical\nexam  vascular doppler us  and angioct imaging and\nbiologically  normalization of c reactive protein  at week\n12 and 22 \n changes in cardiological involvement on physical\nexam  echocardiography  normalization of left ventricular\nfunction and or disappearance of cardiac thrombosis  \nand cardiac magnetic resonance imaging\n diseappearance of gadolinium enhancement and\nnormalization of left ventricular function  and biologically\n normalization of troponin and of c reactive protein  at\nweek 12 and 22 \n changes in other organs involved in bd\n serum concentration measurement of tnfa\ninhibitor at week 22\n change in behcet s disease current activity form\n see appendix 2  at week 12 and 22 ",
    "DESIGN": "design of the trial  bayesian design for phase ii randomized clinical trial that\naims at comparing a new treatment to a reference based\non a binary end point  which offers greater flexibility and\nsimplicity of inference to the monitoring for patient safety\nand evidence of efficacy of small randomized trials scope of the trial  after the collection of their free and informed consent \neligible patients with active behçet s disease will be\nrandomized into one of 2 groups at the randomization visit\n d0  \n  arm a infliximab 5mg kg intravenously at week 0 \n2  6  12  and 18\n  arm b cyclophosphamide 0 7g  m2 up to 1 2 g  m2 \nintravenously at week 0  4  8  12  16 and 20 all patients will receive the same corticosteroid regimen \nall patients will have at inclusion randomisation visit an\noral prednisone at 1 mg kg day  up to 80 mg day  \nthe following schedule of reduction of prednisone will\napply to both groups as long as the disease is inactive \n  week 4   0 8mg kg day\n  week 6  0 7mg kg day\n  week 8   0 6mg kg day\n  week 10  0 5mg kg day\n  week 12   0 4mg kg day\n  week 14  0 3mg kg day\n  week 16  0 2mg kg day\n  week 22    0 1mg kg day",
    "INCLUSION CRITERIA": "population of trial subjects  adult and pediatric patients with severe lifethreatening\nbehçet s disease  inclusion criteria  1  age   12 years old\n2  written inform consent  informed consent should\nbe obtained from the legal guardian in accordance with\nregional laws or regulations for patients 12 to 17 years of\nage \n3  diagnosis of bd according to international criteria\nfor bd  icbd   see appendix 1  \n4  life threatening active bd defined as 1 of the\nfollowing disease categories and according to the\nvalidated international definition \n major vessel disease  arterial aneurysms or\narterial stenosis  myocarditis and or major deep vein\nthrombosis  i e  inferior vena cava  superior vena cava \ncardiac cavity thrombosis  pulmonary embolism  supra\nhepatic vessels  renal and mesenteric vessels   diagnosis of major vessel involvement will be done using vascular\ndoppler sonography  echocardiography  angioct scan\nand or cardiac magnetic resonance imaging  mri  \n central nervous system involvement  encephalitis\nor meningoencephalitis or myelitis  the diagnosis of\nneurobehçet s  cns involvement  will be based on\nobjective neurological symptoms that were associated\nwith neuroimaging  cns and or medullar mri  findings\nsuggestive of bdrelated cns involvement \ncerebrospinal fluid  csf  findings showing aseptic\ninflammation may be associated \n6  chest xray results  posteroanterior and lateral \nwithin 12 weeks prior to inclusion with no evidence of\nactive tuberculosis  active infection  or malignancy\n7  for female subjects of childbearing age  a\nnegative pregnancy test\n8  for subjects with reproductive potential  a\nwillingness to use contraceptive measures adequate to\nprevent the subject or the subject s partner from\nbecoming pregnant during the study and 6 months after\nstopping therapy  adequate contraceptive measures\ninclude hormonal methods used for two or more cycles\nprior to inclusion  e g   oral contraceptive pills \ncontraceptive patch  or contraceptive vaginal ring   barrier\nmethods  e g   contraceptive sponge  diaphragm used in\nconjunction with contraceptive foam or jelly  or condom\nused in conjunction with contraceptive foam or jelly  \nintrauterine methods  iud   sterilization  e g   tubal\nligation or a monogamous relationship with a\nvasectomized partner   and abstinence \n9  a potential subject with a positive interferon\ngamma release assay  igra   e g   quantiferon tb\ngold or tspot tb  test  or a positive tuberculin skin test\n  6 months  is eligible if her his chest xray does not show\nevidence suggestive of active tb disease and there are\nno clinical signs and symptoms of pulmonary and or\nextrapulmonary tb disease  these subjects with a latent\ntb infection who have not already received a prophylactic\ntb treatment must agree in advance to complete such a\ntreatment course \n10  hiv negative serology and negative hbs ag test   1\nmonth ",
    "EXCLUSION CRITERIA": "non inclusion criteria  subjects will be not included from the study if they meet\nany of the following criteria \n1  evidence of active tuberculosis\n2  hiv or active hbv infection  hbs ag   \n3  pregnancy or lactation\n4  have been taking an oral daily dose of a\nglucocorticoid of more than 20 mg prednisone equivalent\nfor more than 6 weeks continuously prior to the inclusion\nvisit or taking more than 3000 mg methylprednisolone 4\nweeks prior to the inclusion visit\n5  alcohol or drug dependance 6  severe renal  creatinine clairance\n 30ml min 1 73m2  or preexisting hemorrhagic cystitis or\nliver insufficiency  hepatic encephalopathy   or urinary\nobstruction\n7  heart failure   stage iii   iv nyha \n8  history of malignancy within 5 years prior to\ninclusion other than carcinoma in situ of the cervix or\nexcised basal cell or squamous cell carcinoma of the skin \n10  history of multiple sclerosis and or demyelinating\ndisorder\n11  history of severe allergic or anaphylactic reactions\nto cyclophosphamide or infliximab\n12  infectious disease \n infection requiring treatment with intravenous\nantibiotics within 2 weeks prior to inclusion\n history of recurrent infection\n14  laboratory values assessed during inclusion \n hemoglobin   8 g dl\n wbc   2 0 x 103 mm3\n platelet count   70 x 103 mm3\n15  use of the following systemic treatments during\nthe specified periods \n treatment with systemic biologic therapy or with\ncyclophosphamide within 3 months prior to inclusion\n if on azathioprine  mycophenolate mofetil  or\nmethotrexate at the time of inclusion  these drugs must be\nwithdrawn prior to receiving the cyclophosphamide or\ninfliximab dose on day 1\n16  any live  attenuated  vaccine within 4 weeks prior\ninclusion  recombinant or killed virus vaccines are\npermitted \n17  lack of affiliation to a social security benefit plan\n as a beneficiary or assignee   patients affiliated to\nuniversal medical coverage  cmu  are eligible for the\nstudy",
    "INTERVENTION": "investigational medicinal\nproduct s   infliximab 5mg kg intravenously at week 0  2  6  12  and\n18 comparator treatment  cyclophosphamide 0 7g  m2 up to 1 2 g m2  intravenously\nat week 0  4  8  12  16 and 20",
    "STATISTICS": "statistical analysis  the experimental design is a multicentric open\nmulticenter randomized clinical trial stratified on the\ncharacteristics of the initial behçet s disease with\nevaluation of the primary assessment criteria at 22 weeks \nthe primary assessment criteria and the final measures\nof corticosteroid sparing will be reviewed by a scientific\ncommittee blinded of the randomization \nthe rct will use a bayesian design for phase ii\nrandomized national multicentre clinical trial that aims at\ncomparing a new treatment to a reference based on a\nbinary endpoint  i e  complete clinical response at week\n22   which offers greater flexibility and simplicity of\ninference to the monitoring for patient safety and evidence\nof efficacy of small randomized trials ",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  itac   induction therapy with antitnfα vs\ncyclophosphamide in severe behçet disease",
    "INVESTIGATOR": "coordinating investigator  pr david saadoun\ncentre de reference des maladies autoimmunes et\nsystémiques rares\ndepartment of internal medicine and clinical immunology\n83 bd de l hôpital\n75013 paris\nhospital pitie salpetriere\ntel 0142178088\nemail david saadoun psl aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included  52 patients  26 patients in each arm",
    "SITES": "number of sites  multicentre national study including 28 centres",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris sources of funding for the trial  phrc"
  },
  "FOCUS": {
    "TITLE": "full title  randomized controlled multicenter study comparing efficacy and safety of\nadalimumab to that of mycophenolate mofetil in steroid dependent non\ninfectious uveitis",
    "JUSTIFICATION": "scientific justification  focus  is the first prospective randomized study comparing standard of\ncare  mycophenolate mofetil  to adalimumab in recently active non\ninfectiuous uveitis  niu  with steroid dependency  there is no firm\nevidence or randomized trials that compared classical immunosuppressive\ncompounds to biological agents  or identified the best treatment in this\ncondition  the burden of niu has been reduced with the use of\nimmunosuppressive agents and biologics  raising the question of which of\nthese compounds should be preferentially used in recently active niu with\nsteroid dependency ",
    "OBJECTIVE": "main objective and\nprimary endpoint  primary objective\nthe objective is to compare the efficacy of adalimumab  80mg at day 0 \nthen 40mg 14 days from w1 to w35 subcutaneously  with that of standard\nof care  mycophenolate mofetil  2g day orally  for 36 weeks  in recently\nactive noninfectious intermediate  posterior uveitis  and panuveitis with\nsteroid dependency \nprimary endpoint\nthe primary efficacy endpoint is the treatment failure rate at 36 weeks \ntreatment failure is defined by any of the following in at least one eye \n new active  inflammatory chorioretinal or retinal vascular lesions \n worsening of best corrected visual acuity  bcva  by 3 lines \n 2 step increase in anterior chamber cell grade and or in vitreous haze\nrelative to baseline\n noabsence of and with steroid discontinuation between week 13 and\nweek 19  as per protocol \nand without any aor any additional immunosuppressive drug or\ninjectable steroids\n study treatment permanent discontinuation secondary\nobjectives and\nendpoints  secondary objectives \ncomparing adalimumab  80mg at day 0  then 40mg 14 days from w1 to\nw35 subcutaneously  to standard of care  mycophenolate mofetil   2g day\norally   for 36 weeks  \n to evaluate the cumulative incidence of treatment failure up to w55\nafter inclusion\n to evaluate the change in best corrected visual acuity  bcva  logmar \nfrom baseline to week w55  \n to evaluate the change in ocular inflammation in the anterior chamber\nand vitreous from baseline to week w55 \n to evaluate the change in other signs including vessel leakage  from\nbaseline to week w55 \n to evaluate the presence of macular edema from baseline to week\nw55 \n to evaluate the quality of life related to uveitis  from inclusion to w55 \n to evaluate steroid sparing effect from baseline to w55 \n to evaluate the number and time to relapse of uveitis  and the\ncharacteristics of uveitis at worsening from baseline to w55 \n to evaluate the effect on underlying systemic disease when appropriate\nfrom baseline to w55 \n to evaluate the safety of adalimumab and mycophenolate mofetil  up to\nw55 \nsecondary endpoints \n time to treatment failure up to w55 \n logmar bcva in each eye  at w4  w8  w12  w16  w20  w24  w30 \nw36 and w55 \n anterior chamber cell grade in each at w4  w8  w12  w16  w20  w24 \nw30  w36 and w55 \n vitreous haze grade  sun criteria  in each eye at w4  w8  w12  w16 \nw20  w24  w30  w36 and w55 \n central retinal thickness in each eye from baseline at w4  w8  w12 \nw16  w20  w24  w30  w36 and w55 \n proportion of patients with central macular thickness  300 microns at\nw4  w8  w12  w16  w20  w24  w30  w36 and w55 \n time to optical coherence tomographic  oct  evidence of macular edema in at least one eye  up to w55 \n nei visual functioning questionaire25  vfq25  composite score  at\nw12  w24  and w36 \n measures of corticosteroid sparing  e g   percent meeting targets   0 1\nmg kg day prednisone   mean change  mean dose at week 55  and\ncumulative dose  \n cumulative incidence of relapse and number of relapses up to w55 \n other clinical manifestations of underlying disease  depending on the\nunderlying disease  will be evaluated up to w55\n safety and tolerability of treatments as assessed by the frequency and\nseverity of adverse events and treatment discontinuation from baseline\nto week 55",
    "DESIGN": "design of the study  this is a prospective phase iii clinical trial  multicenter  openlabel  two\narm randomized  1 1  clinical trial comparing the efficacy and safety of\nadalimumab and standard of care  mycophenolate mofetil  in subjects with\nrecently active intermediate posterior uveitis or panuveitis despite steroid\nuse  i e oral prednisone   7 mg day  or if no prednisone is available use\noral corticosteroid as a replacement for prednisone  equivalent prednisone\ndose    \noral corticosteroids should be at a stable dose at least 2 weeks prior to the\nfirst study drug administration on day 0 ",
    "INCLUSION CRITERIA": "population of study\nparticipants  adult patients with recently active noninfectious uveitis  niu \ndespite oral prednisone   7 mg day  or equivalent prednisone\ndoseoral corticosteroid at equivalent dose  only if prednisone is out\nof stock in the market if no prednisone is available use oral\ncorticosteroid as a replacement for prednisone  equivalent dose or\noral corticosteroid equivalent \nrecently active disease  defined by the presence of at least 1 of the\nfollowing parameters in either eye within the 3 months prior to inclusion\nvisit \n active chorioretinal or retinal vascular lesion\n presence of macular edema by optical coherence \n   2  anterior chamber cells  standardization of uveitis nomenclature\n sun  criteria \n  2  vitreous haze  national eye institute  nei  sun criteria   inclusion criteria  the eligibility criteria will be checked at the screening visit  which takes\nplace four weeks maximum prior to inclusion visit  and at the\ninclusion randomization visit  adult patients meeting the following criteria\nmay be included in the study \n1  provide written  informed consent prior to the performance of any\nstudyspecific procedures\n2   18 years of age\n3  diagnosis of noninfectious intermediate  posterior  or panuveitis in at\nleast one eye fulfilling the international study group classification\ncriteria  standardization of uveitis nomenclature  sun  criteria  of\nposterior  or pan uveitis confirmed by documented medical history\n4  recent activity of niu as defined by the presence of at least 1 of the\nfollowing parameters in either eye within the 3 months prior to inclusion\nvisit despite  7mg day of oral prednisone \n  active chorioretinal or retinal vascular lesion   presence of macular edema by optical coherence \n    2  anterior chamber cells  standardization of uveitis\nnomenclature  sun  criteria \n    2  vitreous haze  national eye institute  nei  sun criteria \n5  chest xray  posteroanterior and lateral  or ctscanner results within\n12 weeks prior to inclusion with no evidence of active tuberculosis \nactive infection  or malignancy\n6  a potential subject with a positive interferongamma release assay\n igra   e g   quantiferon tb gold or tspot tb  test  at inclusion\nis eligible if \na  her his chest xray does not show evidence suggestive of active\ntb disease\nb  and there are no clinical signs and symptoms of pulmonary\nand or extrapulmonary tb disease \nc  and these subjects with a latent tb infection who have not\nalready received a prophylactic tb treatment must agree in\nadvance to complete such a treatment course \n7  for female subjects of childbearing potential  a negative pregnancy\ntest at inclusion\n8  for subjects with reproductive potential  a willingness to use\ncontraceptive measures adequate to prevent the subject or the\nsubject s partner from becoming pregnant during the study and 3\nmonths and 5 months after stopping therapy for mmf and adalimumab \nrespectively  unless sterility is confirmed  the simultaneous use of two\ncomplementary methods of contraception is preferable  methods which\nmay be considered as highly effective methods that can achieve a\nfailure rate of less than 1  per year when used consistently and\ncorrectly are considered as highly effective birth control methods\n according to ctfg recommendations   such methods include \nfor female subjects  \na  combined  estrogen and progestogen containing  hormonal\ncontraception associated with inhibition of ovulation 1 \n  oral\n  intravaginal\n  transdermal\n b   progestogenonly hormonal contraception associated with\ninhibition of ovulation 1 \n  oral\n  injectable\n  implantable\nb  c   intrauterine device  iud \nc  d   intrauterine hormonereleasing system  ius \nd  e   bilateral tubal occlusion\ne  f   vasectomised partner\nf  g   sexual abstinence  in the context of this guidance sexual\nabstinence is considered a highly effective method only if defined\nas refraining from heterosexual intercourse during the entire\nperiod of risk associated with the study treatments  the reliability\nof sexual abstinence needs to be evaluated in relation to the\nduration of the clinical trial and the preferred and usual lifestyle of\nthe subject  \nfor male subjects  \na  use of condoms\nb  vasectomy  with documentation of azoospermia  c  sexual abstinence\n9  affiliated to a social security system",
    "EXCLUSION CRITERIA": "exclusion criteria  subjects will not be included in the study if they meet any of the following\ncriteria \n1  infectious uveitis  masquerade syndromes  idiopathic uveitis is\npermitted \n2  isolated anterior uveitis\n3  monocular patient\n4  active tuberculosis\n5  positive hiv serology or hcv hbs ag test\n6  history of malignancy within 5 years prior to inclusion other than\ncarcinoma in situ of the cervix  nonmetastatic squamous or basal cell\ncarcinoma of the skin \n7  history of severe allergic or anaphylactic reactions to monoclonal\nantibodies  mycophenolate mofetil  rifampicin  isoniazid or fluorescein\n8  infection requiring treatment with intravenous antibiotics within 3 weeks\nprior to inclusion\n9  history of multiple sclerosis and or demyelinating disorder\n10  laboratory values assessed during inclusion \n  hemoglobin   8g dl\n  wbc   2 0 x 103 mm3\n  platelet count   80 x 103 mm3\n  glomerular filtration rates  gfr   30ml min \n  transaminases   3 times upper normal value\n11  use of the following systemic treatments during the specified periods \n  treatment with any systemic alkylating agents within 12\nmonths prior to inclusion  e g   cyclophosphamide \nchlorambucil \n  any live  attenuated  vaccine within 4 weeks prior to\ninclusion \n12  stage iii and iv new york heart association  nyha  cardiac\ninsufficiency\n13  pregnancy or breastfeeding\n14  under legal protection\n15  participation in another interventional study involving human\nparticipants or in the exclusion period at the end of a previous study\ninvolving human participants  if applicable",
    "INTERVENTION": "investigational\nmedicinal product s   eligible patients with recently active niu will be randomized at 1 1 ratio\nbetween \narm 1  adalimumab  80mg at day 0  then 40mg 14 days from w1 to w35\nsubcutaneously \narm 2  standard of care defined by mycophenolate mofetil 2 g day orally\nfor 36 weeks\nthe 2 treatment groups will receive the same corticosteroid regimen  all\npatients with niu will receive oral prednisone   10 mg day  or oral\ncorticosteroid equivalent  with a maximum of 35 mg day of prednisone  or\noral corticosteroid at equivalent prednisone dose  only if prednisone is out\nof stock in the marketif no prednisone is available use oral corticosteroid\nas a replacement for prednisone  equivalent dose  equivalence \na common prednisonetapering programme will be applied to both groups\nwith a decrease until discontinuation between week 13 and week 19  as\nlong as the disease is inactive  comparator  arm 2  standard of care defined by mycophenolate mofetil 2 g day orally treatment  for 36 weeks",
    "STATISTICS": "statistical analysis  this is a prospective  twoarm randomized  openlabel  phase iii trial\ncomparing adalimumab to standard of care  mycophenolate mofetil \nbased on a binary primary endpoint  treatment failure at week 36 of\ntreatment   randomization will be stratified on retinal vasculitis  presence\nor not of macular oedema  underlying disease  idiopathic uveitis or\nunderlying disease associated  and steroid dose at inclusion   20mg d vs \n  20mg d   this trial will be conducted using a group sequential design\nwith one interim analysis after 50  of primary observations have been\ncompleted  with efficacy and futility early stopping rules \nspecifically  assuming a probability of treatment failure  primary endpoint \nof 50  in the soc control population versus 20  under the alternative\nhypothesis with adalimumab  a total number of 106 patients  53 per\nrandomization arm  is required to ensure 90  power with a 2 5  one\nsided type i error risk  accounting for one interim analysis after 50  of\nprimary observations have been completed and using lan   demets\no brien   flemingtype riskspending functions to define efficacy and\nfutility  nonbinding  early stopping rules  moreover  we plan to include a\ntotal of 120 patients  60 per randomization arm  to account for potential\n10  of losttofollowup ",
    "DSMB": "study will have a\ndata safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  focus   aphp211032   eu no  20235051123800",
    "INVESTIGATOR": "coordinating\ninvestigator  pr bahram bodaghi\ncentre national de référence des uvéites\ndepartment of ophtalmology\nhospital pitie salpetriere\ntel   01 42 16 37 28\nemail  bahram bodaghi aphp fr scientific director  if\napplicable   pr david saadoun  \ncentre national de reference maladies autoinflammatoires et amylose\ndépartement de médecine interne et immunologie clinique\npitié salpétrière hospital\ntel  0142178042\nemail  david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  phrc 2020"
  },
  "ICE": {
    "TITLE": "full title  isatuximab in type i cryoglobulinaemia  a prospective pilot\nstudy",
    "JUSTIFICATION": "scientific justification  cryoglobulinaemia is defined as the presence of\nimmunoglobulins in the serum which reversibly precipitate\nand form a gel when the temperature drops below 37 c\nand redissolve upon rewarming  classification includes\nthree subgroups based on ig composition  type i\ncryoglobulinaemia consists of only one isotype or subclass\nof immunoglobulin  types ii and iii are classified as mixed\ncryoglobulinaemia  mc  because they include both igg\nand igm components  overall  cryoglobulinaemia is\nconsidered a rare disease   5 10 000 in the general\neuropean and north american population   although\nprevalence is likely to be higher in some areas such as the\nmediterranean basin  mc vasculitis is a multiorganic\ndisease involving kidneys  joints  skin  and peripheral\nnerves  in type i cryoglobulinaemic vasculitis  searching\nfor an underlying plasmacell neoplasms is mandatory \ncryoglobulinaemia composed of igg is more often found\nin multiple myeloma or monoclonal gammapathy of\nunknown significance  mgus   the course of mc\nvasculitis varies widely and the prognosis is influenced by\nboth mcinduced damage to vital organs and co\nmorbidities associated with underlying diseases  type i\ncryoglobulinaemic vasculitis is a plasma cell associated\ndisorder at the crossroad between autoimmunity and\nplasmacell neoplasm  treatment should be modulated\naccording to the underlying associated disease and the\nseverity of internal organ involvement  the overall 10year\nsurvival after a diagnosis of cryoglobulinaemic syndrome\nranges from 50  to 90  in case of renal involvement  the\nmain therapeutic goal must be the cure of the underlying\nhaematological disease  overwhelmingly plasmacell\nneoplasms   the most common neoplasias are multiple\nmyeloma  predominantly associated with type i\ncryoglobulinaemia and hyperviscosity  in more than 50 \nof cases  treating the underlying monoclonal disorder has\nbeen associated with improvement stabilization of\ncryoglobulinaemic symptoms in most patients with type i\ncryoglobulinemia  although negativation of serum\ncryoglobulins was achieved in only half the patients  alkylating agents and bortezomib are the main therapeutic\noptions but are associated with side effects including\nneuropathy  patients presenting with symptomatic\nhyperviscosity require urgent therapeutic intervention\nusing plasma exchange or plasmapheresis to remove\ncryoglobulins from the circulation  there is no standard of\ncare or international guidelines for treatment of type 1\ncryoglobulinemia  isatuximab is an anticd38 monoclonal\nantibody that has been effective to treat relapsed or\nrefractory multiple myeloma  autoreactive plasma cells\nrepresent a key player in autoimmune disorders and\nparticularly in type i cryoglobulinemia  type i\ncryoglobulinemia is a model of plasma cell associated\ndisorder at the crossroad between autoimmunity and\nplasmacell neoplasm  however  rituximab fails to target\nthis population and is poorly effective in this condition \nthus  there is an unmeet need for plasma cell targeted\ntherapy in type i cryoglobulinemia  clonal plasma cells in\ntype i cryoglobulinemia do express surface cd38 \nproviding a rationale for the use of isatuximab in\ncryoglobulinemia  although the biology of the clonal\nplasma cell in type i cryoglobulinemia is distinct from that\nof al amyloidosis  they are models of hematological\ndiseases associated with monoclonal ig and whose tumor\nmass is low  in al amyloidosis anticd38 targeted therapy\nwas highly efficient as monotherapy in treatment naïve\npatients and relapsers  thus  isatuximab represents a\nhighly promising therapy in type i cryoglobulinemia that\ncould be use as monotherapy ",
    "OBJECTIVE": "main objective and primary\nendpoint  the primary objective is to assess the complete clinical\nresponse rate of isatuximab in type i igg cryoglobulinemia \nprimary endpoint  complete clinical response rate of\ncryoglobulinemia vasculitis symptoms at week  w  20 secondary objectives and\nendpoints  secondary objectives \n  safety and tolerability of treatment as assessed by\nfrequency and severity of adverse clinical events\n  early complete response rate at w12\n  complete  partial  improvement in some but not all\norgans involved at baseline  and non clinical  no clinical\nimprovement  response rate at w12 and w20\n  rate of cryoglobulinemia clearance\n  rate of negativation of rheumatoid factor activity\n  rate of normalization of c4 complement level\n  early failure rate at w4  non clinical response at w4 \n  clinical relapse rate and the time to relapse \n  course of plasma cell associated disorder\n  evolution of gammaglobulin level\n  quality of life scores  sf36   appendix 1  \n  rate of infections  severe or not  and other\ncomplications\n  birmingham vasculitis activity score  bvas   appendix\n2 \n  immunomonitoring  deep immunophenotyping \ncytokines production  spectrometry  fish analysis  single\nplasma cell repertoire  secondary endpoints\n  safety and tolerability of treatment as assessed by\nfrequency and severity of adverse clinical events at w20\n  complete  partial and nonclinical response rate at w12 \nand at w20 \n  rate of cryoglobulinemia clearance  of negativation of\nrheumatoid factor activity and of normalization of c4\ncomplement level at w12  and at w20 \n  rate of early failures  nonclinical response at w4  \n  rate of renal complete remission defined as proteinuria\n 0 5g 24h or proteinuria creatininuria  50 mg mmol \ndisappearance of hematuria  and glomerular filtration rate\n  60ml min 1 73m² at w12  and at w20 \n  clinical relapse rate defined by de novo appearance or\nreappearance of a manifestation attributable to\ncryoglobulinemia vasculitis during 48 weeks of followup \n  rate and time to relapse from baseline to w48\n  course of plasma cell associated disorder w12  and at\nw20 \n  mean change of gammaglobulin level from baseline to\nw20\n  quality of life assessed by the mean variation of the sf\n36 over the 20 weeks \n  rate of infections  severe or not  and other\ncomplications during the 48 weeks of followup\n  proportion of patients remaining in remission with a\nbvas 0 at baseline  w12  and w20 \n  evolution of immunomonitoring  deep\nimmunophenotyping  cytokines production \nspectrometry  fish analysis  single plasma cell\nrepertoire  at baseline  week 12  and week 20",
    "DESIGN": "design of the study  this is a phase 2 pilot prospective study of 21 patients with\ntype i igg cryoglobulinemia treated by isatuximab \nisatuximab will be perform intravenously at 10mg kg at day\n0  week  w 1  w2  w3  and w4 then every 2 weeks for a\ntotal of 12 infusions  scope of the trial  phase ii prospective multicenter study from the french\nplasma cell neoplasm and cryoglobulinemia network is\ncomposed of hematologists  internists  rheumatologists \ndermatologists and nephrologists \nall patients will receive subsequently the same therapy \n21 patients with type i igg cryoglobulinaemia will be\ntreated by isatuximab  isatuximab will be administred\nintravenously at 10mg kg at day 0  w1  w2  w3 and w4\nthen every 2 weeks for a total of 12 infusions ",
    "INCLUSION CRITERIA": "population of study participants  adult patients with type 1 igg active cryoglobulinemia\nvasculitis  inclusion criteria  1  age   18 years\n2  written informed consent\n3  monoclonal gammopathy of unknown significance\n mgus  with monoclonal igg component\n4  active cryoglobulinemia vasculitis defined by positive\n or history of positive  type i igg cryoglobulinemia and\na clinically active cryoglobulinemia with skin  joint \nrenal  pulmonary  cardiovascular  muscular  digestive \ncentral and or peripheral neurological involvement \n5  treated naïve or relapsers type i cryoglobulinemia\npatients\n6  affiliated to national french social security system\n7  contraception  \na  male participants  a male participant must agree to\nuse a highly effective method of contraception during\nthe participation period and for at least 5 months after\nthe last dose of study treatment and refrain from\ndonating sperm during this period  b  female participants  a female participant is eligible\nto participate if she is not pregnant  not breastfeeding \nand with at least one of the following conditions \n  not a female of childbearing potential  fcbp   or\n  a fcbp who must have a negative serum or urine\npregnancy test with a sensitivity of at least 25\nmiu ml within 24 hours of starting study\nmedication and must apply a highly effective\nmethod of contraception during the participation\nperiod and for at least 5 months after the last dose\nof study treatment and refrain from donating oocyte\nduring this period\n8  hiv negative serology  negative hbs ag test  hcv\nnegative serology or negative hcv rna if positive\nhcv serology within 3 months prior inclusion",
    "EXCLUSION CRITERIA": "exclusion criteria  1  patient with a vasculitis unrelated to cryoglobulinemia\n2  patient with nonactive cryoglobulinemia vasculitis \n3  patient with diagnosis of multiple myeloma  except\nindolent myeloma\n4  patient treated with immunosuppressant  e g\nalkylating agent  rituximab  chemotherapy for plasma\ncell neoplasms  introduced or increased in the month\nprior to the inclusion \n5  live vaccines within 30 days prior to baseline or\nconcurrently with isatuximab\n6  infection requiring hospitalization and or use of\nparenteral  iv or im  antibiotics  antibacterials \nantivirals  antifungals  or antiparasitic agents  within\n60 days prior day 0 \n7  active tuberculosis\n8  hiv positive  positive ag hbs  positive hcv rna\n9  any clinically significant  uncontrolled medical\nconditions that  in the investigator s opinion  would\nexpose excessive risk to the patient or may interfere\nwith compliance or interpretation of the study results \n10  hypersensitivity or history of intolerance to steroids \nmannitol  pregelatinized starch  sodium stearyl\nfumarate  histidine  as base and hydrochloride salt  \narginine hydrochloride  poloxamer 188  sucrose or any\nof the other components of study therapy that are not\namenable to premedication with steroids and h2\nblockers or would prohibit further treatment with these\nagents \n11  hypersensitivity to the active substances  isatuximab\nand premedication  or to any of their excipients\n12  received any investigational drug within 14 days prior\nto inclusion or within 5 halflives of the investigational\ndrug  whichever is longer \n13  participation in another interventional study or being in\nthe exclusion period at the end of a previous study \n14  vulnerable populations\no pregnant or breastfeeding women\no persons deprived of liberty by judicial or\nadministrative decision\no persons under psychiatric care without their\nconsent o adults subject to a legal protection measure\no persons unable to express their consent\n15  neutrophils   1000 mm3\n16  platelets   75000 mm3",
    "INTERVENTION": "investigational medicinal\nproduct s   isatuximab administered intravenously at 10mg kg at day\n0  w1  w2  w3 and w4 then every 2 weeks for a total of\n12 infusions comparator treatment  none",
    "STATISTICS": "statistical power and sample\nsize justification   we used the onesample multiple testing procedure for\nphase ii clinical trials  report definitions  fleming  t  r \n1982  biometrics  volume 38  pages 143151  to calculate\nthe sample size \nreport definitions\np0 is the maximum response proportion of a poor drug \np1 is the minimum response proportion of a good drug \nn is the sample size \nif the number of responses   r 1  p0 is rejected \nif the number of responses   r  p1 is rejected \nalpha is the probability of rejecting that p   p0 when this\nis true \nbeta is the probability of rejecting that p   p1 when this is\ntrue \nsummary statements the ice study requires 21 subjects to decide whether the\nproportion responding  p  is less than or equal to 0 400 or\ngreater than or equal to 0 700  if the number of responses\nis 13 or more  the hypothesis that p   0 400 is rejected with\na target error rate of 0 050 and an actual error rate of\n0 035  if the number of responses is 12 or less  the\nhypothesis that p   0 700 is rejected with a target error rate\nof 0 150 and an actual error rate of 0 148  statistical analysis  this is a pilot prospective phase ii clinical trial that aims at\nevaluating safety and efficacy of isatuximab in type 1\ncryoglobulinemia vasculitis  we hypothesize that up to\n70  of the patients receiving isatuximab will achieve a\ncomplete remission of cryoglobulinemia vasculitis at week\n20  w20  \ncontinuous variables  cf variables described in primary\nand secondary objectives  will be presented with the\nmedian and iqr or with the mean   sem  categorical\nvariables will be presented with counts and proportions \nstatistical comparisons will be performed by using the\nmannwhitney test for quantitative unpaired data  ttest for\nquantitative paired data  kruskalwallis for multiple\ncomparisons  spearman correlation test for correlations \nttest for quantitative paired data analysis will be used to\ncompare immunological changes between day 0 and week\n12 and 20 after isatuximab \nall statistical tests will be twotailed with a significance\nlevel of 0 05 ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  ice study  isatuximab in type 1 cryoglobulinemia ",
    "INVESTIGATOR": "coordinating investigator  pr david saadoun\ndepartment of internal medicine and clinical immunology\ncentre national de référence maladies autoimmunes\nsystémiques rares\nhospital pitié salpétrière\ntel  0142161051\nemail   david saadoun aphp fr scientific director  if applicable   pr bertrand arnulf\ndepartment of immunohematology\nhospital saint louis\nemail  bertrand arnulf aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included  21 patients",
    "SITES": "number of sites  multicenter national study including 17 centers",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  sanofi funds the trial and will provide isatuximab budget  350 000 euros\nplus the supply of isatuximab"
  },
  "ETOLE": {
    "TITLE": "full title  evaluation of tomosynthesis in the characterization and\nmanagement of breast",
    "JUSTIFICATION": "rationale  tomosynthesis is an innovative technique developed in\ndigital mammography for obtaining a sectional image of\nthe breast  mammography has the main disadvantage of\nbeing an imaging projection that creates overlays  which\neliminates tomosynthesis ",
    "OBJECTIVE": "objective and primary endpoint    evaluate if birads classification obtained with\ntomosythesis is superior to classification obtained by\nconventional mammography in terms of specificity\nand noninferior in terms of sensitivity \n  joint analysis of true negative and false negative rates\naccording to birads scale as compared to the\nhistological results  or followup outcome  see  gold\nstandard   below  objectives and secondary\nendpoints  evaluate\n  if tomosynthesis with synthetic tomography allows a\nbetter detection of certain signs of poor prognosis for\nmalignant lesions  size and multicentricity of the\ntumour  lymph node extension  skin or pectoral\ninfiltration  \n  if tomosynthesis with synthetic tomography modifies\nthe number of additional views and or number of\nadditional examinations including ultrasound  breast\nmri and biopsy \n  assess whether tomosynthesis reduces the necessary\nnumber of ultrasound and compare the differences in\nratings birads obtained by tomosynthesis with\nsynthetic mammography and then with ultrasound to\nthe differences obtained with conventional\nmammography alone and then combined with\nultrasound \n  if tomosynthesis with synthetic mammography\nchanges the radiation dose received by the patient \n  if tomosynthesis with synthetic mammography\nimproves the reproducibility of the birads\nclassification for abnormalities \n  the costs analysis of tomosynthesis with synthetic\nmammography compared to mammography and or\nmammography   ultrasound ",
    "DESIGN": "experimental design  a randomized multicentric study  phase iii diagnostic\nstudy according to the classification of gluud   gluud \n 1  during the inclusion phase  18 months  a\ntomosynthesis system will be installed at each site by the\nmanufacturer  all patients with a clinical or breast\nimaging abnormally at each of these sites during the study\nperiod and having given informed consent will be\nrandomized to either a conventional mammography or\ntomosynthesis  4 incidences  with synthetic\nmammography  diagnostic method  evaluation of tomosynthesis in the characterization and\nmanagement of breast  reference diagnostic method  conventional digital mammography",
    "INCLUSION CRITERIA": "population concerned  women having clinical or breast imaging abnormalities inclusion criteria    patient having clinical or breast imaging abnormalities\nclassified as birads 3  4  5  table 1    5 \n  patient over 18 years old\n  signed informed consent",
    "EXCLUSION CRITERIA": "noninclusion criteria    patients at high risk of breast cancer  mutations brca\n1 or 2 carriers  li fraumeni  or history of thoracic\nradiation will be excluded because of their greater\nsensitivity to ionizing radiation   3 3 15 1 4  11 \n  patient unable to give informed consent for physical \nmental  or legal reasons \n  patient not affiliated with french social security\ninsurance \n  patient under treatment for breast cancer \n  when mammography is not recommended according\nto good practice by the french health authority\n has  \n  pregnant patient ",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis  the analysis comparison of the birads classifications\nobtained by mammography and then by tomosynthesis\nwill rely on the construction of simultaneous confidence\nintervals for the ratios of true negative rates  specificity \nand false negative rates  1sensitivity  obtained with each\ntechnics in the mammography   tomosynthesis arm  as\ndescribed by alonzo et al ",
    "DSMB": "dsmb  data safety monitoring\nboard   yes",
    "ACRONYM": "acronym  etole",
    "INVESTIGATOR": "coordinating investigator  professor cédric de bazelaire\nservice de radiologie\nhôpital saintlouis  paris\ntél    33 1 42 49 91 33\ncourriel   cedric debazelaire aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects required  2000 subjects",
    "SITES": "number of centers  4 centers  saintlouis hospital  tenon hospital \nlariboisière hospital and hegp ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding  phrc 12070"
  },
  "MAC-HAPLO-MUD": {
    "TITLE": "full title  randomized prospective phase iii clinical trial comparing\nhla 10 10 matched unrelated donor and haploidentical\nallogeneic hematopoietic stem cell transplantation after\nmyeloablative conditioning regimen",
    "JUSTIFICATION": "scientific justification  an unrelated adult donor who is hlamatched to the\nrecipient at the allelelevel  at hlaa  b  c  dqb1 and \ndrb1  is considered the best choice in the absence of an\nhlamatched sibling for patients needing hematopoietic\nstem cell transplantation  sct   however  using matched\nunrelated donors  mud  is limited by  1  a prolonged\ntime to identify and schedule donation for some mud\nallowing some patients to relapse before transplantation\ncan be performed  and  2  limited availability of fully\nhlamud for the noncaucasian population  alternative\ndonors  single hla mismatched unrelated donor \nunrelated umbilical cord blood and grafts from\nhaploidentical related donors  are still associated with\nhigher nonrelapse mortality and delayed immune\nreconstitution \na more recent strategy for haploidentical  haplo  related\ndonor sct  haplosct  have improved dramatically\noutcomes using tcell replete grafts with administration\nof posttransplantation cyclophosphamide  ptcy  which\ntargets alloreactive t cells generated early after an hla\nmismatched transplant  sparing regulatory t cells and\nleaving unaffected the nondividing hematopoietic stem\ncells  and standard posttransplant immune suppression\nwith a calcineurin inhibitor  cni  and mycophenolate\nmofetil  from retrospective studies  haplosct with ptcy\nare associated with similar overall and progressionfree\nsurvivals as with mud stem cell transplantation  mud\nsct   but with lower rates of toxicity and graft versus host disease  gvhd   and thus potentially better results\nthan mudsct after reduced intensity conditioning\nregimen \na phase iii randomized trial is currently addressing this\nquestion in france for elderly patients using a reduced\nintensity conditioning regimen  haplomudelederly01\n phrck 14045   pi  d blaise institut paoli calmettes  \na randomized prospective phase iii clinical trial\ncomparing hla 10 10 mud and haplosct after\nmyeloablative conditioning regimen is urgently needed to\nanswer to this question ",
    "OBJECTIVE": "main objective and primary endpoint  main objective  to improve the 1year progression free\nsurvival  without acute grade iiiv gvhd and without\nmoderate or severe chronic gvhd  using of the haplo\ndonor compared with 10 10hla mud after\nmyeloablative sct \nprimary endpoint  a 1year progression free survival\nwithout grade iiiv acute gvhd and without moderate or\nsevere chronic gvhd of 65  after haplo sct versus\n50  after 10 10hla mud  secondary objectives and endpoints  secondary objectives \n1  to compare the two arms in terms of clinical and\nbiological outcomes \n  kinetic of haematopoietic reconstitution and graft\nfailure  gvhd  progression free survival  relapse \nnon relapse mortality  overall survival \n  interval between inclusion and transplant\n  rehospitalizations\n  treatment related morbidity\n  quality of life\n  chimerism\n  immune reconstitution\n2  to search for prognostic factors of the main outcome\nglobally and in each arm\n3  to search for treatmentbycovariate interactions on\nthe main outcome\nsecondary endpoints \n  interval between inclusion and transplant\n  absolue numbers of neutrophils and platelets at\nm1  m2  m3  m6 and m12 \n  chimerism at m1  m3  m6  m12  m24\n  acute gvhd incidence and grading\n  chronic gvhd incidence and grading\n  relapse incidence\n  progression free survival\n  severe infections  ctcae grade 34 \n  incidence of veinoocclusive disease\n  incidence of cardiac toxicities\n  nonrelapse mortality\n  overall survival\n  quality of life questionnaire  ebmt    number of new days of hospitalization after the\nhospitalization for transplantation\n  immune reconstitution at m1  m3  m6  m12  m24\n t lymphocytes  cd4  cd8  b  nk lymphocytes\nand gammaglobulines ",
    "DESIGN": "design of the trial  randomized prospective phase iii clinical trial comparing\nhla 10 10 matched unrelated donor and haploidentical\nallogeneic hematopoietic stem cell transplantation after\nmyeloablative conditioning regimen scope of the trial  our goal is to show a superiority of haplosct  primary\nendpoint  but even if similar results between both arms\nare obtained  this study might revolutionize the strategy of\nsct since haplo donors will be used in priority compared\nwith mud  quick procedure  cheaper  and available for almost all patients  ",
    "INCLUSION CRITERIA": "population of trial subjects  patients 15 year of age or older with high risk\nhematological malignancies and with an indication of\nallogeneic hematopoietic stem cell transplantation inclusion criteria   patients  \n aged 15 to 55 years old\n with aml all smd smp requiring allogeneic stem cell\ntransplantation\n at least in partial response of their malignant disease\n without hla matched related donor\n with a strong probability to have both a related haplo\n donor and a hla10 10 matched donor available  the\npatient needs to have at least 5 mud identified outside\n the book  bmdw  bone marrow donors worldwide   or\nusing the easy match software  to be included  \n with usual criteria for hsct \n  ecog   2\n  no severe and uncontrolled infection\n  cardiac function compatible with high dose\nof cyclophosphamide\n  adequate organ function  asat and alat\n  2 5n  total bilirubin   2n  creatinine  \n150 µmol l  except if those abnormalities\nare linked to the hematological disease \n with health insurance coverage\n understand informed consent or optimal treatment and\nfollowup\n prescription of two effective contraception methods\nmust be prescribed during all the duration of the study\n having signed a written informed consent  2 parents for\npatients aged less than 18 ",
    "EXCLUSION CRITERIA": "exclusion criteria   patients  \n with cancer in the last 2 years  except basal cell\ncarcinoma of the skin or  in situ  carcinoma of the\ncervix \n with uncontrolled infection\n with seropositivity for hiv or htlv1 or active\nhepatitis b or c\n yellow fever vaccine\n heart failure according to nyha  ii or more \n bile duct obstruction\n preexisting acute hemorrhagic cystitis\n renal failure with creatinine clearance  30ml   min  with pregnancy   hcg positive  or breastfeeding\n with any debilitating medical or psychiatric illness\nwhich preclude the realization of the sct or the\nunderstanding of the protocol\n under protection by law  tutorship or curatorship \n unwilling or unable to comply with the protocol",
    "INTERVENTION": "experimental group  haplo donor myeloablative sct with use of\ncyclophosphamide  50 mg kg day  by intravenous route \nat d 3 and d 4 after stem cell transplantation treatment  transplant modalities   1  conditioning regimen  \nfor patients with myeloid malignancies\na  for haploidentical sct\nthiotepa  5mg kg day  day 7 and 6 \nfludarabine  40mg m2 day  day5 to2 \n iv busulfan  3 2mg kg day   day5  to3 \nb  for hlamatched unrelated donor sct\nfludarabine  30mg m2 day  day6 to2 \niv busulfan  3 2mg kg day  d6  to3 \nfor patients with all \nfludarabine 30 mg m2 day on days 7 to 5 and tbi 200\ncgy twice daily on days 4 to 2  total dose 1200 cgy \n2  stem cell source  \nbone marrow for haploidentical sct\nperipheral blood stem cell  pbsc  for hlamatched\nunrelated transplantation\n3  gvhd prophylaxis  \nfor haploidentical sct  \n cyclophosphamide 50 mg kg day at d 3 and d 4\n ciclosporine and mycophenolate  mmf  from d 5\nfor hlamatched unrelated donor sct  \n antithymocyte globuline  thymogobuline  5 mg kg total\ndose  2 5mg kg at day 3 and 2 \n cyclosporine at day 1 and mmf at day  1\nin the absence of gvhd  mmf will be stopped at d 35 in\nboth arms",
    "STATISTICS": "statistical analysis  justification of sample size\nwe hypothesize the 1year progression free survival\nwithout grade iiiv acute gvhd and without moderate or\nsevere chronic gvhd will be of 65  after haplo sct\nversus 50  after 10 10hla mud \n172 patients in both arms  n 344 overall  are required to\ndemonstrate such a difference  based on a twosided\nlogrank test      0 05 and power   0 80  hr  0 62   with\na required total number of events of 146 \nthe bayesian interim analysis will not inflate   \ninterim analysis at midinclusion\nthis will be based on the bayesian computation of\nstopping rules based on the modeling of the log hazard\nratio  hr  of the main endpoint  spiegelhalter 1994   non\ninformative prior of the loghr will be considered \nterminal analysis after the observation of the required\nnumber of events",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "abbreviated title  machaplomud",
    "INVESTIGATOR": "coordinating investigator  pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of subjects included  344",
    "SITES": "number of sites  36 centres",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  industrial and patients associations funding"
  },
  "SHORTCUT": {
    "TITLE": "full title  efficacy of 7 days versus 14 days of antibiotic therapy for\nacute pyelonephritis in kidney transplant recipients  a\nmulticentre randomized noninferiority trial ",
    "JUSTIFICATION": "scientific justification  infections are a major cause of morbidity and mortality in\nsolid organ transplant recipients  in kidney transplant\nrecipients  ktr  urinary tract infection  uti  represent\n45 72  of all infections  and 30  of all hospitalizations\nfor sepsis  acute transplant pyelonephritis are the most\ncommon complications occurring in more than 20  of\npatients  mainly in the first year after transplantation  they\nare associated with an increased risk of acute kidney\nrejection and longterm kidney graft dysfunction  gram\nnegative bacteria  mainly e  coli  account for more than\n70  of uti in ktr  as those infections are favored by\nurinary tract modifications defects and\nimmunosuppression  they are often recurrent and\nnecessitate repeated courses of antibiotics  selective\npressure due to antibiotic consumption  along with\nfrequent hospital admissions and immunosuppression \nare well known risk factors for the development of\nantibiotic resistant infections  multidrug  mdr  or\nextensively  xdr  drug resistant enterobacteriaceae\nincluding esbl or carbapenemaseproducing\norganisms  are thus increasingly observed in transplant\nunits and represent a global threat as very few new\nantibiotics are expected in the next decade \none main strategy to limit antimicrobial resistance\nis to reduce the duration of antibiotic treatment  a 7 day\ncourse is recommended for simple acute pyelonephritis\n apn  treated with fluoroquinolones or parenteral b\nlactams  prolonged up to 10 or 14 days in the presence of\nunderlying disease at risk of complications  most kt\nteams treat patients between 14 21 days as\nrecommended by american guidelines  however  the\nneed to extend treatment duration in immunosuppressed\npatients is a poorly defined concept and the optimal\nduration of treatment for apn in ktr is not known as\nthese patients are excluded from most studies  as there is an urgent need to reduce antibiotic\nconsumption in this population at high risk of developing\ninfections due to resistant pathogens  the hypothesis is\nthat a 7 daytreatment is sufficient to cure apn with good\nclinical response after 48h of treatment in ktr and is as\neffective as 14 days ",
    "OBJECTIVE": "main objective and primary\nendpoint  to show that a 7 dayantibiotic therapy is not inferior to a\n14 dayantibiotic therapy in the treatment of acute\npyelonephritis in kidney transplant recipients \nprimary endpoint  clinical cure and no additional\nantibiotic treatment since the end of antibiotic treatment\nup to the main evaluation at day 30 \nclinical cure is defined as fever  38 c and no symptoms\nof uti  secondary objectives and\nendpoints  to compare between both arms \nclinical cure at day 90 and day 180\nmicrobiological cure at day 30  90 and 180\ntolerance and safety of antibiotics\nhospitalization length stay\nantibiotic consumption during total follow up\nacquisition of antibiotic resistant enterobacteriaceae\nkidney graft function and transplant rejection\nat day 90 and day 180\n the total costs \nto evaluate risk factors for failure and\nrelapse recurrence \nto evaluate efficacy of the antibiotic treatment at the end\nof treatment  d7 for experimental arm and d14 for control\ngroup \nsecondary endpoints \n clinical cure at day 90 and 180\n microbiological cure *at day 30  90 and 180\n incidence of relapse  recurrence between day 30 and\nday 90\n incidence of adverse events imputable to antibiotic\ntreatment\n kidney function assessed according to mdrd\n modification of diet in renal disease  or ckd  chronic\nkidney disease  epidemiology collaboration  epi\n hospitalization length stay defined by the delay between\nthe date of inclusion and the date of hospital discharge\n antibiotic consumption\n rectal carriage of antibiotic resistant\nenterobacteriaceae at inclusion and day 30 *microbiological cure is defined as a sterile urine or\nuropathogene   103 cfu ml in urine culture ",
    "DESIGN": "design of the trial  multicenter  controlled  randomized  noninferiority  open\nlabel clinical trial with 2 parallel groups  1 1   7 days\nversus 14 days of antibiotic treatment \nthe randomization will be stratified by date of renal\ntransplantation    1 year and   1 year   center and sex\n potential confounders   scope of the trial  phase iv trial",
    "INCLUSION CRITERIA": "population of trial subjects  ktr with acute pyelonephritis inclusion criteria  age  18 years ktr\napn defined by  fever  t  38 c   with or without clinical\nsigns and or symptoms of uti  and pyuria   104 white\nblood cells ml or  10 mm3  and positive urine culture\n uropathogen  103 cfu ml susceptible to the empirically\nadministrated antibiotic \nno confirmed or suspected febrile non urinary bacterial\ninfection\nno urologic renal complication at baseline imaging\n abscess  obstruction    \n favourable early response to antibiotic treatment   48 to\n60 hours after the first dose of antibiotic effective against\nthe causative uropathogen  defined by  t  38 c and\nimprovement  or resolution  of signs and or symptoms of\nurinary tract infection if present at diagnosis \n written informed consent",
    "EXCLUSION CRITERIA": "exclusion criteria  patients with any of the following conditions \nsevere or complicated condition\n any rapidly progressing disease or immediately life\nthreatening illness  including  but not limited to  septic\nshock  current or impeding respiratory failure  acute heart\nor liver failure\n admission or stay in intensive care unit at baseline\n obstruction of the urinary tract\n renal  perinephric or prostatic abscess\n prior inclusion in this study\n current participation to another interventional study\ndual antibiotic therapy   prophylactic antibiotic such as\ncotrimoxazole allowed    only 1 dose of aminoside is\nallowed before randomization \nfirst month post transplantation\ncurrent indwelling catheter  including bladder catheter \nureteral stents  percutaneous nephrostomy tubes \nneurogenic bladder\nenterocystoplasty\nimmunodeficiency or immunosuppressive therapy not\nrelated to kidney transplantation  including hematologic favourable early response to antibiotic treatment   48 to malignancy  cancer  asplenia  neutropenia 500\nneutrophils mm3 \npregnancy  breastfeeding\nhypersensitivity or previous severe adverse drug\nreaction to the antibiotic therapy\nunable or unwilling  in the judgment of the investigator \nto comply with the protocol\nlife expectancy 1 month\npatient under legal guardianship or without healthcare\ncoverage\nhomeless patient\nwomen with childbearing potential not using adequate\ncontraception",
    "INTERVENTION": "comparator treatment  standard  14 days  antibiotic duration",
    "STATISTICS": "statistical analysis  sample sizes of 235 in each group achieve 80  power to\ndetect a noninferiority margin difference between the\ngroup proportions of 0 05  the reference group\nproportion is 0 95  the treatment group proportion is\nassumed to be 0 90 under the null hypothesis of\ninferiority  the power was computed for the case the\nactual treatment group proportion is 0 90  the test\nstatistic used is the onesided z test  unpooled   the\nsignificance level of the test is 0 05",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  shortcut",
    "INVESTIGATOR": "coordinating investigator  dr matthieu lafaurie  infectious diseases  saint louis\nhospital  paris",
    "NUMBER OF INCLUSIONS": "number of subjects included  470",
    "SITES": "number of sites  10",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  ministry of health"
  },
  "CAMOVID": {
    "TITLE": "full title  camovid  a multicenter randomized trial to evaluate the\nefficacy and safety of camostat mesylate for the treatment of\nsarscov2 infection   covid19 in ambulatory adult\npatients",
    "JUSTIFICATION": "scientific justification  since december 2019  a novel coronavirus called sarscov2\n severe acute respiratory syndrome coronavirus 2  has caused\nan international outbreak of respiratory illness described as\ncovid19  on the 22nd march 2020  2920142 confirmed cases\nof covid19 including 12784 deaths were reported by the\nworld health organization  1   on the 31 march 2020  there\nwere 52827 severe cases in france  including 3532 deaths \nthe spectrum of symptomatic infection ranges from mild to\ncritical  if most infections are not severe  15  of infected\npatients will require hospitalization and 5  will require intensive\ncare unit admission  2   the diagnosis of sarscov2 infection\nrelies on clinical symptoms and microbiological testing  to test\nfor sarscov2 infection  testing centers use a reverse\ntranscription polymerase chain reaction  rtpcr  on nasal\nswab in patients with productive cough  a number of\ninvestigational agents are being explored for antiviral treatment\nof covid19  however  to date  there are no controlled data\nsupporting the use of any specific treatment  antiviral drugs or\nimmunomodulatory drugs   and their efficacy for covid19 is\nunknown  3  \nsarscov2 infects human cells through the binding of its\nspike  s  protein to the membranous aminopeptidase called\nace2  angiotensin converting enzyme 2   among other\ntissues  ace2 expression has mainly been found on\npneumocytes  enterocytes  renal tubular cells and podocytes \ncellular entry of sarscov2 requires s protein priming by\ncellular serine protease tmprss2  which entails s protein\ncleavage and allows fusion of viral and cellular membranes  4  \nin a murine model of sarscov pneumonia  iwatayoshikawa\net al  showed that tmprss2ko mice had weakened\ninflammatory cytokine responses and reduced lung injury than\ncontrol mice  5   hoffmann et al  found that a tmprss2\ninhibitor  the camostat mesylate  blocked viral entry and reduce\ninfection of human primary pneumocytes and lung cell lines by\nsarscov2  they also showed that the sera from\nconvalescent sars patients crossneutralized sars2s\ndriven entry  4   another study performed by bojkova et al  5 \nshowed that camostat mesylate reduced cytopathogenic effect\ndue to sarscov2 in human colonic cell lines  camostat\nmesylate is a serine protease inhibitor that is commonly used in\njapan  at a dose of 600 mg day  and has been successfully\nand safely used to treat pancreatitisassociated pain  6  and\npostoperative reflux oesophagitis  7   side effects that have\nbeen reported are rare at these doses  nausea  diarrhea  hypersensitivity in 0 1 to 0 5  of the cases  cytopenias in less\nthan 0 1  and hyperkaliemia and abnormal hepatic function in\nless than 0 05   \nwe hypothesize that camostat mesylate  initiated early in\nsarscov2 infection  can reduce viral infection and viral\ncytopathogenic effect by blocking sarscov2 entry into cells \nand therefore prevent deterioration toward severe forms of\ncovid19 ",
    "OBJECTIVE": "main objective and primary\nendpoint  objective  evaluate the efficacy of camostat mesylate in the\ntreatment of sarscov2 infection in highrisk adult patients\nwith confirmed covid19 not requiring initial hospitalization    in\nterms of hospitalization needs  up to day 21 after randomization\nprimary endpoint  proportion of patients hospitalized for\ncovid19 deterioration or who died without hospitalization\nbetween day 1 and day 21 \nas an indicative basis  criteria for hospitalization will be the\npresence of any of the following  respiratory rate   24  min at\nrest  sp02   95  on room air  blood pressure   100 mmhg \nlethargy or unconsciousness  brutal overall deterioration or\nlethargy in the elderly  hcsp  and any all other reasons\nrequiring hospitalization left at the discretion of the physician secondary objectives and\nendpoints  secondary objectives  \nin adult patients diagnosed with laboratory confirmed covid\n19 not requiring initial hospitalization  to evaluate the impact of\ncamostat mesylate compared to placebo on \n safety up to day 21\n efficacy in terms of need for hospitalization for covid19\nmanagement  by independent blinded committee review\n overall clinical improvement at day 21\n clinical efficacy in terms of intensive care needs  up to day 21\n clinical efficacy in terms of time to hospitalization  up to day\n21\n clinical efficacy on respiratory functions  up to day 21\n overall survival at day 21 and 90 after randomization\n patientreported outcome on initial symptoms  up to day 21\n virological  serological and immunological efficacy  up to day\n90  including surrogacy assessment of candidate markers up to\nday 90\n renal complications  up to day 21\n liver complications  up to day 21\n covid19 transmission within the same household\nsecondary endpoints  \n adverse events  aes    number of aes  number of serious\naes  saes   investigational medication discontinuation  for any\nreason   up to 21 days\n independent endpoint adjudication committeereviewed\nproportion of patients hospitalized between day 1 and day 21 \nfor covid19 deterioration \nthe independent eac will review patients files  blinded to the\nrandomized group  and determine whether hospitalization\ncriteria were related to covid19 or not \n who covid19 clinical improvement ordinal scale  3   at day 7  14 and 21\noms descriptor score\nprogression\nscale\nuninfected no clinical or virological 0\nevidence of infection\nambulatory no limitation of activities 1\nlimitation of activities 2\nhospitalized   hospitalized  no oxygen therapy 3\nmild disease\nhospitalized  oxygen by mask or 4\nnasal prongs\nhospitalized   hospitalized  oxygen by niv or 5\nsevere high flow\ndisease\nintubation and mechanical 6\nventilation\nmechanical ventilation   7\nadditional organ support  \npressors  rrt  ecmo\ndead dead 8\n admission to an icu within 21 days from inclusion\n number of days alive without hospitalization  up to 21 days\n initiation of invasive mechanical ventilation for covid19\nsevere within 21 days from inclusion\n initiation of oxygentherapy for covid19 within 21 days from\ninclusion\n overall survival up to day 90\n number of days alive without symptoms  up to day 21\n sarscov2 virological assessment at day 1  day 7  day 14\nand day 21  nasal swab and droplet quantification of sars\ncov2 rnaemia \n sarscov2 serological assessment at day 1  day 7  day 14 \nday 21\n plasma il6  il1b  tnfa  il8 levels at day 1  7  14\n peripheral blood lymphocyte phenotyping and telomere length\nmeasurement at day 1  day 7  day 14\n acute kidney failure defined as at least serum creatinine\nincrease of 0 3mg dl or 1 51 9 times baseline and or oliguria  \n0 5ml kg h  kdigo2012 scale   within 21 days\n serum electrolytes and estimated glomerular filtration rate\nat day 7  14 and 21\n liver transaminases  gammagt  alkaline phosphatase at day\n7  14 and 21\n percentage of covid19 affected individuals sharing the\nsame household at day 1  7 and 14",
    "DESIGN": "design of the study  multicenter singleblinded placebocontrolled twoarm parallel\n1 1 randomized phase iii trial",
    "INCLUSION CRITERIA": "population of study\nparticipants  ambulatory adult highrisk patients with laboratory confirmed\ncovid19 not requiring initial hospitalization inclusion criteria  1  patients   18 years old\n2  patients with an increased risk of severe covid19\nbelonging to one or more of the following groups  \n* age   50 years\n* body mass index   30 kg m²\n* diabetes\n* hypertension\n* chronic renal failure  egfr  60 ml min \n* chronic heart disease\n*asthma chronic obstructive pumonary disease cystic fibrosis\n* chronic liver disease\n* chronic neurological disease\n* solid organ transplant\n* bone marrow transplant\n* sickle cell anemia  major thalassemias\n* active or currently treated or  1 year diagnosed cancer\n* active or currently treated or  1 year diagnosed malignant\nblood disease\n* immunosuppressive treatment observed for more than 1\nmonth\n3  laboratory confirmed sarscov2 infection with mild\ncovid19  fulfilling all the following criteria \n positive sarscov2 rtpcr nasal or saliva swab samples\nor positive sarscov2 antigen test performed within 96h of\ninclusion visit\nand\n clinical symptoms and signs consistent with sarscov2\ninfection including but not limited to  fever  upper respiratory\ntract infection signs  digestive signs  muscle pain  anosmia \ndysgueusia  1 \n4  informed consent to participate to the trial\n5  patients must be able and willing to comply with study visits\nand procedures",
    "EXCLUSION CRITERIA": "exclusion criteria  1  initial need for hospitalization for covid19 management  \ndefined as any of the following severity criteria   respiratory rate\n  24  min at rest  sp02   95  on room air  blood pressure  \n100 mmhg  lethargy or unconsciousness  brutal overall\ndeterioration or lethargy in the elderly  recommendations\nhcsp  all other reasons requiring immediate hospitalization left\nat the discretion of the physician\n2  pregnancy and breastfeeding\n3  participation to another interventional drug trial\n4  subject protected by law under guardianship or curatorship\n5  absence of health insurance\n6  known hypersensitivity to camostat mesylate\n7  known person sharing the same household already included\nin the study\n8  participation to another covid19 ambulatory interventional\nstudy 9  patients having completed a full sarscov2 vaccine\nimmunization procedure less than 4 weeks prior to covid19\ndiagnosis  last vaccine injection performed less than 4 weeks\nprior to covid19 diagnosis  ",
    "INTERVENTION": "investigational medicinal\nproduct s   camostat mesylate  oral administration\n600mg day  2 x 100mg every 8 hours  for 14 days  day 1 to day\n14  comparator treatment  placebo tablets \nfollowing the same schedule as investigational drug",
    "STATISTICS": "statistical analysis  descriptive analyses will use either frequencies and\npercentages for categorical variables  or median and\ninterquartile range for quantitative variables  number of missing\nvalues will be reported \nthe primary endpoint  probability of hospitalization within 21\ndays  will be compared between groups using a twosided z\ntest \nsecondary endpoints will be compared across groups using\nfisher s exact test when comparing probabilities between\ngroups and wilcoxon s rank sum test when comparing\nquantitative endpoints \nall analyses will be performed under the intentiontotreat\nprinciple \na 5  twosided significancelevel will be used for comparisons\nof secondary endpoints ",
    "DSMB": "study will have a data\nsafety monitoring board  yes",
    "ACRONYM": "acronym reference  camovid",
    "INVESTIGATOR": "coordinating investigator  dr david boutboul scientific director  pr lara zafrani",
    "NUMBER OF INCLUSIONS": "number of participants\nincluded  n 596 planned\nfrom the current knowledge on sarscov2 infection in adults  \nwe expect roughly 20  of newly diagnosed highrisk patients\nbeing hospitalized within 21 days  8  \nthe design initially included a planned interim analysis after\none third of observations had been completed  a maximum\ntotal sample size of 536 evaluable patients  268 per treatment\ngroup  would allow 90  power to detect an absolute difference\nof 10  in the probability of hospitalization at day 21 between\ngroups  e g  reduction from 20  to 10    using a ztest  with\nonesided 2 5 significance level for efficacy  using lan  \ndemets riskspending functions  o brien   fleming boundaries\napproximation   for efficacy and futility stopping rules \noverall  596 patients  298 in each group  would be included to\nanticipate a potential 10  dropout rate  given the ambulatory\nfollowup \nhowever  due to the status of the pandemics as of fall 2021 and\nglobal use of vaccines  the scientific comittee decided to stop\nrecruitment to eventually discontinue the trial early  the\nplanned interim sample size has not been reached  eventually \nonly a single final analysis will be performed at the 2 5  one\nsided significance level  for the primary endpoints  other\nendpoints will be analysed as planned ",
    "SITES": "number of centres  recruiting centers \n1  emergency department of saint louis hospital  paris\n2  covid19 screening center at bichat hospital\n3  emergency department of argenteuil hospital\n4  centre de santé richerand  75010 paris\n5  emergency department of h  mondor hospital  créteil\n6  outpatient consult of the infectious disease deparment  \ncovid screening center of henri mondor hospital \ncréteil\n7  outpatient consult of the sickle cell disease and\ninherited red blood cell genetic disorders  coordinating\nreferral center at h mondor hospital  créteil\n8  postemergency   internal medicine department of h \nmondor hospital  créteil\n9  department of infectious and tropical diseases   public\nhealth unit  groupe hospitalier sud ile de france\n ghsif   melun\n10  emergency department of lariboisière hospital  paris\nnonrecruiting centers  followup visits    internal medicine department of argenteuil hospital\n office of dr k  amazzough  75011 paris\n office of dr j marzouk  75017 paris",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  phrc covid19200095"
  },
  "GREEN": {
    "TITLE": "full title  a randomized  doubleblind  multicenter \nplacebocontrolled  efficacy and safety\nstudy of glenzocimab used as an addon\ntherapy on top of mechanical\nthrombectomy for acute ischemic stroke",
    "JUSTIFICATION": "scientific justification  emergent reperfusion is the main goal for acute ischemic stroke\ntherapy  ais   endovascular therapy  evt  is recommended\nwithin 6 hrs of stroke onset  and up to 24 hrs following\nperfusion imaging criteria \ndespite the major benefit associated with mt  more than 50 \nof the patients remain disabled at 3 months  reperfusion rates\nafter mt are critical to determine functional outcome \nhowever  complete reperfusion is obtained in only 50   of the\npatients  due to  at least in part  erratic emboli and or noreflow\nprocesses \nthrombus composition analysis has shown that platelet rich\nclots are more resistant to alteplase  suggesting that platelets\ninhibition represent a relevant target to improve reperfusion \nnevertheless  the currently available molecules are not\nrecommended at the acute phase due to the associated sich\nrisk  therefrom  there is still a need for a safe and efficient\nantithrombotic agent administrable at the acute phase without\ninducing a bleeding risk in order to reduce the size of the clot \nto favour cerebral reperfusion \nthe results obtained during the escalating dose phase of the\nactimis study showed very promising safety data  after the\ncompletion of the five cohorts where a dose progression has\nbeen carried out  the study dsmb members recommended to\nuse the highest dose  1000 mg  for the consolidation phase  of 60 ais patients recruited  12 were treated with the highest\ndose  they experienced no symptomatic ichs  a lowest rate of\nasymptomatic ich and a similar incidence of saes susars\nin comparison to patients treated with each lower dose  125 \n250  500 mg and placebo \nthe consolidation phase was conducted in additional 106 ais\npatients with a parallelgroup design glenzocimab 1 000 mg\nversus placebo  both in addon of the reperfusion standard of\ncare  the global safety results combining both phases  n 166 \nconcern the incidence of symptomatic ichs observed in all\ndose  1 event 102 patients  1   and 1 000 mg  no event 66\npatients  0   glenzocimab groups was lower than that one\nshown in placebo group  5 events 64 patients  8   \nthe incidence of nonsymptomatic ichs observed in alldose\n 30 events 102 patients  30   and 1 000 mg  20 events 66\npatients  30   glenzocimab groups was lower when compared\nto the placebo group  30 events 64 patients  48   \nthe kaplanmeier curve showed a reduced mortality in all\ndose and 1 000 mg glenzocimab groups when compared to\nplacebo group  with a p value of 0 03 and 0 04 respectively \ntwenty deaths occurred  5 in phase ib and 15 in phase 2a  and\n12 of them were a strokerelated outcome \nglenzocimab 1000 mg showed a favorable safety profile  in\nterms of hemorrhagic events  as well as more generally \nincluding in patients aged above 80 years  40  of the\npopulation   and despite concomitant medical conditions \nthough not powered for a showing of efficacy  in this study\nglenzocimab 1000 mg showed a real benefit in terms of death\nrate  and was shown to decrease the proportion of patients with\nthe most severe level of handicap \nthese encouraging results have to be confirmed in ongoing and\nfuture studies \nplatelet glycoprotein vi  gpvi  belongs to the\nimmunoglobulin superfamily and its expression is restricted to\nthe megakaryocyte platelet lineage  gpvi is a key receptor for\ncollagen and plays a major role in platelet activation  platelet\nrecruitment and thrombus growth \nstudies have also demonstrated that gpvi is a platelet receptor\nof polymerized fibrin and this interaction contributes to the\nthrombus growth and to its reformation  furthermore \ninhibition of the gpvi does not impair hemostasis and subjects\nwith a genetic or acquired gpvi deficiency are not prone to\nexcessively bleed  gpvi is therefore a major target in the\ngrowth and stabilization of the thrombus  offering a new\ntherapeutic approach with a high safety profile  this study aims\nto evaluate the efficacy of gpvi inhibitor  glenzocimab  in\naddition to evt \nthe current protocol allows any standard of care to be used for\nthrombolysis  depending on routine practice in each study site \nin particular  the simpler mode of administration of\ntenecteplase with its single bolus injection  led many sites to adopt tenecteplase as an alternative to alteplase for all ais\npatients ",
    "OBJECTIVE": "study objectives  primary objective \nto evaluate the efficacy of glenzocimab in addition to evt and\ncompared to evt plus placebo  whether or not associated with\nivt  on functional outcome at day 90 \nsecondary objectives\n  to evaluate the impact of glenzocimab in addition to evt\ncompared to evt  whether or not associated with ivt  plus\nplacebo on overall survival at day 90 and 1 year\n  to evaluate the impact of glenzocimab in addition to evt\ncompared to evt  whether or not associated with ivt  plus\nplacebo on \n1  reperfusion at the end of evt\n2  early clinical improvement at 24 hrs\n3  symptomatic intracranial haemorrhage at 24 hrs\n4  overall intracranial haemorrhage at 24 hrs\n5  serious adverse events  saes \n6  suspected unexpected serious adverse\nreactions  susars  at 24 hrs and at day 90\n7  bleedingrelated events  bres  at 24 hrs and at\nday 90\n8  quality of life at day 90 and 1 year\n  to evaluate the cost effectiveness of glenzocimab in\naddition to evt compared to evt plus placebo study endpoints  primary efficacy endpoint \nthe primary efficacy endpoint is the functional outcome\nat day 90 assessed by the modified mrs at day 90    15\ndays \nsecondary endpoints \nefficacy  \n  favourable functional outcome defined by a mrs\nscore   2 at day 90\n  proportion of patient with severe handicap  mrs 4\n6  at day 90\n  overall survival at day90 and 1 year\n  early reperfusion outcomes \no stroke volume by brain imaging at 24 hrs\no reperfusion at the end of mt procedure\nassessed by etici score\no early neurological improvement by nihss\nat 24 hrs\n  eq5d5l at day 90 and 1 year safety \n  incidence of symptomatic or nonsymptomatic\nintracranial hemorrhages  ich  at 24 hrs\n  incidence of symptomatic intracranial\nhemorrhages  ich  at 24 hrs\n  incidence of nonsymptomatic intracranial\nhemorrhages  ich  at 24 hrs\n  incidence  nature and severity of adverse\nevents  saes  susars  bleedingrelated\nevents  bres  and treatmentemergent\nadverse events  teaes   at 24 hrs  at\nd7 discharge  30 days and 90 days\n  incidence of bleedingrelated events at 90 days\n  antiglenzocimab antibodies  ada  at baseline\n predose  and at 3 months for at least 50 patients \ncost effectiveness\n  cost per qaly  quality adjusted life year \ngained with the use of glenzocimab in addition\nto evt\n  cost per patient with a mrs score   2 gained\nwith the use of glenzocimab in addition to evt",
    "DESIGN": "design   phase   category  this is a national  multicenter  prospective  randomized  1 1\nratio   parallel group  doubleblinded  placebo controlled \nphase ii iii study  category 2",
    "INCLUSION CRITERIA": "population of study participants  patients over 18 with a clinical diagnosis of ais from a large\ncerebral vessel occlusion  lvo  between 0 and 24 hrs of\nsymptom onset or when a patient has been seen the last time\nwell and eligible for evt based on perfusion imaging for the\ntime window 624 hours  inclusion criteria  1  age 18 years or older  age 18 years \n2  no significant prestroke disability  prestroke mrs\nmust be equal to 0 or 1  \n3  indication of evt within the timewindow of 0 to 24\nhrs in participants  treated with or without intravenous\nthrombolysis  and presenting with a clinico\nradiological mismatch  defined by a nihss 10 and\nan aspect score  6 \n4  occlusion of the cervical or intracranial internal\ncarotid artery  ica  or the proximal middle cerebral artery  mca  m1 and or m2   on magnetic resonance\nangiography  mra  or  when this is not possible  on\nct angiography  cta  \n5  informed consent signed \n  by the patient \n  or informed consent signed by a family\nmembers trustworthy person if his condition does not\nallow him to express his consent by written as per l \n11116 \n  in a situation urgently and in the absence of family\nmembers trustworthy person  the patient can be\nenrolled  the consent to participate to the research will\nbe requested as soon as the condition of the patient will\nallow him to consent \n6  postmenopausal women defined as not having menses\nfor 12 months without an alternative medical cause  for\nwocbp  a highly effective birth control method should\nbe in place that can achieve a failure rate of less than 1 \nper year that should last for at least 2 months after imp\nadministration \nbirth control methods which may be considered as\nhighly effective in wocbp include \n combined  estrogen and progestogen containing \nhormonal contraception associated with inhibition of\novulation  intravaginal  transdermal  \n progestogenonly hormonal contraception associated\nwith inhibition of ovulation  injectable  implantable \n intrauterine device  iud  \n intrauterine hormonereleasing system  ius  \n bilateral tubal occlusion \n vasectomized partner \nbirth control methods which may be considered as highly\neffective for men and that should last for 4 months after\nimp administration include \n vasectomy \n use of condom combined with a highly effective\nbirth control method for their wocb partner \nplease note that hormonal contraception is a risk factor for\nthromboembolic events and attention should be called to\nreconsider it passed the acute stroke phase \n7  women of childbearing potential  wocbp  must have\na negative serum urine pregnancy test at baseline \nwomen of childbearing potential  i e   fertile  are defined\nas women following menarche and until becoming post menopausal unless permanently sterile  i e   having\nundergone hysterectomy  bilateral salpingectomy and\nbilateral oophorectomy \n8  affiliation to social security or any health insurance",
    "EXCLUSION CRITERIA": "non inclusion criteria  1  contraindications to evt \n2  contraindication to contrast agents\n3  preexisting neurologic and psychiatric disease\nwith mrs   2 \n4  unknown symptom s onset or last seem well  \n24 hours \n5  patients under or needing immediate dapt\nadministration \n6  significant mass effect with midline shift as\nconfirmed on ct mri \n7  gastrointestinal or urinary tract hemorrhage in\nprevious 21 days \n8  patient with intracranial haemorrhage\n9  known platelet count  100 000 mm3 \n10  pregnant or breastfeeding woman \n11  known hypersensitivity to glenzocimab or to any\nof the excipients \n12  known severe renal insufficiency  grades 45 \nwith a glomerular filtration rate  \n30ml min 1 73m2 \n13  participation in another interventional clinical\ntrial within 30 days prior to the inclusion \n14  persons deprived of their liberty by a judicial or\nadministrative decision  persons subject to\npsychiatric care under sections l 32121 et\nl 32131 and persons admitted to a health or\nsocial institution for purposes other than research\n l 11216 \n15  adults subject to a legal protection measure\n l 11218 \n16  the patient or his her family  if the patient is\nunable to give his her opinion  expresses an\ninability to return for protocol visits\n17  patients receiving anticoagulants  i e  heparin\nwithin 48 hours and an elevated aptt greater\nthan upper limit of normal for laboratory \n current use of oral anticoagulants  ex  warfarin \nand inr  1 7  current use of direct thrombin\ninhibitors or direct factor xa inhibitors  as\nalready mentioned in the nonauthorized\nconcomitant treatments\n18  patients who have already received another\nhumanized fragment of monoclonal antibody\nwith a suspicion of hypersensitivity exclusion criteria  1  withdrawal of consent\n2  patient s wish to withdraw from the trial\n3  persons deprived of their liberty by a judicial or\nadministrative decision  persons subject to psychiatric care\nunder sections  and persons admitted to a health or social\ninstitution for purposes other than research  l 11216 ",
    "INTERVENTION": "concomitant treatments  nonauthorized concomitant treatments \npatients should not receive any other experimental therapies\nduring the 90 days of the study participation \nin addition to the aforementioned exclusion criteria  patients\nshould not receive a dual antiplatelet therapy  dapt  required\nafter an intra and or extracranial stent  or a thrombolysis with\ntenecteplase  during glenzocimab infusion \nauthorized concomitant treatments \nall other symptomatic treatments used routinely for disease\nrelated symptoms will be allowed in all patients involved in\nthis trial  specific treatments for any adverse events will also\nbe permitted \nthrombolysis with alteplase antiplatelet monotherapy are\nallowed  glenzocimab should be started as soon as possible in\naddition with alteplase \ndetails of all treatments or procedures must be recorded in the\necrf  investigational medicinal\nproduct s   glenzocimab  act017  acticor biotech  is formulated for iv\nadministration as a sterile product with 20 mm sodium citrate\nand 130 mm sodium chloride buffer at ph of 5 0 \nit is supplied for clinical trial use in vials containing 50 ml of\nthe drug product at a concentration of 10 mg ml \neach vial contains 500 mg of glenzocimab \ntwo vials  2x500 mg  of glenzocimab should be administered\nconcomitantly for eligible patients for a total daily dose of 1g  comparator treatment  placebo of glenzocimab is 0 9 nacl  acticor biotech  for iv\nadministration \nit is supplied for clinical trial use in vials of 50 ml \ntwo vials of placebo of glenzocimab should be administered\nconcomitantly for eligible patients  study intervention  the administered study treatment will be glenzocimab or\nplacebo  as per central randomization allocation to the study\ngroup into which the patient is randomized \none arm will receive glenzocimab and the other arm the\nplacebo in addition to evt  evt itself is not added by the\nresearch \nglenzocimab or the placebo is intended to be administered as\nan iv infusion over 6 hrs  with ¼ of the dose administered by a\n15minute bolus and ¾ of the dose administered by 5h45min\nslow infusion  this is the proposed scheme to obtain a rapid effect during the emergency phase  and to cover a period of\ntime long enough to avoid downstream complications ",
    "STATISTICS": "statistical analysis  an interim analysis will be performed when 30  of the\npatient enrolment will be achieved  78 patients  \nin the control group  we considered that the distribution\nof the mrs is  0  0 10   1  0 17   2  0 19   3  0 17 \n 4  0 16   5  0 06   6  0 15  we calculated that a sample\nof 258 patients would yield a power of 80  to detect a\ntreatment effect associated with an or of 1 85 considered\na twosided p value of 0 05  as we planned an interim\nanalysis at 78 patients with an o brien and fleming\nscheme  we increased the sample size to 260  the first\ninterim analysis will be considered as statistically\nsignificant if the p value is below to 0 0054  the final\nanalysis will be considered as statistically significant if the p value is below 0 0492  interim analysis will also\nallowed a stop for futility  futility bound has been\ncalculated using o brien   fleming type beta spending \nafter inclusion of 78 patients  if the statistic of the wald\ntest value associated with the or is below 0 523 in\nfavour of the placebo group  the trial will be terminated\nfor futility ",
    "DSMB": "dsmb   data safety monitoring\nboard  dsmb will be composed by four members  three\nneurologists  and one statistician ",
    "ACRONYM": "short title  glenzocimab for reperfusion in the setting of endovascular\ntherapy for brain infarction study acronym  green study clinical trial code  aphp201028   actcs004",
    "INVESTIGATOR": "coordinating investigator  prof mikael mazighi   department of neurology  aphp\nlariboisière hospital   2  rue ambroiseparé  75010 paris\n france  scientific director  if applicable   jeanmarc olivot department of neurology  university of\nhospital of toulouse",
    "NUMBER OF INCLUSIONS": "number of participants included  260",
    "SITES": "number of centres  13",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris  aphp  and by\ndelegation  délégation à la recherche clinique et à\nl innovation  drci  clinical research and innovation\ndepartment \nhôpital saintlouis  1  avenue claude vellefaux\n75010 paris  france funding sources  anr"
  },
  "TEOREM": {
    "TITLE": "full title  multicenter randomized doubleblind clinical trial assessing\nthe benefit of adherent invasive e coli eradication in adult\nileal and ileocolonic crohn disease",
    "JUSTIFICATION": "scientific justification  current medical treatment of crohn disease  cd  consists\nof immunosuppressive drug therapy  corticosteroids \nazathioprine  methotrexate  antitnf monoclonal\nantibodies   these agents control symptoms of cd in most\npatients but their withdrawal leads to disease relapse \nthey are also associated with serious side effects\n infections  lymphoma  cancer  liver toxicity   antitnf\nmonoclonal antibodies are the most efficient but are cost\nprohibitive  moreover  each year  roughly 10  of\nresponders to antitnf become refractory to treatment \nmost often because they become tolerized to these drugs \nfuture cd drugs are small molecules or biologics that\nantagonize proinflammatory cytokines or gut homing of\nlymphocytes  yet  they have similar safety issues as the\nimmunosuppressive agents currently in use \nthe current therapeutic algorithm for cd does not take into\naccount the site of inflammation or composition of\nintestinal microbiota  moreover  dysregulated intestinal\nimmunity and overproduction of proinflammatory\ncytokines are not the only components of cd\npathophysiology  intestinal microbiota is abnormal and\nplays an important role in the pathogenesis of cd  an e \ncoli specie with adhesive and invasive properties \nadherentinvasive e  coli  aiec   has been described in\nileal mucosa of patients with cd  aiec has been found in\n36  of patients with ileal cd and 6  of controls\nthe role of aiec in cd has been thoroughly investigated\nin several laboratories around the world and has shown\nthat aiec is proinflammatory and could play an important\nrole in intestinal inflammation associated with cd  1   as\nsuch  it may be an important therapeutic target  this\nrandomized trial proposes a novel approach to the\ntreatment of cd  it is individualized to patients colonized\nwith aiec who will be prescribed fdaapproved antibiotics\nthat have been shown to be active against the bacteria in\nvitro  the treatment will be discontinued after 12 weeks \nwe hope to obtain clinical and endoscopic remission in\npatients who have been randomized into the experimental\narm  if this trial is successful  it will be the first of its kind\nand will facilitate a new era of clinical research in patients with cd and concomitant infection with aiec ",
    "OBJECTIVE": "primary objective and\nassessment criterion  the primary objective of this trial is to assess whether a\n12week treatment with ciprofloxacin and rifaximin is\nsuperior to placebo to obtain endoscopic remission in\naieccolonized patients with ileal cd  with or without\ninvolvement of the caecum or the right colon \nthe primary endpoint is the overall response at week\n12  using centralized  anonymous and blinded reading of\nileocolonoscopies \noverall response is defined by segmental response in at\nleast one segment in which the cdeis was  8 at baseline \nwith no more than 20  increase of cdeis in the other\nsegment and a cdeis 8 in this segment \nsegmental response in the segment in which the cdeis\nwas  8 at baseline  is defined by \n in the case of isolated aphtoid ileitis and or colitis \ndecrease   50  of lesions \n otherwise  either decrease   50  of surface of\nulcerations  either deep or superficial   or loss of\ndeep ulcerations  if present at inclusion  with no\nmore than 20  increase in superficial ulcerated\nsurface  secondary objectives and\nassessment criteria  the secondary objectives are \n cid 1  to test the correlation between endoscopic\nremission and aiec eradication at 12 weeks \n cid 1  to assess the evolution of endoscopic lesions at\nweek 12 \n cid 1  to assess the rate of clinical remission without\nsteroids  antitnf  and surgery at 48 weeks  in\npatients whose aiec has  or has not been\neradicated  and in patients who have  or have not \nreached the primary endpoint \n cid 1  to assess the rate of biological remission  during\nthe study \n cid 1  to assess side effects in the experimental and\nplacebo group \nthe secondary endpoints are  \n  endoscopic remission at 12 weeks  assessed by\ncentralized reading of ileocolonoscopies   defined\nby a cdeis   6 in all the segments\n cid 1  mean variation of segmental cdeis  at 12 weeks\n centralized reading of ileocolonoscopies  \n cid 1  complete endoscopic remission at 12 weeks\n centralized reading of ileocolonoscopies  defined\nby a cdeis  3  in all the segments\n cid 1  no ulceration at 12 weeks \n cid 1  clinical remission as defined by cdai 150 without\nsteroids  antitnf  and resection surgery for cd at\n12 and or 48 week \n cid 1  biological remission as defined crp serum level\n 5 mg l and fecal calprotectin  250 µg g at week\n4  8  12  24  36 and 48 \n cid 1  side effects ",
    "DESIGN": "experimental design  this is a phase ii clinical trial  it is a multicentre \nprospective  randomized  doubleblind  placebocontrolled\nadaptive clinical trial  with two parallel arms \n cid 1  experimental arm  oral ciprofloxacin 500 mg bid\nand oral rifaximin 800 mg bid for 12 weeks\n cid 1  control arm  a placebo of ciprofloxacin bid and a\nplacebo of rifaximin bid for 12 weeks",
    "INCLUSION CRITERIA": "population involved  cd adult patients infected with aiec  preinclusion criteria   cid 1  age 18 to 80 years\n cid 1  cd of the ileum  with or without involvement of the\ncaecum or the right colon\n cid 1  most severe lesions are confined within the ileum\nand or the right colon  this is defined by \n segmental cdeis  8 in the ileum and or right\ncolon \n and segmental cdeis  8 in each of the other\nsegments  transverse  left colon and rectum  \n cid 1  informed consent to participate in this study\n cid 1  cd either clinically inactive or active  but not severe\n cdai 450 \n cid 1  for patients with clinically active disease\n cdai 150    prescription of steroid treatments  \nbudesonide  prednisone  or prednisolone \nindependently from entry in study\nnote  patients with or without previous surgery for cd  with\nor without cd anal lesions  with or without draining fistulas\nand setons  can be enrolled  inclusion criteria   cid 1  patients with clinically active disease  cdai 150 \nwho respond to budesonide  initial dose 9 mg d  or\nprednisone or prednisolone  initial dose 40 mg d   by\na 70 points decrease in cdai between the pre\ninclusion and the inclusion visit  or patients with\nclinically inactive disease  cdai 150 \n cid 1  patients colonized with aiec on initial ileal biopsies ",
    "EXCLUSION CRITERIA": "nonpreinclusion and\nnoninclusion criteria   cid 1  ileal stenosis that cannot be crossed by the\nendoscope \n cid 1  infliximab treatment received less than 8 weeks\nbefore preinclusion in this study \n cid 1  methotrexate and azathioprine started less than\nthree months before preinclusion\n cid 1  adalimumab treatment received less than 4 weeks\nbefore preinclusion in this study \n cid 1  vedolizumab treatment received less than 8 weeks\nbefore preinclusion  in the study\n cid 1  hypersensitivity to ciprofloxacin  to other\nquinolones  or to any of the excipients  cellulose\nmicrocrystalline  crospovidone  maize starch \nmagnesium stearate  silica colloidal anhydrous \nhypromellose titanium dioxide e171  macrogol\n4000  \n cid 1  treatment with tizanidine  probenecid  theophylline  xanthine derivatives  phenytoin  oral\nanticoagulants  and ropinirole \n cid 1  hypersensitivity to rifaximin  or to any excipients\n sodium starch glycolate type a  glycerol distearate \ncolloidal anhydrous silica  talc  microcrystalline\ncellulose  hypromellose  titanium dioxide  disodium\nedentate  propylene glycol  red iron oxide e172  \n cid 1  previous extensive ileal surgery    1 meter as\nmeasured on the pathology and or surgical report  \n cid 1  short bowel syndrome \n cid 1  need for an intestinal resection for fistula  abscess\nor intestinal obstruction \n cid 1  renal failure  creatinine clearance 30\nml min 1 73m2  \n cid 1  liver failure  v factor 50   \n cid 1  past history of epilepsy \n cid 1  no health insurance \n cid 1  pregnant or lactating women \n cid 1  refusal to have a double effective contraception \nie hormonal   barrier method  intrauterine device  \nbarrier method  double barrier method   highly\neffective methods of contraception are  hormonal\ncontraceptives  e g  combined oral contraceptives \npatch  vaginal ring  injectables  and implants  \nintrauterine device  iud  or intrauterine system\n ius   vasectomy and tubal ligation  effective\nmethods are  barrier methods of contraception  e g \nmale condom  female condom  cervical cap \ndiaphragm  contraceptive sponge  \n cid 1  patients already included in a biomedical research\nother than an observational study  e g registry \ncohort  ",
    "INTERVENTION": "treatment being tested  association of two antibiotics \n cid 1  oral ciprofloxacin  tablets of 500 mg  every 12 hours\nduring 12 weeks\n cid 1  oral rifaximin  tablets of 200 mg   800 mg every 12\nhours during 12 weeks benchmark treatment  association of two placebos \na placebo corresponding to each antibiotic will be\nmanufactured  tablet of the same appearance   it will be\nadministrated every 12 hours during 12 weeks ",
    "STATISTICS": "statistical analysis  data will be analyzed on an intenttotreat basis\nthe trial is based upon an adaptive scheme  allowing the\nreestimation of the required number of included patients\n   sample size reestimation  ssr  design     taking into\naccount the uncertainty of endoscopic remission rate at\nweek 12 in the placebo arm  thus  one interim unblind\nstatistical analysis will be performed once one half of the\npatients have been successively enrolled \nprimary endpoint analysis concerns the comparison of\nthe main end point  ie  the percentage of endoscopic\nremission in each group that will be compared using the\nchisquare test unless validity violated  or the fisher exact\nwill be used  \nsecondary endpoints will be analyzed once the whole\nsample size will be reached ",
    "DSMB": "data safety monitoring board\nanticipated  no",
    "ACRONYM": "acronym  teorem",
    "INVESTIGATOR": "coordinating investigator  dr franck carbonnel\ngastroenterology department\nkremlin bicêtre hospital \n78  rue du général leclerc\n94275 le kremlinbicêtre",
    "NUMBER OF INCLUSIONS": "number of subjects chosen  252 screened patients will be needed on average to obtain\n62 randomized patients",
    "SITES": "number of centres  26",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding source  broad medical research program  mayolyspindler  alpha\nwassermann  and phrc national "
  },
  "SALMA": {
    "TITLE": "full title  phase i ii clinical trial assessing the combination of\nsulfasalazine with standard of care induction therapy in\nnewly diagnosed acute myeloid leukemias  aml  patients\n60 years or older   the salma study",
    "JUSTIFICATION": "scientific justification  nonfavorable aml in older patients is an unmet\nmedical need \nacute myeloid leukemia  aml  is a heterogeneous\nclonal myeloid neoplasm where abnormal proliferation\nand impaired differentiation of hematopoietic stem and\nmyeloid progenitor cells impedes normal hematopoiesis \ndespite the significant progress made in understanding\naml oncogenesis over the past decades  this disease\nremains devastating with about 18 000 new cases every\nyear in europe and a fiveyear overall survival of only\n17  1\nthe median age at diagnosis of aml is 69 years and the\ncure rate of patients older than 60 has not improved in\nthe recent decades 2 the standard of care  soc  of\nnewly diagnosed aml includes a  7 3  cytarabine\nanthracyclin combination followed by repeated courses\nof high dose cytarabine with or without allogeneic\nhematopoietic stem cell transplantation  hsct  3\nrecent advances in this soc approach include the\naddition of the multikinase inhibitor midostaurine during\ninduction and consolidation in patients with flt3 gene\nmutations 4 maintenance with oral azacitidine after\ncompletion of induction with or without consolidation in\npatients ineligible for transplantation 5 and use of a\nliposomal formulation of the cytarabinedaunorubicin\ncombination instead of conventional 7 3 in patients with\nhighrisk features 6\nin patients older than 60y with adequate performance\nstatus and few comorbidities deemed  fit  for intensive\nchemotherapy  a 7 3 induction course combining 3 days\nof idarubicin  ida  with a 7day continuous cytarabine\n arac  infusion can induce complete remission  cr  or\ncr with incomplete platelet recovery in 64  of cases\nwith nonfavorable cytogenetics 7 recent advances in\nthe supportive care of these patients  notably\nprogresses in the antifungal armementarium  have\nlowered the toxicity of the 7 3 induction courses  with\nearly date  ed  rates within the 510  range 8 however \ndespite high cr and low ed rates with 7 3  the median\neventfree survival  efs  remains 9 3 months in patients\n 60 years old with nonfavorable cytogenetics  owing to\nfrequent relapses 7 improving the antileukemic efficacy\nof the 7 3 induction course can contribute to better long\nterm prognosis in these patients 9 however  modifications of the 7 3 induction course must rely on\nany additional toxicity to limit the risk of ed  and not to\njeopardize postremission therapy  repositioning of\ndrugs with excellent safety profiles appears as a\npromising approach in this regard 10\nas such  nonfavorable risk aml in older patients\nrepresents an unmet medical need  novel options to\nimprove the efficacy of the 7 3 induction course are thus\nnecessary \nend of induction measurable residual disease predicts\nlongterm outcome in older aml patients treated\nintensively \nstandardization of molecular techniques and\ndevelopment of multiparameter flow cytometry  mfc \nassays have made it possible to assess measurable\nresidual disease  mrd  at different time points during\nthe course of aml therapy in virtually all patients 11\nin older patients treated with 7 3  mrd measured at the\nend of induction course  eoi  time point based on\nnpm1c transcripts in npm1mutated patients  or with\nmfc assays  leukemia aberrant immunophenotypes\n laip  and or leukemic stem cell  lsc  methods \npredict longterm outcome 12 in npm1mutated patients\nyounger than 60  the role of eoi mrd assessed by\nrelative npm1c transcript levels is also well\nestablished 13 although data is scarcer in older\npatients 14 altogether  eoi mrd appears a relevant\nsurrogate endpoint to estimate efficacy of alternative\ninduction regimens in older aml patients with non\nfavorable cytogenetics \ncystine import is a targetable vulnerability in aml \nthe metabolic rewiring of leukemic cells is increasingly\nrecognized as a targetable vulnerability in aml \nleukemic stem cells  lscs  endowed with increased\nquiescence and chemoresistance 15 have specific\nmetabolic profiles that may for instance underpin the\nremarkable efficacy of the azacitidinevenetoclax\ncombination in patients ineligible for 7 3 16 17 lscs\nnotably rely on high levels of the cysteine amino acid to\nfuel glutathione synthesis and maintain low levels of\nreactive oxygen species  ros  18 chemical depletion\nof the intracellular pools of cysteine and its precursor\ncystine have preclinical antileukemic activity in vitro 19\nby querying transcriptional profiles of multiple aml\npatients  cohorts  we have identified a close correlation\nbetween the expression of stemness programs and an\nactive cysteine metabolism pathway  querying a crispr\nscreen conducted in 500  cancer cell lines revealed a\nspecific dependence of aml cell lines on cysteine\nmetabolism  among genes belonging to this pathway \nhigher expression of slc7a11 was identified to bear\npoor prognostic relevance in 3 aml cohorts  genetic silencing of slc7a11 reduced viability and\ncolony formation of aml cell lines in a cysteine\ndependent fashion  slc7a11 encodes the xct neutral\namino acid antiporter that imports cystine against\nglutamate  the xct antiport is broadly expressed in\naml cell lines  three chemical inhibitors of xct with\ndifferent chemical backbones including erastin  s4\ncarboxyphenylglycine  cpg  and sulfasalazine  ssz \nhad highly concordant  cystinedependent  anti\nleukemic activity on a panel of 20 aml cell lines  these\ndata suggested that cystine import could represent a\ntargetable vulnerability in aml \nsulfasalazine can be repurposed to inhibit cystine import\nin aml \nsulfasalazine  ssz  is a broadly available  well tolerated\nantiinflammatory medicine approved for the treatment\nof ulcerative colitis and rheumatoid arthritis 20 intact\nssz  but not its metabolites 5 aminosalicylic acid and\nsulfapyridine  competitively inhibits xct 21 ssz is thus\nan ideal candidate for drug repurposing in aml  in vitro \nssz inhibited the viability of 12 primary aml specimens \nwith a   10fold increased sensitivity compared to\ncd34  hematopoietic stem and progenitor cells from\nheathly donors  ssz ic50 in aml 176µm   40µm versus\n2 94mm   4 21mm in healthy cd34  cells  p 0 0011  \nssz 250µm  a concentration in the same range as peak\nplasma concentrations of ssz in healthy individuals 22\nalso significantly reduced the in vitro longterm culture\ninitiating potential of 6 primary aml samples  finally \ntwicedaily intraperitoneal administration of single agent\nssz significantly reduced the leukemic burden in two\ndistinct aml patientderived xenografts  pdx  models \nfinally  compassionate administration of oral ssz at 3\n6 g d over a 20day period in a patient with advanced\nrefractory aml resulted in a transient  but clinically\nmeaningful cytoreduction  mechanistic studies found\nssz to induce global metabolic rewiring of the cysteine\nand onecarbon pathway  resulting in glutathione\ndepletion and rosdependent cell death partly\ncorresponding to ferroptosis 23 total protein expression\nof slc7a11 did not correlate with ssz activity  thus \nssz can be repurposed to inhibit cystine import and\nimpair leukemic viability in aml \nsulfasalazine improves the efficacy of anthracycline\ncytarabine combination chemotherapy in preclinical\naml models \nin two distinct aml cell lines  the anthracycline\ndaunorubicin  dnr  was identified among a panel of 8\naml drugs as the one with top synergism when\ncombined with ssz  this observation may be\nunderpinned by the rosinducing potential of\nanthracyclins 24 in a cohort of 48 primary aml samples  addition of ssz at a low concentration  4 µm  mimicking\ntrough concentrations in healthy donors 22 significantly\nincreased the antileukemic activity of the combination\nof dnr with arac on both the total leukemic bulk and on\ngpr56  lscs in a nichelike ex vivo drug screening\nplatform combining stromal coculture  hypoxia and\nplasmalike medium 25 finally  addition of ssz with a\nregimen combining 3 days of the anthracycline\nadriamycin with 5 days of cytarabine  maximally\ntolerated regimen in immunocompromised nogexl\nmice  further decreased the leukemic burden in a pdx\nmodel and significantly prolonged survival over\nadriamycincytarabine chemotherapy alone  pardieu et\nal  manuscript in preparation  data to be presented at the\n2021 annual meeting of the european hematology\nassociation   these data support the clinical evaluation\nof the addition of ssz with 7 3 in aml \naddition of sulfasalazine to standard of care\nchemotherapies is manageable \nrepurposing of ssz to inhibit xct has been investigated\nalone or with standards of care chemotherapies in solid\ntumors 2628\na first study conducted of singleagent ssz in 10 highly\ndebilitated patients with high grade  progressing\nglioblastomas was terminated prematurely based on\nlack of efficacy  in this trial  the toxicity of ssz at low\ndoses  1 56 g d  was mostly neurological  suggestive of\ntumorspecific poor tolerability possibly caused by drug\nrelated peritumoral edema  26\nconversely  another doseescalation study of single\nagent ssz up to 12 g d for 14 days in 11 patients with\nadvanced gastric cancer identified 12 g d as mtd with\ngrade 3 anorexia as dlt  other grade 3 aes included\nelevated ast  n 1  and bilirubin  n 1   fatigue  n 2  \nnausea  n 1   vomiting  n 1  and hyponatremia  n 1  \nthere was no grade   3 hematological or grade 4 non\nhematological ae in this trial  the median number of\nssz cycles was 2  range 1 4  with a mean relative dose\nintensity of 85  for dose level 1  8 g d  and 60  at mtd\n 12 g d  28\nfinally  a phase 1 study combining ssz thrice daily for\n21 days with cisplatin and pemetrexed on day 1 of each\nssz cycle was conducted in 15 patients with advanced\nnonsmallcell lung cancers \nthe mtd was 3 g day  and the recommended phase 2\ndose  rp2d  was 1 5 g day  dlts included grade 3\nelevations of ast and alt aminotransferase levels \nhypotension  pneumonitis  and anorexia  overall  the\ncombination appeared manageable  and promising\nactivity was noted in terms of overall response rate\nprogressionfree survival compared to historical\ncontrols 27 the antitumor activity of ssz continues to be\nexplored in solid tumors  nct nct04205357   overall  addition of ssz to chemotherapy appears feasible in\ncarefully designed dose escalation phase 1 trials \ncollectively  these preclinical findings provide a strong\nrationale for the clinical evaluation of the addition of\nsulfasalazine to standard of care 7 3 induction regimen\nin nonfavorable aml patients older than 60 years  the\npurpose of this phase i study is to evaluate the safety\nand feasibility of such strategy  provide preliminary\nsignals of efficacy  and identify potential biomarkers ",
    "OBJECTIVE": "main objective and primary\nendpoint  primary objectives \nphase i\nto assess the safety  characterize the doselimiting\ntoxicities  dlts   and identify the maximal tolerated dose\n mtd   anticipated to be the recommended phase ii dose\n rp2d  of the combination of sulfasalazine  ssz  with\nidarubicin  ida  and cytarabine  arac  in patients with\nnewly diagnosed nonfavorable aml \nprobability of dlt should not exceed 33  at the end of\nthe induction cycle  eoi  of idaarac   ssz treatment  up\nto day 42  \nphase ii\nto assess preliminarily the antileukemia efficacy of the\ncombination of idaarac   ssz  mainly in phase ii  in\nnewly diagnosed nonfavorable aml with reference from\nhistorical data on complete remission rate   as defined in\neln 2022 guidelines  and mrd  by centralized flow\ncytometry  \nprimary endpoints\nphase i \ndocumentation during the dose escalation of dose limiting\ntoxicity  dlt   identification of a maximal tolerated dose\n mtd  anticipated to be the recommended phase ii dose\n rp2d  \n  dose limiting toxicity  dlt \ndlt will be defined during a safety observation period\ncorresponding to the induction cycle with idaarac   ssz\n up to day 42   events occurring after the onset of a\nsecond treatment cycle  i e  salvage or consolidation \nwill not be considered as dlts \nany of the following events will be considered a dlt\nunless the event can be attributed by the investigator to a\nclearly identifiable cause such as underlying illness or disease progression  concurrent other illness  or\nconcomitant medication \no prolonged myelosuppression defined as grade  \n3 neutropenia or thrombocytopenia on day 42\nfrom start of therapy or later without evidence of\nleukemia  assessed by bone marrow aspiration\nand or biopsy  \no grade  3 hemorrhages until day 42 \no grade  3 non hematological toxicity until day 42\nwith the exception of \n  grade 3 infection  grade 3 fever with\nneutropenia  nb  grade 4 infections and grade\n4 fever with neutropenia are considered as\ndlts  \n  grade  3 nausea  vomiting or diarrhea that\ncan be managed to   grade 2 within 72 hours\nof symptomatic treatment \n  grade  3 asymptomatic liver enzymes\nelevation that improves to   grade 2 within 72\nhours of onset \n  grade  3 tumor lysis syndrome that resolves\nwithin 72 hours of onset with medical\ntreatment \n  maximal tolerated dose  mtd \nmtd is defined by a target dlt rate of 33   assessed\nduring the dose escalation phase by a continual\nreassessment method \n  recommended phase ii dose  rp2d \nrp2d is anticipated to be the mtd  however  it could be\nequal to one dose level lower than the mtd  it will be\ndetermined in interaction with the dsmb  insofar that this\ndose level is validated by pk pd studies and efficacy\npreliminary data \nphase ii\nmrdnegative complete response at eoi  day 2842 \nper eln 2022 criteria \n  complete response is defined as complete\nremission cr or cri  cr with incomplete\nhematologic recovery  meaning cr with platelet\ncount  100 000 µl or absolute neutrophil count\n 1000 µl  and crh  cr with partial hematologic\nrecovery  meaning cr not fulfilling cr or cri peripheral blood count criteria but with platelet\ncount  50 000 µl and absolute neutrophil count\n 500 µl  \n  mrdnegativity is defined as an 8color bone\nmarrow fcm mrd   0 1  at eoi \n  of note  npm1transcript based mrd in the bm\nand pb will be carried as exploratory endpoint in\nnpm1mutated patients  secondary objectives and\nendpoints  secondary objectives\n  to characterize the pharmacokinetics  pk  and the\npharmacodynamics  pd  of ssz  ida and arac when\nadministered in combination  during the dose escalation phase\n1a  and to confirm it during the phase 2 of the trial \n  to describe during the phase i of the trial the response\nof the leukemia to the treatment  the survival of patients up to\n12 months after the end of induction  eoi  visit \n  to document further during the phase ii of the trial the\nsafety profile and confirm the rp2d of the ida  arac and ssz\ncombination \nsecondary endpoints\n1  assessment of safety\n  safety outcome measures will be assessed\ncontinuously during the study \n  monitoring of ecgs and clinical laboratory values are\nintegral to safety assessment \n  adverse events  ae   treatment emergent adverse\nevents  teae  and treatmentrelated teaes will be\nevaluated according to the nci ctcae version 5 0 \nserious adverse events will be defined per protocol\naccording to ema ich criteria  causality relationship\nwith the experimental treatment should be assessed by\nthe investigator \n  frequency  duration and maximal severity of each\nteae  treatmentrelated teaes  teaes leading to\ntreatment discontinuation  serious adverse events\n saes  and deaths should be documented during\nphase i and ii of the trial \n  patients should be followed until all treatment related\nteaes have returned to grade   1 or baseline or are\ndeemed irreversible by the investigator \n2  pharmacokinetics\nto assess ssz and its metabolites  ida  and its metabolite  and\narac  this will allow to determine a pk model for ssz at an\nearly and late time point and confirm the lack of interaction\nbetween ssz and ida or arac  the pk plan is detailed in a\nsection below \npharmacokinetic  pk  study will be conducted on patients\nrecruited in the phase i part of the trial to assess the pharmacokinetics of sulfasalazine  and its main metabolites 5\nasa  mesalazine  and sulfapyridine which is mostly involved in\nadverse events  pk will be performed at days 0 and 3 and 14 \npk profiling of cytarabine and idarubicine    idarubicinol  at day\n4 will confirm the lack of drugdrug interaction \nfollowing pk parameters will be determined using non\ncompartmental analysis  winnonlin pharsight corporation \nmaximum plasma concentration  cmax   maximum plasma\nconcentration time  tmax   area under the plasma\nconcentration time curve  auc   clearance  cl   mean\nresidence time  mrt   and distribution volume  vd f  \nfor pharmacokinetic analysis  the dose of ssz will be\nadministered orally together with 200 ml water after the patient\nhas fasted overnight  with a meal being permitted after blood\nsampling at 4 h after the drug is given \nblood samples will be obtained \n on day 0 before  predose  and at 1  2  3  4  6 and 8h\nafter first ssz dose \n on day 3 predose and at 5   10   20   40   1h  4  8  24h\nof start of ida injection \n on day 14 before  predose  and at 1  2  3  4 and 6h\nafter first ssz dose \nblood samples will be collected into heparinized tubes \nimmediately after collection  tubes will be inverted several times\nand kept at approximately 4  c until centrifugation  the tubes\nwill be centrifuged for 10 min at 1500 g at 4  c within 60 min of\ncollection to separate plasma  the plasma will be separated into\n2 aliquots in polypropylene screwcap tubes and placed at \n80 c until analysis \nall samples will be labeled with patient identification  study\nidentification  sample number  and actual date and time at which\nthe sample was collected  the plasma concentration of ssz\nand metabolites will be determined by a validated\nultraperformance liquid chromatography and tandem mass\nspectrometry method 28\n3  pharmacodynamics\npharmacodynamic assays aim at demonstrating ros induction\nupon ssz exposure relative to pretreatment levels  they will\nbe done on peripheral blood  because repeated bone marrow\naspiration over a shorttime period is unethical  blood sampling\nfor pd will be done on \n day 0  effect of ssz alone\n day 1  combined effect of ssz  ida and arac \npd assays will include \n  plasma levels of malondialdehyde  mda   glutathione\n reduced oxidized   two robust biomarkers of oxidative\nstress biomarkers previously involved in ferroptosis\nand or ssz mode of action  our preclinical results and\n29  that can be assessed in all patients and at all time\npoints regardless of white blood cell count and\npercentage of circulating leukemic cells    in patients with circulating leukemic cells  ros levels\nof peripheral blood mononuclear cells by flow\ncytometry  h2dcfda  \n4  antileukemia activity\n  response at eoi assessment  day 2842  per eln 2022\ncriteria \no morphologic leukemiafree state  mlfs   blastic\ncriteria of response on the bone marrow aspirate \nabsence of extramedullary disease and no\nrequirement of hematologic recovery \no partial response  pr   absence of circulating\nblasts  absence of extramedullary disease \ndecrease of bone marrow blast percentage to 5 to\n25  and decrease of pretreatment bone marrow\nblast percentage by at least 50 \no overall response rate  orr  being defined as cr \ncri and crh  mlfs and pr rates \no primary refractory disease defined as patients\nlacking criteria for any of the above defined\nresponses  cr  cri  crh  mlfs and pr  at eoi\nassessment  excluding patients with death in\naplasia or death due to indeterminate cause as\ndefined per eln 2022 criteria \no death in aplasia and death due to indeterminate\ncause as defined per eln 2022 criteria \n  survival assessment at 12 months\no eventfree survival  efs   here events are\ndefined as \n  non achievement of hematologic\nresponse including cr  cri  crh\n  hematologic relapse or progressive\ndisease\n  initiation of any subsequent antileukemic\ntherapy  excluding hydroxyurea \n  deaths prior to one of the events\nmentioned above \nreasons for subsequent therapy initiation  including\nintolerance  resistance  hematologic relapse  unsatisfactory\nmrd evolution   its type  intensive  lessintensive  best\nsupportive care  and its frame  clinical trial  offlabel or\ncompassionate use  will be prospectively recorded \no duration of response  dor \no relapse free survival  rfs \no overall survival  os  o incidence of subsequent allogeneic hsct \noverall and in responding patients specifically \napart from specific mentions  all these hematological endpoints\nwill be defined according to the latest recommendations from\nthe european leukemia network  eln  currently the 2022 eln\nrecommendations  ",
    "DESIGN": "design of the study  phase iii  open label  multicenter clinical trial with 2 subsequent\nphases \n  phase i  doseescalation with a design using a\nsurvival continual reassessment method to identify the maximal\ntolerated dose  mtd  and recommended phase ii dose  rp2d  \n  phase ii  extension at the rp2d chosen by the\ndata and safety monitoring board  dsmb   to confirm the safety\nof rp2d and preliminarily documents its clinical efficacy ",
    "INCLUSION CRITERIA": "population of study\nparticipants  patients   60 years with a recently diagnosed non favorable\naml and eligible for intensive chemotherapy inclusion criteria   patients aged 60 years or older\n with newly diagnosed aml  short course treatment with\nhydroxyurea and or steroids is acceptable   patients\nwith aml secondary to an antecedent myelodysplastic\nsyndrome  mds  or myeloproliferative neoplasm\n mpn  are eligible  as those with therapyrelated aml \n eligible for an intensive chemotherapy according to\nthe investigator s opinion\n multiparameter flow cytometry at screening\ncompatible with mfcbased mrd monitoring\naccording to eln criteria  phase ii only  \n ecog performance status  2\n ast and alt  3 0 x upper the limit of normal  uln \nand total and direct serum bilirubin   1 5 x uln unless\nconsidered due to leukemia \n estimated glomerular filtration rate  gfr    50 ml min\naccording to the mdrd equation \n written informed consent obtained prior to any\nscreening procedures \n eligible for national health insurance in france ",
    "EXCLUSION CRITERIA": "exclusion criteria   myeloid sarcoma with   20  bone marrow blasts\n patient who has received a vaccine injection with live\nattenuated virus in the last three weeks\n proven central nervous system leukemic involvement \n favorable risk cytogenetics  t 15 17   t 8 21   inv 16 \nor t 16 16  or pmlrara  runx1runx1t1  cbfb\nmyh11 fusion transcript \n presence of flt3itd or tkd mandating treatment\nwith midostaurin \n concurrent therapy with any cytotoxic drug within 3\nweeks before the first study dose  only hydroxyurea for\nthe control of blood counts is permitted \n patients planned to received cpx351 for\nmyelodysplasiarelated changes or therapyrelated\naml \n previous treatment with sulfasalazine in the last 5 years\nor ongoing treatment with sulfasalazine or 5\naminosalicylic acid  5asa  for ulcerative colitis or\ninflammatory rheumatisms \n history of allergic reaction to sulfonylarylamines sulfonamides  salicylates  or sulfasalazine excipients \n history of allergic reaction to idarubicin or idarubicin\nexcipients\n history of allergic reaction to cytarabine or cytarabine\nexcipients\n known glucose 6phosphate dehydrogenase deficiency\n known acute intermittent porphyria or porphyria\nvariegata \n uncontrolled systemic fungal  bacterial  or viral infection\n defined as ongoing signs symptoms related to the\ninfection without improvement despite appropriate\ntreatment \n other uncontrolled or active malignant disease within\nprior 12 months  excluding myelodysplastic syndrome \ncutaneous basal cell carcinoma   insitu  carcinoma of\nthe cervix or breast  or other local malignancy excised \n known human immunodeficiency virus  hiv  infection\nor hivrelated malignancy \n clinically active hepatitis b or hepatitis c infection \n inability to swallow \n known malabsorption syndrome or other condition that\nmay significantly impair absorption of oral study\nmedications \n participation in another therapeutic interventional\nclinical study within 30 days of enrolment \n administration of any therapy that is considered\ninvestigational  i e   used for nonapproved\nindications s  or in the context of a research\ninvestigation  within 5 drug halflives  whichever is\nlonger  prior to the first dose of study drug \n previous treatment by anthracyclines\n any contraindication to use anthracyclines including\nuncontrolled coronary disease  severe renal failure \nsevere hepatic failure  recent myocardial infarction \nsymptomatic congestive heart failure  severe\ncardiomyopathy  significant arrhythmia as estimated by\nthe investigator or lvef  53  as assessed by\nechocardiography or muga  anterior treatment by\nidarubicin and or anthracyclines and anthracenediones\nbeyond the maximum cumulative dose \n any contraindication to use cytarabine including\ndegenerative and toxic encephalopathy \n any condition requiring treatment with digoxin \n any of concurrent severe and or uncontrolled medical\ncondition  which could compromise participation in the\nstudy \n females who are pregnant or breastfeeding \n in a man whose sexual partner is a woman of\nchildbearing potential  unwillingness or inability of the\nman or woman to use a highly effective contraceptive\nmethod for the entire treatment period and for at least\n6 months after completion of protocol treatment \nhighly effective contraception methods include \ncombined  estrogen and progestogen containing \nhormonal methods associated with inhibition of\novulation  intrauterine device  surgical sterilization\n including bilateral tubal occlusion  partner s vasectomy  or sexual abstinence if this is the preferred\nand usual lifestyle of the patient \nmale patients must not freeze or donate sperm starting\nat screening and throughout the treatment period and 3\nmonths after the administration of the final dose of study\nmedication \n in a heterosexually active woman of childbearing\npotential  unwillingness or inability to use a highly\neffective contraceptive method  as described above  for\nthe entire treatment period and for at least 6 months\nafter the administration of the final dose of study\nmedication \nwomen are not regarded as of childbearing potential if\nthey are postmenopausal  at least 2 years without\nmenses  or are surgically sterile  at least 1 month\nbefore enrollment  \nfemale patients must not donate or retrieve  for their\nown use  ova from the time of screening and throughout\nthe treatment period  and for 12 weeks after the\nadministration of the final dose of study medication \nfemale patients must agree not to breastfeed from the\ntime of screening and throughout the protocol period \nand for  5 1 2 lives  days after the administration of the\nfinal dose of study medication \n adults subjects to a legal protection order or unable to\ngive their consent\n persons deprived of their freedom by judicial or\nadministrative decision  person hospitalized without\ntheir consent by virtues of articles l 32121 and l3213\n1 and who are not subject to the provisions of article l\n11218 ",
    "INTERVENTION": "investigational medicinal\nproduct and auxiliairy\nmedicinal products  investigational medicinal product  sulfasalazine  approved and\nmarketed for years as treatment of inflammatory diseases\ntablets dosed at 500 mg\noral route with water at the following dose levels  dl  tested\nduring the phase i \ndl2  0 5 g  bid hence 1 0 g d  days 07\ndl1  0 5 g  tid hence 1 5 g d  days 07\ndl1  0 5 g  tid hence 1 5 g d  days 014\ndl2  1 0 g  tid hence 3 0 g d  days 014\ndl3  1 5 g  tid hence 4 5 g d  days 014\ndl4  2 0 g  tid hence 6 0 g d  days 014\ndl5  2 0 g  four times per day hence 8 0 g d  days 014\nat all dose levels  patients will receive the standard of care\nidaarac backbone  considered as auxiliary medicinal\nproducts in this clinical trial 7 consisting of  drug doses administration days time\nidarubicin* ** 12 iv  30mn 3 day 1 to 3\nmg m2 days\ncytarabine* 200 civ over 24h 7 day 1 to 7\nmg m2 days\n*for these two drugs the body area should not be capped to 2 m2\ndose escalation will be conducted according to the survival\ncontinual reassessment method  the number of patients\nassessed at each dose level depending on the safety\nobservations \npatients should be hospitalized during the induction course at\nleast until day 21 and or achievement of a neutrophil count  \n500 µl  thereafter they can be discharged if  according to the\njudgment of the investigator  their medical condition allows it\nand when all nonhematological treatmentemergent aes\nresolve to grade   2 \npatients should have adequate iv hydration during ssz\nexposure \nfollowing the eoi visit  patients will continue to be followed for\ntreatment related teaes for 30 days following the end of ssz\nexposure  and for postinduction therapy  relapse and survival\nfor 12 months after the eoi visit  treatments beyond eoi are\nleft to the clinicians  choice and may include consolidation\nchemotherapy  oral maintenance and or allogeneic stem cell\ntransplantation  alfa guidelines for postremission therapy in\naml patients 60 years or older treated intensively are provided\nin the protocol appendices \na minimal followup for transplantation  relapse and death for an\nadditional 5 years after study exit will be undertaken  comparator treatment  none",
    "STATISTICS": "statistical analysis  phase i\na bayesian adaptive dose escalation design will be used for the\ntrial objectives  it allows sequential monitoring of data during the\ntrial  using all current evidence for straightforward inference on\nsafety and efficacy and decision making to select and evaluate\nan optimal dose \nthe design will rely on the bayesian continual reassessment\nmethod  crm  for the phase i  with cohorts of size 1 and a\nmaximum sample size of 20 patients 30 the target dlt rate for\nthe definition of the mtd will be 33  within the eoi observation\nwindow  the timetoevent extension of the crm  survcrm \ndesign will be used depending on the anticipated accrual rate\ncompared to the dlt observation window 31  this will allow\naccounting for rightcensored toxicity observation in sequential\nmtd estimation and dose assignment process \nphase ii\nonce phase i has been completed providing the estimated\nmtd  the rp2d will be determined based on dsmb\nrecommendations according to safety data and efficacy signals\nfrom phase i \ninclusion criteria will be the same as in phase i with the addition\nof an additional inclusion criteria  laip detected at baseline\nfcm assessment  related to the primary endpoint of complete\nresponse with negative mrd \nbased on historical data  the rate of mrdnegative complete\nresponse in the study population is estimated at  50   british\naml16 data  12 spanish pethema data 32 british aml17 data\n s  freeman  pers  comm    \na simon minimax twostage design will be used for this phase\n simon r  optimal twostage designs for phase ii clinical\ntrials  controlled clinical trials 1989 10  110   this phase ii\nassessment will require a maximum total of 44 subjects to\ndecide whether the proportion responding  p  is less than or\nequal to 0 50 or greater than or equal to 0 70  at the first stage\n that is among the first 22 included patients   if the number of\nresponses is lower than or equal to r1 11  the phase ii will\nstopped early  for futility  otherwise  if r1   12  enrollment will\ncontinue up to a maximum of 44 patients  overall  if the number\nof responses r becomes 28 or more  the hypothesis that p  \n0 50 is rejected with a target type i error rate of 0 05  if the total\nnumber of responses is r 27 or less  the hypothesis that p  \n0 70 is rejected with a target type ii error rate of 0 15  of note \nphase i patients treated at the rp2d of choice will be included\nin this analysis if they are assessable by fcm mrd  presence\nof a laip  ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  salma",
    "INVESTIGATOR": "coordinating investigator  prof raphaël itzykson scientific director  dr alexandre puissant",
    "NUMBER OF INCLUSIONS": "number of participants\nincluded  total  64 patients\nphase i  20 patients\nphase ii  44 patients",
    "SITES": "number of centers    8 centers in phase i\n  13 centers in phase ii\nconducted only in france  in hematology centers",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  fondation arc"
  },
  "ERYTHROSIM": {
    "TITLE": "full title  randomized prospective trial evaluating the efficacy of the\nanticd38 monoclonal antibody isatuximab in the\ntreatment of pcra by major abo mismatch after\nallogeneic hematopoietic stem cell transplantation ",
    "JUSTIFICATION": "scientific justification  a quarter of allogeneic hematopoietic stem cell\ntransplantation are performed in a situation of major abo\nmismatch exposing patients to the risk of immunological\npure red cell aplasia  prca  after transplant  pcra after\ntransplant is defined as anemia with low reticulocytes\ncount  under 10 g l  after day 60 despite good leucocytes\nand platelet engraftment  full donor chimerism  associated\nwith the persistence of recipients hemagglutinins  antia\nor antib antibodies   bone marrow evaluation when\nperformed show erythroid hypoplasia  red blood cells\ntransfusions are necessary every two weeks until\nremission leading to impaired quality of life  anemia \nrepeated hospitalization   iron overload  and need for iron\nchelation therapy  treatments currently used are\ninefficient  anti cd20 monoclonal antibodies  epo \nsteroids  plasma exchanges  proteasome inhibitors  or at\nrisk of severe acute gvhd  donor lymphocytes infusion  \nprca has been demonstrated to be associated with the\npersistence of recipient s plasma cells \nanticd38 monoclonal antibodies which targets plasma\ncells secreting hemagglutinins responsible of pcra are a\npromising treatment  6 cases reported in the literature\nsupport a rapid and sustain efficacy  chapuy  nejm  2018\nbathini  amjhematol  2019  rautenberg  bmt  2019\nsalas et al  eur j haematol 2019  preethi et al  blood cell\nmol dis 2020  yates et al  transfusion 2021   but a\nprospective randomized evaluation of its efficacy and\nsafety in this context is necessary ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  efficacy of the treatment of prca by\nisatuximab after allogeneic hematopoietic stem cell\ntransplant compared to supportive care only control group\n reduction in prca resolution time in days \nprimary endpoint \ntime to obtention of transfusion independence for patients\nwith prca  time interval between randomization\n corresponding to the m6 posttransplant  and resolution\nof prca  date of resolution of reticulocytopenia  treated\nor not by the anticd 38 monoclonal antibody isatuximab  secondary objectives and\nendpoints  secondary objectives\n1  to evaluate the two arms in term of clinical and\nbiological outcomes   reduction of red blood cells transfusion needs with\nisatuximab\n evolution of iron overload\n adverse events related to isatuximab in the context\nof allogeneic sct  ctcae grade   2 in each group\nafter m6 posttransplant \n quality of life  functional repercussions of chronic\nanemia  iterative transfusions and iron overload at\nd29  3  6  9 months after randomization\n overall survival and without relapse at m6  m9  m12\nand m15 posttransplant\n2  to identify prognostic factors of spontaneous resolution\nof prca by major abo mismatch between d60 and m6\n type of donor  cell stem cell and conditioning regimen \noccurrence of acute or chronic graft versus host disease \ndiscontinuation of immunosuppression \n3  to evaluate the interest of followup of group\nhemagglutinins\n4  to compare both arms in term ofcost effectiveness\n cost of isatuximab treatment  hospitalizations  transfusion\nsupport and chelation treatments \nsecondary endpoints \nnumber of red blood cell transfusions after randomization\nferritin levels at m6  m9 and m15 posttransplant\nadverse events  ctcae grade   2  after randomization\nquality of life questionnaire  eortc qlqc30 v3  at\nd60  d100  m6  m9  m12  m15 posttransplant\nfactors associated with spontaneous resolution of\nprca between d60 and m6 posttransplant\n antibody level  anti a and or anti b titers  at d60  d100 \nm6 posttransplant then at each visit d15  d29  d45  and\nm3  m6  m9 post randomization \n number of days of hospitalization  transfusions support\nand chelation treatments",
    "DESIGN": "design of the study  randomized prospective phase ii clinical trial assessing\nthe efficacy and safety of the anticd38 antibody\nisatuximab in patients with persistent prca at 6 months\nafter allogeneic hsct  including patients at day 60 after\ntransplant will help to define the factors associated with\nunresolved prca to m6 and thus identify patients that\ncould benefit of isatuximab treatment earlier in the future \ninterim analysis will be performed after observations of 22\nevents  primary endpoint  in the trial ",
    "INCLUSION CRITERIA": "population of study participants  allogeneic stem cell transplant recipient 15 years of age\nor older with prca inclusion criteria  patients \n aged 15 years or older\n having receiving an allogeneic hematopoietic stem cell\ntransplantation in condition of major abo mismatch  pcra defined by persistent red blood cell transfusion\ndependence at day 60 posttransplant with reticulocytes\ncount under 10 g l despite full donor chimerism and a\ngood leucocytes   1 g l  and platelet   50g l  recovery\n no relapse or progression of underlying disease\n contraception methods must be prescribed during all the\nduration of the clinical trial and using effective\ncontraceptive methods during treatment for women of\nchildbearing age  continue abstinence from heterosexual\nintercourse is accepted  and for man during the study\ntreatment period and for at least 5 months after the last\ndose of study treatment and refrain from donating sperm\nduring this period\n with health insurance coverage\n having signed a written informed consent  2 parents\nfor patients aged less than 18 ",
    "EXCLUSION CRITERIA": "exclusion criteria  patients \n aged   15 years\n relapse of underlying disease\n leucocyte chimerism   95 \n prca related to parvovirus b19 infection  positive\nblood pcr \n known to be hiv  or to have hepatitis a  b  or c active\ninfection\n active tuberculosis\n pregnancy  βhcg positive  or breastfeeding \n patient receiving recombinant human erythropoietin \n patient receiving proteasome inhibitor  bortezomib for\nexample  \n patient receiving thrombopoietin receptor agonists\n artpo  \n patient receiving plasma or plasmapheresis exchanges\nafter transplant \n planned to receive any investigational drug within 14\ndays or 5 halflives of the investigational drug  whichever\nis longer \n any clinically significant  uncontrolled medical\nconditions that  in the investigator s opinion  would\nexpose excessive risk to the patient or may interfere with\ncompliance or interpretation of the study results \n hypersensitivity to the active substance or history of\nintolerance to steroids  mannitol  pregelatinized starch \nsodium stearyl fumarate  histidine  as base and\nhydrochloride salt   arginine  hydrochloride  poloxamer\n188  sucrose or any of the other components of study\ntherapy that are not amenable to premedication with\nsteroids and h2 blockers or would prohibit further\ntreatment with these agents \n who have any debilitating medical or psychiatric illness\n under tutorship or curatorship\n who not understand informed consent for an optimal\ntreatment and followup",
    "INTERVENTION": "experimental treatment  isatuximab treatment at a dose of 10 mg kg by intravenous\nroute  the first injection of isatuximab will be performed at\nrandomization  m6    2 days   a second injection may be\nperformed at d15  2d if the reticulocytes  10 g   l  and a\nthird at d29  2d if reticulocytes  10 g   l  patients will be\nassessed on day 1  day 15  day 29  day 45  2 months  3\nmonths  6 months and 9 months after randomization ",
    "STATISTICS": "statistical analysis  a bilateral logrank test considering a sample size of 45\nrandomized patients in 2 1  30 in the experimental group\nwith median transfusion independence under h1 of 1 5\nmonths  15 in the control group with median transfusion\nindependence under h1 of 4 5 months  achieves a power\nof 86 4  with an alpha risk of 0 05  considering that only\n50  of patients included at d60 will be randomized at 6\nmonths  90 patients should be included \ninterim analysis will be performed after observations of\n22 events  primary endpoint  in the trial ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  erythrosim",
    "INVESTIGATOR": "coordinating investigator  dr xhaard aliénor",
    "NUMBER OF INCLUSIONS": "number of participants included  90 patients  45 randomized\nthe inclusion period will be increased to include patients\n even more than the 90 expected  until to randomize the\n45 patients needed  notably if less than 50  of the 90\nenrolled patients are still prca at m6 ",
    "SITES": "number of centres  24 centers  pediatrics and adults  in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  ministry of health  phrc 2019 \nexperimental treatment  free supply by sanofi company"
  },
  "EQUAALL01": {
    "TITLE": "full title  evaluation of longterm health status and quality of life in\nadult survivors with philadelphianegative acute\nlymphoblastic leukemia lymphoma treated with an\nintensive pediatric or pediatricinspiredinspired protocol ",
    "JUSTIFICATION": "scientific justification  the overall survival of adult patients  1559y  with philadelphia\nnegative acute lymphoblastic leukemia lymphoma  all ll  was\ndramatically improved by the use of full pediatric or pediatric\ninspired protocols  graall2003 05ll03fralle2000  that\naimed to reduce the risk of relapse by adopting more intensive\nchemotherapeutical schedule  this approach led to a global\nimprovement in overall survival  5yos  57   whatever patient\nage but was responsible for an excess of treatmentrelated\nmortality in patients older than 45 years  5ytrm in patients  \n45y  19    pediatric longitudinal studies pointed out that long\nterm leukemia survivors have an increased risk of developing\nspecific adverse events like dysmetabolic syndrome  obesity \ndecreased fertility  organ dysfunction  osseous events  or\nimpaired cognitive functions  this study aims to evaluate the\nimpact in term of longterm events and qol in adult patients that\nreceived an intensified therapeutic approach recently\nimplemented in adult cooperative groups ",
    "OBJECTIVE": "main objective and primary\nendpoint  to evaluate the prevalence of late effects in adult patients\ntreated 10 years ago for all ll with an intensified pediatric\ninspired protocol  graall2003 05ll03fralle2000  that\nexposed patients to increased cumulative doses of\nchemotherapy  central nervous system irradiation or w o\nallogeneic transplant after total body irradiationbased regimen\nw o boost irradiation on central nevous system \nthe primary endpoint is thus defined by the prevalence of\nadverse events  including  \n metabolic troubles  dysmetabolic syndrome  dyslipidemia \ndiabetes \n osseous events   osteoporosis\n cardiac and vascular troubles\n neurologic troubles\n lung dysfunctions\n endocrinal troubles\n ophthalmological troubles\n fertility disorders\n secondary neoplasia secondary objectives and\nendpoints   to evaluate the quality of life of these patients \n to correlate the prevalence of late effect or qol status with\nprevious social situation  previous medical condition to all \ntreatment schemes including administration of protocols phases\n delayed intensification  maintenance   centralnervous system\nirradiation  allogeneic sct  graftversus host disease\noccurrence   \n to elaborate riskadapted recommendations for the longterm\nfollowup of adult patients treated for all with reinforced\ntherapeutic strategies \nthe secondary endpoints are thus  the prevalence of metabolic troubles  dysmetabolic syndrome \ndyslipidemia  diabetes  \n the prevalence of osseous events   osteoporosis \n the prevalence of cardiac and vascular troubles \n the prevalence of neurologic troubles \n the prevalence of lung dysfunctions \n the prevalence of endocrinal troubles \n the quality of life  sf36 \n the prevalence of ophthalmological troubles\n the prevalence of fertility disorders\n the prevalence of secondary neoplasia",
    "DESIGN": "design of the study  this is a multicenter  crosssectional  interventional minimal\nrisks and constraints human research study",
    "INCLUSION CRITERIA": "population of study participants  adult patients aged 1559y at diagnosis treated ten years ago\nfor a ph1negative acute lymphoblastic leukemia lymphoma\n all ll  inclusion criteria   patient with philadelphianegative all or ll treated in or\naccording to a pediatriclike or pediatricinspired protocol\n graall or fralle  with or without allogeneic transplant \n patients older than 15 years old and less than 60 years old at\ndiagnosis\n patient with a followup from first complete remission of more\nthan 10 years \n patient who gave informed signed consent for baseline\nexamination",
    "EXCLUSION CRITERIA": "exclusion criteria   patient who experienced all ll relapse within the 5 past\nyears \n philadelphia positive all patients",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis  the analysis will handle the left data truncation  given only\npatients who survive until 2016 are able to be included in the\nstudy  \napproximately 1000 patients were included in the graall2003\nand 2005  among them 630 before august 2009 \nconsidering that 363 630 patients were alive at last followup \nthe opportunity to include patients treated according to these\nprotocols  and a 80  inclusion success  approximately 300\npatients will be recruited \nthis allows assessing the prevalence of troubles with a 95 ci\nwidth at 7  about assuming a 10  prevalence or to 0 10\nassuming a 30  prevalence  and detection of or at 2 5 or 2 \nrespectively  this also allows reaching a statistical power of at\nleast 80  for detecting or at 2 ",
    "DSMB": "",
    "ACRONYM": "acronym  equaall01",
    "INVESTIGATOR": "coordinating investigator  pr nicolas boissel\nhematology department\nsaintlouis hospital\n 33142499643\nnicolas boissel aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants included  300",
    "SITES": "number of sites  approximatively 36 centers of the graall network",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of monetary support  ministry of health"
  },
  "EFRAIM-II": {
    "TITLE": "full title  empirical steroids and or antifungals in\nimmunocompromised patients with acute respiratory\nfailure from undetermined etiology  a multicenter\ndoubleblind randomized controlled trial",
    "JUSTIFICATION": "scientific justification  acute respiratory failure  arf  is the leading reason of\nicu admission in immunocompromised patients \nfailure to identify the arf etiology is associated with\nincreased mechanical ventilation and mortality rates \nthis was confirmed in the large efraim 1 study\npublished in 2017  where undetermined arf etiology\naffected 609 1611  38   patients at day 3  402  25  \npatients at day 7 and 199  12 3   patients overall  and\nwas associated with a case fatality of 55   vs  40  in\nother patients   in lung biopsy autopsy findings from\nthese patients  invasive fungal infection  steroid\nsensitive affections  organized pneumonia  non\ninfectious interstitial involvement  drugrelated\npulmonary toxicity    and lung infiltration by the\nunderlying disease  lymphoma  carcinomatous\nlymphangitis  systemic vasculitis  connective tissue\ndiseases  etc   were the leading etiologies  no study\nhas evaluated survival benefits from empirical steroids\nand or antifungals in immunocompromised patients with\narf from undetermined etiology ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective\nto reduce the 90day mortality in immunocompromised\npatients with arf from undetermined etiology at day3 \nthe intervention would evaluate the impact of steroids  \nisavuconazole for 14 days or until icu discharge \nprimary endpoint\nmortality at day 90 secondary objectives and\nendpoints  the secondary study objectives are to evaluate\n how early empirical therapy can affect icu \nhospital and day28 mortality\n whether steroids increase the proportion of\npatients with icu acquired microbiologically\ndocumented bacterial infections within 3 months\nfollowing randomization\n the proportion of patients with invasive fungal infection within 3 months following randomization \n the proportion of patients with hsv  vzv or\ncmv reactivation within 3 months following\nrandomization\n whether steroids are complicated by severe\nhypokalemia   2 5 meq l   newly acquired or\ndecompensated diabetes  or severe or newly acquired\nhypertension\n whether isavuconazole will favor the emergence\nof infections with aspergillus or mucorale species with\ndecreased sensitivity to isavuconazole\n occurrence of candida infection\n how steroids affect psychiatric symptoms such\nas posttraumatic stress disorder  anxiety and\ndepression at 6 months\n how this early intervention can improve quality\nof life at 6 months\nsecondary end points\n icu mortality\n hospital mortality\n day 28 mortality\n proportion of patients with icu acquired\nmicrobiologically documented bacterial infections\n proportion of patients with invasive fungal infection\nwithin 3 months following randomization\n proportion of patients with hsv  vzv or cmv\nreactivation within 3 months following randomization\n occurrence of severe hypokalemia   2 5 meq l  \ndecompensated diabetes or severe or newly acquired\nhypertension\n emergence of aspergillus species with decreased\nsensitivity to isavuconazole\n incidence of candida infection\n incidence of posttraumatic stress disorder  iesr  \nanxiety and depression at 6 months  hads \n quality of life at 6 months  sf36 ",
    "DESIGN": "design of the study  multicenter doubleblind randomized controlled trial \nbased on a 2x2 factorial design ",
    "INCLUSION CRITERIA": "population of study participants  in immunecompromised patients with acute respiratory\nfailure  arf  from undetermined etiology  either\nintervention  steroids and or antifungals  will be\nassociated with improved day90 survival  acute\nrespiratory failure  arf  is the leading reason of icu\nadmission in immunocompromised patients  admission  inclusion criteria  1  age  18 years and  90 years  2  a \nimmunosuppressive drug b solid organ\ntransplant  c  solid tumor  d  hematological\nmalignancies  e  primary immune deficiency  3 \nicu admission for acute respiratory failure as\ndefined by a  respiratory distress with tachypnea\n respiratory rate 30 min   b  cyanosis  c \nlaboured breathing  d  need for more than 6l of standard oxygen to maintain spo2 95   or for\nhigh flow oxygen  noninvasive or invasive\nmechanical ventilation  4  no established arf\netiology 24 hours after hospital admission  5 \npatient admitted for at least 24 hours at hospital\n6  informed consent signed \n by the patient \n or informed consent signed by a family\nmembers trustworthy person if his condition\ndoes not allow him to express his consent by\nwritten as per l  11116 \nor in a situation urgently and in the absence of\nfamily members trustworthy person  the patient\ncan be enrolled  the consent to participate to\nthe research will be requested as soon as the\ncondition of the patient will allow him to consent \nnote  patient with pneumocystis pneumonia can be\nincluded given that their treatment does not require the\nuse of neither antifungal drugs nor corticosteroids",
    "EXCLUSION CRITERIA": "exclusion criteria  1  patient who improved enough to be discharged from\nthe icu before inclusion  2  documented invasive\nfungal infection requiring antifungal therapy  3   \npatient needing or receiving prophylactic or\nempirical antifungal treatment for clinical care 4  patient\nreceiving corticoid therapy  5  palliative care with\ncomfort measures only  do not intubate  dni  and do\nnot resuscitate  dnr  patients can be included   6 \npregnant or breastfeeding  7  no social security\ncoverage  8  known hypersensitivity to isavuconazole\nor to any of excipients of cresemba  specialty  9 \ntreatment with ketoconazole  ritonavir  or any\ncyp3a4 5 inductor  10  short qt syndrome and or\npatient with a family history of short qt syndrome  11 \nliver insufficiency  any stage   12  moribund patients \n13  participation in another interventional research on\nacute respiratory failure  14  person deprived of liberty \n15  person subject of psychiatric care  16  patient\nunder enforced hospitalization  17  adults under legal\nprotection or unable to give their consent 18  isolated\nhi",
    "INTERVENTION": "investigational medicinal\nproducts  methylprednisolone  will be given once a day at a\ndose of 2 mg kg day for three days as recommended in\nfibrosing pneumonitis in deeply hypoxemic patients  as\nof day 4  the daily dose will be tapered to 1 mg kg day\nuntil day 7  followed by 0 5 mg kg day from day 8 to day\n14 \nisavuconazole  will be given at a dose of 200 mg every\n8 hours for 2 days  6 administrations  and then once\ndaily until day 14 or icu discharge  which event occurs\nfirst \npatients of one of the arms will receive isavuconazole\nand methylprednisolone whith an established\ninteraction  the investigator must check the smpc where all needed information are available  comparator treatment  placebo methylprednisolone and placebo\nisavuconazole",
    "STATISTICS": "statistical analysis  an interim analysis will be performed after the\nrecruitment of 120 patients  or after 50 day90 deaths \nwhichever will occur first  ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  efraimii",
    "INVESTIGATOR": "coordinating investigator  prof  elie azoulay\nservice de réanimation médicale\nhôpital saint louis  paris  france\noffice phone   33  0  1 42 49 34 21\nfax   33  0  1 42 49 94 26\nemail  elie azoulay aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants\nincluded  420",
    "SITES": "number of centers  19 centers in france ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  phrcn 2018"
  },
  "RECORDS": {
    "TITLE": "title  rapid recognition of corticosteroid resistant or sensitive sepsis ",
    "JUSTIFICATION": "background  who estimates that  yearly  30 million people develop sepsis and\n11million die  aprocchs  a phase 3  placebocontrolled trial \ndemonstrated a 6  absolute reduction in sepsis mortality with\nhydrocortisone fludrocortisone  a number of factors may\npositively negatively impact corticosteroids  cs  benefits in sepsis",
    "OBJECTIVE": "main objective and\nprimary endpoint  to compare the effect hydrocortisone plus fludrocortisone vs  placebo\non a composite of death or persistent organ dysfunction   defined as\ncontinued dependency on mechanical ventilation  new renal\nreplacement therapy  or vasopressors   assessed at 90 days on\nintensive care unit  icu  adults and having different biological profiles\nfor immune responses and corticosteroids bioactivity\nthe primary endpoint is death or persistent organ dysfunction  defined\nas continued dependency on mechanical ventilation  renal\nreplacement therapy  or vasopressors  and with sofa score  6 up to\n90 days  secondary objectives\nand endpoints    mortality and healthrelated quality of life at 6 months \n  daily organ function  sofa score days 1  2  3  4  7  10  14  28  and\n90  \n  daily secondary infections  up to 90 days \n  daily blood and urinary levels of glucose  sodium and potassium  up\nto 28 day \n  daily gastroduodenal bleeding  up to 28 day \n  daily cognitive function and muscles  strength  days 1 to 28  90 and\n180 days ",
    "DESIGN": "study design  multiarms parallel blinded randomized controlled trial preceded\nby a 6month runin observational period \n observational phase  runin period \n interventional phase ",
    "INCLUSION CRITERIA": "inclusion criteria\nobservational\nphase \n n 1 2 3 4 6 7 8 9 \ninterventional\nphase \n n 1 2 3 4 5 6 7 8    1  patients  18 years old \n2  admitted to icu with proven or suspected infection as the main\ndiagnosis \n3  community acquired pneumonia related sepsis or\nvasopressors dependency  norepinephrine  epinephrine \nvasopressin  dopamine  phenylephrine  or septic shock\n singer 2016  vasopressor to maintain mean blood pressure of\nat least 65 mmhg and lactate levels above 2 mmol l  or acute\nrespiratory distress syndrome  ards   ranieri 2012  a acute\nonset  i e  within one week of an apparent clinical insult and\nwith progression of respiratory syndrome  b bilateral opacities\non chest imaging not explained by other pulmonary\npathologies  e g  pleural effusion  atelectasis  nodules etc  c\nno evidence for heart failure or volume overload  d pao2 fio2\n  300 mm hg   peep   5 cm h2o\n4  patient who has signed an informed and written consent\nwhevener he she is able of consent  if not  if not ascent from\nhis her representant whenever he she is present at time of\nscreening for inclusion 5  patients who have been tested for one or more records\nspecific biomarkers \na  circi\nb  endocan\nc  gilz\nd  dusp1\ne  mdw\nf  lymphopenia\ng  transcriptomic srs2\nh  endotype b\ni  pcr covid19\nj  pcr influenza\nk  pcr other respiratory virus\nl  cutaneous vasoconstrictor response to\nglucocorticoids\n6  affiliation to a social security system or to an universal health\ncoverage  couverture maladie universelle  cmu  \n7  patients under guardianship or curatorship will be included \n8  patients in case of simple emergency  legal definition  will be\nincluded \n9  patients managed with covid 19 and having biological\nsamples available",
    "EXCLUSION CRITERIA": "exclusion criteria\nobservational\nphase   n 1 2 3 \ninterventional\nphase \n n  1 2 3 4 5 6 7 8    1  pregnancy \n2  expected death or withdrawal of lifesustaining treatments within\n48 hours \n3  previously enrolled in this study\n4  formal indication for corticosteroids according to most recent\ninternational guidelines\n5  vaccination with live virus within past 6 months\n6  hypersensitivity to hydrocortisone or fludrocortisone or\n microsined betamethasone dipropionate*  or any of their\nexcipients  spc \n7  women of childbearing potential not using contraception\n8  nursing women\n* for patients included in this stratum  if applicable  do not apply the\ncream to an infected or ulcerated area",
    "INTERVENTION": "study intervention  observational phase  runin period   additional biological samples\nfor the restrospective part  covid patients   telephone\nfollowup\ninterventional phase \ninvestigational products or their placebo will be administered to\npatients on the basis of records signatures\ninvestigational products included \n hydrocortisone hemisuccinate 50 mg  one intravenous injection\nevery 6 hours  and\n 9 alpha fludrocortisone 50 μg  one tablet per day via a nasogastric\ntube \nall treatments will be stopped after 7 days or until the patient has left\nthe intensive care unit  whichever occurs first  without tapering off ",
    "STATISTICS": "sample size  we will enroll a total of at most 1800 patients in this adaptative trial \nsites are expected to enroll at least 1or 2 patients per month  by\nenrolling 376 evaluable patients per arm  the study will have 80 \npower to detect a 10  absolute risk reduction  from 45  to 35   which\ncorresponds to a 20  relative risk reduction  ",
    "DSMB": "",
    "ACRONYM": "acronym reference  records",
    "INVESTIGATOR": "coordinating\ninvestigator and\nscientific director  pr djillali annane",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "clinical sites  french adult general icus",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris"
  },
  "KAPKEY": {
    "TITLE": "full title  phase ii multicentric study of pembrolizumab in classic or\nendemic kaposi s sarcoma",
    "JUSTIFICATION": "scientific justification  classic and endemic kaposi s sarcoma  ks  are\nlymphangioproliferations associated with human herpes virus 8\n hhv8   which treatment is poorly codified  chemotherapies\ngive at best 3060  of transient responses  while interferon\nresponses are frequent  this drug is often poorly tolerated in\nelderly patients  therefore new therapies are needed  classic\nks represents an ideal model for evaluating new drugs since\npatients do not receive concomitant immunosuppressive\nregimens nor antiviral therapies \npembrolizumab  an antipd1 monoclonal antibody has recently\nbeen shown to improve survival in several solid tumors  in ks\nfew data are available on the role of pd1pdl1 axis  a\nsignificant pdl1 expression on hhv8associated pleural\neffusion lymphomas and on ks samples have been recently\nreported  our experience in classical and endemic ks supports\nthe role of this pathway with expression of pdl1 by\nsubpopulations of t cells but also nk cells in peripheral blood\ncells from these patients and expression of pdl1 by tumor cells\nin ks lesions \nin this study we will evaluate the benefit and safety profile of\npembrolizumab in classic and endemic ks ",
    "OBJECTIVE": "primary objective and\nassessment criterion  simon s 2stage optimal design  \nthe main objective is to assess whether pembrolizumab is\nclinically inactive  partial complete response probability π0 5  \nor truly active  partial complete response probability π1 30  \nin classic and endemic kaposi s sarcoma  ks   using the\nsimon s 2 stage optimal design \nthe primary endpoint will be the best overall response rate\n borr  defined by the occurrence of complete response or\npartial response following actg criteria recorded from the start\nof treatment until 6 months or the beginning of any other specific\nsystemic therapy for ks if it occurs before 6 months \nextension phase \nin the event of a truly active conclusion of simon s 2step\noptimal design  an extension phase would be performed to\nevaluate more elements \nan extension phase would be performed to further evaluate the\nefficacy of pembrolizumab in our setting \nan additional 20 patients will be included to obtain a more\naccurate estimate of the treatment effect up to 24 months  the primary endpoint of this extension phase will be the best\noverall response rate according to the actg criteria  recorded\nfrom the start of treatment to 6 months or the start of any other\nksspecific systemic therapy if it occurs before 6 months  secondary objectives and\nassessment criteria  secondary objectives are   for simon s 2 stages optimal design\nand extension stage \n1  to assess the safety profile of pembrolizumab in classic and\nendemic kaposi s sarcoma \n2  to characterize the efficacy of pembrolizumab related to\npharmacodynamics assessment\nsecondary endpoints \nefficacy endpoints\ndifferent aspects of clinical response will be evaluated \n1  best overall response rate according to the pga criteria\nuntil 24 months or the beginning of any other specific\nsystemic therapy for ks if it occurs before 6 months \n2  response rate at month 3  month 6  month 9  month 12 \nmonth 18 and month 24 according to actg and pga criteria\n3  response rate on number of lesions at month 3  month\n6  month 9  month 12 and month 24 at best response as\ndefined following the pga\n4  response rate on the size of target lesions at month 3 \nmonth 6  month 9 month 12 and month 24 atbest response\nas defined following the pga\n5  response rate on tumor infiltration of target lesions at\nmonth 3  month 6  month 9 month 12 andmonth 24 at best\nresponse as defined following the pga\n6  response rate on lymphedema  circumference  scale of\n0  absence  to 3  painful or oozing   at month 3  month 6 \nmonth 12 and month 24 at best response as defined\nfollowing the pga\n7  time to response defined as the time to first response\nrecorded from the start of treatment\n8  time to progression defined as the time from starting\ntreatment to progression in all patients\n9  response rate according to actg and pga criteria at\nmonth 9  month 12  month 18 and month 24 for the\nextension stage\n10 duration of response defined as the time from starting\nresponse to progression in patients achieving partial or\ncomplete response\n11  quality of life following the qlc30 and dlqi kaposi\nat baseline  cycle 5   cycle 10   cycle 15  every 3\nmonths and eot  early study termination or at months\n24 \nsafety endpoints\nsafety will be assessed in terms of drug toxicity evaluated by\nclinic and on laboratory parameters  and scored according to\ncommon terminology criteria for adverse events  ctcae \nversion 5 0 during all the study ",
    "DESIGN": "experimental design  uncontrolled openlabel multicentric phase ii study",
    "INCLUSION CRITERIA": "population involved  adult with classic or endemic kaposi s sarcoma inclusion criteria  the patients meeting the following criteria may be included in the\nstudy   for simon s 2stage optimal design and extension stage \n  classic or endemic histologically confirmed ks\n  progressive disease\n  ks with more than 10 lesions or involving more than one\nlimb segment or with involvement  3  body surface\n  ks with at least 4 lesions  5mm\n  ks with at least 1 other cutaneous tumor available for\nrepeated pharmacodynamics evaluation and be willing to\nprovide tissue from cutaneous biopsy of a tumor lesion\n  at least 4 weeks washout for all ks specific therapies\nincluding chemotherapy and immunotherapy\n  provide written  informed consent prior to the performance of\nany study specific procedures\n  be   18 years of age on day of signing informed consent \n  have a performance status of 0 or 1 on the ecog\nperformance scale \n  demonstrate adequate organ function \n hematological   absolute neutrophil count  anc \n 1 000 mm3  platelets  100 000   mm3 \nhemoglobin  8 g dl\n renal  calculated creatinine clearance   30ml min\n using mdrd formula \n hepatic  ast  sgot  and alt  sgpt    2 5xuln \nserum total bilirubin   1 5xuln or direct bilirubin  \nuln for participants with total bilirubin levels\n 1 5xuln \n  female subject of childbearing potential should have a\nnegative serum pregnancy within 72 hours prior to receiving\nthe first dose of study medication\n  have a health insurance",
    "EXCLUSION CRITERIA": "noninclusion criteria  the patients meeting the following criteria must be not included\nin the study   for simon s 2stage optimal design and extension\nstage \n  has a known history of organ transplantation\n  is receiving systemic steroid therapy or any other form of\nimmunosuppressive therapy within 7 days prior to the first\ndose of trial treatment \n  has ks with symptomatic visceral involvement unless no\nother therapeutic option is available\n  previously received treatments with an antipd1  antipd\nl1  antipdl2  antictla4 antibody or any other antibody\nor drug specifically targeting tcell costimulation or immune\ncheckpoint pathways \n  uncontrolled infection with hiv  hbv  or hcv infection  or\ndiagnosis of immunodeficiency that is related to  or results in\nchronic infection \npatients with known hepatitis b  hepbsag   who have controlled\ninfection  serum hepatitis b virus dna pcr that is below the limit of detection and receiving antiviral therapy for hepatitis b  are\npermitted  patients with controlled infections must\nundergo periodic monitoring of hbv dna per local standards\nand must remain on antiviral therapy for at least 6 months\nbeyond the last dose of investigational study drug \npatients who are known hcv ab  who have controlled infection\n undetectable hcv rna by pcr either spontaneously or in\nresponse to a successful prior course of antihcv therapy  are\npermitted \n  has an active infection requiring systemic therapy \n  has hypersensitivity to pembrolizumab  keytruda  or any\nof its excipients \n  has had a prior anticancer monoclonal antibody  mab \nwithin last 4 weeks or who has not recovered  i e     grade\n1 at selection  from adverse events due to agents\nadministered more than 4 weeks earlier \n  has had prior chemotherapy  targeted small molecule\ntherapy  or radiation therapy within 3 weeks  or 5 half lives \nprior to study day 1 or who has not recovered  i e     grade\n1 at selection  from adverse events due to a previously\nadministered agent  note  participants with   grade 2\nneuropathy are an exception to this criterion and may qualify\nfor the study    note  if subject received major surgery  they\nmust have recovered adequately from the toxicity and or\ncomplications from the intervention prior to starting therapy  \n  has a known additional malignancy that is progressing or\nrequires active treatment  exceptions include basal cell\ncarcinoma of the skin or squamous cell carcinoma of the skin\nthat has undergone potentially curative therapy or in situ\ncervical cancer \n  has active autoimmune disease that has required systemic\ntreatment in the past 2 years  i e  with use of disease\nmodifying agents  corticosteroids or immunosuppressive\ndrugs   replacement therapy  eg   thyroxine  insulin  or\nphysiologic corticosteroid replacement therapy for adrenal or\npituitary insufficiency  etc   is not considered a form of\nsystemic treatment  patients with vitiligo  type i diabetes\nmellitus  hypothyroidism  psoriasis non requiring systemic\ntreatment are permitted to enroll \n  has active noninfectious pneumonitis or known history of\nnoninfectious pneumonitis that required steroids  severe\npulmonary disease or hypoxia\n  has known psychiatric or substance abuse disorders that\nwould interfere with cooperation with the requirements of the\ntrial \n  is pregnant or breastfeeding  or expecting to conceive or\nfather children within the projected duration of the trial  or not\nwilling to use adequate contraceptive methods from study\nvisit 1 throughout the study period up to 120 days after the\nlast dose of study therapy \n  has received a live vaccine within 30 days prior to the first\ndose of trial treatment or while participating in the trial    is currently participating or has participated in a study of an\ninvestigational agent within 4 weeks of the first dose of\ntreatment \n  has a history or current evidence of any condition  therapy \nor laboratory abnormality that might confound the results of\nthe trial  interfere with the subject s participation for the full\nduration of the trial  or is not in the best interest of the subject\nto participate  in the opinion of the treating investigator \n  patient under guardianship or curatorship",
    "INTERVENTION": "investigational medicinal\nproduct s   simon s 2stage optimal design\nphase of development  phase ii\ntreatment  pembrolizumab\nroute  intraveinous infusion\ndose regimen  200 mg per infusion every 3 weeks\nduration of treatment  6 months  8 cycles \nextension stage \nphase of development \nphase ii treatment  pembrolizumab\nroute  intraveinous infusion\ndose regimen  200 mg per infusion every 3 weeks\nduration of treatment  up to 24 months  35 cycles   or until\nconfirmed complete response as defined in the simon s 2 stage\noptimal design if it occurs before 24 months  after 6 months of\npembrolizumab treatment  cycle 8  and lasting 2 further cycles \nif the complete response is observed and confirmed during at\nleast 1 month  the pembrolizumab will be stopped  comparator treatment  na",
    "STATISTICS": "statistical analysis  simon s 2stage optimal design \nthis is a multicenter uncontrolled phase ii study  based on a 2\nstage phase ii simon s optimal design  sample size computation was based on statistical hypotheses\nwith regards to treatment effect on the main endpoint  best\noverall response rate \nwith a 0 05 type i error and a 90  statistical power  the sample\nsize was computed to assess whether the drug is inactive\n partial complete response probability π0 5   or truly active\n partial complete response probability π1 30   \nbased on our hypotheses  it was computed that 9 patients would\nbe accrued in stage 1  if necessary inclusion will be stopped\nduring 6 months after the 9th inclusion waiting for the primary\nendpoint  the trial will stop with conclusion of inactivity if no\nresponse is observed in this stage  otherwise  8 additional\npatients will be recruited to a total sample size of 17 patients \nwith at least 3 responses to indicate that the drug is effective\nenough  in case an observed response before the end of stage\n1 the stage 2 will directly begin withouit any stop \nextension stage \nonly the 20 patients included in the extension stage will be\nconsidered in this main analysis  with an expected complete\nbest overall response rate  complete response  partial response \nat 6 months of 14 20  70    we would obtain a 95 ci interval of\nthe complete response rate equal to  46  88   \na secondary analysis will be performed on the 20 patients\nincluded in the extension stage plus the 17 patients included in\nthe simon s 2 stage optimal design  with an expected best\noverall response rate at 6 months of 26 37  70 3    this analysis\nwill reach a 95 ci interval of the complete response rate equal\nto  53  84   ",
    "DSMB": "data safety monitoring\nboard anticipated  yes",
    "ACRONYM": "acronym  kapkey",
    "INVESTIGATOR": "coordinating investigator  pr céleste lebbe  dermatologie  hôpital saint louis  paris \n0142494679   celeste lebbe aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants\nchosen  simon s 2stage optimal design 9 patients will be enrolled in the first part of the study with another\n8 patients in the second part  total 17 patients   it implies have\nto screen a maximum of 34 patients \nextension stage  20 additional patients will be enrolled ",
    "SITES": "number of centers  multicentric french study\nfor simon s 2stage optimal design  8 participating centers of\nthe french national group  groupe de cancérologie cutanée  \nfor the extension stage  10 participating centers of the french\nnational group  groupe de cancérologie cutanée ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding source  msd"
  },
  "UPFRONT-MUD": {
    "TITLE": "full title  upfront matched unrelated donor transplantation in\npediatric patients with idiopathic aplastic anemia  a\nphase ii feasibility study",
    "JUSTIFICATION": "scientific justification  pediatric patients with idiopathic aplastic anemia  aa \nrespond better than adults to immunosuppressive\ntherapy  ist  but the longterm risks of relapse \nciclosporine dependence  and clonal evolution are high \nuk investigators reported a 5year estimated failurefree\nsurvival  ffs  after ist of 13 3   in contrast  in 44\nsuccessive children who received a matched unrelated\ndonor  mud   hematopoietic stem cell transplantation\n hsct   there was an excellent estimated 5year ffs of\n95   forty of these children had previously failed ist \nbecause of those excellent results  upfront fully matched\nunrelated donor  mud  hematopoietic stem cell\ntransplantation  hsct  became an attractive firstline\noption  in 2005 to 2014  a uk cohort of 29 children with\nidiopathic aa thus received mud hscts as firstline\ntherapy  they did not receive ist prior to hsct   results\nwere excellent  with low graft versus host disease rates\nand only 1 death  idiopathic pneumonia   this cohort was\nthen compared with historical matched controls \ntransplanted or not  outcomes for the upfront unrelated\ncohort hsct were similar to matched related donor\nhsct and superior to ist and unrelated hsct postist\nfailure  since then  many investigators are offering up\nfront mud hsct in pediatric patients worldwide \nhowever  those results should be treated with extreme\ncaution  1  the design is retrospective  2  the excellent up\nfront mud hsct may arise from the use of alemtuzumab\nin the conditioning regimen  alemtuzumab is not easily\navailable worldwide  and 3  there was no formal quality\noflife assessment  moreover  this strategy is highly\ndependent on donor identification  caucasian patients\nhave the highest likelihood of having a mud  and donor\navailability  we thus don t know how many patients did\nnot eventually receive hsct because of the risk of\ninfections complications caused by unexpected donor\ndelays or cancellation  prospective trials are thus urgently\nneeded to address the feasibility of such procedure  in\nterm of timing  delay to offer mud hsct  and\nconditioning regimen  nothing is known of the use of other\nregimens  non alemtuzumabbased  in this setting  ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to realize upfront hsct within 2\nmonths once a mud has been identified primary endpoint  upfront mud hsct effectively\nperformed within 2 months  60 days  after identification of\na mud secondary objectives and\nendpoints  secondary objectives \nclinical and biological outcomes \n graft failure  graft versus host disease  gvhd  \nprogression free survival  relapse  nonrelapse mortality \noverall survival\n quality of life\n chimerism\n immune reconstitution\nsecondary endpoints \n graft failure incidence \n neutrophils and platelets engraftment at day 100  first\nday of 3 consecutive days with neutrophils  0 5 g l and\nfirst day of 7 consecutive days with platelets  20 g l   \n absolute numbers of neutrophils and platelets at m1 \nm2  m3  m6 and m12  day of last platelet and red blood\ncell transfusions \n acute gvhd incidence at month 3  m3   date and\nmaximum grading  first line treatment  response to\nsteroids  treatment courses in case of steroid refractory\ngvhd  \n chronic gvhd incidence  date and grading at m24  \n relapse incidence at m12 and m24\n progression free survival at m12 and m24\n incidence of cmv and ebv infection at m12\n severe infections  ctae grade 34  à m3  m6  m12 and\nm24\n nonrelapse mortality m24\n overall survival at m24\n quality of life questionnaire  pedqql  at inclusion  post\ntransplantation  m3  m6  m12  m24\n chimerism at m1  m3  m6  m12 \n immune reconstitution by analyzing t  b  nk  regulatory\nt cell levels in the peripheral blood at m3  m6  m12 and\nm24 posttransplantation\n ferritin levels at m3  m6  m12  m24",
    "DESIGN": "design of the study  phase ii multicenter  national  prospective cohort study",
    "INCLUSION CRITERIA": "population of study participants  pediatric patients aged less than 18 years with idiopathic\naplastic anemia and an indication for treatment  severe\naplastic anemia or moderate aplastic anemia requiring\ntransfusions   inclusion criteria  patients \n age 18years old\n pediatric patients aged less than 18 years with idiopathi\naplastic anemia and an indication for treatment  severe\naplastic anemia or moderate aplastic anemia requiring\ntransfusions \n with a good probability to have a hla10 10 matched\nunrelated donor available  the patient needs to have at least 3 mud identified within the book bmdw  bone\nmarrow donors worldwide  or using the easy match\nsoftware to be included \n with usual criteria for allosct \n  lansky  70  for those below 16 years and\nkarnofsky   70  for those above 16 years\n  no severe and uncontrolled infection\n  adequate organ function  asat and alat   5n* \ntotal bilirubin   2n  creatinine clearance   70  of higher\nnormal values for age \n with health insurance coverage  bénéficiaire ou ayant\ndroit  \n contraception methods** for young girl and men of\nchildbearing age must be prescribed during all the\nduration of the research \n parents having read and understand the information\nnote and signed a written informed consent  the\npatient s agreement depending on his age will be\nsought \n*because typical presentation of aplastic anemia posthepatitis\n** nb   the authorized contraceptive methods are \n for women of childbearing age and in absence of permanent\nsterilization  oral  intravaginal or transdermal combined hormonal\ncontraception  oral  injectable or transdermal progestogenonly\nhormonal contraception  intrauterine hormonalreleasing system\n ius  \n for man in absence of permanent sterilization  condoms",
    "EXCLUSION CRITERIA": "exclusion criteria  patients \n with a matched related donor available\n with uncontrolled infection\n with seropositivity for hiv or htlv1 or active\nhepatitis b or c defined by a positive pcr hbv or hcv\nand associated hepatic cytolysis\n renal failure with creatinine clearance below 70  of\nhigher normal values for age\n pregnant  βhcg positive  or breastfeeding\n with heart failure according to nyha  ii or more \n preexisting acute hemorrhagic cystitis\n urinary tract obstruction\n yellow fever vaccine within 2 months before\ntransplantation\n who have any debilitating medical or psychiatric\nillness  which preclude understanding the inform\nconsent as well as optimal treatment and followup\n depending of his age and understanding  \n with contraindication to treatments used during the\nresearch",
    "INTERVENTION": "transplant modalities  1  conditioning regimen\n  for patients aged less than 14 years\nfludarabine  30mg m2 day  day 6 to day 3  \ncyclophosphamide  30 mg kg day  day 6 to day 3   and antithymocyte globulin  3 75 mg kg day  day 6 to day \n3  \n  for patients aged 14 or more\nfludarabine  30mg m2 day  day 6 to day 3  \ncyclophosphamide  30 mg kg day  day 6 to day 3   anti\nthymocyte globulin  3 75 mg kg day  day 4 and day 3 \nand total body irradiation 2 gray  day 1  \nhowever  it is allowed to realize tbi before fludarabine\nfor local planning reasons  tbi day 5  antithymocyte\nglobulin d4 et d3  fludarabine d4 to d1 \ntbi d5    fludarabine d4 to d1 cyclophosphamide d\n4 to d1 \n2  stem cell source\nonly bone marrow\nwith a minimal target dose of 4x108 nucleated cells kg\nrecipient ideal body weight  if the graft is less rich than\nthe minimum target dose  it can be administered at the\ndiscretion to the physician \n3  gvhd prophylaxis\ngvhd prophylaxis with consist in the association of\ncyclosporine plus methotrexate  mtx   iv cyclosporine\n3 mg kg j at day 1 until 1 year post hsct plus\nmethotrexate  mtx  iv 10mg m2 given on day 1  and\nsubsequently at 8 mg m2 on days  3 and day 6 \nprevention of ebv reactivation\nrituximab 150mg m2 iv at day 5 post hsct  infusion of\nrituximab will be preceded by administration of anti\npyretic and an antihistaminic  e g  paracetamol and\ndiphenhydramine ",
    "STATISTICS": "statistical analysis  justification of sample size\nwe use the simon minimax twostage phase 2 design \nto demonstrate success  primary outcome  in 70  of\npatients  to consider treatment as a valuable option \nagainst less than 45   considered as unacceptable  \ninterim analysis\nan interim analysis will be performed after 12 inclusions \nthe trial will be terminated if 5 or fewer do not receive\nupfront mud hsct  then the study ends with conclusion\nof inefficacy  otherwise  inclusions are pursued until a\ntotal of 25 patients  to conclude treatment efficacy  at\nleast 16 successes should be identified among the 25\npatients ",
    "DSMB": "study will have a data safety\nmonitoring board  yes ",
    "ACRONYM": "acronym reference  upfrontmud",
    "INVESTIGATOR": "coordinating investigators  pr jeanhugues dalle  pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included  25 patients with an interim analysis after 12 inclusions",
    "SITES": "number of centres  13 centres in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  ministry of health  phrcn 2019 "
  },
  "HAPLORESCUE": {
    "TITLE": "full title  haploidentical allogeneic hematopoietic stem cell\ntransplantation with posttransplant cyclophosphamide for\nrescuing patients with graft failure  a phase ii study",
    "JUSTIFICATION": "scientific justification  prognosis of patients with graft failure is dismal  and re\ntransplantation is the sole option for longterm survival \ncurrently  there is no consensus concerning therapeutic\noptions in patients with primary or secondary  within the\n60 days posttransplantation  graft failure and finding a\nnew donor within an acceptable delay is challenging \nliterature is poor on the subject while the overall survival\nof such patients is about 30  at 1 year  1  2   this\nsituation thus represents today a very challenging unmet\nmedical need \nrecently  haploidentical  haplo  related donor stem cell\ntransplantation  haplosct  have improved dramatically\noutcomes using tcell replete grafts with administration of\nposttransplantation cyclophosphamide  ptcy  which\ntargets alloreactive t cells generated early after an hla\nmismatched transplant  sparing regulatory t cells and\nleaving unaffected the nondividing hematopoietic stem\ncells  and standard posttransplant immune suppression\nwith a calcineurin inhibitor  cni  and mycophenolate\nmofetil  3   our group retransplanted a patient who\nexperienced two consecutive graft failures and was\nsuccessfully managed through a third haplosct from\nher son using ptcy  5   we then retrospectively collected\nand analyzed data from 26 primary graft failure patients\ntransplanted between 2011 and 2017 in 15 centers on\nbehalf of french society for stem cell transplantation\nand cell therapy  sfgmtc   the study population\nconsisted mainly of patients with primary or secondary\n within the 60 days posttransplantation  graft failure who\nunderwent haplosct and received ptcy as graft\nversushostdisease prophylaxis  the 1year overall\nsurvival was about 60  suggesting that this approach\nmight be a valid option in this particular poor clinical\nsituation but now need validation through a phase ii\nmulticenter  national  prospective cohort study  4  ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to rescue patients with graft failure after\na first allogeneic sct  allosct  using haplosct with\nptcy\nprimary endpoint  overall survival rate compared to an\nhistorical controls of 30  at 1 year  secondary objectives and\nendpoints  secondary objectives \n graft failure  gvhd  progression free survival  relapse \nnonrelapse mortality\n interval between first allosct and rescue haplosct\n quality of life\n chimerism\n immune reconstitution\nsecondary endpoints \ngraft failure incidence \nneutrophils and platelets engraftment at day 100  3\nconsecutive days with neutrophiles  0 5 g l and 7\nconsecutive days with platelets  20 g l   absolute\nnumbers of neutrophils and platelets at m1  m2  m3  m6\nand m12  day of last platelet and red blood cell\ntransfusions  the use of growth factors for poor\nhematopoietic reconstitution\nacute gvhd incidence at month 3  m3   date and\nmaximum grading  first line treatment  response to\nsteroids  treatment courses in case of steroid refractory\ngvhd \nchronic gvhd incidence  date and grading at m24  \nrelapse incidence at m12 and m24\nprogression free survival at m12 and m24\nincidence of cmv and ebv infection at m12\nsevere infections  ctae grade 34  à m3  m6  m12 and\nm24\nnonrelapse mortality m3  m6  m12 and m24\nincidence of cardiac toxicities at m3\noverall survival at m24\ninterval between first allosct and rescue haplosct\nquality of life questionnaire  eortc qlqc30 v3  at\ninclusion  posttransplantation  m3  m12  m24\nchimerism at   m3  m12\nimmune reconstitution by analyzing t  b  nk  regulatory\nt cell levels in the peripheral blood at m1  m3  m6  m12\nand m24 posttransplantation",
    "DESIGN": "design of the trial  phase ii multicenter  national  prospective cohort study scope of the trial  primary or secondary  within the 60 days post\ntransplantation  graft failure is a rare but devastating\ncondition after sct  a recent strategy for haplo related\ndonor transplantation  which has had some success  is\ntransplantation of tcell replete grafts with intensive\nimmune suppression  few retrospective noncontrolled\nregistry studies recently suggest that outcomes after\nhaplosct using ptcy approach might be superior to\nactual standard of care  i e  retransplantation from an\nunrelated donor   moreover  haplosct with ptcy is a\nquick procedure  cheap  and available for almost all\npatients  this study might thus favor this strategy in case\nof primary or secondary  within the 60 days post\ntransplantation  graft failure after 1st sct ",
    "INCLUSION CRITERIA": "population of trial subjects  patients over 3 years old and all hematological diseases\nsuffering from primary or secondary  within the 60 days\nposttransplantation  graft failure after a 1st allogeneic\nhematopoietic stem cell transplantation  allosct  inclusion criteria  patients \naged from 3 years and older\nall hematological diseases\nsuffering from primary or secondary  within the 60 days\nposttransplantation  graft failure\nafter a 1st allosct\nwith usual criteria for allosct \n  ecog   2\n  no severe and uncontrolled infection\n  cardiac function compatible with high dose of\ncyclophosphamide   adequate organ function  asat and alat   2 5n \ntotal bilirubin   2n  creatinine clearance  30ml  \nmin\nwith identification of a haploidentical donor  brother \nsister  parents  adult children or cousin \nabsence of donor specific antibody  dsa  detected in\nthe patient with a mfi   2000  antibodies directed\ntowards the distinct haplotype between donor and\nrecipient \n with health insurance coverage  bénéficiaire ou ayant\ndroit  \n understand informed consent or optimal treatment and\nfollowup \n contraception methods must be prescribed during all\nthe duration of the research  women and men of\nchildbearing age must use contraceptive methods\nwithin 12 months and 6 months after the last dose of\ncyclophosphamide  respectively \nhaving signed a written informed consent  2 parents for\npatients aged less than 18 ",
    "EXCLUSION CRITERIA": "exclusion criteria  patients \n aged  3 years old\n with uncontrolled infection\n with seropositivity for hiv or htlv1 or active\nhepatitis b or c defined by a positive pcr hbv or\nhcv and associated hepatic cytolysis\n yellow fever vaccine within 2 months before\ntransplantation\n cancer in the last 5 years  except basal cell\ncarcinoma of the skin or  in situ  carcinoma of the\ncervix \n uncontrolled coronary insufficiency  recent myocardial\ninfarction  6 month  current manifestations of heart\nfailure  uncontrolled cardiac rhythm disorders \nventricular ejection fraction  50 \n heart failure according to nyha  ii or more \n preexisting acute hemorrhagic cystitis\n renal failure with creatinine clearance   30ml   min\n urinary tract obstruction\n pregnant  βhcg positive  or breastfeeding\n who have any debilitating medical or psychiatric illness \nwhich preclude understanding the inform consent as well\nas optimal treatment and followup\n tutorship or curatorship\n contraindications to treatments used during the\nresearch",
    "INTERVENTION": "transplant modalities\nmedical product provided by the\nsponsor  conditioning regimen\nfludarabine  30mg m2 day from day 6 to day 4  \ncyclophosphamide  14 5 mg kg day at day 6 and day 5 \nexcept for patients who received a total dose of\ncyclophosphamide  100mg kg during the first bone\nmarrow transplantation\ntotal body irradiation  2 gray on day 1  \nsource of stem cell source\nperipheral blood stem cell\nminimal target dose of 4 106 cd34  cells kg of recipient\ngvhd prophylaxis\ncyclophosphamide 50 mg kg day at d 3 and d 4\nciclosporine from day 5  residual 200 à 300ng l \nmycophenolate mofetyl at 15mg kg x2 day from day 5\nprevention of ebv reactivation\nrituximab   150mg m2 at day 5 post haplosct",
    "STATISTICS": "statistical analysis  overall survival will be estimated using the kaplan\nmaier s estimator with its 95  confidences intervals \ncomparaison with the historical controls of 30  at 1 year\nwill be performed using the onesample logrank test\nproposed by sun x et al in 2011 \nterminal analysis will be performed after the followup of\nthe last included patient ",
    "DSMB": "trial will have a data monitoring\ncommittee  yes",
    "ACRONYM": "acronym  haplorescue",
    "INVESTIGATOR": "coordinating investigator  pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of subjects included  for an objective of 31 patients to be allografted  we\nanticipate 35 patients to include ",
    "SITES": "number of sites  37 centres in france\n2 centres in belgium  affiliated to sfgmtc \n1 centre in switzerland  affiliated to sfgmtc ",
    "FUNDING": "sponsor  assistance publiquehôpitaux de paris sources of funding for the trial  phrck 2019"
  },
  "FIRST": {
    "TITLE": "full title  upfront related donor transplantation in\npatients with myelodysplastic syndrome  a\nphase 2 trial",
    "JUSTIFICATION": "scientific justification  three recent prospective  transplant no transplant  studies\nconcluded to an advantage of os with transplantation in\npatients with high or intermediate2 ipss risk  not significant\nin kröger s study  1 3 no prospective randomized trial has\nassessed the pretransplant therapy in mds patients yet but\nsome information can be extracted from these 3 recent\nstudies  in the french study  n 162   72  patients with a\ndonor received hsct  previously treated by hypomethylating\nagent  hma  in 71  of them 3 there was a trend to a better\nsurvival in patients achieving a complete remission with pre\ngraft therapy  hr  0 55  p 0 088  and higher risk of death in\nunresponsiveness patients transformed into aml  hr  2 36 \np 0 008   in nakamura s study  n 384   83  of patients with\na donor were transplanted  previously treated by hma in\n68 2  the multivariable cox model for overall survival  os \nand leukemiafree survival showed an excess risk in patients\ntreated by hma  moreover  responders still have a higher risk\nof mortality as compared to patients who did not receive any\npregraft therapy  hr  2 417  p 0 0054   in the german\nstudy  the aim was to initiate azacytidine at inclusion and to\ntransplant patients after 4 cycles if a donor was identified1 \namong 170 registered patients  162 initiated 5aza but 36 \nof them were  lost during this pregraft therapy  before\nallocation to  donor  or  nodonor  arm  for different reasons\nincluding death  n 12   after 4 cycles of 5aza  79 81 patients\n donor arm  were transplanted  the multivariable analysis\nshowed remission status did not influence os  those 3\nprevious clinical trials thus suggest that a substantial number\nof patients planned for transplantation are not transplanted\nnowadays while no evidence of hma benefit before hsct\nhas been clearly identified  this phase 2 study aim to assess\nthe feasibility of upfront hsct in patients with high risk mds\nin order to increase the probability to be transplanted and to\nachieve a subsequent remission and better survival ",
    "OBJECTIVE": "main objective and primary\nendpoint  primary objective \nto demonstrate an improved diseasefree survival  dfs  in\npatients undergoing upfront transplantation from a related\ndonor as compared to 0 35  historical prospective cohort  \nprimary endpoint \ndfs 2 years after transplantation secondary objectives and\nendpoints  secondary objectives \nclinical and biological outcomes \n overall survival  os \n incidence of transplantation after donor identification\n incidence of transformation into aml\n relapse or progression\n engraftment\n acute and late rejection\n nonrelapse mortality  nrm \n acute gvhd\n chronic gvhd\n severe infections  ctae grade 34 \n cardiac events grade 24 ctae\nsecondary endpoints \n os  at 24 months after inclusion and after\ntransplantation\n nrm at 24 months after transplantation\n cumulative incidence of transformation into acute\nmyeloid leukemia from inclusion at 24 months\n acute gvhd and grading at 100 days post hsct\n chronic gvhd and grading at 2 years post hsct\n engraftment at m3  hematological recovery and donor\nchimerism   95  \n graft failure  acute or late rejection and non\nengraftment  at 2 years post hsct\n severe infections  ctae grade 34  at m3  m6  m12\nand m24\n cardiac events grade 24 ctae at m1 and m3",
    "DESIGN": "design of the study  this study uses an uncontrolled phase 2 openlabel design \nto increase the level of incidence  external comparisons will\nbe secondly performed to  i  demethylating agents using\nindividual patient data from a prospective cohort  robin 2015 \nor  ii  5azacytidine  using aggregated data from a published\nrandomized clinical trial  kröger 2021  ",
    "INCLUSION CRITERIA": "population of study participants  adults  50 years and older  patients with mds diagnosis for\nwhom transplantation is indicated from a related donor\nidentified  inclusion criteria  inclusion criteria\n age   50 and   70 years\n an hla matched sibling donor or familial haploidentical\ndonor has been identified\n the disease fulfills at least one of the following criteria \no intermediate2 or high risk according to classical\nipss\no intermediate1 risk if marrow fibrosis   grade i or\npoor risk cytogenetics according to r ipss or\nclassified high or very high risk according to r ipss\nor if the mds is therapyrelated neoplasm  usual criteria for hsct \no ecog   2\no no severe and uncontrolled infection\no cardiac function compatible with high dose of\ncyclophosphamide lvf   50 \no adequate organ function  asat and alat   2 5n \ntotal bilirubin   2n  creatinine clearance   30 ml min\n according to cockroft formula \n in case of transplantation with a haploidentical donor \nabsence of donor specific antibody  dsa  detected in\nthe patient with a mfi  1000  antibodies directed\ntowards the distinct haplotype between donor and\nrecipient  as recommended in ebmt guidelines \ncontraception methods must be prescribed for women of\nchildbearing age during all the study  if cyclophosphamide is\nused  effective contraceptive methods for men during 6\nduring all their participation in the study  \n with health insurance coverage\n with a written informed consent signed\nnb  the authorized contraceptive methods are \n for women of childbearing age and in absence of\npermanent sterilization  oral  intravaginal or transdermal\ncombined hormonal contraception\n oral  injectable or implantable progestogenonly\nhormonal contraception\n intrauterine device  iud \n intrauterine hormonal releasing system  ius \n bilateral tubal occlusion\n vasectomised partner\n sexual abstinence  only if this the preferred and usual\nlifestyle of the participants \n for man in absence of permanent sterilization \nsexual abstinence  condoms",
    "EXCLUSION CRITERIA": "exclusion criteria  exclusion criteria\n marrow blast   15  at time of inclusion\n mds with excess blast  10  and npm1 mutation or a\nrecurrent genetic abnormality related to aml  who 2022 \n chemotherapy  aml like intensive chemotherapy or\ndemethylating agent  to treat mds at the current stage\n disponibility of an unrelated donor 10 10  mud  in\nabsence of genoidentical donor\n patient with uncontrolled infection\n cancer in the last 5 years  except basal cell carcinoma of\nskin or  in situ  carcinoma of the cervix\n renal failure with creatinine clearance  30ml   min\n according to cockroft formula \n with contraindications to treatments used during the\nresearch\n uncontrolled coronary insufficiency  recent myocardial\ninfarction  6 month  current manifestations of heart\nfailure  uncontrolled cardiac rhythm disorders  ventricular\nejection fraction  50 \n with heart failure according to nyha  ii or more   patient with seropositivity for hiv or htlv1 or active\nhepatitis b or c defined by a positive pcr hbv or\nhcvyellow fever vaccine or any alive vaccine within 2\nmonths before transplantation\n pregnancy  βhcg positive  or breastfeeding\n who have any debilitating medical or psychiatric illness \nwhich would preclude giving well understand informed\nconsent or optimal treatment and followup\n under protection by law  tutorship or curatorship ",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis  a  twosided  onesample  logrank test calculated from a\nsample of 55 subjects achieves 90 36  power at a 0 050\nsignificance level to detect a proportion surviving of 0 5500 in\nthe new group when the proportion surviving in the historic\ncontrol group is 0 3500  such an historical proportion has\nbeen estimated from our previous french cohort study  as\npublished in leukemia where a 2year dfs rate of 35  was observed in patients with a donor who were not transplanted\nupfront   by contrast  ebmt studies have reported that 2year\ndfs in patients with mds is expected to be 55  \nthese surviving proportions are for a period of 24 0 months \nsubjects are accrued for a period of 24 0 months  followup\ncontinues for a period of 24 0 months after the last subject is\nadded \nthe probability that a subject experiences an event during the\nstudy is 0 5860  the expected number of events during the\nstudy is 24 \nit is assumed that the survival time distributions of both\ngroups are approximated reasonably well by the weibull\ndistribution with a shape parameter of 1 00 \nto increase the level of evidence  external indirect\ncomparisons will be secondly performed to  i  demethylating\nagents using individual patient data from a prospective cohort\n robin 2015  or  ii  5azacytidine  using aggregated data from\na published randomized clinical trial  kröger 2021  ",
    "DSMB": "dsmb  yes",
    "ACRONYM": "acronym reference  first allo mds",
    "INVESTIGATOR": "coordinating investigator  dr  marie robin\ndepartment of hematology\nhôpital saintlouis\nparis",
    "NUMBER OF INCLUSIONS": "number of participants included  55 patients",
    "SITES": "number of centres  multicenter national study  16 hematology departments in\nfrance  3 centres aphp  ",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  fondation msd avenir"
  },
  "APARR": {
    "TITLE": "full title  evaluation of an optimized allogeneic hematopoietic stem cell\ntransplantation protocol with posttransplant cyclophosphamide\nin patients aged 40 to 60 years old with acquired aplastic\nanemia refractory or in relapse after immunosuppression",
    "JUSTIFICATION": "scientific justification  hematopoietic stem cell transplantation  hsct  is a major\ntherapeutic option for patients with acquired aplastic anemia\n aa   improved survival has been achieved in patients younger\nthan 40 years old  thanks to better donor selection  conditioning\nregimens and graft versus host disease prophylaxis  together\nwith improved supportive care \nhowever  this has never been the case for patients over the age\nof 40 for whom the overall survival after hsct never exceeded\n60  at 5 years using available sibling or unrelated donor\n ref 3   thus  the standard immunosuppressive therapy\n ist  associating cisclosporine  horse antithymocyte globuline \ntogether with the addition of eltrombopag  epag  is now\nconsidered as the standard of care in adult patients older than\n40 years with aa  ref 1  \nindeed  outcomes for patients who are refractory to firstline ist\nremain poor because of the lack of other nontransplant\ntreatment and because of the poor results of transplantation\nat this age  ref 2  37   during the past 2 decades  there has\nbeen a significant decrease in infectionrelated mortality in this\npopulation after initial ist but risk of hemorrhage and longterm\nfatigue are still present  moreover  clonal evolution including\nparoxysmal nocturnal hemoglobinuria  pnh   myelodysplastic\nsyndrome  mds   and acute myeloid leukemia  aml  still occur\nin the longterm with a grim prognosis for mds aml  ref 2  \nthe overall survival of such adult patients with acquired aa\nrefractory or in relapse after ist outside hsct is thus about\n60  at 2 years  ref  2  \nrecently  new strategies to prevent acute and chronic graft\nversus host disease  including tcell replete grafts with\nadministration of posttransplantation cyclophosphamide\n ptcy   have revolutionized the field \nthese changes extended the option of hsct primary for\npatients with refractory relapse aa who lack an hla matched\ndonor  ref 4   more recently the optimized baltimore protocol\nusing ptcy strategy also appears to improve engraftment and\nreduce graft versus host disease  gvhd  in other more\nclassical setting  sibling and matched unrelated hsct outside\naa   ref 5   one of the first cause of death after hsct in\npatients older than 40 years of age with refractory relapse aa\nis gvhd and the use of the optimized baltimore protocol for all\ntype of donors  haplo but also sibling and matched unrelated transplantation  within the field of aa rapidly appears promising\n ref 6 7  \nusing an optimized hsct procedure  marrow as source of\nstem cells and a ptcy strategy  not only in haploidentical\ndonor setting but also in case of an available matched sibling\nor unrelated donor might prevent drastically gvhd and\neventually be practice changing  evaluating this new transplant\nprotocol as a new strategy is the main objective of  aparr  ",
    "OBJECTIVE": "main objective and primary\nendpoint  main objective  to demonstrate a benefit in terms of the 2\nyear grfs  graft versus host disease  gvhd  and primary\nand secondary graft failurefree survival  from 50   historical\nrates in patients with refractory relapse aa undergoing hsct\n ref 8  up to 70  using an optimized hsct procedure\n marrow as source of stem cells and a ptcy strategy  on\npatients over 40 years old and not only in haploidentical donor\nsetting \nprimary endpoint  2year grfs following hcst\nthis primary composite endpoint is measured as the time from\nhsct to the first of the following events  primary and secondary\ngraft failures  grade 34 acute gvhd  severe chronic gvhd\nand death  secondary objectives and\nendpoints  secondary objectives\nto demonstrate a benefit in terms of clinical and biological\noutcomes \n primary and secondary graft failure\n mortality  overall survival\n quality of life\ntreatment related morbidity and notably severe infections \ncardiac toxicities\n chimerism\n immune reconstitution\nsecondary endpoints\n  100day engraftment  3 consecutive days with\nneutrophiles  0 5 g l and 7 consecutive days with platelets\n 20 g l  with donor chimerism   85   on the total blood \n  absolute numbers of neutrophils and platelets at m1 \nm3  m6  m12  m24 and day of last platelet and red blood cell\ntransfusions\n  acute gvhd incidence grade 24 at m3\n  chronic gvhd incidence at m24\n  severe chronic gvhd at m24\n  secondary graft failure at m12 and m24\n  severe infections  ctcae grade 34  at m1  m3  m6 \nm12  m24\n  incidence of cardiac toxicities at m12\n  incidence of cmv and ebv infection at m12\n  mortality at m12  m24\n  overall survival at 12 months and 24 months   quality of life questionnaire at pretransplant  m6  m12 \nm24\n  chimerism at m1  m3  m6  m12  m24\n  immune reconstitution at m1  m3  m6  m12  m24  t\nlymphocytes  cd4  cd8  b  nk lymphocytes and\ngammaglobulines ",
    "DESIGN": "design of the study  a phase ii multicenter  national  prospective  singlearm trial ",
    "INCLUSION CRITERIA": "population of study participants  patients aged from 40 to 60 years with refractory relapse aa\nafter ist eligible to hsct  inclusion criteria  patients\n  aged from 40 to 60 years old\n  suffering from acquired refractory severe idiopathic\naplastic anemia after at least 6 months treatment with\nantithymocyte globulin and cyclosporine with t\neltrombopag or in relapse\n  allograft validated in the national multidisciplinary\nexpertise meetings of the french reference centre for\naplastic anemia\n  with an available genoidentical donor or 10 10\nmatched donor or haploidentical donor\n  with the absence of donor specific antibody detected in\nthe patient with a mfi   1500  antibodies to the distinct\nhaplotype between donor and recipient \n  usual criteria for hsct \n  ecog   2\n  no severe and uncontrolled infection\n  cardiac function compatible with high\ndose of cyclophosphamide\n  with adequate organ function asat\nand alat   3n  conjugated bilirubin  \n2n  or total bilirubin   2n if not\navailable   clearance creatinine  50ml  \nmin\n  with health insurance coverage\n  women of childbearing potential and men must use\ncontraceptive methods during their participation to the\nresearch and for 12 months and 6 months after the last\ndose of cyclophosphamide  respectively \n  having signed a written informed consent\nnb  the authorized contraceptive methods are  for women\nof childbearing potential and in absence of permanent\nsterilization \noral  intravaginal or transdermal combined hormonal\ncontraception \noral  injectable or transdermal progestogenonly hormonal\ncontraception \nintrauterine hormonalreleasing system  ius  \nsexual abstinence  need to be evaluated in relation to the\nduration of clinical trial and the preferred and usual lifestyle of\nthe participants   for men in absence of permanent sterilization  sexual\nabstinence  condoms \nindividuals must meet all of the inclusion criteria as verified at\nthe screening   inclusion visit to be eligible to participate at the\nstudy ",
    "EXCLUSION CRITERIA": "exclusion criteria  patients\n  with morphologic evidence of clonal evolution  patients\nwith isolated bone marrow cytogenetic abnormalities\nare also eligible excepted chromosome 7 abnormalities\nand complex karyotype  \n  with seropositivity for hiv or htlv12 or active\nhepatitis b or c and associated hepatic cytolysis\n  cancer in the last 5 years  except basal cell carcinoma\nof the skin or  in situ  carcinoma of the cervix \n  pregnant  βhcg positive  or breastfeeding\n  yellow fever vaccine and all others live virus vaccines\nwithin 2 months before transplantation and during the\nresearch\n  with uncontrolled coronary insufficiency  recent\nmyocardial infarction  6month  current manifestations\nof heart failure according to nyha  ii or more  \nventricular ejection fraction  50 \n  with renal failure with creatinine clearance  50ml  min\n  any contraindication mentioned in the smpc and the\ninvestigator s brochure of all medicinal products\nplanned to be used in the trial including conditioning\nregimen  gvhd prophylaxis  prevention of ebv\nreactivation  infection prophylaxis\n  known allergy or intolerance to all medicinal products\nand or excipients planned to be used in the trial\nincluding conditioning regimen  gvhd prophylaxis \nprevention of ebv reactivation  infection prophylaxis \naccording to investigator s brochure and smpc \n  who have any debilitating medical or psychiatric illness \nwhich precludes understanding the inform consent as\nwell as optimal treatment and followup\n  under legal protection  tutorship or curatorship \n  under state medical aid\n  participation to another interventional trial on a\nmedicinal product or cell therapy\nindividuals meeting any of the exclusion criteria verified at the\nscreening   inclusion visit will be ineligible to participate at the\nstudy ",
    "INTERVENTION": "transplants modalities  1 conditioning regimen\nthymoglobulin  0 5 mg kg à d9  2 mg  kg at d8 and 2 5 mg kg\nà d7   fludarabine  30mg m2 day i v  day 6 to day 2   pre\ntransplant  cyclophosphamide  14 5 mg kg day i v  day 6 and\nday 5   and total body irradiation  2 gray on day 1   2 stem cell source\nbone marrow only  target of 4   108 nucleated cells kg recipient\nbody weight  granulocyte colony stimulating factor is given\nsubcutaneously starting on day  5 at 5 mg  kg day until the\nabsolute neutrophil count is greater than 1 5   109 l for 3 days \n3  gvhd prophylaxis\ncyclophosphamide 50 mg kg day at d 3 and d 4  tacrolimus\n 0 2 à 0 3 mg kg day per os divided into 2 doses or 0 05 to 0 1\nmg kg d ivse  and mycophenolate  mmf  will begin from d 5 \nin absence of gvhd  mmf will be stopped between d35 and\nd45 and tacrolimus at day 365 \n4  prevention of ebv reactivation\nrituximab 150mg m2 intravenously at day 5 post hsct\n except patients and their donor with ebv serology and ebv\npcr negative   each infusion of rituximab will be preceded by\nadministration of antipyretic and an antihistaminic  e g \nparacetamol and diphenhydramine\nnb  however  it is permissible to delay the administration of rituximab\nby 24 hours if d 5 occurs on a sunday for greater safety at the\ndiscretion of the investigator",
    "STATISTICS": "statistical analysis  sample size calculation\na twosided  onesample logrank test calculated from a sample\nof 52 subjects achieves 80  power at a 0 05 significance level\nto detect a 2years grfs of 70  in the new group when the 2\nyears grfs in the historic control group is 50  if all patients\nare followed 2 years \nanalysis of primary endpoint\nseveral interim analyses of the primary outcome measure are\nplanned once every 12 months  unless less than 20 enrolled\npatients   based on a bayesian approach \nat the end of the trial  accrual followup   grfs will be\nestimated using kaplan meier method with its corresponding\n95  confidence interval and compared to historical rate using\none sample twosided logrank test \nan additional terminal analysis will use external patients from\nan observational cohort  with propensity score weighting  to\nensure an unbiased comparison and enhance the level of\nevidence of the treatment effect ",
    "DSMB": "study will have a data safety\nmonitoring board  yes",
    "ACRONYM": "acronym reference  aparr",
    "INVESTIGATOR": "coordinating investigator  régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included  52 patients",
    "SITES": "number of centres  28 centers affiliated at sfgmtc in france",
    "FUNDING": "sponsor  assistance publique   hôpitaux de paris funding sources  phrcn 2022"
  }
}